2





Professor

Department of Medicine

Division of Oncology

Alvin J. Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri

Associate Professor

Department of Medicine

Division of Oncology

Alvin J. Siteman Cancer Center at

Washington University School of Medicine

St. Louis, Missouri

3





Acquisitions Editor: Julie Goolsby Senior Product Development Editor: Emilie Moyer

Senior Editorial Assistant: Brian Convery

Production Project Manager: Bridgett Dougherty

Design Coordinator: Hol y McLaughlin

Manufacturing Coordinator: Beth Welsh

Marketing Manager: Rachel Mante Leung

Prepress Vendor: Aptara, Inc.

4th edition

Copyright © 2016 Wolters Kluwer.

3rd edition Copyright © 2012 and 2nd edition Copyright © 2009 by Lippincott Wil iams & Wilkins, a Wolters Kluwer business. Copyright © 2005 by Lippincott Wil iams & Wilkins.

Al rights reserved. This book is protected by copyright. No part of this book may be reproduced or transmitted in any form or by any means, including as photocopies or scanned-in or other electronic copies, or utilized by any information storage and retrieval system without written permission from the copyright owner, except for brief quotations embodied in critical articles and reviews. Materials appearing in this book prepared by individuals as part of their official duties as U.S. government employees are not covered by the above-mentioned copyright. To request permission, please contact Wolters Kluwer at Two Commerce Square, 2001 Market Street, Philadelphia, PA 19103, via email at

permissions@lww.com, or via our website at lww.com (products and services).

9 8 7 6 5 4 3 2 1

Printed in China

Library of Congress Cataloging-in-Publication Data

Names: Govindan, Ramaswamy, editor. | Morgensztern, Daniel, editor.

Title: Devita, Hel man, and Rosenberg’s Cancer, principles & practice of oncology review / editors, Ramaswamy Govindan, Daniel Morgensztern.

Other titles: Cancer, principles & practice of oncology review Description: 4th edition. | Philadelphia : Wolters Kluwer, [2016] |

Supplement to: DeVita, Hel man, and Rosenberg’s cancer / editors, Vincent T. DeVita, Jr., Theodore S. Lawrence, Steven A. Rosenberg. 10th ed. [2015]

| Includes bibliographical references and index.

Identifiers: LCCN 2016011573 | ISBN 9781496310804

Subjects: | MESH: Neoplasms | Examination Questions

Classification: LCC RC261 | NLM QZ 18.2 | DDC 616.99/4–dc23

4

LC record available at http://lccn.loc.gov/2016011573

This work is provided “as is,” and the publisher disclaims any and al warranties, express or implied, including any warranties as to accuracy, comprehensiveness, or currency of the content of this work.

This work is no substitute for individual patient assessment based upon healthcare professionals’ examination of each patient and consideration of, among other things, age, weight, gender, current or prior medical conditions, medication history, laboratory data, and other factors unique to the patient. The publisher does not provide medical advice or guidance and this work is merely a reference tool. Healthcare professionals, and not the publisher, are solely responsible for the use of this work including al medical judgments and for any resulting diagnosis and treatments.

Given continuous, rapid advances in medical science and health information, independent professional verification of medical diagnoses, indications, appropriate pharmaceutical selections and dosages, and treatment options should be made and healthcare professionals should consult a variety of sources. When prescribing medication, healthcare professionals are advised to consult the product information sheet (the manufacturer’s package insert) accompanying each drug to verify, among other things, conditions of use, warnings and side effects and identify any changes in dosage schedule or contraindications, particularly if the medication to be administered is new, infrequently used or has a narrow therapeutic range. To the maximum extent permitted under applicable law, no responsibility is assumed by the publisher for any injury and/or damage to persons or property, as a matter of products liability, negligence law or otherwise, or from any reference to or use by any person of this work.

LWW.com

5





6





Assistant Professor

Internal Medicine

Washington University School of Medicine

St. Louis, Missouri

Professor

Internal Medicine–Medical Oncology

Washington University School of Medicine

St. Louis, Missouri

Professor

Department of Surgery

Washington University School of Medicine

St. Louis, Missouri

Assistant Professor

Department of Medicine

Division of Oncology

Washington University School of Medicine

St. Louis, Missouri

Leonard M. Mil er Professor of Medicine

Department of Medicine

University of Miami

Professor of Medicine

Medicine/Division of Hematology–Oncology

University of Miami Sylvester Cancer Center

Miami, Florida

Clinical Fel ow

Department of Medicine

Division of Oncology

Washington University School of Medicine

7

Barnes-Jewish Hospital

St. Louis, Missouri

Clinical Pharmacist

Medical Oncology

Barnes Jewish Hospital

St. Louis, Missouri

Associate Professor

Department of Medicine

Oncology Division

Medical Oncology Section

Department of Cel Biology & Physiology

Washington University School of Medicine

St. Louis, Missouri

Clinical Pharmacy Specialist

Medical Oncology

Barnes-Jewish Hospital

St. Louis, Missouri

Assistant Professor

Department of Medicine

Division of Oncology

Washington University School of Medicine

St. Louis, Missouri

Resident

Department of General

Barnes-Jewish Hospital

St. Louis, Missouri

Assistant Professor

Division of Biostatistics

Washington University School of Medicine

St. Louis, Missouri

8

Professor and Chairman

Nancy B. and Jake L. Hamon Distinguished Chair in Therapeutic Oncology Research Department of Radiation Oncology

UT Southwestern Medical Center

Dal as, Texas

Associate Professor

Department of Medicine

Division of Oncology

Washington University School of Medicine

St. Louis, Missouri

Clinical Fel ow

Division of Hematology/Oncology

Washington University School of Medicine

St. Louis, Missouri

Clinical Fel ow

Department of Obstetrics and Gynecology

Division of Gynecology

Washington University School of Medicine

Barnes-Jewish Hospital

St. Louis, Missouri

Clinical Fel ow

Department of Medicine

Division of Medical Oncology

Washington University School of Medicine

St. Louis, Missouri

Clinical Fel ow

Department of Hematology and Medical Oncology

Emory University School of Medicine

Atlanta, Georgia

Professor

9

Department of Oncology

Karmanos Cancer Institute

Wayne State University

Detroit, Michigan

Assistant Professor

Department of Medicine (Medical Oncology)

Yale School of Medicine

New Haven, Connecticut

Assistant Professor

Department of Internal Medicine

University of Oklahoma

Health Science Center/Stephenson Cancer Center

Oklahoma City, Oklahoma

Clinical Fel ow

Hematology/Oncology

Washington University School of Medicine

St. Louis, Missouri

Assistant Professor

Department of Medicine

Division of Oncology

Washington University School of Medicine

St. Louis, Missouri

Assistant Professor

Department of Surgery

Washington University School of Medicine

St. Louis, Missouri

Associate Professor of Oncology

Department of Internal Medicine

Co-Director Liver and Pancreas Tumor Center

Roswel Park Cancer Institute

Buffalo, New York

10

Clinical Fel ow

Department of Internal Medicine

Division of Medical Oncology

Washington University School of Medicine

St. Louis, Missouri

Professor

Internal Medicine

University of Michigan

Ann Arbor, Michigan

Clinical Fel ow

Department of Hematology & Oncology

Washington University School of Medicine

St. Louis, Missouri

John Skoglund Chair of Lung Cancer Research

Department of Medicine

University of Minnesota Medical School

Minneapolis, Minnesota

Assistant Professor

Department of Radiation Oncology

UT Southwestern Medical Center

Dal as, Texas

Clinical Research Specialist

Internal Medicine–Medical Oncology

Washington University School of Medicine

St. Louis, Missouri

Associate Professor

Department of Medicine

Division of Oncology

Washington University School of Medicine

St. Louis, Missouri

11

Associate Professor of Medicine

Department of Internal Medicine

Division of Oncology

Washington University School of Medicine

St. Louis, Missouri

Associate Professor of Medicine

Internal Medicine–Medical Oncology

Washington University School of Medicine

St. Louis, Missouri

Associate Professor

Department of Medicine

Division of Oncology

Alvin J. Siteman Cancer Center

Washington University School of Medicine

St. Louis, Missouri

Nurse Practitioner

Medical Oncology

Washington University School of Medicine

St. Louis, Missouri

Vice Chairman of Gynecology

Obstetrics and Gynecology

Washington University School of Medicine

St. Louis, Missouri

Assistant Professor

Department of Medicine

Oncology Division

Medical Oncology Section

Washington University School of Medicine

St. Louis, Missouri

Resident

12

Department of Medicine

Washington University School of Medicine

Barnes-Jewish Hospital

St. Louis, Missouri

Associate Professor

Obstetrics and Gynecology

Washington University School of Medicine

St. Louis, Missouri

Assistant Dean for Cancer Research

Professor

Emory University School of Medicine

Deputy Director

Director of Medical Oncology

Hematology and Medical Oncology

Winship Cancer Institute

Atlanta, Georgia

Professor of Medicine

Medicine and Molecular Microbiology

Washington University School of Medicine

St. Louis, Missouri

Clinical Fel ow

Department of Medicine

Washington University School of Medicine

St. Louis, Missouri

Assistant Professor of Medicine

Medicine/Oncology

Washington University School of Medicine

St. Louis, Missouri

Professor

Department of Thoracic/Head and Neck Medical Oncology

Division of Cancer Medicine

13

Chief

Section of Experimental Therapeutics

The University of Texas MD Anderson Cancer Center

Houston, Texas

Assistant Professor

Department of Medicine

Division of Oncology

Washington University School of Medicine

St. Louis, Missouri

Associate Professor

Division of Hematology/ Oncology

University of North Carolina

Chapel Hil , North Carolina

Associate Professor of Medicine

Medicine/Oncology

Washington University School of Medicine

St. Louis, Missouri

Assistant Professor of Medicine

Department of Medicine

Division of Oncology

Washington University School of Medicine

St. Louis, Missouri

Research Statistician

Biostatistics Shared Resource

Siteman Cancer Center

Washington University School of Medicine

St. Louis, Missouri

School of Biomedical Informatics

University of Texas Health Science Center

Houston, Texas

14

Assistant Professor

Department of Internal Medicine

Washington University School of Medicine

St. Louis, Missouri

Professor

Department of Medicine

Section of Bone Marrow Transplantation and Leukemia

Washington University School of Medicine

St. Louis, Missouri

Associate Professor of Oncology

John Hopkins Medicine

Director of Lymphoma Drug Development

Johns Hopkins University

Baltimore, Maryland

Associate Professor

Department of Medicine

Oncology Division

Medical Oncology Section

Washington University School of Medicine

St. Louis, Missouri

Assistant Professor

Internal Medicine/Division of Oncology

Washington University School of Medicine

St. Louis, Missouri

Associate Professor

Department of Medicine

Washington University School of Medicine

Associate Program Director, Internal Medicine Residency

Department of Medicine

Barnes-Jewish Hospital

St. Louis, Missouri

15





We are pleased to publish the fourth edition of the companion review book for DeVita, Hel man, and Rosenberg’s Cancer: Principles and Practice of Oncology, 10th edition (PPO). While these review books are often seen as study aids for last-minute cramming for the board examinations, we hope this book wil enable readers to learn key points from each chapter of the PPO textbook. Each chapter in the review book corresponds to one or more chapters in the main textbook just as they were in the rst three editions. We hope you nd this book useful and informative. Please do not hesitate to contact us with comments, criticisms, and suggestions.

16





The past decade has witnessed numerous advances in cancer therapy. Even since the publication of the previous edition of Cancer: Principles and Practice of Oncology (PPO), or simply known as the “DeVita book,” several new drugs have been approved for cancer therapy. Cancer Genome Sequencing projects are going ahead ful steam. Molecular mechanisms that underline the course of several cancer types and responses to speci c therapies are understood better than before. This companion review book, now in its third edition, is an attempt to cul out the key learning pointsfrom the massive tome of “the DeVita book” that captures al these advances in a timely manner. While these review books are often seen as “study-aids” for last minute cramming for the board examinations, we hope this book would serve to highlight key points from each chapter of PPO. Each chapter in the review book corresponds to one or more chapters in the main textbook just as they were in the rst two editions. We hope you nd this book useful and informative. Please do not hesitate to contact me with comments, criticisms, and suggestions. You can reach me by email at rgovinda@dom.wustl.edu.

17





At the outset, I want to thank the contributors for their diligence, time, and patience.

My special thanks to Dr. Daniel Morgensztern for his hard work, dedication, and commitment to make this project successful. I want to thank Julie Goolsby and Emilie Moyer from Wolters Kluwer for their support.

Needless to say, these projects take a sizeable amount of time away from the family. I wil always be grateful to my wife Prabha and my two children, Ashwin and Akshay.

I would like to thank my mentor Ramaswamy Govindan for the opportunity to participate as a co-editor on the fourth edition of the PPO review, the contributors for their excel ent chapters, and Julie Goolsby and Emilie Moyer from Wolters Kluwer for their constant support. I am also very grateful to my parents Silvia and Felipe, my lovely wife Marcela and my three delightful children Alan, David, and Michael.

18





Robert A. Kratzke

Viralkumar Vaghani and George R. Simon

Thomas E. Stinchcombe

Shirish M. Gadgeel

Megan E. Wren

Lingling Du, Richard Chen, Daniel Morgensztern, and Rebecca Aft Jennifer Ivanovich

Hak Choy and Aaron Laine

Sara K. Butler and Leigh M. Boehmer

Sarah B. Goldberg

Vinicius Ernani and Suresh S. Ramalingam

Ling Chen and Kathryn Trinkaus

Douglas R. Adkins, Jessica C. Ley and Loren Michel

19

Siddhartha Devarakonda and Saiama N. Waqar Gregory P. Kalemkerian

Hassan Hatoum and Renuka Iyer

Thomas Regenbogen and Andrea Wang-Gil am

Benjamin R. Tan, Jr.

Ashley Morton and Benjamin R. Tan, Jr.

Russel K. Pachynski

Pasquale Benedet o

Mat hew A. Powel and Laura Divine

David G. Mutch

Foluso C. Ademuyiwa, Ron Bose, and Cynthia X. Ma

Tanner M. Johanns, Jian Li Campian and George Ansstas Brian A. Van Tine and Angela C. Hirbe

Gerald P. Linet e

Nina Wagner-Johnston and Dilan Patel

20

Amanda F. Cashen

Pavan Bhamidipati and Keith Stockerl-Goldstein

Ravi Vij and Jesse Kel er

Lee Ratner

Brian Hess and Rizwan Romee

Preet Paul Singh

21





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 1.1 Completion of the Human Genome Project has revealed that human cel s have a repertoire of genes of which approximate number?

A. 2,500 genes

B. 25,000 genes

C. 250,000 genes

D. 2,500,000 genes

Question 1.2 One of the reasons to use cancer cel culture experiments in preclinical studies of cancers is:

A. Al ows evaluation of cancer cel interaction with the tumor microenvironment.

B. Cel cultures are amenable to easily manipulated experimental techniques.

C. Adaptation of cancer cel s to growth in culture corresponds exactly to cancer cel growth in vivo.

D. Al ows evaluation of cancer cel interaction with the native immune system.

Question 1.3 Which of the fol owing is TRUE with regard to genetic mutations in cancer?

A. Gain-of-function mutations (oncogenes) are general y dominant at the cel ular level.

B. Loss-of-functions mutations (tumor suppressor genes) are general y recessive at the cel ular level.

C. Ninety percent of germ line mutations in familial cancer syndromes are in tumor suppressor genes.

D. Al of the above.

Question 1.4 Which of the fol owing proteins has inhibitory activity in the cel cycle?

A. Cyclin D1

B. E2F

C. p16INK4a

D. Cyclin-dependent kinase 4

Question 1.5 Which of the fol owing contributes to cancer progression?

22

A. Autophagy

B. Apoptosis

C. Senescence

D. Angiogenesis

Question 1.6 Which of the fol owing prevents successful invasion and metastasis ?

A. Senescence

B. Angiogenesis

C. Evasion of apoptosis

D. Self-sufficiency in growth signals

Question 1.7 Which of the fol owing best describes the term “protooncogene”?

A. A normal cel ular gene that has been transduced by a retrovirus that is then mutated fol owing viral replication.

B. A homologue of a known oncogenic element identified in prehistoric specimens.

C. A transforming viral gene that can cause malignant transformation in fibroblasts in vitro.

D. The first oncogene discovered to be associated with human cancer.

E. A viral oncogene that, fol owing infection, is the direct causative agent of human cancer.

Question 1.8 The DNA damage checkpoints are located in which phase of the cel cycle?

A. G1/S

B. S/G2

C. M

D. Al of the above

Question 1.9 Which of the fol owing is a potential flaw in microarray studies?

A. Inadequate controls

B. Biased estimation of prediction accuracy

C. Correlation between clusters and clinical outcome

D. Al of the above

Question 1.10 Which of the fol owing statements about miRNAs is/are TRUE?

A. Consist of RNA 19 to 24 nucleotides in length

B. Cannot be evaluated in array format as part of clinical studies C. Alters gene expression and protein translation

D. A and C

Question 1.11 The proteome is which of the fol owing: 23

A. The set of al expressed gene products at a given time B. The proteins expressed preferential y in malignant cel s C. The set of al proteins potential y expressed by the genome D. The set of protonated peptides subject to matrix-assisted laser desorption ionization time-of-flight analysis

Question 1.12 Which one of the fol owing statement is CORRECT with regard to molecular profiling using gene arrays and proteomics?

A. Gene arrays can predict protein–protein interactions.

B. Protein levels and protein function do not correspond directly with gene transcript levels.

C. Polymerase chain reaction can be used to amplify biopsy material for use in gene arrays, whereas no signal amplification technology is standard in protein arrays.

D. Al of the above

E. B and C

Question 1.13 Which of the fol owing is TRUE about the peptidome?

A. Included peptides must be less than 50,000 daltons.

B. Consists of fragments of larger proteins.

C. May not be amplified in the circulation.

D. Peptide fragments do not bind blood proteins, such as albumin.

Question 1.14 Which of the fol owing statements is CORRECT?

A. Hereditary nonpolyposis colon cancer syndrome (HNPCC) is associated with a 25%

lifetime risk of developing colorectal cancer.

B. Approximately 10% of al cases of colorectal cancer are associated with HNPCC.

C. Microsatel ite instability is associated with resistance to 5-fluorouracil chemotherapy.

D. None of the above.

Question 1.15 Which of the fol owing is a DNA hypomethylating agent?

A. Suberoylanilide hydroxamic acid (SAHA)

B. 5-Azacytidine

C. Depsipeptide

D. A and C

Question 1.16 The presence of mutations in p53 has been associated with which of the fol owing properties on cel s:

A. Loss of the G2 checkpoint fol owing treatment with DNA-damaging agents B. Enhanced capacity to undergo apoptosis fol owing exposure to radiation C. Increased capacity for DNA amplification

24

D. A and C

Question 1.17 Which of the fol owing is an example of gene ampli cation found in cancer?

A. N-myc amplification in neuroblastoma

B. C-myc amplification in smal cel lung cancer

C. Her2/neu amplification in breast cancer

D. Al of the above

Question 1.18 Which of the fol owing is TRUE regarding microsatel ite instability in colon cancer?

A. Approximately 15% of patients with hereditary nonpolyposis coli have mutations in MLH1 or MSH2.

B. There is potential resistance to 5-fluorouracil.

C. It has a less favorable prognosis.

D. Evidence is in favor of it occurring only late in sporadic colon cancer cases.

Question 1.19 Which of the fol owing is TRUE about excision repair mechanisms?

A. Increased expression of ERCC1 in non–smal -cel lung cancer is associated with response to cisplatin.

B. There are two nucleotide excision repair (NER) pathways.

C. Base excision repair is involved in response to damage from chemicals and radiographs.

D. B and C.

Question 1.20 ATR/CHK1 signaling is associated with al of the fol owing statements, A. Bone marrow failure

B. Predisposition to squamous cel carcinoma

C. Predisposition to acute leukemia

D. Al of the above

Question 1.21 Which of the fol owing syndromes are associated with abnormalities in the double-strand repair?

A. Xeroderma pigmentosum

B. Fanconi anemia

C. Lynch syndrome

D. Bloom syndrome

Question 1.22 Decreased expression of Aurora B kinase could lead to the fol owing: A. Inability for sister chromatids to separate before anaphase B. Rapid cel division

25

C. Aneuploidy

D. Increased disassembly of kinetochore proteins

Question 1.23 Which of the fol owing characterizes cytogenetic abnormalities in most human cancers?

A. Universal (monoclonal) population of cel s containing identical cytogenetic abnormalities

B. Completely normal karyotype

C. Heterogeneous complex karyotypes

D. Complete loss of X or Y chromosomes

Question 1.24 The “Hay ick phenomenon,” which is the name given to the limited replicative potential of cel s, is thought to arise from which of the fol owing?

A. The sequential loss of genetic material from the ends of chromosomes (telomeres) with each round of division

B. The gradual accumulation of uncorrected genetic defects passed on during division leading to senescence or malignancy

C. The activation of telomerase in aging cel s leading to enzymatic loss of genetic material from telomeres

D. Dividing eukaryotic cel s outgrowing their vascular supply Question 1.25 Which of the fol owing statements is TRUE regarding telomerase?

A. It has both a DNA and a protein component.

B. It is a DNA topoisomerase.

C. Telomerase protects the integrity of the chromosomal ends.

D. Overexpression of telomerase is found in al cancer specimens.

Question 1.26 Which of the fol owing wil induce a quiescent state?

A. Telomere shortening

B. Prolonged DNA damage

C. High-density growth

D. Oncogene activation

Question 1.27 Al of the fol owing is/are evidence for senescence as a tumor suppressor mechanism, EXCEPT:

A. Several “tumor suppressor” proteins that are involved in senescence pathways (e.g., p16INK4a) are mutated in familial cancer syndromes.

B. Mice and humans with impaired p16INK4a and p53 function develop normal y other than an age-dependent decrease in cancer and decreased susceptibility to cancer in response to carcinogen exposure.

26

C. Reestablishment of p53 activity in sarcoma and hepatocel ular carcinoma has led to cessation of tumor growth.

D. Growth arrest in lung epithelium has been demonstrated in response to oncogenic events.

E. A, C, and D.

Question 1.28 Which of the fol owing is/are potential therapeutic strategy (ies) to promote apoptosis in cancer cel s?

A. Inhibition of p16INK4a activity

B. Inhibition of p16INK4a activity via activation of DNA methyltransferases C. Activation of MDM2

D. Promotion of p16INK4a-p53 interactions

Question 1.29 Breakage–fusion–bridge cycles lead to the fol owing: A. Methylation

B. Aneuploidy

C. Amplifications

D. Deletions

E. B, C, and D

Question 1.30 Telomerase-nul mice are associated with which of the fol owing?

A. Decreased sensitivity to radiation

B. Decreased sensitivity to chemotherapy that induces double-strand breaks (DSBs) C. Decreased genomic stability in the presence of p53 deficiency D. Decreased rate of spontaneous malignancy

Question 1.31 Which of the fol owing are receptor tyrosine kinases?

A. Platelet-derived growth factor receptor

B. Insulin-like growth factor receptor 1

C. cKit

D. Al of the above

Question 1.32 Which of the fol owing is TRUE about receptor tyrosine kinases?

A. They are always monomeric.

B. Activation always requires tyrosine phosphorylation in al classes.

C. Different types of ligands can activate the same class of receptors.

D. Different types of ligands induce the same receptor conformational changes on binding.

Question 1.33 Which of the fol owing is TRUE about receptor phosphotyrosine phosphatases?

27

A. Several ligands for these have been described.

B. They rarely function to antagonize tyrosine kinases.

C. Inactivation could increase intracel ular phosphorylation under certain circumstances.

D. Receptor phosphatases containing two catalytic domains are rare.

28

Question 1.1 The answer is B.

One of the surprising findings of analysis of the sequenced human genome is the presence of only approximately 25,000 expressed genes in human cel s. However, only a few thousand of these seem to be expressed at any given time. Previous estimates, based on the known approximate size of human chromosomes, were that there were up to 100,000 or more individual genes expressed in human cel s.

Question 1.2 The answer is B.

Preclinical and clinical studies into cancer cel pathogenesis and response to potential treatments can be guided initial y with cel culture experiments because these experiments can be manipulated in a reproducible manner. However, cel culture experiments do not al ow for evaluation of the interaction between cancer cel s and the tumor microenvironment. Some techniques such as cel ular assays that evaluate for cel ular migration and invasion through a Matrigel can mimic the tumor microenvironment, but they cannot replicate al of the cel ular–environmental interactions. In addition, cancer cel s can acquire genetic changes through multiple passages in culture such that they may not completely reflect in vivo cancer cel –host interactions.

Question 1.3 The answer is D.

Ninety percent of germ line mutations in familial cancer syndromes are in tumor suppressor genes. It is thought that many dominant oncogene mutations likely cause fetal demise and therefore do not arise in familial cancer syndromes. Dominant mutations in cancer genes denote oncogenes and make up 90% of al cancer genes.

Question 1.4 The answer is C.

The cel cycle is composed of the phases G0, G1, S, G2, and M. Regulation of the cel cycle depends on an interplay of multiple proteins. Cyclin-dependent kinases are serine/threonine kinases that are ubiquitous in the cel cycle. They general y require phosphorylation and association with cyclins for activity. Cyclin-dependent kinase 4

phosphorylates retinoblastoma protein, al owing depression of transcription factors (of which E2F is an example) essential to progression of the cel cycle. A series of inhibitors (INK4 family) act to decrease the activity of cyclins, of which p16INK4a is a member.

Question 1.5 The answer is D.

Angiogenesis encompasses a cascade of events that al ow a tumor’s vascular supply to be enhanced, thereby increasing cel ular proliferation. Apoptosis and autophagy are two distinct mechanisms of cel death. Apoptosis is regulated via caspase cascades and 29

mitochondrial-mediated pathways. Autophagy often is induced via nutrient starvation (as sensed by the mTor kinase) and involves autodigestion of intracel ular organel es.

Senescence, the permanent arrest of cel division, is regulated via the ARF-p53 and p16INK4a-retinoblastoma pathways.

Question 1.6 The answer is A.

Senescence is the permanent arrest of cel division, which would not contribute to cancer progression via invasion and metastasis. The other choices are al required for such progression. In addition, insensitivity to growth inhibitory signals and limitless replicative potential is also necessary for the complex processes of invasion and metastasis.

Question 1.7 The answer is A.

It has been known for almost a century that certain viruses can cause malignant transformation. The responsible genetic elements identified in the viral genomes are cal ed viral oncogenes (v-oncogenes). It was found that homologues of these v-oncogenes existed in the eukaryotic genome from which they had likely originated.

These normal human genetic elements were given the name protooncogene. One of the first of these, Src, was identified in the avian Rous sarcoma virus that had been studied as a transforming virus decades earlier. In most human cancers, mutations or aberrant expressions of oncogenes have been identified.

Question 1.8 The answer is A.

There are three major DNA checkpoints, occurring at G1/S, G2/M, and S. These pathways promote cel cycle arrest and coordinate the recruitment of repair proteins to the sites of DNA damage.

Question 1.9 The answer is D.

Microarray technology is dependent on unbiased and rigorous statistical analysis, and as such, is susceptible to user bias. To help address the continuing need for standardization guidelines in the clinical use of microarray technology, the Minimum Information About A Microarray Experiment (MIAME) was published as a demonstration that microarray data can be independently verified, thereby reducing bias. The answers listed al may contribute to flawed interpretation of microarray data.

Question 1.10 The answer is D.

MicroRNA (miRNA) consists of an RNA sequence of 19 to 24 nucleotides in length and participates in cel processes such as apoptosis and development via the effect on gene expression and protein translation. Recently, miRNA array signatures have been evaluated in clinical samples from patients with lung cancer, chronic lymphocytic 30

leukemia, and breast cancer. In a recent lung cancer study, the miRNA profile correlated with survival.

Question 1.11 The answer is C.

The term “proteome” is general y taken to refer to al potential y expressed proteins encoded by the genome. However, many operational definitions specify only those proteins expressed at a given time or under certain conditions, so option “A” denotes a relatively common use of the term as wel . Increasingly, the term “proteome” is used in conjunction with a modifier such as “serum,” cel ular,” or even “malignant” to denote a more limited set of conditions. Protonation is a preparative step before proteomic evaluation by current means. Most proteomic analyses require cleavage of the proteins in the samples fol owed by protonation of the resulting peptides before matrix-assisted laser desorption ionization time-of-flight analysis.

Question 1.12 The answer is E.

Current gene array technology is focused mostly around the detection of gene transcript levels. Smal quantities of nuclear material from minimal biopsy material can be amplified via polymerase chain reaction. However, protein–protein interactions and posttranslational processing cannot be predicted. Multiple technologies have been used to detect “proteomic signatures,” which include two-dimensional gel electrophoresis, affinity tagging, liquid chromatography coupled with mass spectrometry, and antibody arrays. Limitations of proteomic technologies include disruption of the native three-dimensional protein conformations in addition to the need for larger amounts of biopsy material needed compared with genomic arrays. This requires sensitive proteomic technology, such as antibodies in the femtomolar range.

Question 1.13 The answer is A.

The term “peptidome” refers to the low–molecular-weight range of the proteome that consists of peptides or protein fragments general y less than 50,000 daltons. It is thought that these peptide fragments are secreted from various tumors and exist in the circulation bound to carrier proteins. Studies are under way to determine if the secreted pattern of such fragments can be correlated with disease states. A confounding factor in peptidome analysis may be the susceptibility of peptides to protease degradation in the blood after secretion from the tumor. It remains to be seen if consistent patterns can be determined after protease degradation.

Question 1.14 The answer is C.

HNPCC is associated with a 60% to 80% lifetime risk of developing colorectal cancer and accounts for 2% to 5% of al cases of colorectal cancer. In both sporadic and HNPCC cases, microsatel ite instability has been associated with a more favorable prognosis but potential resistance to 5-fluorouracil chemotherapy.

31

Question 1.15 The answer is B.

SAHA and depsipetide are examples of histone deacetylase inhibitors whereas 5-azacytidine and 5-Aza-2′-deoxycytidine are DNA hypomethylating agents.

Question 1.16 The answer is D.

Mutations of p53 are among the most commonly identified in human cancers. Wild-type p53 has a function in signaling cel s with damaged DNA to undergo programmed cel death (apoptosis). In the presence of an inactivating mutation of p53, commonly used genotoxic agents, such as radiation and chemotherapy, may prove less effective with the intact p53 signal. This has been demonstrated in preclinical models and correlates with some human clinical trial data. It must be noted, however, that many common malignancies harboring p53 mutations, such as smal cel lung cancer and ovarian cancer, are sensitive to chemotherapy and radiation. The capacity of p53 to trigger apoptosis is associated with the cel -cycle checkpoints that have been identified as critical nodal moments at which the cel may “choose” to continue to divide or, if sufficiently damaged, progress down a path to cel death and deletion of the potential y damaged clone. Interestingly, p53 mutant transgenic mice are viable and develop normal y. However, they have an accelerated rate of tumor formation under certain tumorigenic stimuli.

Question 1.17 The answer is D.

Gene amplification as a mechanism resulting in overexpression of gene products involved in tumorigenesis or tumor progression has been reported in several cancers. It is known that N-myc amplification in neuroblastoma can be a useful prognostic factor aiding in designing therapy. In smal cel lung cancer, c-myc amplification has been identified in up to 10% of specimens, a percentage that may increase after treatment.

Her2/neu amplification occurs in up to 30% of breast cancers and is useful in predicting response to Her2/neu-targeted therapy.

Question 1.18 The answer is B.

Microsatel ite instability refers to frequent mutations in regions of simple repeat sequences. Early studies in kindreds with HNPCC demonstrated mutations in MSH2

and MLH1, which are mismatch repair genes. Approximately 85% of patients with HNPCC have mutations in MSH2 and MLH1. Microsatel ite instability is associated with a resistance to 5-fluorouracil treatment, more favorable prognosis, and lack of p53

mutations. The protein MSH2 complexes with MSH6 to recognize mismatched bases, and subsequent recruitment of MLH1 and PMS2 initiates the steps of repair (excision, DNA synthesis, and ligation).

Question 1.19 The answer is D.

32

The mismatch repair machinery of the cel includes two major pathways: nucleotide excision repair (NER) and base excision repair (BER). These pathways respond to lesions created by DNA-damaging agents, such as chemicals and radiation from numerous sources. Early discoveries in the NER pathway were made via the study of xeroderma pigmentosum, where patients exhibit extreme sun sensitivity. Two NER pathways have been described: The first involves global genome scanning for lesions and the second detects lesions that interfere with RNA polymerases. In BER, the repair machinery responds mainly to chemical and x-ray damage and base loss by using DNA glycosylates to remove damaged bases and a complex of APEX1 endonuclease, PARP, DNA polymerase/ligase, and XRCC1 to recognize abasic sites. As of now, no inherited cancer syndromes caused by mutations in BER have been discovered.

Question 1.20 The answer is D.

DSBs can promote major cytogenetic abnormalities and are repaired via homologous recombination or nonhomologous end-joining. ATR/CHK1 signaling leads to activation of the Fanconi anemia repair pathway. Defects in Fanconi anemia lead to bone marrow failure, congenital abnormalities, predisposition to acute leukemias and squamous cel cancer, and increased sensitivity to DNA cross-linking agents such as cisplatin and mitomycin C.

Question 1.21 The answer is B.

Xeroderma pigmentosum, Lynch syndrome, and Bloom syndrome are caused by abnormalities in the NER, mismatch repair, and helicase, respectively. Fanconi anemia is caused by abnormalities in Fanc genes, involved in the double-strand DNA repair.

Question 1.22 The answer is A.

The mitotic spindle is central to cel division, and Aurora kinase B is intricately involved in the process of cel division. The linking of sister chromatids before anaphase is lost partly because of the action of Aurora B kinase. Aurora B kinase also phosphorylates other kinetochore proteins to aid disassembly of kinetochore-microtubule attachments not under proper tension (as part of spindle checkpoint activation). Amplification of Aurora B kinase has been associated with sporadic tumors.

Question 1.23 The answer is C.

Human cancers are largely characterized by complex karyotypes with multiple different populations. In particular, solid tumors such as lung and colon cancer exhibit great heterogeneity that is likely the result of the high level of genomic instability found in cancers. Some less common malignancies, such as CML, are characterized by the relatively uniform presence of an abnormal karyotype, often with a limited number of detectable breakpoints and translocations. In fact, the presence of a uniform karyotypic abnormality raises the possibility of a germ line cytogenetic defect that may be further 33

evaluated by examining the karyotype of noncancerous circulating lymphocytes from the same patient. The absence of any karyotypic abnormality in cancer cel populations is less common but can occur. For example, the presence of a normal karyotype is a wel -

recognized observation in acute myelogenous leukemia and gives important clinical information conferring an intermediate prognosis. The loss of a single X or Y

chromosome is a normal variant commonly observed in older patients. It carries little clinical significance.

Question 1.24 The answer is A.

Hayflick and Moorehead documented a landmark finding of cel biology when they observed that normal eukaryotic cel s would only replicate approximately 50 to 100

times before dying. This limited replicative capacity of nontransformed cel s is cal ed the

“Hayflick phenomenon.” It is now known that the ends of the chromosomes, cal ed

“telomeres,” gradual y shorten, losing 25 to 200 base pairs with each round of division.

After 50 to 100 rounds of division, the telomeres reach a critical y shortened length, triggering cel senescence. Telomeres can be maintained by the enzymatic activity of telomerase, which function to restore and maintain telomeres at their ful length.

Activation of telomerase is a key mechanism by which some cel s, such as cancer cel s, evade senescence. Although gene defects occur spontaneously in cel s and wil lead to programmed cel death, this usual y occurs in the immediate generation after the defect is established. Tumor growth does require neovascularization, but the “Hayflick phenomenon” applies to programmed senescence in nontransformed cel s.

Question 1.25 The answer is C.

Telomerase is the DNA polymerase that synthesizes the repeating six base pair motif (TTAGGG) that comprises the ends of al chromosomes. It is a nucleoprotein with both a protein and RNA component. With cel division, the telomere ends become progressively shorter until a critical length is reached and programmed cel death is initiated.

Synthesizing and repairing the ends of the shortening telomeres al ows cel s to maintain the integrity of the chromosomal ends and is important for cel s that need to divide without reaching senescence, such as cancer cel s. In light of this, it is not surprising that the majority of cancer cel s overexpress telomerase, but there are cancers that appear to have invoked alternative mechanisms to repair telomeres. Indeed, telomerase-deficient (deleted) mice can be induced to develop tumors.

Question 1.26 The answer is C.

Senescence refers to a state in cultured cel s where growth arrest is permanent.

Senescence differs from quiescence in that quiescent cel s can reenter the cel cycle in response to appropriate mitogenic cues. Quiescence is general y induced by serum starvation, growth factor deprivation, high-density growth, and transient DNA damage.

Senescence can be induced by prolonged DNA damage, oxidative stress, telomere 34

shortening, and oncogene activation. Additional differences include uninducible c-fos expression in response to serum stimulation and increased PAI expression in senescence versus quiescence.

Question 1.27 The answer is B.

Cel -cycle inhibitors that lead to senescence include p16INK4a and p53, among others.

It fol ows that mice and humans with impaired p16INK4a and p53 function develop normal y other than an age-dependent increase in cancer and increased susceptibility to cancer in response to carcinogen exposure. Aside from the other correct answers listed, other evidence is supportive. Minimal residual disease data demonstrate frequent oncogenic events as evidence for a need for tumor suppression. Mice are highly susceptible to inactivation of p16INK4a and/or p53 as evidenced by experiments demonstrating development of primary tumors at 8 weeks of age (normal life span is approximately 100 weeks).

Question 1.28 The answer is D.

Knockout of INK4a and ARF loci separately and in combination leads to an increase in spontaneous tumors. Silencing of p16INK4a via hypermethylation has been wel described and is associated with numerous types of cancers. Inhibition of methylation is thought to increase expression of p16INK4a. Gene therapy as a method to replace p16INK4a activity has been achieved in the laboratory. ARF leads to MDM2 activation and subsequent p53 degradation. Inhibition of MDM2 activity is thought to increase p53 levels and lead to apoptosis and senescence. p53 and p16INK4a do not interact directly.

Question 1.29 The answer is E.

Chromosomal rearrangements are thought to contribute to the malignant phenotype of many different cancers. Such rearrangements are the result of breakage–fusion–bridge cycles. Unprotected chromatids can fuse to form a dicentric chromosome. The fused chromosomes break during anaphase and create atelomeric chromosomes. Atelomeric chromosomes can fuse with other chromosomes and perpetuate the cycle.

Amplification, deletions, and aneuploidy can arise this way. Methylation is an epigenetic phenomenon that is not thought to be directly related to chromosome fusion.

Question 1.30 The answer is C.

It is thought that one of the mechanisms of cancer pathogenesis is related to short telomeres that contribute to genomic instability fol owed by increased telomerase activity. Paradoxical y, genomic instability can increase with decreased telomerase activity in the presence of concomitant p53 deficiency, suggesting that telomerase inhibition by itself is likely not sufficient as a cancer therapeutic. However, increased sensitivity to radiation and DSB-inducing chemotherapeutics is associated with 35

decreased telomerase activity and suggests possible additive or synergistic effects.

Question 1.31 The answer is D.

Phosphorylation of tyrosine residues by tyrosine kinases is an important signal for cel stimulation and cancer growth. Each transmembrane tyrosine kinase is activated by its associated ligand. Increasingly, tyrosine kinases are an important target for novel therapeutics as wel . Examples of this class of agents already in common use include both imatinib mesylate (Gleevec) and gefitinib (Iressa). Al of the examples listed above are receptor tyrosine kinases except for Akt. Akt is a threonine/serine kinase and a key component of the downstream phosphatidylinositol 3 kinase-signaling pathway through which many of the tyrosine kinases transmit their signaling.

Question 1.32 The answer is C.

Receptor tyrosine kinases general y consist of an extracel ular binding domain, a transmembrane domain, and an intracel ular kinase domain. These receptors bind ligands that are usual y peptides or proteins. Most are monomeric with the exception of the insulin-receptor family, which consists of heterodimers covalently bound by disulfide bonds. Six major classes exist. Activation of the receptor general y requires phosphorylation of a tyrosine on the receptor, but the insulin binding to the insulin receptor is an exception to this rule and activation is generated by an insulin-induced conformational change. Outside of this, most receptor tyrosine kinases are activated by oligomerization, which brings intracel ular kinase domains into proximity to al ow cross-phosphorylation. Ligands general y stimulate oligomerization. Although receptor classes have been defined by particular ligands, it is accepted that particular receptor classes may bind more than one class of ligand. A particular ligand may have different conformational changes in the same receptor, leading to distinct downstream signal pathway activation.

Question 1.33 The answer is B.

Receptor phosphotyrosine phosphatases (RPTPs) are similar in structure to receptor tyrosine kinases in that they consist of an extracel ular domain, a single transmembrane domain, and an intracel ular catalytic domain (general y two domains). Although no true ligands for RPTPs have been described, some RPTPs contain structural repeats that suggest adhesion molecule recognition. Although RPTPs act as phosphatases, they do not always function in opposition to tyrosine kinases. Particular phosphorylation events can be inhibitory to tyrosine kinases, and activation of phosphatase activity could then increase tyrosine kinase global activity.

Corresponding chapters in Cancer: Principles & Practice of Oncology, Tenth Edition: 1 (The Cancer Genome), 2 (Hal marks of Cancer: An Organizing Principle for Cancer Medicine), 36

and 3 (Molecular Methods in Cancer).

37





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 2.1 The correct order of mitosis is:

A. Prometaphase, metaphase, anaphase, telophase, prophase B. Prometaphase, metaphase, prophase, anaphase, telophase C. Prophase, prometaphase, metaphase, anaphase, telophase D. Telophase, anaphase, prophase, metaphase, prometaphase Question 2.2 The cyclin responsible for facilitating the progress of the cel into and through mitosis is:

A. Cyclin A

B. Cyclin B

C. Cyclin D

D. Cyclin E

Question 2.3 Which of the fol owing are means of regulating cyclin-dependent kinases (CDKs)?

A. Positive regulatory acetylation

B. Negative regulatory phosphorylation

C. CDK inhibitors

D. B and C

E. A and C

Question 2.4 Which of the fol owing is necessary for the G1/S-phase transition?

A. Cyclin B-CDK1 complex accumulation

B. Cyclins E and A accumulation

C. Dephosphorylation of T14 and Y15

D. CDK1 activation along with binding of CDC20 to anaphase promoting complex/cyclosome (APC/C)

Question 2.5 Which of the fol owing has no role in cel -cycle exit?

A. Downregulation of CDKs and cyclins

38

B. Activation of APC/C

C. Reduction in protein synthesis

D. A and C

E. B and C

Question 2.6 Activation of antimitogenic signaling involves the fol owing molecules: A. Transforming growth factor (TGF)-β

B. Interferon (IFN)-α

C. Upregulation of CDK inhibitors and downregulation of cyclins D. Al of the above.

Question 2.7 Select the FALSE statement regarding microRNAs?

A. microRNAs encode protein kinases that regulate cel cycle.

B. They regulate mRNA expression.

C. There is at least five clusters of microRNAs targeting mRNA that encodes cel -cycle regulatory proteins.

D. miR-15a/16 cluster targets cyclin E1 and cyclin D1.

Question 2.8 Of the genes listed below, select the gene that is involved in both cel -cycle regulation and DNA repair?

A. TP53

B. NBS1

C. PTTG1

D. CHK2

Question 2.9 Replicative senescence is initiated by means of: A. Downregulation of cyclins

B. p53 activation

C. Progressive telomere shortening

D. Upregulation of IFNs

Question 2.10 Genes that encode negative regulators of growth and proliferation are: A. Protooncogenes

B. Oncogenes

C. S-phase genes

D. Tumor suppressor genes

Question 2.11 Select the syndrome that is associated with a mutation in the gene encoding Nbs1, leading to microcephaly and a strong predisposition to lymphoid malignancies?

39

A. Nijmegen disease

B. Von Hippel–Lindau (VHL) syndrome

C. Familial malignant melanoma syndrome

D. Li–Fraumeni syndrome

Question 2.12 Type I cel death is also known as: A. Autophagy

B. Apoptosis

C. Necrosis

D. Autolysis

Question 2.13 Which of the fol owing proteins serve as are ligands for the death receptor pathway?

A. TNFα

B. Fas

C. Noxa

D. A and C

E. A and B

Question 2.14 Taxanes specifical y target this BH3-only Bcl-2 protein: A. Nbk/Bik

B. Bim

C. Puma

D. Bad

Question 2.15 RAF is inhibited by which of these therapeutic agents that induce apoptosis?

A. Sorafenib

B. Imatinib mesylate

C. Bortezomib

D. Taxanes

Question 2.16 Bcl-2 smal molecule inhibitors like ABT-737 induce apoptosis by: A. Binding to the BH3-binding pocket.

B. Inhibiting tyrosine kinase activity of Bcr/Abl restoring Bim function.

C. Stimulating Bim expression

D. Blocking proteasome degradation of Bim

Question 2.17 Angiogenesis inhibitors theoretical y induce apoptosis by which of the fol owing means?

40

A. Tyrosine kinase inhibition

B. Histone deacetylase inhibition

C. Inhibition of antiapoptotic proteins

D. Nutrient deprivation

Question 2.18 Type II programmed cel death, autophagy, is regulated by: A. mTOR in the PI3-kinase/AKT pathway

B. Bax/Bak

C. BH3-only proteins

D. APC/C

Question 2.19 Autophagy has a role in the fol owing: A. Recycling of normal cel ular components.

B. Protection against aging.

C. Cel lysis caused by surrounding inflammation.

D. A and B.

E. A and C.

Question 2.20 Select the property that is specific to apoptosis?

A. Rapid cel ular swel ing

B. Lysosome activation

C. Loss of plasma membrane integrity

D. Release of intracel ular components to the extracel ular compartment Question 2.21 The Warburg effect describes:

A. Exponential cel growth in response to an exogenous stimulant.

B. Inefficient energy production by most cancer cel s, resulting in rapid adenosine triphosphate (ATP) depletion and necrotic cel death.

C. Initiation of neoplasia requires two somatic mutations for initiation of sporadic neoplasms and hereditary neoplasms require a genetic plus a somatic mutation.

D. Sculpting of normal human tissues as a result of cel death.

Question 2.22 Bevacizumab is:

A. A monoclonal antibody to basic fibroblast growth factor (bFGF).

B. A monoclonal antibody to vascular endothelial growth factor (VEGF).

C. A monoclonal antibody to phospholipid lipid growth factor (PLGF).

D. A monoclonal antibody to epidermal growth factor receptor (EGFR).

Question 2.23 The first step in tumor angiogenesis is: A. A localized degradation of the surrounding basement membrane of a parental venule.

41

B. Paracrine signaling causing increased leakiness of a parental venule’s basement membrane.

C. An inflammatory response causing recruitment and activation of leukocytes that mediate angiogenesis

D. Release of endothelial cel (EC) progenitors from the bone marrow Question 2.24 Which of the fol owing functions is ascribed to pericytes?

A. Paracrine signaling

B. Mediation of resistance to antiangiogenic therapy

C. Enhances endothelial survival

D. Al of the above

Question 2.25 Tumor vasculature is characterized by?

A. Increased dilation

B. Increased red blood cel (RBC) flow

C. Increased tortuosity

D. A and B

E. A and C

Question 2.26 Functions ascribed to VEGF are?

A. Stimulation of endothelial cel division

B. Migration of endothelial cel s.

C. Enhancing endothelial cel survival.

D. A and B

E. A, B and C

Question 2.27 VEGF is inducible by many factors, of which the most important may be: A. H1F1α

B. TSP-1

C. pVHL

D. p53

Question 2.28 Which of the fol owing is thought to promote tumor angiogenesis?

A. TSP-1

B. IL-6, IL-8

C. DLL4

D. Vasohibin

Question 2.29 Metronomic low-dose chemotherapy describes: A. Continuous low-dose treatment with chemotherapeutics

42

B. Pulse dosing with low doses of chemotherapeutics C. Continuous low-dose treatment with intermittent pulse dosings of chemotherapeutics D. Treatment of refractory tumors with continuous low doses of chemotherapeutics in conjunction with metronidazole

Question 2.30 Which of the fol owing is/are potential toxicity(ies) of antiangiogenic agents?

A. Hypertension

B. Aplastic anemia

C. Arteriothrombotic event

D. A and B

E. A and C

Question 2.31 Which of the fol owing factors is/are associated with risk of metastasis?

A. Tumor grade

B. Depth of invasion beyond normal cel ular compartments C. Lymphovascular invasion

D. Al of the above

Question 2.32 The percentage of tumor cel s that can give rise to metastases is?

A. <0.01%

B. 1%

C. 20%

D. >80%

Question 2.33 Genes that can mediate tumorigenic functions and secondarily serve metastatic-speci c functions either in a general way or with particular organ selectivity is best known as:

A. Tumorigenic genes

B. Metastasis progression genes

C. Metastasis virulence genes

D. Protooncogenes

Question 2.34 Cel s that mediate the breakdown of the basement membrane al owing for tumor invasion are known as:

A. Carcinoma-associated fibroblasts

B. Pericyte-derived fibroblast

C. Tumor-associated macrophages (TAMs)

D. Dendritic cel s

Question 2.35 Cel ular loss of this molecule leads to decreased cel ular attachment and 43

enhanced tumor invasion/motility:

A. E-cadherin

B. β-Catenin

C. α-Tubulin

D. Ankyrin

Question 2.36 The fol owing are the selective pressures experienced by circulating tumor cel s (CTCs)

A. Shear stress

B. Nitric oxide

C. Nutrient deprivation

D. A, B, and C

Question 2.37 Which of the fol owing molecules are known to assist in the extravasation of CTCs?

A. Ezrin

B. VEGF

C. CXCL12

D. CXCR4

E. Al of the above

Question 2.38 Osteoblastic bone metastases are characteristic of which type of cancer?

A. Breast

B. Prostate

C. Lung

D. Renal cel

Question 2.39 Which of the fol owing cancers rarely metastasize to the liver?

A. Colon cancer

B. Breast cancer

C. Prostate cancer

D. Melanoma

Question 2.40 The stochastic model of tumor heterogeneity is best described as: A. Every cel has equal potential to initiate and sustain tumor growth, but most cel s do not proliferate extensively because of the low cumulative probability of permissive events.

B. Cancer stem cel s (CSCs) are biological y distinct from the bulk cel population, which does not possess tumor-initiating activity.

C. Tumors are heterogeneous secondary to random, acquired mutations.

44

D. Tumors are pressured into heterogeneity by variable pressures applied to the tumor.

Question 2.41 The hierarchy model of tumor heterogeneity is best described as: A. Every cel has equal potential to initiate and sustain tumor growth, but most cel s do not proliferate extensively because of the low cumulative probability of permissive events.

B. CSCs are biological y distinct from the bulk cel population, which does not possess tumor-initiating activity.

C. Tumors are heterogeneous secondary to random, acquired mutations.

D. Tumors are pressured into heterogeneity by variable pressures applied to the tumor.

Question 2.42 The drug vemurafenib (PLX4032) targets which gene in the MAPK/ERK

pathway?

A. RAS

B. BRAF

C. BIM

D. ERK

Question 2.43 Which of the fol owing agents targets tumor metabolic pathways?

A. Pemetrexed

B. 5 FU

C. Temsirolimus

D. Al of the above

45

Question 2.1 The answer is C.

Mitosis is divided into prophase, prometaphase, metaphase, anaphase, and telophase.

Most of the internal membranous components of the cel are dissembled and dispersed in prophase. Prometaphase prepares the cel for metaphase by forming bivalent attachments to the spindle driving them to the cel ular equator. Paired chromatids align along the spindle during metaphase, fol owed by anaphase where sister chromatids pul to opposite poles. During telophase, prophase is reversed. Mitosis is completed by daughter cel s separating during cytokinesis.

Question 2.2 The answer is B.

Cyclins are the required positive regulatory subunits of CDKs. B-type cyclins, along with CDK1, are responsible for getting cel s into and through mitosis. Cyclin B1 accumulates during S and G2 phase and then is degraded at the metaphase–anaphase transition.

Question 2.3 The answer is D

After phosphorylation of the T loop, there is an increase in CDK-cyclin contacts and changes in the binding site. Proteins from the INK4 (p15, p16, p18, and p19), Cip/Kip (p21Cip1, p27Kip1, and p57Kip2), and Rb (p107 and p130) families al act as inhibitors of CDKs. Function of CDKs is dependent on cel ular availability of cyclins for them to have enzymatic activity. Last, nuclear import/export regulation further regulates the activity of CDKs.

Question 2.4 The answer is B.

Accumulation of cyclins E and A via transcriptional induction and interaction with CDK2 al ows for entry into S phase from G1 and is regulated by proteins from the Cip/Kip family. Cyclin B-CDK1 similarly accumulates al owing for the transition into M

phase from G2. Entry into M phase is signaled by the dephosphorylation of T15 and Y15

resulting in the activation of CDK1. Activation of CDK1 and binding of CDC20 to APC/C is the trigger for which sister chromatids separate and move to opposite poles during anaphase.

Question 2.5 The answer is D.

Positive cel -cycle machinery is dismantled after the reduction of CDKs and cyclins.

Cel -cycle exit is also usual y associated with a transient increase in the number of CDK

inhibitors, such as those from the INK4, Cip/Kip, and Rb protein families. Cel s in quiescence also have a reduced rate of protein synthesis. Protein synthesis is largely dependent on growth factors and mitogens activating the cel through the mitogen-activated protein kinase/extracel ular signaling-regulated kinase pathway and the 46

phosphoinositide 3 (PI3) kinase/AKT pathway.

Question 2.6 The answer is D

TGF-β is a cytokine that binds to a class of transcription factors known as SMADs that translocate to the nucleus, where they complex with DNA-binding transcription factors and coactivators to transactivate specific genes. IFNs are another class of cytokines that have antiproliferative effects by means of upregulation of CDK inhibitors and downregulation of cyclins. INK family proteins are CDK inhibitors of which p15

specifical y inhibits CDK4 and CDK6 directly and cyclin E-CDK2 and cyclin A-CDK2

indirectly. The final outcome of antimitogenic signaling involves the upregulation of CDK inhibitors and downregulation of cyclins.

Question 2.7 The answer is A.

MicroRNAs regulate mRNA expression by degradation or inhibition of translation. Some of them target mRNA encoding cel -cycle regulatory proteins but none of them directly encode proteins that regulate cel cycle.

Question 2.8 The answer is B.

Al of these genes are involved in regulation of cel cycle. The NBS1 gene regulates checkpoints in cel cycles and also is involved in DNA repair. Mutation involving the NBS1 gene results in the Nijmegen breakage syndrome 1. Patients diagnosed with this syndrome have increased risk of developing non-Hodgkins lymphoma.

Question 2.9 The answer is C.

Secondary to the topology of telomeres and the requirements of DNA replication, each cel cycle causes progressive shortening of the telomeres. In most, if not al , somatic cel s, when sufficient telomere attrition has been reached, cel s enter into a chronic checkpoint response, which is the molecular basis of senescence. Germ line cel s forego this checkpoint by means of a special replicase, telomerase. For a somatic cel to undergo malignant transformation, the senescence barrier must be overcome al owing for unlimited proliferative capacity.

Question 2.10 The answer is D.

Tumor suppressor genes usual y encode negative regulators of growth and proliferation, thereby conferring protection to cel s against malignancy. Protooncogenes encode genes in which mutations may cause gain of function or an enhanced level of function leading to malignancy. Mutations of both tumor suppressor genes and protooncogenes may lead to uncontrol ed proliferation and malignancy.

Question 2.11 The answer is A.

47

Li–Fraumeni syndrome is caused by an inherited mutation in TP53, the gene encoding the checkpoint effector p53. Nijmegen disease is caused by mutation of the gene encoding Nbs1, which is required for the activation of Chk1 and Chk2 kinases. This disease is characterized by microcephaly, immunodeficiency, increased sensitivity to radiation, and a predisposition to lymphoid malignancies. VHL is caused by a mutation in the pVHL tumor suppressor gene causing development of sporadic hemangioblastomas and clear-cel renal carcinomas. Familial malignant melanoma syndrome is caused by mutation in CDKN4A, the gene encoding p16.

Question 2.12 The answer is B.

Apoptosis is a genetical y programmed means of rapid and efficient kil ing of unnecessary or damaged cel s. It is characterized by cel shrinkage, blebbing of the plasma membrane, chromatin condensation, and intranucleosomal DNA fragmentation without being fol owed by surrounding inflammation.

Question 2.13 The answer is E

The death receptor pathway is involved in the modulation of apoptosis. It involves the ligands TNFα, Fas, TRAIL, and their receptors. Noxa is a member of the BH3-only protein family and can induce apoptosis.

Question 2.14 The answer is B.

Taxanes specifical y induce apoptosis by stimulating Bim expression. Nbk/Bik stimulates apoptosis by inhibiting protein synthesis. Puma and Noxa mediate apoptosis by p53

activation. After growth factor withdrawal, Bad stimulates apoptosis.

Question 2.15 The answer is A.

Sorafenib directly inhibits RAF, thereby causing MAP kinase inhibition and restoring apoptotic function. Imatinib mesylate, by means of blocking the constitutively active tyrosine kinase activity of the Bcr/Abl fusion gene, restores Bim and Bad apoptotic function. Bortezomib is a proteasome inhibitor that blocks Bim degradation, knowing it to induce apoptosis. Taxanes induce apoptosis by stimulating Bim expression.

Question 2.16 The answer is A.

Bcl-2 inhibitors like ABT-737 binds to the BH3-binding pocket of Bcl-2, Bcl-xL, and Bcl-w, thereby blocking the antiapoptotic effect of Bcl-2. ABT-737 exhibits some activity against some human lymphomas and smal cel lung cancers in vitro. Inhibition of the tyrosine kinase activity of Bcr/Abl is accomplished through imatinib mesylate. Taxanes stimulate Bim expression, restoring apoptosis. Bortezomib blocks the proteasomal degradation of Bim.

Question 2.17 The answer is D.

48

Tumor cel s general y have a reduced metabolic capacity that is frequently coupled with high-energy demand sustaining rapid cel growth. One means for specifical y targeting tumor cel s is through therapeutic nutrient deprivation. This is the basis for the use of angiogenesis inhibitors.

Question 2.18 The answer is A.

Autophagy is regulated by mTOR in the PI3-kinase/AKT pathway that functions to link nutrient availability to cel ular metabolism. Defective autophagy has been implicated in carcinogenesis in certain human breast, ovarian, and prostate tumors. Type I programmed cel death, apoptosis, is regulated by Bax/Bak and BH3-only proteins.

APC/C is the anaphase promoting complex/cyclosome that regulates sister chromatid separation in mitosis.

Question 2.19 The answer is D.

Autophagy is involved in recycling normal cel ular constituents, damaged protein/organel e removal, innate immunity by removal of cel s infected by intracel ular pathogens, acquired immunity by promoting T-cel survival/proliferation, and protection against aging. Cel lysis secondary to surrounding inflammation or insult is a feature of necrosis.

Question 2.20 The answer is B.

Lysosome activation is a feature of apoptosis, as is cel shrinkage, blebbing of the plasma membrane, chromatin condensation, and intranucleosomal DNA fragmentation without being fol owed by surrounding inflammation. Necrosis is characterized by rapid swel ing of the cel , loss of plasma membrane integrity, and release of intracel ular components into the extracel ular compartment resulting in an acute inflammatory response.

Question 2.21 The answer is B.

The Warburg effect describes an observation where most cancer cel s produce energy by anaerobic glycolysis even when oxygen is plentiful. This is an inefficient way of producing energy that generates less ATPs per mole of glucose metabolized, which explains the high glucose requirement by tumors.

Question 2.22 The answer is B.

Bevacizumab is the first successful antiangiogenic agent that has shown activity in randomized phase III trials. It is a monoclonal antibody to VEGF. It has been shown to be effective in combination with chemotherapy for the treatment of metastatic colorectal cancer, breast cancer, renal cel carcinoma, and non–smal -cel lung cancer.

Question 2.23 The answer is A.

49

Tumor angiogenesis is first mediated by several proteolytic enzymes, such as matrix metal oproteinases, and urokinase plasminogen activator, causing a focal degradation of a venule’s basement membrane. This is likely a consequence of various proangiogenic growth factors secreted by the tumor-cel population or reactive stromal cel s.

Question 2.24 The answer is B.

The single layer of periendothelial smooth muscle cel s is formed by pericytes. These cel s modulate EC function and are critical for the development of a mature vessel network.

In addition to regulation of vessel diameter and permeability, they provide mechanical support and survival of ECs through paracrine signaling. Because of their ability to maintain EC survival, they have become an important target for antiangiogenic therapy and it is hypothesized that they may mediate resistance to this therapy.

Question 2.25 The answer is E.

The vasculature of solid tumors has several notable abnormalities. These vessels are classical y much dilated with little to no basement membrane and have excessive tortuosity. A decreased number of pericytes portrays a relative lack of support and excessive vascular leakiness. These features contribute to the highly heterogeneous and often sluggish flow through solid tumors and create areas of relative nutrient deprivation and hypoxia. The increased leak from these vessels also al ows for extravasation of high–molecular-weight plasma proteins, leading to areas of elevated interstitial fluid pressures.

Question 2.26 The answer is E.

VEGF promotes tumor angiogenesis is various ways, including stimulation of EC division, inducing EC locomotion/migration, enhancing EC survival by upregulating various inhibitors of apoptosis, and mobilizing endothelial progenitor cel s from the bone marrow to sites of angiogenesis. Further, VEGF is approximately 50,000 times more potent than histamine in increasing vascular permeability. VEGF is expressed in most if not al of human cancers, and increased levels carry a poor prognosis.

Question 2.27 The answer is A.

H1F1α is upregulated by hypoxia. H1F1α then, in turn, activates numerous other genes, of which VEGF may be the most important.

Question 2.28 The answer is B.

IL-6/8 is thought to be secondarily angiogenic. TSP-1, DLL4, and vasohibin are al shown to inhibit angiogenesis. Embryologic studies have shown that Notch/DLL4 is important in early angiogenesis; however, in the adult, it has been shown to be an inhibitor of tumor angiogenesis.

50

Question 2.29 The answer is A.

The effectiveness of antiangiogenic therapy is profoundly reversed during episodes of drug-free breaks. This is thought to be mediated by the rapid mobilization and homing of ECs to the drug-treated tumors. This has led to the concept of metronomic low-dose chemotherapy. By reducing or eliminating altogether drug-free periods with continuous low-dose chemotherapy, the rapid reversal of antiangiogenic therapy may be prevented.

Question 2.30 The answer is E.

Antiangiogenic therapy is not without side effects. Anti-VEGF therapy has been shown to lead to specific toxicities, such as hypertension, proteinuria, bowel perforation, hemorrhage, arteriothrombotic events, and others. Among these, aplastic anemia has not been documented.

Question 2.31 The answer is D.

Tumor grade, depth of invasion, and lymphovascular invasion al carry a higher risk of metastasis. Proper immune function would hinder the development of metastasis because CTCs would be targeted for destruction.

Question 2.32 The answer is A

By using radioactive nucleotides incorporated into tumor DNA, it has been shown that less than 0.01% of tumor cel s can give rise to metastases.

Question 2.33 The answer is B.

Metastasis progression genes promote tumor metastases among other functions.

Tumorigenic genes are genes that promote primary tumor growth. Metastasis virulence genes confer protection to tumor cel s in the distant environment but confer no protection to the primary tumor.

Question 2.34 The answer is C.

TAMs can comprise a large percentage of the bulk of a tumor mass. Through secretion of FGF, EGF receptor ligands, and PDGF, they can stimulate tumor cel growth and motility. Furthermore, by producing uPA, MMP7, and MMP9, TAMs help degrade basement membrane al owing tumor cel s to invade and metastasize.

Question 2.35 The answer is A.

Invasion starts with loss of cel ular adhesion. This is largely mediated by loss of E-cadherin, the prototypic protein of the cadherin family. Cadherins are transmembrane glycoproteins that mediate cel ular attachment. They anchor the cel through attachments to the actin cytoskeleton via another family of proteins cal ed the catenins.

51

Question 2.36 The answer is D.

CTCs experience multiple stressors in the circulation, leading to a short half-life. Of these, physical stressors such as shear forces or mechanical injury may limit CTC life span. Also, EC-mediated stressors such as nitric oxide may induce apoptosis in CTCs.

DARC, a Duffy blood group glycoprotein, interacts with KAI1 expressed on CTCs causing them to undergo senescence.

Question 2.37 The answer is E.

Ezrin links the cel membrane to the actin cytoskeleton and has been found to assist in extravasation of CTCs via activation of the MAPK pathway. VEGF has been shown to assist in CTC extravasation by causing disruptions in EC junctions and increased vascular permeability. CTC expression of CXCR4 interacts with CXCL12 expressed on certain organs, such as lung, liver, bone, and lymph nodes, al ows for selective extravasation.

Question 2.38 The answer is B.

Breast, lung, and kidney cancer typical y cause osteolytic lesions on metastasizing to bone. Unlike these lesions, prostate cancer causes osteoblastic lesions on metastases to bone. In contrast with osteolytic metastasis, osteoblastic lesions result from the preferential stimulation of osteoblasts or the inhibition of osteoclasts. This is mediated through many different molecules, including bone morphogenetic proteins such as WNT, TGF-β, IGF, PDGF, FGF, and VEGF.

Question 2.39 The answer is C.

Because of the microenvironment the liver provides and the dual blood supply (from the portal vein and hepatic artery), the liver is a common site of metastasis. Colon cancer general y seeds the liver via the portal system, whereas breast, lung, and melanoma approach the liver via the systemic circulation through the hepatic artery.

Question 2.40 The answer is A.

In the stochastic model of tumor heterogeneity, every cel within the tumor has equal potential but low probability of initiating tumor growth.

Question 2.41 The answer is B.

The hierarchy model of tumor heterogeneity hypothesizes the existence of functional y distinct classes of cel s within the tumor, and only those with unique self-renewal ability produce new tumor growth.

Question 2.42 The answer is B.

PLX4032 is an oral y available inhibitor of the mutated BRAF gene. It has shown activity 52

in patients with malignant melanoma that carry the BRAF V600E mutation. About 60%

of al patients with melanomas have the V600E BRAF mutation.

Question 2.43 The answer is D.

Pemetrexed is a folate antimetabolite that targets enzymes involved in purine and pyrimidine synthesis. 5-Fluorouracil is an antimetabolite that targets thymidylate synthase. Temsirolimus is mammalian target of rapamycin (mTOR) inhibitor that targets the PI3-kinase pathway. The PI3-kinase pathway is involved in regulation of glucose metabolism.

Corresponding Chapters in Cancer: Principles & Practice of Oncology, Tenth Edition: 1 (The Cancer Genome), 2 (Hal marks of Cancer: An Organizing Principle for Cancer Medicine), and 3 (Molecular Methods in Cancer).

53





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 3.1 Which of the fol owing is CORRECT about cohort studies?

A. Cohort studies only fol ow subjects prospectively

B. Subjects are free of disease at the time of study entry C. The incidence of the disease in the exposed group is compared to members of the general population who have been matched for selected characteristics D. Cohort studies are useful for estimating the prevalence of a disease Question 3.2 Potential weaknesses in case-control studies include: A. Selection biases related to choosing and enrol ing subjects B. Recal biases related to previous exposures

C. Cases may not be representative of disease

D. Al of the above

Question 3.3 Confounding factors and interaction (also known as e ect modi cation) are common in epidemiologic studies. Which of the fol owing statements is TRUE in regards to confounding and interaction?

A. Confounder is not associated with exposure

B. Confounder is associated with the disease and dependent on the exposure C. Confounder may be an intermediate step between exposure and disease D. Confounder is not a true relationship and interaction is true relationship between an exposure and disease

Question 3.4 Statistical methods are required to evaluate the role of chance, and a usual way to estimate chance is to calculate the upper and lower limits of a 95% con dence interval around a point estimate for relative risk. Which of the fol owing are TRUE related to the use and interpretation of confidence intervals? (Select two correct responses) A. If the confidence interval does not include 1, the observed association is statistical y significant. If the confidence includes 1, then the observed relationship is not statistical y significant

B. The width of the confidence interval is directly related to the number of participates in a study or sample size

54

C. The choice of 95% confidence interval is commonly used, but the upper and lower limits of the interval (e.g., 90% or 99%) can certainly be calculated and interpreted accordingly

D. Al of the above

Question 3.5 Dr. Bush wishes to study the relationship between diet soda consumption and the development of gastric cancer. He selects the cases of gastric cancer detected over the last 15 years, and then to obtain his controls he selects for patients who referred to the gastroenterology clinic. This is as an example of:

A. Information bias

B. Selection bias

C. Misclassification bias

D. Al of the above

Question 3.6 For which of the fol owing analytical studies is the group the unit of analysis?

A. Ecologic

B. Cross-sectional

C. Cohort

D. Case-control

Question 3.7 Genome-wide association studies (GWAS) have revealed an association between CHRNA3 and CHRNA5, and lung cancer A. True

B. False

Question 3.8 Which of the fol owing cancer is increasing in incidence?

A. Lung cancer among women

B. Colorectal cancer

C. Breast cancer

D. Melanoma

Question 3.9 The discontinuation of the routine use hormone replacement therapy fol owing the publication of the Women’s Health Initiative study is thought to contribute to the declining rate of which of these cancers

A. Breast cancer

B. Lung cancer

C. Colorectal cancer

D. Stomach cancer

Question 3.10 Which of the fol owing is TRUE about the Surveil ance, Epidemiology, and End Results (SEER) Program?

55

A. It covers approximately 10% of the US population B. Staging, treatment and outcome assessment is highly standardized C. It provides the most precise measure of long-term trends in cancer incidence D. Al of the above

56

Question 3.1 The answer is B.

Patients in cohort studies are free of the specific disease and then are fol owed for a certain period of time, often years. A cohort study can prospective or retrospective based on past exposure (e.g., occupational cohort based on employment records). Cohort studies are useful for determining risk of disease while cross-sectional studies are useful for determining the prevalence of disease. In a cohort study subjects in the exposed group are compared to subjects in the unexposed group rather than subjects in the general population which is typical for a case-control study.

Question 3.2 The answer is D.

Case-control studies provide a method of estimating the odds ratio or relative risk, and more efficient in terms of time and number of subjects than cohort studies. The need for fol ow-up is avoided as wel . However, they have several deficiencies that need to be recognized. Case-control studies are susceptible to biases. Specific biases include recal (the status of the subject, case or control, may influence how they recal and report previous exposures), selection (individuals in the study, as cases or controls, are different from the target population), and misclassification (occurs if the ascertainment of disease by observer is influenced by the exposure status; for example a physician may examine the subject if he or she knows the subject has been exposed and likely at a higher risk, and the exposed subject visits the doctor more often if he or she thinks they are at higher risk related to an exposure)

Question 3.3 The answer is D.

Confounding factors and interaction (also known as effect modification) are confusing and both may be present in the same study. In order to be confounding factor the factor must fulfil three criteria: (1) be associated with exposure; (2) be associated with disease independent of exposure; and (3) not be an intermediate step between exposure and disease (i.e., not be in casual pathway). Interaction is another variable that impacts risk of disease (i.e., may be synergistic with other risk factor or protective factor).

Confounding is considered a nuisance which the investigator seeks to remove through epidemiologic methods, and interaction is a more detailed relationship between an exposure and disease.

Question 3.4 The answers is D.

Confidence intervals are a method of evaluating chance, and a 95% confidence interval means that the confidence interval wil include the correct value of the measure 95% of the time. The width of the confidence interval is directly related to the sample size, and with increasing sample size the width of the confidence interval decreases. If the confidence interval includes 1 it is not considered statistical y 57

significant and if does not include 1 then it is considered statistical y significant. While the 95% confidence interval is the most frequently used confidence interval other confidence intervals can be used.

Question 3.5 The answer is B.

The patient population that has been referred to the gastroenterology clinic may be significantly different than the general population in terms of the incidence of gastric cancer and/or soda consumption.

Question 3.6 The answer is A.

Ecologic studies uses groups of people as the unit and are performed when measures of exposure and/or outcome are available. An example would be the relationship between dietary fat intake and the incidence of a type of cancer by country. The other types of studies use the individual as the unit of study.

Question 3.7 The answer is True.

These genes encode neuronal nicotinic acetylcholine receptor subunits, and different genotypes of these subunits appear to influence an individual’s addiction to tobacco which leads to different smoking exposure and lung cancer risk.

Question 3.8 The answer is D.

The incidence of lung cancer among women increased throughout the 1990’s, stabilized from 2000 to 2005, and declined in the period of 2005 to 2010. This pattern reflects the trends of cigarette use among women. The rate of colorectal cancer (CRC) is declining, possibility related to down decreasing rates of tobacco use, increased use of endoscopic removal of adenoma preventing the development of CRC and intermittent used of nonsteroidal anti-inflammatory agents. The incidence of breast cancer is declining since 2000, and this may be due to a reduction in the use of hormone replacement therapy. The rate of melanoma is increasing most likely due to the effects of previous sun exposure and increased awareness and surveil ance of pigmented skin lesions.

Question 3.9 The answer is A.

The decline in the use of hormone replacement therapy (HRT) is thought to be a contributing factor in the incidence of breast cancer. HRT may reduce the rate of CRC

and the discontinuation of the widespread use of HRT may adversely affect CRC trends.

The rate of gastric cancer is decreasing due to historic improvements in nutrition and the declining prevalence of chronic Helicobacter pylori infection and the declining rates in lung cancer are related to the decreasing prevalence of cigarette use.

Question 3.10 The answer is D.

58

The SEER program started in 1973 col ects highly standardized assessment of staging, treatment and outcomes, and includes 10% of the US population. This program provides the most precise information about cancer incidence trends. It does not capture behavioral risks that affect cancer risk which is captured by the Health Interview Survey and in the annual reports by the Behavioral Risk Factor Surveil ance System.

Corresponding chapters in Cancer: Principles & Practice of Oncology, Tenth edition: 11

(Epidemiologic Methods) and 12 (Trends in United States Cancer Mortality).

59





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 4.1 Which of the fol owing statements regarding the relationship between cigarette smoking and lung cancer are CORRECT? (Select two correct responses) A. The duration of smoking is a strong risk factor for developing lung cancer in smokers.

B. Smoking is only associated with a risk of developing squamous cel lung cancer and not adenocarcinoma of the lung.

C. The risk of developing lung cancer in ex-smokers drops to the level of never smokers 2

years after smoking cessation.

D. The risk of developing lung cancer increases with the number of cigarettes smoked.

Question 4.2 Which of the fol owing statements regarding the role of speci c tobacco products and tobacco related carcinogens in the development of cancer are CORRECT?

A. Polycyclic aromatic hydrocarbons in cigarette smoke are major causative factors for development of lung cancer.

B. Nicotine is an important carcinogen in the causation of laryngeal cancer.

C. Cigarettes with lower tar yields are associated with reduced risk of diseases from cigarette smoking.

D. Smokeless tobacco products don’t contain high amounts of carcinogens.

Question 4.3 Which of the fol owing is TRUE regarding cigarette smoking causing cancer?

A. DNA adducts caused by carcinogens in cigarette smoke are responsible for mutations that can eventual y cause cancer.

B. Nicotine can reduce apoptosis and promote angiogenesis.

C. Compounds that promote inflammation may play a role in cancer development D. Al of the above.

Question 4.4 The HPV vaccine Gardasil

A. Is a quadrivalent vaccine containing virus-like particles (VLPs) from four different types of HPV.

B. Protects from al HPV-causing cervical cancer.

C. Is recommended only for sexual y active women.

D. Is recommended for treating cervical cancer.

60

Question 4.5 The role of EBV in cancer is characterized by the fol owing: A. EBV DNA is present in the tumor of al Burkitt lymphoma patients.

B. EBV is universal y present in al CNS lymphomas in AIDS patients.

C. Nasopharyngeal carcinoma is the only nonlymphoid malignancy associated with EBV.

D. Involvement in al Hodgkin lymphoma.

Question 4.6 Association of Hepatitis C and Hepatitis B viruses with hepatocel ular carcinoma (HCC) is characterized by

A. Coinfection with Hepatitis D is necessary for development of HCC in patients infected with Hepatitis B.

B. Antiviral therapy for Hepatitis C does not reduce the risk of HCC.

C. Surveil ance for HCC, with ultrasound, is recommended in Hepatitis C infected individuals with cirrhosis.

D. In the United States, more than 60% of HCC cases are associated with Hepatitis B.

Question 4.7 Role of inflammation in carcinogenesis has the fol owing feature: A. Inflammation is involved in several steps of carcinogenesis but not in malignant transformation.

B. Inflammation and angiogenesis are two independent steps in cancer formation and progression.

C. Inflammation can cause cancer cel proliferation and cancer cel invasion.

D. None of the above.

Question 4.8 Data on markers of inflammation and prognosis of cancer patients shows A. Glasgow Prognostic Score (GPS) is based on absolute white cel count, neutrophil to lymphocyte ratio, and platelet count.

B. Glasgow Prognostic Score predicts for higher risk of death in prostate cancer patients.

C. In a study of renal cancer patients, inflammatory markers did not correlate with overal survival.

D. Elevated C reactive protein levels are associated with higher disease free survival in breast cancer patients.

Question 4.9 Carcinogenic effects of chemicals are characterized by A. Most chemical carcinogens undergo metabolic activation by enzymes such as cytochrome P450s.

B. Direct DNA damage leading to mutations or chromosomal alterations.

C. Induction of epigenetic changes such as altered DNA methylation.

D. Al the above.

Question 4.10 Chemical carcinogenesis is characterized by 61

A. Individual susceptibility that varies based on genetic polymorphisms.

B. Biomarkers are available to assess cancer risk of an individual from chemical carcinogenesis.

C. Direct correlation with the chemical’s ability to cause DNA damage.

D. None of the above.

Question 4.11 Examples of chemical carcinogens include A. Benzene has been linked to myelodysplastic syndrome and acute myeloid leukemia.

B. Heterocyclic amines are associated with breast and colon cancer.

C. Aryl aromatic amines found in tobacco smoke and in dyes have been associated with bladder cancer.

D. Al of the above.

Question 4.12 Cel ular response to correct and prevent damage from ionizing radiation (IR) is characterized by

A. DNA damage induced by IR can be repaired by mechanisms such as homologous recombination repair pathway and nonhomologous end joining pathway.

B. If the DNA is damaged by IR, there are no mechanisms in place to prevent cel s with DNA damage from entering into critical phases of cel cycle.

C. Al cel s in the body are equal y sensitive to radiation-induced cel kil ing.

D. IR-induces cel death through apoptosis alone.

Question 4.13 Risk of cancer from ionizing radiation (IR) is characterized by A. Most cancers in areas of atomic bomb explosion occurred within 20 years of the exposure.

B. Older individuals are at the highest risk of developing cancer in areas of massive IR

exposure.

C. The largest source of IR exposure to the population in the US is exposure from radiology studies.

D. The most sensitive tissues for development of cancer from IR are thyroid, lung, breast, and bone marrow.

Question 4.14 The fol owing is TRUE about ultraviolet (UV) light: A. UVA light induces reactive oxygen species which in turn causes DNA damage.

B. Risk of melanoma appears to be linked to cumulative lifetime exposure to UV light.

C. UV light initiates carcinogenesis only by inducing DNA lesions.

D. Melanoma occurs only in sun exposed areas of the skin.

Question 4.15 Alcohol consumption and risk of cancer (Select two correct responses) A. Alcohol is not a carcinogen since it only induces cancer indirectly by causing 62

inflammation.

B. Types of alcoholic drinks can influence the risk of cancer.

C. Mechanisms of inducing cancers include direct damage to cel s, modulation of DNA methylation, and causing DNA adducts.

D. Alcohol can increase the risk of breast cancer.

Question 4.16 Which statement is CORRECT concerning dietary in uence on risk of cancer

A. Dietary fat intake is an important contributor to breast cancer incidence.

B. Cancer risk is more related to the types of foods consumed than the total caloric intake.

C. Data supports a link between consumption of fat-containing animal products and incidence of prostate cancer.

D. A higher intake of vegetable fat was associated with greater risk of breast cancer in premenopausal women.

Question 4.17 Fruit and vegetable consumption and risk of cancer are characterized by A. There is an inverse relationship between consumption of fruits and vegetables and risk of colon cancer.

B. An inverse relationship between intake of fruits and vegetables and risk of estrogen receptor negative breast cancer has been shown by the Nurse’s Health Study.

C. Consumption of fruit and vegetables reduces total cancer incidence.

D. None of the above.

Question 4.18 Data on the influence of specific nutrients and risk of cancer shows A. Individuals with higher 25 (OH) D levels have a lower risk of colorectal cancer.

B. Higher intake of beta carotene reduces the risk of lung cancer.

C. In the Selenium and Vitamin E Cancer Prevention Trial (SELECT) trial selenium was found to protect from development of prostate cancer.

D. High intake of calcium protects development of prostate cancer.

Question 4.19 Obesity and physical activity as risk factors for breast cancer is characterized by

A. Low level of physical activity is a risk factor for breast cancer in postmenopausal women but not premenopausal women.

B. Obesity is associated with reduced risk of breast cancer in postmenopausal women.

C. Obesity is associated with reduced risk of breast cancer in premenopausal women.

D. None of the above.

Question 4.20 Obesity and physical activity are associated with fol owing cancers: 63

A. Obesity but not low physical activity is associated with risk of colon cancer.

B. Obesity is not a risk factor for endometrial cancer.

C. Higher lifetime physical activity is associated with lower risk for pancreatic cancer.

D. Obesity lowers the risk of gal bladder cancer.

64

Question 4.1 The answers are A and D.

A common index of cancer risk is pack-years, or the number of packs of cigarettes smoked per day multiplied by the number of years smoked in the lifetime. In general, the higher the number of pack-years, the greater the cancer risk. Risk for lung cancer declines with smoking cessation and the longer a former smoker remains off of cigarettes the more the risk declines. However, excepting those smokers who quit with relatively few pack-years accumulated (typical y before age 40), cancer risk rarely approaches that of a never smoker. Smoking increases the risk of developing al histologic types of lung cancer including adenocarcinoma, squamous cel carcinoma, large cel carcinoma, and smal cel carcinoma.

Question 4.2 The answer is A.

Cigarette smoke consists of many carcinogens. Data from carcinogenicity studies, product analyses, and biochemical and molecular biologic investigations support a significant role for certain carcinogens in specific types of tobacco-induced cancers. In this regard, evidence suggests a significant role for polycyclic aromatic hydrocarbons and N-nitrosamines as causative factors in lung cancer. Nicotine itself is not known to initiate cancer formation, but recent evidence suggests that nicotine through nicotinic receptors may promote cel ular proliferation. After tar yields from cigarettes were recognized as an important contributor to smoking caused diseases, many manufactures reduced the tar yield of cigarettes. However, these reductions in tar yields have not led to changes in disease risk from cigarette smoking. Smokeless tobacco contains substantial level of carcinogens, most prominently N-nitrosamines.

Question 4.3 The answer is D.

Many cigarette smoke carcinogens are not active and require metabolic activation to transform them into active carcinogens. Cytochrome P450 enzymes convert these compounds into electrophilic entities that can covalently bind to DNA-forming DNA adducts. The cigarette smoke carcinogens can undergo detoxification by glutathione-S-transferases and uridine diphosphate-glucuronosyltransferases. Therefore, cancer susceptibility may be determined by the balance achieved between activation of the carcinogens in cigarette smoke and their detoxification. In addition, polymorphisms in genes encoding these enzymes may influence an individual’s risk of cancer from these carcinogens. Cel ular repair systems can remove the DNA adducts formed by smoke carcinogens and repair the DNA, but they are not involved in metabolic activation of carcinogens in cigarette smoke. Nucleotide excision repair enzymes are a component of these repair systems. Nicotine, although not a carcinogen, is known to reduce apoptosis and increase angiogenesis and thus can promote cancer growth. Compounds in cigarette smoke that are toxic to the cilia, that can cause inflammation and that have 65

oxidizing properties can influence likelihood of development of cancer.

Question 4.4 The answer is A.

Gardasil vaccine for HPV consists of VLPs (virus like particles) from HPV-16, HPV-18, HPV-6, and HPV-11. These VLPs present the epitopes that are necessary for the development of a high titer neutralizing antisera. HPV-16 and HPV-18 are associated with approximately 70% of cervical cancers and HPV-6 and HPV-11 are associated with 90% of al genital warts. There are HPV types other than HPV-16 and HPV-18 that can cause cervical cancer and therefore vaccinated individuals at risk should continue to receive cervical cancer screening. In addition, the VLPs that are in the vaccine may not be expressed in latently infected keratinocyte stem cel residing on the epithelial basement membrane and therefore may not eradicate infections existing at the time of vaccination. The vaccine does not treat cervical cancer. The current recommendations of the US Centers for Disease Control and Prevention are that both boys and girls should be vaccinated.

Question 4.5 The answer is B.

Although nearly al cases of endemic Burkitt lymphoma contain EBV DNA in the tumor, only about 20% of sporadic cases arising in immunocompetent individuals contain EBV.

EBV is universal y present in al CNS lymphomas in AIDS patients and therefore a PCR

test for EBV together with radiologic findings in these patients can obviate the need for a biopsy. EBV is associated with nasopharyngeal carcinoma and a smal percentage (5%

to 15%) of gastric cancers. EBV is associated with about 50% of Hodgkin lymphomas.

Question 4.6 The answer is C.

Hepatitis D virus (HDV) infection occurs only in individuals infected with HBV. HDV

infection results in more severe complications than infection with HBV alone, with a higher likelihood and more rapid progression to cirrhosis and HCC. However, coinfection with HDV is not necessary for HCC to occur in patients infected with Hepatitis B. A meta-analysis of eight randomized trials has shown that antiviral therapy for Hepatitis C

virus reduces the risk of HCC by 50%. The American Association for the Study of Liver Diseases, as wel as the European and Asian Pacific Associations for the Study of the Liver, endorse surveil ance in HCV-infected individuals with cirrhosis using ultrasound every 6 months. Viral eradication does not ful y eliminate the risk of HCC, and thus, continued surveil ance is stil recommended in cirrhotic patients. In the United States, more than 60% of HCC are associated with Hepatitis C infection.

Question 4.7 The answer is C.

Transformation is the process by which the cel ular and molecular makeup of a cel is altered as it becomes malignant. Numerous factors are involved in the process of cel transformation, including inflammation. Angiogenesis is tightly linked to chronic 66

inflammation and cancer. Angiogenesis is one of the molecular events that bridge the gap between inflammation and cancer. Inflammation can cause several aspects of carcinogenesis including cel ular proliferation and cancer cel invasion.

Question 4.8 The answer is B.

Glasgow prognostic score (GPS) combines plasma C reactive protein and albumin.

Prostate cancer patients with elevated GPS had a higher risk of death overal as wel as high grade disease. In a study of 416 renal cel cancer patients, inflammatory markers such as elevated neutrophil count, elevated platelet count and high neutrophil to lymphocyte ratio correlated with shorter overal survival. Elevated C-reactive protein levels correlate with reduced disease free survival in breast cancer patients.

Question 4.9 The answer is D.

Most chemical carcinogens first undergo metabolic activation by cytochrome P450s or other metabolic pathways so that they react with DNA and/or alter epigenetic mechanisms. This activation process generates reactive carcinogenic intermediates that can bind to DNA and cause mutations and other alterations. Chemical carcinogens can cause both DNA damage resulting in mutations or chromosomal alteration and epigenetic changes. Both these changes can contribute to carcinogenesis.

Question 4.10 The answer is A.

Genetic polymorphisms may modify an individual’s susceptibility to the carcinogenic effects of chemicals. No single biomarker has been considered to be sufficiently validated for use as a cancer risk marker in an individual as it relates to risk from chemical carcinogenesis. The carcinogenic effect of chemicals is not only related to its ability to cause DNA damage but is a composite of the net result of carcinogen exposure, activation, lack of detoxification, lack of effective DNA repair, and lack of programmed cel death.

Question 4.11 The answer is D.

Epidemiologic and experimental studies have linked benzene to hematologic toxicity, including aplastic anemia, myelodysplastic syndrome, and acute myeloid leukemia.

Heterocyclic amines are formed from the overheating of food with creatine, such as meat, chicken, and fish. Heterocyclic amines, estimated based on consumption of wel -

done meat, have been associated with breast and colon cancer, presumably through metabolic activation mechanisms and DNA damage. Aryl aromatic amines have been implicated in bladder carcinogenesis, especial y in occupational y exposed cohorts (e.g., dye workers) and tobacco smokers.

Question 4.12 The answer is A.

67

Both homologous recombination and nonhomologous end joining pathways can repair damage from IR. To prevent cel s with damaged DNA from entering into these critical stages of the cel cycle, cel s can activate cel -cycle checkpoints. The major sensor of radiation-induced damage in cel s is the ataxia-telangiectasia mutated (ATM) kinase, which, fol owing activation, can phosphorylate more than 700 proteins in cel s. Two ATM substrates, p53 and Chk2, are critical for the activation of cel cycle arrests at multiple sites in the cel cycle. Terminal y differentiated and stationary cel s, such as kidney, lung, brain, muscle, and liver cel s, are general y more resistant to radiation-induced kil ing than are cel s with a high turnover rate, such as different epithelial cel s, spermatogonia, and hair fol icles. However, the spleen and thymus, which consist of mostly nondividing cel s, are among the most radiosensitive tissues, implying that the rate of cel proliferation is not the sole determiner of the radiation sensitivity of a tissue.

IR can induce cel death in tissues by many different mechanisms. Apoptosis can occur rapidly in a p53-dependent manner or later in a p53-independent manner. Cel death induced by IR may in some cases be associated with autophagy. Final y, tissue can undergo necrotic cel death fol owing exposure to IR.

Question 4.13 The answer is D.

Twenty years after the atomic bomb explosions in Japan during World War II, significant increases in the incidence of thyroid cancer and leukemia were observed. However, it took almost 50 years before solid tumors appeared in the population as a result of radiation exposure from the atomic bombs. Young children were the most vulnerable to radiation exposure, with much higher rates of thyroid cancer in younger children. The largest source of radiation exposure to the US population is radon, which is a natural radioactive gas formed as a decay product of radium in the decay chain of uranium.

The most sensitive tissues for the development of secondary cancer have been found to be bone marrow (leukemia), the thyroid, breast, and lung.

Question 4.14 The answer is A.

UVA light can induce reactive oxygen species which in turn can form single strand breaks and base lesions in the DNA of exposed cel s. The risk of nonmelanoma skin cancers relates to cumulative lifetime exposure to UV light. However, the risk of melanoma is related to high sunlight exposure during childhood. UV light is a potent carcinogen since it not only induces DNA lesions but also suppresses the immune system. Melanoma can develop in both sun exposed and shielded areas of the skin.

Question 4.15 The answers are C and D.

Although alcohol can cause liver cancer by causing alcoholic hepatitis and cirrhosis, alcohol is also a carcinogen and can cause direct damage to cel s, modulation of DNA methylation, and acetaldehyde, the main metabolite of alcohol can form DNA adducts.

For most cancer sites, no important difference in associations was found with the type of 68

alcoholic beverage, suggesting a critical role of ethanol in carcinogenesis. A smal but significant risk for breast cancer has been found even with one drink per day.

Question 4.16 The answer is C.

Although evidence suggests that a high intake of animal fat early in adult life may increase the risk of premenopausal breast cancer, this is not likely to be due to fat per se because vegetable-fat intake was not related to risk. The most important impact of diet on the risk of cancer is mediated through body weight. Thus, caloric intake is more important than specific food types with regards to cancer risk. At present, the available evidence most strongly suggests an association between animal-fat consumption and risk of prostate cancer, particularly the aggressive form of this disease.

Question 4.17 The answer is B.

The results from the largest studies, the Nurses’ Health Study and the Health Professionals’ Fol ow-Up Study, suggested no important association between the consumption of fruits and vegetables and the incidence of cancers of the colon or rectum during 1,743,645 person-years of fol ow-up. In a recent analysis within the Nurses’ Health Study, an inverse association was seen between vegetable intake and the risk of estrogen receptor–negative breast cancer. The comprehensive report of the World Cancer Research Fund and the American Institute for Cancer Research, published in 2007 and titled Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective, reached the consensus based on the available evidence: “findings from cohort studies conducted since the mid-1990s have made the overal evidence, that vegetables or fruits protect against cancers, somewhat less impressive. In no case now is the evidence of protection judged to be convincing”.

Question 4.18 The answer is A.

A meta-analysis, including five nested case-control studies with prediagnostic serum, suggested a reduction of colorectal cancer risk by about half among individuals with serum 25 (OH) D levels of more than 82 nmol/L compared to individuals with less than 30 nmol/L. A subsequent meta-analysis including eight studies confirmed these associations. In a detailed analysis of prospective studies, no association was seen between the intake of beta carotene and the risk of lung cancer. In a recent meta-analysis, plasma/serum selenium was also inversely correlated with prostate cancer. In the SELECT, no protective effect of selenium was found for prostate cancer. However, the trial was terminated prematurely after 4 years, which is a short period in which to expect a reduction in cancer. In multiple studies, a high intake of calcium or dairy products has been associated with an increased risk of prostate cancer.

Question 4.19 The answer is C.

Low level of physical activity is an established breast cancer risk factor among 69

postmenopausal women and, to a lesser extent, premenopausal women. Obesity appears to have a paradoxical relationship with breast cancer risk in that it is associated with an elevated risk in postmenopausal women but may offer some protection for breast cancer in premenopausal women.

Question 4.20 The answer is C.

Both low physical activity and obesity are associated with risk of colon cancer.

Epidemiologic studies have established a strong association between obesity and endometrial cancer risk. A meta-analysis of 28 studies of pancreatic cancer showed that higher total lifetime physical activity and occupational activity were associated with a lower risk. Obesity was associated with an increased risk of gal bladder cancer.

Corresponding chapters in Cancer: Principles & Practice of Oncology, Tenth Edition: 4

(Tobacco), 5 (Oncogenic Viruses), 6 (In ammation), 7 (Chemical Factors), 8 (Physical Factors), 9 (Dietary Factors), and 10 (Obesity and Physical Activity).

70





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 5.1 Studies of screening for cancer are subject to several types of bias. If screening detects a cancer earlier (before it becomes symptomatic), but treatment has no e ect on the course of the disease, then the subject wil seem to live longer than if he/she had presented symptomatical y (i.e., the cancer is known for a longer period of time, but the time of death is not altered). This type of bias is known as A. Lead-time bias.

B. Length bias.

C. Selection bias.

D. Overdiagnosis bias.

Question 5.2 In planning a prostate cancer screening program you are concerned that a prostate speci c antigen (PSA) threshold of 4 ng/mL has a sensitivity of just 24% for the diagnosis of prostate cancer. You can anticipate that lowering the PSA threshold to 2.5

ng/mL threshold wil

A. Decrease the positive predictive value (PPV).

B. Decrease the rate of true-positive results.

C. Decrease the sensitivity.

D. Increase the positive predictive value (PPV).

E. Increase the specificity.

Question 5.3 In the PLCO Cancer Screening Trial men were randomized to receive annual PSA testing for 6 years or usual care. At the conclusion of the 13 year fol ow-up period it was found that there was a high rate of PSA testing among men randomized to the control arm. This “drop-in” had what effect on the results?

A. Increased the positive predictive value (PPV) of the PSA test.

B. Increased the relative risk reduction (RRR) of the screening arm as compared with the control arm.

C. Reduced the sensitivity of the PSA test.

D. Reduced the statistical power of the study to detect differences in outcome between the two arms.

71

Question 5.4 The U.S. Preventive Services Task Force (USPSTF) A. Is composed of government employees with limited clinical experience.

B. Formulates recommendations based on expert opinion more than on evidence based medicine.

C. Weighs benefits and harms of screening tests in the context of cost effectiveness.

D. Weighs benefits and harms of screening tests without considering cost effectiveness.

Question 5.5 A new screening test for ovarian cancer was developed. It was tested in a tertiary care academic medical center in a group of women with breast cancer (BRCA) mutations and was found to have a sensitivity of 70%, speci city of 90%, and positive predictive value (PPV) of 10%. If a woman in the study population is found to have a positive (abnormal) test result, how would you interpret it?

A. There is a 30% chance that this represents a false-positive result.

B. There is a 10% chance that this represents a false-positive result.

C. There is a 9 in 10 chance that this represents a false-positive result.

D. You can be 90% sure that your patient has the disease.

Question 5.6 If the use of this test (from Question 5.5) is expanded to the general population, it is expected that

A. The test sensitivity wil be lower.

B. The test specificity wil be lower.

C. The PPV wil be lower.

D. The test specificity wil be higher.

Question 5.7 In analyzing a randomized control ed trial of a screening test which is the best indicator of effectiveness?

A. Absolute reduction in mortality

B. Evidence of stage shift

C. Increased 5-year survival

D. Relative reduction in mortality

Question 5.8 Which statement regarding screening for breast cancer is TRUE?

A. The monthly breast self-examination (BSE) is a crucial component of breast cancer screening programs.

B. The BSE has been shown to be ineffective for breast cancer screening.

C. Increasing the interval of mammographic screening from 1 year to 2 years results in a halving of the mortality benefit.

D. Mammography has a higher positive predictive value (PPV) for women aged 40 to 49

as compared with women aged 50 to 59.

72

Question 5.9 The American Cancer Society (ACS) recommends annual screening mammography and MRI starting at age 30 for women at high risk for breast cancer including which of the fol owing? (Select two correct responses) A. Women with a history of fibrocystic breast disease

B. Women with a history of mantle radiation for Hodgkin disease C. Women with a known BRCA mutation

D. Women with increased mammographic breast density

Question 5.10 A 19-year-old woman presents for a health maintenance visit. She has been sexual y active for 4 years and has had one episode of chlamydia. What is the recommended approach to cervical cancer screening for her?

A. Begin annual screening with cervical cytology (Pap smear) plus HPV cotesting.

B. Begin annual screening with cervical cytology alone.

C. No cervical cancer screening at this time; start screening at age 21 with cervical cytology alone.

D. No cervical cancer screening at this time; start screening at age 21 with cervical cytology and HPV cotesting every 3 years.

Question 5.11 A 40-year-old woman had her rst screening mammogram and was noted to have increased mammographic breast density. Current evidence suggests that the best recommendation for future breast cancer screening would be A. Annual mammography alone.

B. Annual mammography + annual MRI.

C. Annual mammography + monthly breast self-examination (BSE).

D. Annual mammography + monthly breast self-examination (BSE) + annual MRI.

Question 5.12 The United States Preventive Services Task Force (USPSTF), the American Col ege of Obstetricians and Gynecologists (ACOG), and the American Col ege of Physicians (ACP) agree on which one of the fol owing recommendations for ovarian cancer screening in women ages 20 to 65 years without oophorectomy?

A. Annual pelvic examination for al women

B. Annual serum CA-125 measurement

C. No population-based screening is recommended

D. Transvaginal ultrasound every 5 years

E. Two-stage screening: annual CA-125, then transvaginal ultrasound if elevated or rising CA-125

Question 5.13 A 44-year-old woman had a total hysterectomy for broids and menorrhagia. What is the recommended approach to cervical cancer screening for her?

A. Cervical cytology testing should be discontinued.

73

B. Cervical cytology testing should be performed annual y indefinitely.

C. Cervical cytology testing should be performed every 1 to 3 years until age 65 years.

D. Cervical cytology testing plus HPV cotesting should be performed every 5 years until age 65 years.

Question 5.14 In the Mayo Lung Project randomized control ed trial more than 9,200

male smokers were randomized to intensive screening (sputum cytology and CXR every 4

months for 6 years) or a control group (same tests performed annual y). After nearly 20

years of fol ow-up there were more lung cancers diagnosed in the intensive screening arm versus the control arm (585 vs. 500) but the intensive screening arm did not show improvement in lung-cancer mortality (4.4 lung cancer deaths per 1,000 person-years in the intensively screened arm vs. 3.9 per 1,000 person-years in the control arm). This is best explained by

A. Lead-time bias.

B. Overdiagnosis.

C. Selection bias.

D. Stage shift

Question 5.15 Based on the results of the National Lung Screening Trial (NLST) several organizations recommended consideration of lung cancer screening with low-dose computerized tomography (LDCT) for patients who would have quali ed for the trial.

Eligible patients had to have which two of the fol owing criteria? (Select two correct responses)

A. Age less than 60 years

B. At least a 30 pack-year smoking history

C. At least a 50 pack-year smoking history

D. Current smoker

E. Relatively good health

Question 5.16 Which of the fol owing statements regarding prostate cancer screening is TRUE?

A. Intensity of prostate cancer screening has been shown to correlate with the degree of mortality benefit.

B. Prostate cancer screening and therapy are associated with significant harms.

C. PSA levels are unaffected by benign prostate diseases.

D. Routine annual PSA testing is recommended for al men ages 55 to 74 years.

Question 5.17 A 50-year-old-man has no family history of colorectal cancer or polyps. He inquires about CT colonography (“virtual colonoscopy”) for screening as compared to traditional colonoscopy (endoscopy). Which one is TRUE?

A. CT colonography does not require a ful bowel preparation 74

B. CT colonography requires sedation

C. CT colonography is only diagnostic; a colonoscopy would be required if any polyps need removal

D. CT colonography is only half a sensitive as colonoscopy Question 5.18 More frequent screening for colorectal cancer (CRC) is recommended in certain high risk individuals. Which two of the fol owing groups need to have screening increased to colonoscopy every 5 years starting by age 40? (Select two correct responses) A. First-degree relative with CRC or adenomatous polyp at age ≥60 years B. One first-degree relative with CRC or adenomatous polyps diagnosed at age <60 years C. One second-degree relative with colorectal cancer

D. Two or more first-degree relatives with CRC

E. Two second-degree relatives with CRC

Question 5.19 Which of the fol owing CRC screening tests can directly prevent colorectal cancer?

A. CT colonography (“virtual colonoscopy”)

B. Double-contrast barium enema

C. Fecal immunochemical testing (FIT)

D. High-sensitivity fecal occult blood testing (FOBT)

E. Optical colonoscopy (endoscopy)

75

Question 5.1 The answer is A.

Lead-time bias is the interval between the diagnosis of disease at screening and when it would have been detected because of the development of symptoms. Length bias is the overrepresentation among screen-detected cases of those with a long preclinical period (thus, less rapidly fatal), leading to the incorrect conclusion that screening was beneficial. Selection bias occurs when enrol ees in a clinical study differ from the general population. Volunteers who choose to participate in screening programs tend to be healthier than the general population.

Question 5.2 The answer is A.

Lowering the PSA threshold wil lead to more positive test results, both true positives and false positives. Finding more true positives results in an increased sensitivity of the test.

Finding more false positives results in a decreased sensitivity of the test. Note that for a given screening test, sensitivity and specificity are inversely related. The increase in false positives (the decrease in sensitivity) results in a decrease in the positive predictive value (PPV).

Question 5.3 The answer is D.

Sensitivity and specificity are characteristics of a test itself. The PPV is related to the test sensitivity, test specificity, and population prevalence of the disease. “Drop-in” or

“contamination” by screening in the control arm potential y decreased the mortality in the control arm, minimizing the difference between the groups (RRR). Both drop-ins and drop-outs reduce the statistical power of a clinical trial to detect differences in outcome between the two arms.

Question 5.4 The answer is D.

The USPSTF is a panel of experts in prevention and evidence based medicine, and are primary care providers specializing in internal medicine, pediatrics, family practice, gynecology and other fields. They adhere to high standards for recommending a screening test, focusing on whether there is evidence to show that the benefits outweigh the harms of a screening test. Cost effectiveness is not considered.

Question 5.5 The answer is C.

The sensitivity of a test reflects its ability to detect a known disease, and the specificity reflects the ability of a test to give a normal result when the disease is known to be absent. From the point of view of the clinician, the presence or absence of a disease is unknown, and the pertinent question is the accuracy of the test result. The PPV is an estimate of the accuracy of the test in predicting the presence of disease; the negative 76

predictive value (NPV) is an estimate of the accuracy of the test in predicting the absence of disease. The PPV represents the proportion of al positive tests that are true positives: TP/(TP+FP). A PPV of 10% means that 10% of positive test results are true positives, so 90% are false positives.

Question 5.6 The answer is C.

The sensitivity and specificity are characteristics of the test itself and are not affected by the population characteristics. On the other hand, the PPV and NPV values are influenced by the disease prevalence in the population being tested. The general population wil have a lower prevalence of breast cancer than a group of women with known BRCA mutations.

Question 5.7 The answer is A.

Absolute risk reduction conveys more information than relative risk reduction. A large relative risk reduction applied to a very smal risk translates to a smal number of lives saved. For example, reducing mortality from one in a mil ion to two in a mil ion is an impressive sounding 50% risk reduction but only saves one more life per mil ion patients.

Stage shift is the diagnosis of a cancer at an earlier stage than would have occurred in the absence of screening. This is necessary but not sufficient for a screening test to be effective in terms of reducing mortality. Survival time after diagnosis can be inflated by lead-time bias. Mortality rates are a better measure of effectiveness.

Question 5.8 The answer is B.

Large trials of careful BSE instruction have shown a lack of mortality benefit, so BSE is no longer a standard component of breast cancer screening programs (the American Cancer Society lists BSE as an option). Mammography has a lower PPV for women in their 40s due to a lower prevalence of breast cancer and a lower sensitivity of mammography (due to increased breast density in premenopausal women). Biennial screening only marginal y decreases the number of lives saved while halving the false-positive rate as compared with annual screening.

Question 5.9 The answers are B and C.

Annual mammography and MRI starting at age 30 is recommended for women at high risk due to a known BRCA mutation, women who are untested but have a first-degree relative with a BRCA mutation, women who had been treated with radiation to the chest for Hodgkin disease, and women with an elevated lifetime risk (> 20% to 25%) based on breast cancer risk estimation models.

It has yet to be determined whether supplemental imaging reduces breast cancer mortality in women with increased breast density.

Question 5.10 The answer is C.

77

Screening guidelines recommend that cervical cancer screening with cytology not begin until age 21 and HPV testing not begin until age 30. Although HPV infections are common in young women, the overwhelming majority of these HPV infections and associated CIN wil spontaneously regress. Screening young women could lead to overdiagnosis, aggressive treatment, and unnecessary harm from ablative surgical procedures.

Question 5.11 The answer is A.

Large trials of careful BSE instruction have shown a lack of mortality benefit for BSE.

MRI screening is only indicated in women at very high risk for breast cancer.

Question 5.12 The answer is C.

The USPSTF, ACOG, and ACP al discourage routine screening for ovarian cancer in the general population. The currently available screening tests do not have adequate sensitivity and specificity, especial y considering the relatively low prevalence in the population.

Question 5.13 The answer is A.

Women without a cervix are not at risk for cervical cancer unless there was a history of cervical cancer (in that case the cytology testing is for fol ow-up of the cancer, not for screening). Vaginal cuff smears are unnecessary; they have an extremely low likelihood of detecting vaginal dysplasia, and the false-positive rate is high.

Question 5.14 The answer is B.

Overdiagnosis is an extreme form of length bias and refers to the detection of tumors that fulfil the histologic criteria for malignancy but are not biological y destined to harm the patient within his/her lifespan. Lead-time bias is the interval between the diagnosis of disease at screening and when it would have been detected because of the development of symptoms. Selection bias occurs when enrol ees in a clinical study differ from the general population. Volunteers who choose to participate in screening programs tend to be healthier than the general population. In stage shift a cancer diagnosis is made at an earlier stage than would have occurred in the absence of screening.

Question 5.15 Answers are B and E.

The NLST eligibility criteria includes

• Age 55 to 74 years;

• At least a 30 pack-year smoking history;

• Currently smoke or have quit within the past 15 years;

• Relatively good health (i.e., able to tolerate therapy for lung cancer and have the life expectancy benefit from it).

78

Question 5.16 The answer is B.

Prostate cancer screening and therapy are associated with significant harms. Experts do not agree as to whether the benefits of screening for this disease outweigh the harms.

Professional organizations recommend that screening should only be done in the context of ful y informed consent. Prostate cancer mortality rates have declined in many countries that have not widely adopted screening suggesting that improvements in treatment have contributed to the observed decline in prostate cancer mortality.

Aging and noncancerous diseases of the prostate are associated with rising PSA levels.

Question 5.17 The answer is C.

CT colonography is only diagnostic and a colonoscopy would be required if any polyps need removal. CT colonography involves the same preparation as a colonoscopy, but does not involve sedation. The sensitivity of CT colonography for the detection of polyps ≥6

mm appears to be comparable to that of optical (endoscopic) colonoscopy.

Question 5.18 The answers are B and D.

Patients with two or more first-degree relatives with CRC, or one first-degree relative with CRC or adenomatous polyps diagnosed at age <60 years need to have colonoscopy every 5 years, beginning at age 40 years or 10 years younger than the earliest diagnosis in the family, whichever comes first. Those with one first-degree relative with CRC or an adenomatous polyp at age ≥60 years, or two second-degree relatives with CRC need to start screening at age 40 but can otherwise fol ow the guidelines for average-risk persons.

Question 5.19 The answer is E.

Endoscopy with polypectomy can remove precancerous lesions (adenomatous polyps) thus reducing the incidence of subsequent CRC.

Corresponding chapter in Cancer: Principles & Practice of Oncology, Tenth edition: 34 (Cancer Screening).

79





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 6.1 Which of the fol owing statements regarding nicotine replacement therapy (NRT) is TRUE?

A. NRT increases the odds of quitting smoking compared to placebo.

B. NRT is associated with increased risk of carcinogenesis in the general population.

C. a and b

D. None of the above

Question 6.2 Which of the fol owing statement is TRUE?

A. Continued smoking after the diagnosis of localized prostate cancer does not increase the risk of recurrence.

B. The adverse effect of smoking is not acutely reversible. Therefore smoking cessation is not recommended before surgical resection for esophageal cancer.

C. Current smoking does not increase the risk of postoperative death in lung cancer patients undergoing surgery.

D. Current smoking increases the toxicities associated with radiotherapy in patients with head and neck cancer.

Question 6.3 Varenicline (Chantix) is associated with which of the fol owing side effects?

A. Hypertension

B. Anorexia

C. Suicidal ideation

D. Elevated liver enzymes

Question 6.4 Which of the fol owing is recommended as second-line pharmacotherapy for tobacco dependence?

A. Clonidine

B. Nortriptyline

C. Both a and b

D. None of the above

Question 6.5 Which of the fol owing neoplasias is an intraepithelial marker for invasive 80

cancer?

A. Cervical ectropion

B. Junctional nevus

C. Seborrheic keratosis

D. Leukoplakia

Question 6.6 In clinical trials, systemic retinoids and beta carotene were shown to reduce cancer incidence in this group of high-risk individuals

A. Skin cancer in patients with xeroderma pigmentosum

B. Lung cancer in heavy smokers

C. Cervical cancer in patients with cervical dysplasia

D. Colorectal cancer in patients with adenoma

Question 6.7 Which of the fol owing was associated with selenium supplementation in randomized clinical trials?

A. Decreased risk of squamous cel skin cancer

B. Reduced incidence of prostate cancer

C. Increased incidence of nonmelanoma skin cancer

D. Increased risk of prostate cancer

Question 6.8 Which of the fol owing statements is/are TRUE regarding calcium and vitamin D?

A. Calcium reduces the risk of recurrent colorectal adenoma.

B. The combination of vitamin D and calcium decreased the risk of developing colon cancer in postmenopausal women in the Women’s Health Initiative (WHI) trial.

C. The combination of vitamin D and calcium reduced the risk of breast cancer in postmenopausal women in the WHI trial.

D. High serum level of vitamin D is associated with decreased risk of pancreatic cancer.

Question 6.9 Which of the statements is/are TRUE regarding nonsteroidal anti-inflammatory drugs (NSAIDs) in the prevention of colorectal cancer?

A. Chemopreventive effects of low-dose aspirin on colorectal cancer development were demonstrated in clinical trials, and its overal benefits outweigh the risks in adults at average risks of developing colorectal cancer.

B. High-dose sulindac prevents the development of new polyps, although it does not cause the regression of established polyps.

C. In randomized trials, both rofecoxib and celecoxib were shown to reduce the risk of metachronous colorectal adenomas and colorectal cancer.

D. Considering the risks associated with these agents, screening strategy alone is recommended in average-risk adults.

81

Question 6.10 Which of the statement is TRUE regarding tamoxifen and raloxifene?

A. Tamoxifen reduces the risk of ER-negative breast cancer.

B. Raloxifene reduces breast cancer-specific mortality rates.

C. Tamoxifen is more effective than raloxifene in reducing breast cancer incidence.

D. Both tamoxifen and raloxifene decrease the risk of in situ breast neoplasms.

Question 6.11 The risk of which of the fol owing toxicities is increased in patients treated with raloxifene?

A. Endometrial cancer

B. Vertebral fracture

C. Stroke

D. Coronary artery heart disease

Question 6.12 Which of the fol owing statement is TRUE regarding the role of 5-alpha-steroid reductase inhibitors in preventing prostate cancer?

A. Finasteride does not reduce the incidence of prostate cancer.

B. Patients treated with finasteride or dutasteride who develop prostate cancer are more likely to have tumors of a high Gleason score compared to patients treated with placebo.

C. Finasteride decreases the survival after prostate cancer diagnosis compared to placebo.

D. Dutasteride increases the risk of prostate cancer.

Question 6.13 Which of the fol owing is TRUE regarding statins?

A. Simvastatin was shown to decrease the overal cancer risk in several large randomized trials.

B. Statins reduces the risk of breast cancer and colon cancer in randomized studies.

C. Both a and b.

D. None of the above.

Question 6.14 Which of the fol owing is TRUE?

A. Bisphosphonates reduces the risk of recurrent breast cancer in postmenopausal women with breast cancer.

B. Metformin decreases the risk of invasive breast cancer in patients with type 2 diabetes mel itus in large randomized studies.

C. Both a and b.

D. None of the above.

Question 6.15 Which of the fol owing is TRUE regarding diet-derived natural products?

A. There have been no large prospective trials demonstrating the efficacy of natural products in reducing cancer risk.

82

B. Berry formulations reduce esophageal dysplasia and oral leukoplakia in phase II studies.

C. Both a and b.

D. None of the above.

Question 6.16 Helicobacter pylori infection is associated with increased risk of which of the fol owing?

A. Esophageal adenocarcinoma

B. Gastric cardia carcinoma

C. Esophageal squamous cel carcinoma

D. Intestinal-type gastric adenocarcinoma

Question 6.17 In performing risk-reducing salpingo-oophorectomy for high-risk patients: A. An open approach is required to perform an en-bloc resection of ovaries, uterus, and nearby pelvic lymph nodes.

B. BRCA mutation confers a high risk of uterine cancer.

C. Patients may be subsequently protected from al breast cancers.

D. Patients with Lynch syndrome should undergo simultaneous hysterectomy.

Question 6.18 In patients with medul ary thyroid carcinoma (MTC), which of the fol owing preoperative basal calcitonin levels is an indication for ipsilateral central and lateral neck dissection?

A. 15 to 20 pg/mL

B. 20 to 50 pg/mL

C. 50 to 200 pg/mL

D. 200 to 500 pg/mL

Question 6.19 What is TRUE regarding the risk of endometrial cancer for patients with Lynch syndrome?

A. The risk for women with Lynch syndrome varies from 20% to 60% and is higher than development of ovarian cancer.

B. Clinical y, these cancers are frequently poorly differentiated, present at an advanced stage, and associated with poor prognosis.

C. Risk reducing hysterectomy should be performed shortly after menarche.

D. Estrogen replacement is contraindicated in women with Lynch syndrome undergoing bilateral salpingo-oophorectomy.

Question 6.20 What is the best treatment of a patient with FAP presenting with approximately 300 colorectal polyps and 15 rectal adenomas?

A. Observation

83

B. Total proctocolectomy with permanent ileostomy (TPC) C. Proctocolectomy with ileal pouch-anal anastomosis (IPAA) D. Total colectomy with ileorectal anastomosis (IRA)

Question 6.21 Which of the fol owing malignancies are associated with germ line mutations in the RET protooncogene?

A. Multiple endocrine neoplasia (MEN) 2A

B. MEN 2B

C. Sporadic medul ary thyroid carcinoma

D. Al the above

84

Question 6.1 The answer is A.

NRT increases the odds of quitting smoking by approximately twofold compared with placebo. Studies have also shown that NRT is not associated with increased risk of carcinogenesis in the general population.

Question 6.2 The answer is D.

Studies have demonstrated that current smoking increases the risk of recurrences in multiple cancers, including head and neck cancer, lung cancer, prostate cancer, and bladder cancer. Stopping smoking before surgery is advised since it reduces postoperative morbidity and mortality. Current smoking also increases radiotherapy-associated toxicities in multiple types of cancers.

Question 6.3 The answer is C.

Although recent safety studies have shown no difference in neuropsychiatric side effects between varenicline and NRTs, varenicline carries a FDA-issue box warning that some patients develop suicidal thoughts after its use. Anorexia, hypertension, and elevated liver enzymes are not commonly seen with varenicline.

Question 6.4 The answer is C.

Both clonidine and nortriptyline are recommended as second-line pharmacotherapies for tobacco dependence.

Question 6.5 The answer is D.

Intraepithelial neoplasias could be used as surrogate end points in chemopreventive studies. Intraepithelial neoplasias include colorectal adenoma, Barrett esophagus, actinic keratosis of skin, dysplastic nevus, cervical intraepithelial neoplasia, leukoplakia, prostate intraepithelial neoplasia, bronchial dysplasia, and pancreatic intraepithelial neoplasia.

Cervical ectropion, junctional nevus, and seborrheic keratosis are not intraepithelial neoplasias and do not confer increased risk of developing cancer.

Question 6.6 The answer is A.

In smokers, the Alpha-Tocopherol, Beta-Carotene Trial (ATBC) and the Carotene and Retinol Efficacy Trial (CARET) showed increased risk of lung cancer in patients receiving beta-carotene with or without retinol. Although topical al -trans retinoic acid (ATRA) might cause regression of cervical dysplasia, this effect was not seen in studies involving systemic retinoids or beta-carotene. Prospective studies found no protective effect of beta-carotene supplementation. Retinoids and beta-carotene have been studied extensively in both clinical and epidemiologic trials. Systemic retinoids reduce 85

skin cancer incidence by 63% during therapy in patients with xeroderma pigmentosum, although the protective effect is lost after discontinuation of the treatment.

Question 6.7 The answer is C.

Selenium increased the incidence of total nonmelanoma skin cancer and squamous cel skin cancer in patients with a history of nonmelanoma skin cancer. In the SELECT trial, the incidence of prostate cancer was not significantly different between the selenium arm and placebo arm, or between the selenium+vitamin E arm and the placebo arm.

Question 6.8 The answer is A.

Calcium decreased the risk of recurrent colorectal adenoma in a randomized study. In the WHI trial, the combination of vitamin D and calcium did not decrease the risk of developing either colon cancer or breast cancer. There has been no evidence to suggest that high levels of vitamin D decrease the risk of pancreatic cancer.

Question 6.9 The answer is D.

Several studies have shown protective effects from NSAIDs in patients with colorectal cancer. Although regular use of aspirin was associated with protective effects in population base studies, the benefit of low-dose aspirin was not yet clear in randomized clinical trials. The limited benefit of NSAIDS, including low-dose aspirin, in preventing colorectal cancer, does not justify their use in average-risk individuals. Sulindac, at high dose, was associated with both regression of existing polyps and prevention of new polyps in patients with FAP, but the protection was transient and incomplete. Although the cyclooxygenase-2 inhibitors rofecoxib and celecoxib were shown to reduce the risks of metachronous adenoma, the studies were terminated early because of their side effects, being unable to detect the reduction of colorectal cancer incidence. Although NSAIDs reduce the risk of colorectal adenoma and colorectal cancer, these agents are associated with significant gastrointestinal and cardiovascular toxicities, which outweigh the benefits. Therefore, the best strategy for the general population remains effective screening.

Question 6.10 The answer is C.

Tamoxifen is more effective than raloxifene in decreasing the breast cancer incidence.

Neither tamoxifen nor raloxifene reduces the risk of ER-negative breast cancer or breast cancer-specific mortality. Tamoxifen, but not raloxifene, reduces the risk of in situ breast neoplasm.

Question 6.11 The answer is C.

Raloxifene is a nonsteroidal selective estrogen receptor modulator that binds to estrogen receptor leading to estrogen agonist effects in some tissues and estrogen antagonist 86

effects in others. Raloxifene has estrogen agonist activity in the bone but is less active than tamoxifen in the uterus. Unlike tamoxifen, raloxifene was not associated with increased risk of uterine cancer. Because of raloxifene’s agonist activity in bone, it reduced the risk of vertebral fracture. Raloxifene does not increase the risk of coronary artery heart disease, but studies showed increased risk of stroke.

Question 6.12 The answer is B.

In randomized placebo-control ed trials, patients treated with either finasteride or dutasteride had reduced incidence of prostate cancer. However, patients who received either drug were more likely to develop tumors of a high Gleason score compared to those received placebo. Neither the overal survival nor the survival after prostate cancer diagnosis was different between the finasteride group and the placebo group.

Question 6.13 The answer is D.

Although the Women’s Health Initiative study found that lovastatin conferred a lower risk of colorectal cancer, there has been no strong evidence that statins decrease general cancer risks. The Nurse’s Health Study showed no association with statin use and risk of breast cancer.

Question 6.14 The answer is A.

Bisphophonates reduce the risk of recurrent breast cancer in postmenopausal women with breast cancer in randomized studies. Although the Women’s Health Initiative observed a lower incidence of breast cancer in diabetic women treated with metformin, this association has not been validated in large randomized studies.

Question 6.15 The answer is C.

No diet-derived natural products have been studied in large randomized trials regarding their role in reducing cancer risk. In human phase II trials, berry formulations decreased esophageal dysplasia and oral leukoplakia.

Question 6.16 The answer is D.

H. pylori infection increases the risk of intestinal-type gastric adenocarcinoma. Studies have showed that the eradication of H. pylori reduces the risk of gastric cancer in high-risk populations. Some studies suggested that H. pylori infections might be associated with a reduced risk of esophageal adenocarcinoma and gastric cardia carcinoma.

Question 6.17 The answer is D.

In most women, bilateral salpingo-oophorectomy may be performed safely using a laparoscopic approach, and the uterus can be spared. The BRCA mutation does not increase the risk of uterine cancer. However, patients with mutations of the mismatch-87

repair genes in Lynch syndrome have an increased rate of ovarian and endometrial cancers. After risk-reducing salpingo-oophorectomy (RRSO), patients may be subsequently protected from estrogen-positive breast cancers, however, there is no protection from estrogen-negative cancer.

Question 6.18 The answer is B.

Based on current guidelines, surgical therapy for patients with MTC can be stratified according to their preoperative basal calcitonin levels. For levels <20 pg/mL, a total thyroidectomy alone is needed. For levels 20 to 50 pg/mL, an ipsilateral central and lateral neck dissection is added. For 50 to 200 pg/mL, the contralateral central neck is explored, and the contralateral lateral neck is dissected for levels between 200 and 500

pg/mL. Mediastinal exploration is reserved for patients with imaging showing disease.

Question 6.19 The answer is A.

In women with Lynch syndrome (LS), endometrial cancers have been reported at rates of 20% to 60%. Ovarian cancers are detected at rates of 12%. Endometrial and cancers associated with LS have clinical y favorable features, including wel -differentiated tumors that are early in stage and have survival of 90%. Risk-reducing surgery is offered once the woman has completed childbearing. Estrogen replacement is not contraindicated in women who have otherwise undergone only bilateral salpingo-oophorectomy.

Question 6.20 The answer is D.

Because of the virtual y universal risk of developing cancer by the age of 40 years in the absence of therapy, patients with FAP should undergo surgery, with the timing depending on the extent of disease. Among the surgical options, TPC is rarely used and most patients wil be treated with IRA or IPAA. One of the main factors in deciding whether to remove the rectum is the risk of rectal cancer. Therefore, IRA may be considered in patients with less than 1,000 colorectal polyps and less than 20 rectal adenomas. In contrast, patients with a higher number of rectal adenomas, adenomas larger than 3 cm, or severe dysplasia should undergo proctectomy in addition to colectomy, through IPAA.

Question 6.21 The answer is D.

MEN 2A, MEN 2B, familial medul ary thyroid carcinoma and sporadic medul ary carcinoma are associated with germ line mutations in the RET gene.

Corresponding Chapters in Cancer: Principles & Practice of Oncology, Tenth Edition: 31

(Tobacco Use and the Cancer Patient), 32 (Role of Surgery in Cancer Prevention), and 33

(Cancer Risk Reducing Agents).

88





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Refer to the fol owing pedigree for Questions 7.1 to 7.4.

89

Question 7.1 The family depicted has Lynch syndrome (previously referred to as the hereditary nonpolyposis colon cancer [HNPCC]) syndrome. This syndrome is characterized by a high risk to develop colon and endometrial cancer and an increased risk to develop various other tumor types. Before her death, individual III-2 had genetic testing of the MLH1 and MSH2 genes, and an MSH2 gene mutation was identi ed. Speci cal y, the mutation is c.942 + 3A > T. MLH1 and MSH2 gene mutations account for 80% to 90% of families with HNPCC. Individual II-1, depicted with the arrow, has not been diagnosed with cancer. He has undergone frequent colonoscopy screening. He has also had genetic testing and was found to carry the family MSH2 gene mutation. The nding that individual II-1 has not been diagnosed with cancer can be explained by which of the fol owing concepts?

A. Genetic testing laboratory error

B. Clinical variability

C. Genetic heterogeneity

D. Reduced penetrance

Question 7.2 Assuming individual II-3 has the family MSH2 gene mutation, what is the calculated probability Diane (individual IV-1) has inherited the MSH2 gene mutation?

A. 0%

B. 12.5%

C. 25%

D. 50%

Question 7.3 Diane (individual IV-1) is 24 years of age. She approaches her primary care physician about her medical management, given her family history of the Lynch syndrome.

She has a healthy body weight and does not smoke. Both her paternal grandmother (II-3) and her father (III-6) refuse to have genetic testing. In addition to her annual Pap smear, which of the fol owing cancer screening is most appropriate for Diane?

A. Colonoscopy screening to begin at 50 years of age

B. Sigmoidoscopy screening to begin by 25 years of age

C. Colonoscopy screening to begin by 25 years of age

D. Colonoscopy and mammography screening to begin by 25 years of age Question 7.4 Diane (individual IV-1) decides to pursue genetic testing to aid in her medical management. She states that her father wil not undergo genetic testing. What specific genetic test should be ordered?

A. Ful sequencing of the MSH2 gene

B. Ful sequencing of the MSH2 and MLH1 genes C. Mutation specific analysis of the MSH2 gene

D. Deletion analysis using multiplex ligation-dependent probe amplification 90



Question 7.5 Which of the fol owing factors suggest that a family may have hereditary cancer?

A. Young age at diagnosis

B. Bilateral cancer in an affected family member

C. Multiple affected generations

D. Al of the above

Refer to the fol owing pedigree for Questions 7.6 to 7.8.

Olivia is a 38-year-old healthy woman who presents to her primary care physician concerned about her family history of cancer. She has no chronic health concerns. Both her mother’s and father’s family are of Ashkenazi Jewish ancestry. Olivia pursues an evaluation with a clinical geneticist for assessment and genetic testing.

Question 7.6 The clinical geneticist diagnoses the family with which cancer predisposition syndrome?

A. HNPCC syndrome

B. Hereditary breast cancer 1 ( BRCA1) syndrome

91

C. Li–Fraumeni syndrome

D. Hereditary BRCA2 syndrome

E. None of the above

Question 7.7 Genetic testing is recommended to begin with which family member(s)?

A. Olivia, III-2

B. Olivia’s oldest sibling, individual III-4

C. Olivia and her two siblings should be tested at the same time D. Olivia’s maternal first cousin, individual III-1

Question 7.8 Which of the fol owing statements regarding prophylactic oophorectomy is TRUE?

A. Prophylactic bilateral salpingo-oophorectomy (BSO) is the most effective therapy to reduce the risk of ovarian cancer in women with BRCA1 or BRCA2 gene mutation.

B. BSO in BRCA1 or BRCA2 gene mutation carriers is indicated at age 30.

C. BSO in BRCA1 or BRCA2 gene mutation carriers has no effect on the risk of developing breast cancer.

D. Al the above.

Question 7.9 Jennifer is a 38-year-old woman who was diagnosed with stage IIA ductal carcinoma at 30 years of age. She undergoes direct genetic testing of the BRCA1 and BRCA2 genes and is found to have a BRCA2 gene variant. Speci cal y the variant is Q713L

(2366A > T), which results in the substitution of leucine for glutamine at amino acid 713

of the BRCA2 protein. The functional signi cance is unknown. Jennifer’s sister, Angela, is 40 years of age and has no personal history of cancer. Which is the most appropriate genetic testing approach for Angela?

A. Genetic testing is recommended for Angela because it wil clarify her breast cancer risk.

B. Genetic testing is not recommended for Angela because it wil not clarify her breast cancer risk.

C. Genetic testing is recommended for Angela because it wil help clarify Jennifer’s genetic test results.

D. A and C.

Question 7.10 Which of the fol owing statements regarding people with a BRCA1 or BRCA2

gene mutation are TRUE?

A. The majority of BRCA1 gene mutation carriers who develop breast cancer develop estrogen receptor–positive breast tumors, and BRCA 2 gene mutation carriers most often develop estrogen receptor–negative breast tumors.

B. BRCA1 and BRCA2 gene mutation carriers have an increased risk to develop pancreatic cancer.

92



C. BRCA2 gene mutations are associated with an increased risk for fol icular thyroid cancer

D. Prophylactic bilateral mastectomy decreases the risk of breast cancer by more than 90% among women with a BRCA1 or BRCA2 gene mutation.

Refer to the fol owing pedigree for Questions 7.11 and 7.12.

Question 7.11 Pauline, the family proband as designated by the arrow, is a healthy 36-year-old woman who presents to her gynecologist concerned about her breast cancer risk.

She requests genetic testing. No other family member has undergone genetic testing. The gynecologist orders BRCA1 and BRCA2 gene testing. No mutation is identified. Which of the fol owing statements is the CORRECT interpretation of Pauline’s testing?

A. Pauline’s test result is a true negative.

B. Pauline’s test result is a variant of uncertain significance.

C. Pauline’s test result is uninformative.

93

D. Pauline’s test result is positive.

Question 7.12 Pauline’s sister, individual III-2, is currently undergoing neoadjuvant chemotherapy for an aggressive ductal carcinoma of the breast. She is not interested in pursuing genetic testing at this time given the demands of her treatment. What breast health screening recommendations do you make for Pauline given her negative genetic testing?

A. Mammography beginning at age 40 years

B. Mammography and breast ultrasound beginning at age 40 years C. Mammography and breast ultrasound beginning now

D. Mammography and breast MRI beginning now

Question 7.13 Which of the fol owing malignancies does NOT have a signi cant increase in incidence among people with Lynch syndrome?

A. Colon cancer

B. Cervical cancer

C. Ovarian cancer

D. Endometrial cancer

Question 7.14 A 28-year-old woman with bilateral ductal cancer presents to the medical oncologist for assessment and treatment. Her medical history is notable for intussusception at 6 years of age. On her physical examination, the medicine resident notices smal blue/black hyperpigmented macules on her lips, buccal mucosa, and ngertips. What is her diagnosis?

A. Hereditary BRCA1 syndrome

B. Hereditary BRCA2 syndrome

C. Li–Fraumeni syndrome

D. Peutz–Jeghers syndrome

E. Cowden syndrome

94

Question 7.1 The answer is D.

Penetrance may be defined as the proportion of individuals with a mutant genotype who show any manifestation of a given disorder. A disorder that is expressed in less than 100% of individuals with the mutant genotype is said to have reduced penetrance. For example, if only 60% of individuals with the genotype express clinical features, the disease is considered to be 60% penetrant. Expression in hereditary cancer syndromes occurs when an individual is diagnosed with one of the associated malignancies or benign lesions. Almost al cancer syndromes show reduced penetrance. This concept is important to understand because many families believe if a family member has not developed a specific cancer, he/she cannot pass on the gene mutation to a child.

Question 7.2 The answer is C.

The Lynch syndrome is an autosomal-dominant disease. Calculation of Diane’s probability to have inherited the gene mutation is based on autosomal-dominant inheritance. By assuming individual II-3 has the MSH2 gene mutation, the calculated probability Diane’s father (III-6) has inherited the mutation is 50%. The probability Diane has inherited it from her father is 50%. Thus, Diane’s calculated probability to have inherited the MSH2 gene mutation is 25% (50% × 50%). Most hereditary cancer syndromes identified to date are inherited in an autosomal-dominant manner with reduced penetrance. In a clinical setting, it would be important not to assume that individual II-3 has the mutation. Although she has been diagnosed with colon cancer, the cardinal feature of the Lynch syndrome, individuals may be diagnosed with an associated cancer type and not have the causal gene mutation. That is, an individual may develop a sporadic cancer that does not result from the underlying family gene mutation. If individual II-3 does not have the MSH2 gene mutation, her sporadic colon cancer would be a phenocopy, a mimic of the syndrome phenotype. II-3’s daughter, who died of breast cancer at 39 years of age, does not provide any insight as to whether II-3 has the gene mutation. It remains under investigation if breast cancer is one of the associated cancer types in the Lynch syndrome.

Question 7.3 The answer is C.

The Lynch syndrome is associated with a 70% to 80% lifetime risk for colon cancer and a 20% to 60% risk for endometrial cancer. There are also increased risks for gastric (intestinal type), ovarian, urinary tract, and central nervous system tumors, with the level of risk varying for each cancer type. Colonoscopy screening is recommended to begin by 20 to 25 years of age or 10 years before the youngest age of cancer diagnosis and repeated every 1 to 2 years. Sigmoidoscopy is not recommended because of the predominance of right-sided colon cancers. Approximately two-thirds of al colon cancers in the Lynch syndrome occur in the ascending colon. Consensus 95

recommendations also include consideration of endometrial cancer surveil ance with transvaginal ultrasound and endometrial biopsy; however, the efficacy of this screening regimen is unknown. Although Diane’s (IV-1) paternal aunt (III-5) died of breast cancer at a young age, there are insufficient data to prove breast cancer is one of the associated cancers in the Lynch syndrome. As such, intensified mammography screening is not warranted. Intensified surveil ance recommendations are available for many hereditary cancer syndromes. Limited data exist to prove the efficacy of these screening protocols. However, until larger data sets are developed, consensus recommendations are issued to help guide clinicians in the care of high-risk families.

Question 7.4 The answer is C.

The MSH2 gene mutation, c.942 + 3A > T, identified in an affected family member, results in an A > T change at the third nucleotide of the splice-donor site of intron 5

and causes an in-frame deletion of exon 5. The mutation can be detected using sequencing.

Mutation specific analysis for the MSH2 gene c.942 + 3A > T mutation is the only test that is needed. Ful sequencing of the MSH2 gene is unnecessary and may result in excess cost to the individual pursuing genetic testing. Approximately 20% of MSH2 gene mutations are large deletions or gene rearrangements. These mutations cannot be detected using sequencing. Southern blot analysis and multiplex ligation-dependent probe amplification are techniques used to detect large deletions. A working knowledge of the types of mutations that have been described for a given gene, as wel as an understanding of the limitations of the techniques used by a given laboratory, is crucial in overseeing the clinical genetic testing of a family.

Diane (IV-1) has the right to pursue clinical genetic testing to aid in her medical management. If her testing is positive for the MSH2 gene mutation, then her father and paternal grandmother may gain information they have previously chosen not to obtain.

In advance of ordering the testing, it is crucial to discuss if and how Diane is going to communicate her test results with her family and their potential reactions. By facilitating this discussion, the clinician acknowledges some of the psychosocial implications associated with hereditary disease and providing anticipatory guidance as to how Diane may address potential reactions from her family.

Question 7.5 The answer is D.

Several factors suggest the possibility of hereditary disease including young age at diagnosis, bilateral organ involvement in an affected family member, multiple affected family members in multiple generations, rare tumor histology such as medul ary thyroid cancer, and unusual presentation of a tumor such as male breast cancer.

Question 7.6 The answer is E.

The family cancer history meets the diagnostic criteria for the hereditary diffuse gastric 96

cancer syndrome (HDGC). HDGC is an autosomal-dominant, highly penetrant cancer predisposition syndrome that results from mutations in the E-cadherin gene ( CDH1) in one-third of families. The genetic etiology is unknown for the remaining families. This syndrome is associated with a 70% cumulative lifetime risk for diffuse gastric cancer, an adenocarcinoma that causes thickening of the gastric wal (linitis plastica) without a distinct mass. There is also a 40% lifetime risk for lobular breast cancer among female mutation carriers. The youngest reported case of gastric cancer is 14 years with a median age at diagnosis of 38 years. Intensified surveil ance with upper endoscopy and breast mammography with MRI is recommended. Prophylactic gastrectomy may also be considered given the limitation in detecting diffuse lesions. Precancerous lesions have been detected in a smal series of “prophylactic” gastrectomy specimens.

It is a chal enge for healthcare providers to stay wel informed of advances in their own medical discipline, let alone to maintain a working knowledge of the advances for other specialties and rare syndromes. Working col aboratively with a clinical geneticist and genetic counselor may help to facilitate the identification of families with hereditary cancer. Although these syndromes may be considered “rare,” they often go unrecognized and the opportunity for positive medical intervention for a family is lost.

The first step in the identification of hereditary cancer begins with a thorough col ection and evaluation of the family cancer history. Detailed reviews of many hereditary cancer syndromes can be found at

http://www.ncbi.nlm.nih.gov/books/NBK1116/.

Question 7.7 The answer is D.

The most informative approach to genetic testing is to begin with an affected family member, diagnosed with one of the associated cancers for the suspected cancer predisposition syndrome. If an affected family undergoes testing first and if a gene mutation is discovered, then the underlying genetic basis for the cancer predisposition in the family has been identified, the testing is informative, and other family members may pursue mutation specific analysis. If a gene mutation is not identified, then the underlying genetic basis for disease has not been identified, the testing is noninformative, and consequently predictive genetic testing is not available for other family members.

For this family, if individual III-A does not have a CDH1 gene mutation, the family would stil be considered to have the hereditary diffuse gastric cancer syndrome, however an informative genetic test would not be available to help guide Olivia’s medical care.

Question 7.8 The answer is A.

BSO in BRCA carriers is the most effective procedure to reduce the risk of ovarian cancer and is general y recommended upon completion of childbearing. BSO also decreases the risk of subsequent breast cancer.

97

Question 7.9 The answer is B

Missense variants result in the substitution of one amino acid for another. These variants occur frequently in the BRCA1 and BRCA2 genes. The functional significance cannot be determined with gene sequencing alone. Functional analysis of the BRCA1

and BRCA2 proteins is not available clinical y. Angela has a 50% probability to have the BRCA2 gene variant, but because the functional significance is unknown, testing Angela does not provide her with any clinical y relevant information. Furthermore, because Angela has not been diagnosed with cancer, genetic analysis does not provide any new information to clarify Jennifer’s test results. If Angela had been diagnosed with early-onset breast cancer, then analysis for the BRCA2 gene variant would have been offered for research purposes only to help determine whether the variant is tracking with disease in the family.

For this family, genetic testing did not provide any new information to facilitate their medical decision making. Individuals with these types of gene variants are often left intel ectual y and emotional y frustrated by the testing. Imagine deciding to pursue genetic testing with the intention of using the results to guide your personal and family medical care only to learn the testing provides no clear answer. As clinical genetic testing quickly becomes available fol owing gene discovery, clinicians must contend with the identification of variants of unknown functional significance. The development of functional, rather than descriptive, testing wil help to address this chal enging clinical issue. Until such techniques are developed, it is important to inform individuals of the possibility of identifying these types of variants of unknown before the initiation of genetic testing.

Question 7.10 The answer is B and D.

BRCA1 and BRCA2 gene mutations have a high risk for breast and ovarian cancer and an increased risk for other cancer types, including pancreatic cancer. Studies evaluating the efficacy of prophylactic mastectomy, conducted specifical y among female BRCA1

and BRCA2 gene mutations, have demonstrated a greater than 90% reduction in the risk to develop breast cancer. Women with a BRCA1 gene mutation most often develop estrogen receptor–negative breast cancers and women with BRCA2 gene mutations develop estrogen receptor–positive breast tumors. Fol icular thyroid cancer is an associated cancer in the Cowden syndrome, and has not been noted to occur more frequently among individuals with a BRCA1 or BRCA2 gene mutation.

Question 7.11 The answer is C.

Pauline’s testing is uninformative because the underlying genetic basis for cancer predisposition has not yet been identified in her family. When possible, genetic testing should always begin with an affected family member. In essence, when evaluating a family with genetic disease, testing should begin with the person who expresses features of the inherited condition. In the case of hereditary cancer syndromes, expression is 98

defined as a person who is diagnosed with one of the associated malignancies or benign lesions. If Pauline’s sister undergoes clinical BRCA1 and BRCA2 genetic testing, then these results may change the interpretation of Pauline’s testing. For example, if Pauline’s sister’s testing is positive for a mutation, then Pauline’s testing would be interpreted as a true negative. If Pauline’s sister’s testing is negative, then Pauline’s testing was of no clinical value because the basis for disease remains unknown. Without prior knowledge of the family’s gene mutation, Pauline’s negative testing may have provided a false and dangerous sense of security.

Question 7.12 The answer is D.

The underlying genetic basis for cancer predisposition remains unknown. Even though Pauline had negative genetic testing, it is not known whether she inherited the disease causing gene mutation. As such, Pauline, and her paternal family members, should continue to be considered at high risk and fol owed accordingly. The clinician must return to the family cancer history to determine her medical fol ow-up. The family history is consistent with the clinical diagnosis of either the hereditary BRCA1 or BRCA2

syndrome. Pauline should fol ow the same recommendations as families with a confirmed diagnosis of one of these syndromes, until genetic testing proves informative for her family. Intensified surveil ance with mammography and breast MRI screening, beginning by 25 years of age, is recommended. In studies of individuals with an increased breast cancer risk, the combination of mammography and breast MRI proved to be more effective in identifying abnormal breast lesions than mammography alone.

The combination of mammography and breast ultrasound for women with an increased breast cancer risk is stil under investigation. In a 1997 study published by Giradel o and col eagues in the New England Journal of Medicine, approximately one-third of al ordering physicians misinterpreted the results of APC gene testing. The majority of errors arose as physicians misinterpreted a negative test result when the genetic basis for disease had not previously been established in a given family. Ongoing genetics education is needed for practitioners who assume the genetics care and testing of families with hereditary disease.

Question 7.13 The answer is B.

The Lynch syndrome is primarily associated with a high risk for colon and endometrial cancer and an increased risk for other tumors including ovary, stomach, smal intestine, hepatobiliary tract, urinary tract, brain, and skin. Cervical cancer is not one of the known associated cancer types. The life time risk for colon cancer is estimated to range from 60% to 80% and for uterine cancer as high as 60% lifetime risk.

Question 7.14 The answer is D.

Peutz–Jeghers syndrome is characterized by the association of hyperpigmented macules, increased cancer risk, and gastrointestinal polyposis. Blue/black macules may 99

be found around the mouth, buccal mucosa, nostrils, eyes, and fingertips. These lesions may fade over time. Hamartomatous polyps (Peutz–Jeghers type) most commonly occur in the smal bowel but can also develop in the colon or the stomach. Recurrent obstruction and intussusception may occur. Individuals with Peutz–Jeghers syndrome are at increased risk for various tumors, including breast, colorectal, ovarian, gastric, and pancreatic cancers. Affected females are also at increased risk for adenoma malignum of the cervix and a benign ovarian tumor, sex cord tumors with annular tubules (SCTAT).

Peutz–Jeghers syndrome results from mutations in the STK11 gene found on chromosome 19. The Peutz–Jeghers syndrome serves as an example of the importance of a detailed physical examination, in combination with the family cancer history, to identify individuals with a hereditary cancer syndrome. Other physical features that provide important diagnostic clues include the mucosal neuromas of the lips and tongue in the multiple endocrine neoplasia syndrome type 2B, trichilemmomas or papil omatous lesions in the Cowden syndrome, and sebaceous adenomas in the Lynch syndrome.

Corresponding Chapter in Cancer: Principles & Practice of Oncology, Tenth Edition: 35

(Genetic Counseling).

100





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 8.1 Which of the fol owing describes the speci c pathways for the repair of double-stranded DNA breaks?

A. The repair may be by homologous recombination (HR) or nonhomologous end-joining (NHEJ) pathway.

B. The HR repair pathway functions by degrading the single strand at each side of the break and then annealing the two ends.

C. The NHEJ pathway functions by replicating the missing genetic information from the homologous DNA template.

D. NHEJ is a minor component of mechanism for repair of double-stranded DNA breaks in mammalian cel s.

Question 8.2 Which of the fol owing is TRUE about ionizing events in tissues caused by x-rays?

A. Radiation dose describes the quantity of energy deposited.

B. The direct effect of radiation is primarily due to injury to cel ular membranes.

C. The relative biological effectiveness (RBE) describes the ratio of doses required to give the same amount of kil ing under normoxic and hypoxic conditions.

D. Indirect action of ionizing radiation where hydroxyl radicals damage target tissues is commonly seen.

Question 8.3 Which of the fol owing statements describes the DNA damage/repair process associated with ionizing radiation?

A. Single-stranded breaks of the DNA are thought to represent the lethal event.

B. Al of the radiation-induced, double-stranded breaks are rejoined in cel s within 2

hours.

C. In mammalian cel s, choice of repair can be biased by phase of the cel cycle and by abundance of repetitive DNA.

D. Nonhomologous end-joining (NHEJ) is effective in rejoining DNA double-strand break because it is an error free process.

Question 8.4 Which of the fol owing statements describes the dose-related cel ular 101

response to radiation?

A. In mammalian cel s, there is general y a linear and quadratic relationship between the cel kil ing and the dose given.

B. The term “D0” describes the quasi-threshold dose, defining the width of the shoulder C. Densely ionizing radiation leads to an extended shoulder on the survival curve.

D. In general, postirradiation conditions that accelerate the cel division are the ones most favorable to repair of potential y lethal damage.

Question 8.5 Which of the fol owing statements is TRUE regarding independent events (4

R’s) that occur during fractionated radiotherapy?

A. Repopulation refers to spontaneous repopulation and induced cel proliferation or recruitment of cel s after irradiation.

B. Repair explains the linear portion of the radiation survival curve showing that cel s can repair some of the radiation damage.

C. Redistribution explains migration of cel s away from an irradiation source.

D. Reoxygenation describes the decrease of tumor oxygen levels during fractionated radiation.

Question 8.6 Which of the fol owing acute e ects are related to radiation-induced cel death?

A. Cystitis

B. Esophagitis

C. Dermatitis

D. Proctitis

E. Al of the above

Question 8.7 The abscopal effect of radiation is

A. Attributed to the activation of antigen and cytokine release.

B. Commonly seen because immune system evasion by cancer cel s is rarely present.

C. Seen more frequently with lower doses and greater fractions.

D. Activation of the humoral immune response.

E. Double-stranded breaks in DNA in nonirradiated cel s

Question 8.8 Which of the fol owing best describes the modern linear accelerator?

A. A modern linear accelerator (LINAC) can deliver energies up to 1 MeV.

B. Generate Bremsstrahlung x-rays by bombarding a target with high-energy electrons C. Primarily uses 60Cobalt which is always “on” and must be kept in a shielded position until the beam is needed for treatment.

D. The focal point of the gantry’s rotation is cal ed the field edge.

102

Question 8.9 Which of the fol owing statements describes the role of oxygen in radiation effects?

A. A greater dose of radiation is required for cel kil ing in an oxic condition compared with a hypoxic condition.

B. A randomized trial showed that epoetin b improved survival in patients with head and neck cancer.

C. Oxygen need not be present at the time of irradiation for oxygen enhancement of radiotherapy to occur.

D. Hyperbaric oxygen often shows a dramatic increase in curability with standard fractionated radiotherapy.

E. The oxygen enhancement ratio (OER) has more relevance on the exponential portion of the cel survival curve.

Question 8.10 Which of the fol owing best describes the concept of altered fractionation?

A. Accelerated fractionation does not reduce the overal treatment time.

B. Hyperfractionation refers to a radiotherapy schedule that uses multiple daily treatments more than 6 hours apart with reduced fraction size and increased number of fractions.

C. Standard fractionation is commonly defined as 3 to 5 Gy/day D. The goal of accelerated fractionation is to complete radiation before accelerated reoxygenation occurs

Question 8.11 Which of the fol owing statements regarding interaction of chemotherapy and radiation therapy is TRUE?

A. Rationale for combining radiation therapy with radiosensitizing chemotherapy is primarily to confer an additive effect.

B. Gemcitabine is a potent radiosensitizer and special consideration is not required when administered with radiation for treatment of lung and head and neck cancers.

C. Paclitaxel radiosensitizing effect to due to G1 cel -cycle arrest D. Mechanism of radiosensitization by cisplatin may be due to its ability to inhibit DNA repair of radiation induced DNA double-strand breaks.

Question 8.12 Which of the fol owing statements is TRUE regarding intensity-modulated radiation therapy (IMRT)?

A. It is an uncomplicated method to deliver radiation in a nonconformal manner.

B. Is delivered only using a limited number of beam orientations.

C. Optimization of each individual beamlet can create sharp dose gradients.

D. Does not take into account organs at risk (OARs) when developing the treatment plan.

Question 8.13 Which of the fol owing statements best describes the tissue e ects from radiation?

103

A. Early or acute effects typical y occur within months after irradiation.

B. Large α/β> ratio has a smal “shoulder” in the low-dose portion.

C. The frequencies of late effects depend strongly on radiation fraction size.

D. Typical human tumors and early-responding normal tissues have a smal α/β ratio.

Question 8.14 Which of the fol owing statements describes of the interaction of x-rays with biologic material?

A. In modern treatment with greater than 4 MeV photons, photoelectric effect dominates the interaction.

B. In Compton scattering, an incoming x-ray transfers al its energy to an inner orbit electron, which is ejected from the atom. A photon is produced as an outer shel electron fil s the vacant hole.

C. In photoelectric effect, energy from the x-ray is both absorbed and scattered. The photon emerges with reduced energy and a change in direction.

D. In pair production, an electron and a positron are produced.

Question 8.15 Which of the fol owing statements describes the depth dose characteristics of radiation?

A. Higher-energy photons deposit more dose to the skin surface.

B. For a given energy, electrons general y penetrate deeper in tissue compared with photons.

C. Electron beams deposit less dose to the skin surface as the incident electron energy increases.

D. Depth of maximum dose increases as the energy of the incident beam increases.

Question 8.16 Which of the fol owing statements is TRUE regarding brachytherapy?

A. Isotopes with properties of long half-lives and high energy are typical y used for permanent implants.

B. Brachytherapy refers to placement of radioactive sources next to or inside the tumor, or within body or surgical cavities.

C. The fluence drops in intensity as 1 over the distance from the source.

D. A potential advantage of brachytherapy is its ability to produce conformal treatments with high normal tissue dose.

Question 8.17 Which of the fol owing can be a subacute toxicity from radiation therapy?

A. Pneumonitis

B. Myelitis.

C. Brain necrosis.

D. B and C.

Question 8.18 Which of the fol owing best describes the treatment planning process?

104

A. At the time of image acquisition for planning, tumor motion caused by respiration must be determined.

B. Immobilization is not important because it does not add to accuracy.

C. Three-dimensional dose distribution in each patient is easily measured.

D. Intensity-modulated radiation therapy (IMRT) cannot control the shaping of the dose distribution.

Question 8.19 Which of the fol owing is TRUE regarding charged particle beams?

A. Charged particle beam therapy includes photon-based therapy.

B. Protons have shown to confer a definite clinical benefit over photon-based therapies for most clinical cancer applications.

C. Ability of charged particles to stop at a given depth gives it a potential advantage for treatment of tumors in close proximity to critical structures.

D. Charged particle therapy is relatively inexpensive in terms of the cost involved with production and operation of such facility.

105

Question 8.1 The answer is A.

There are two general y accepted mechanisms of repair for DNA double-strand breaks.

They are broadly known as the homologous recombination (HR) or nonhomologous end-joining (NHEJ) pathways. HR functions by replicating the missing genetic information from the homologous DNA template. NHEJ functions by degrading the single strand at each side of the break and then annealing the two ends in a region of microhomology.

NHEJ may result in loss or gain in genetic information and is mutation prone. Some have suggested that HR and NHEJ have overlapping complementary roles. NHEJ is a dominant mechanism for repairing double-stranded DNA breaks in mammalian cel s.

Several investigators have demonstrated enhanced radiosensitivity of human cel lines by inhibiting the proteins required for NHEJ.

Question 8.2 The answer is D.

Al other statements are false. The indirect effects of x-rays predominate the biologic effects seen with x-rays. The photons cause ejection of fast electrons. The ejected fast electrons can directly damage the DNA (direct action) or, more commonly, the fast electrons interact with plentiful water molecules to produce hydroxyl radicals (OH–), which in turn can damage the biologic target (indirect action). Radiation dose is the energy deposited per mass of tissue. Although injury to cel ular membranes contributes to radiation response, the primary effect is due to DNA damage. The RBE describes the ratio of doses required to yield an equivalent biologic event.

Question 8.3 The answer is C.

Although single-stranded and double-stranded breaks are observed from ionizing radiation, it is the double-stranded breaks that are thought to represent the lethal event. Although the majority of the radiation-induced, double-stranded breaks are rejoined in cel s within 2 hours after exposure, the process can continue for 24 hours. In mammalian cel s, choice of repair is biased by phase of cel cycle and by abundance of repetitive DNA. HRR is used primarily in late S to G2 phase of cel cycle, and NHEJ

predominates in the G1 phase of cel cycle. However, this is not an absolute, and factors in addition to cel cycle phase are important in determining which mechanism wil be used to repair DNA strand breaks. NHEJ while effective is known to be highly error prone.

Question 8.4 The answer is A.

D0 is related to the slope of the exponential survival curve and represents a dose that is required to reduce the surviving fraction to 0.37% or 37% of the original population. Dq is the quasi-threshold dose. Mammalian cel lines display a “shoulder” in the low-dose 106

region and the exponential relation at higher doses. The “shoulder” represents a reduced efficiency of cel kil ing. The linear quadratic model rather than the linear model best describes the cel ular response to radiation for low-ionizing radiation, while the linear model best describes response to densely ionizing radiation. The shoulder disappears for densely ionizing radiation. The postirradiation conditions that suppress the cel division are the ones most favorable to potential y lethal damage repair.

Question 8.5 The answer is A.

Repair explains the shoulder of the radiation survival curve showing that cel s can repair some of the radiation damage. The majority of sublethal damage repair occurs within 6

hours after irradiation. Redistribution explains differences in cel -cycle radiation sensitivity, with the mitotic (M) phase being the most sensitive. Cel s gradual y increase in resistance as they proceed through the late G1 and S phases. Repopulation refers to spontaneous repopulation and induced cel proliferation or recruitment of cel s after irradiation. This may occur in some tumors but occurs less than that in normal tissues.

Reoxygenation explains how a proportion of hypoxic cel s present in a tumor return to preradiation level. Some tumor cel s may reoxygenate after radiotherapy and the proportion of the hypoxic cel s that was present before irradiation may be seen. Tumor oxygen levels increaser during a course of fractionated radiation.

Question 8.6 The answer is E.

Acute effects of radiation usual y occur in organs dependent on rapid self-renewal and are mostly caused by radiation-induced cel death during mitosis. In the case of nausea and fatigue however, these toxicities are most likely related to the release of cytokines.

Question 8.7 The answer is A.

Abscopal effects are not commonly seen due to an inherent characteristic of cancer cel s for immune system evasion. The abscopal effect is more commonly seen with higher doses and fewer fractions of radiation than conventional fractionation. The activation of tumor-specific T cel s is the primary mechanism immunogenic tumor cel death.

Double-stranded breaks are a direct action on irradiated cel s.

Question 8.8 The answer is B.

A modern LINAC can deliver energies up to 25 MeV. The focal point of the gantry’s rotation is cal ed the isocenter. The 60Cobalt teletherapy unit is a megavoltage machine that relies on radioactive cobalt, not electrons, to produce a photon beam. A modern LINAC uses accelerated electrons to bombard a high-Z target to generate Bremsstrahlung x-rays.

Question 8.9 The answer is E.

107

Greater doses of radiation are required for cel kil ing in hypoxic conditions. The oxygen enhancement is seen more readily during the exponential portion of the survival curve because of the reduced capacity for cel s to repair sublethal damage under hypoxic conditions. Tumor cel s growing in a physiologic hypoxic condition have reduced capacity to repair sublethal damage. The OER is the ratio of dose required for equivalent cel kil ing in the absence of oxygen compared with the dose required in the presence of oxygen. The range of OER varies from 2.5 to 3.5. Oxygen must be present at the time of irradiation for oxygen enhancement of radiotherapy to occur. OER is more important for radiation that damages cel s via hydroxyl radical intermediates. Hyperbaric oxygen often does not show a dramatic increase in curability with standard fractionated radiotherapy. However, hyperbaric oxygen appears to increase curability in a smal number of fractions. A meta-analysis showed that hyperbaric oxygen improves the local control of solid tumors by approximately 10%. Unfortunately, a randomized trial published recently showed that epoetin b did not improve cancer control or survival in patients with head and neck cancer.

Question 8.10 The answer is B.

Hyperfractionation refers to a radiotherapy schedule that uses multiple daily treatments more than 6 hours apart with reduced fraction size and increased number of fractions.

Accelerated fractionation reduces the overal treatment time. It delivers the same dose with the same fraction size but in a shorter overal treatment time in an attempt to complete radiation before accelerated repopulation occurs. Standard fractionation for radiation therapy is the delivery of one treatment of 1.8 to 2.25 Gy/day.

Question 8.11 The answer is D.

The two proposed reasons for combining chemotherapy with radiation therapy include radiosensitization and spatial additivity. The former concept theoretical y may yield synergistic effect which is greater than simply adding the two together. Gemcitabine is a potent radiosensitizer due to the induction of dATP depletion and redistribution of the cel s into the early S phase. Although ful dose gemcitabine can be safely combined with radiation therapy for the treatment of local y advanced pancreatic carcinoma in cases without involved lymph nodes, including the regional lymph nodes in the radiation field can be extremely toxic. Cisplatin, 5-fluorouracil, and paclitaxel are also radiosensitizers.

Paclitaxel radiosensitizing is thought to be attributable to the redistribution of cel s into G2/M. Mechanism of cisplatin radiosensitization is related to its ability to cause inter-and intrastrand DNA cross links. Two possible explanations are that cisplatin inhibits repair of radiation induced DNA double-strand breaks or increases the number of lethal radiation-induced double-strand breaks.

Question 8.12 The answer is C.

IMRT is a highly complex, computer intensive treatment planning process that typical y 108

utilizes multiple beam orientations to provide many degrees of freedom and to create highly sculpted dose distributions. Each treatment beam is broken down into beamlets to facilitate optimization. When developing a treatment plan, the target coverage in addition to sparing of excess dose to OARs is usual y taken into account.

Question 8.13 The answer is C.

Early or acute effects typical y occur within weeks after irradiation. They often occur in tissues that have rapid turnover, and it is thought to result from the depletion of the clonogenic or stem cel s within that tissue. The frequencies of late effects depend strongly on radiation fraction size. There are fewer late effects with smal er fraction size.

Large α/β ratio has a large “shoulder” in the low-dose portion. The α/β ratio represents the dose at which the quadratic (b) and linear (a) components of cel kil are equivalent.

The dose response to radiation can be described by the formula S = exp (–αD – βD2), where S is surviving fraction and D represents dose. Typical human tumors and early-responding normal tissues have large α/β ratios (9 to 13 Gy).

Question 8.14 The answer is A.

The relative probabilities of photoelectric, Compton, and pair production interaction depend on the photon energy and the atomic number of the irradiated material. In modern treatment machines with greater than 4 MeV photons, the Compton interactions and pair productions are commonly seen. At diagnostic equipment energy range (25 kVp), photoelectric effect predominates. In photoelectric effect, an incoming x-ray transfers al its energy to an inner orbit electron, which is ejected from the atom. A photon is produced as an outer shel electron fil s the vacant hole. In Compton scattering, energy from the x-ray is both absorbed and scattered. The photon emerges with reduced energy and a change in direction. In pair production, an electron and a positron are produced, which then deposit energy through col isions with other electrons. The threshold energy for pair production is 1.02 MeV.

Question 8.15 The answer is D.

Higher-energy photons deposit less dose to the skin surface. Thus, it is cal ed the skin-sparing effect of high-energy photons. Depth of maximum dose increases as the energy of the incident beam increases. It is often desirable to use high-energy photons (>10

MeV) to reach deeply located tumors. For a given energy, electrons do not penetrate deeper in tissue compared with photons. It is for this reason that electron beams are often used to treat superficial y located tumors such as skin cancer. Electron beams, unlike photons, deposit more dose to the skin surface as the incident electron energy increases.

Question 8.16 The answer is B.

Isotopes with properties of very short half-lives and low energy are used for permanent 109

implants, such as for prostate cancer treatment with iodine-125 with a half-life of 59.4

days and an x-ray energy of 27 to 35 keV. Brachytherapy is a form of treatment that uses direct placement of radioactive sources or materials within tumors (interstitial brachytherapy) or within body or surgical cavities (intracavitary brachytherapy), either permanently or temporarily. Relative to external beam therapy energies, the emitted spectra are of low energy, but high doses can be delivered within few centimeters of the source. The fluence drops in intensity as 1 over the square of the distance from the source. The ability to irradiate tumors from close range can lead to conformal treatments with potential y lower normal tissue doses.

Question 8.17 The answer is A.

Radiation related adverse effects can be divided into acute, subacute, and chronic (late) effects. Acute effects tend to occur in organs (typical y within the field of radiation) that depend on rapid self renewal. Acute effects commonly occur and typical y are self limiting. Examples include mucositis, esophagitis, diarrhea, and skin reaction. Subacute toxicities typical y occur 2 weeks to 3 months after radiation has been completed. Radiation-induced pneumonitis is usual y a subacute toxicity. Late effects from radiation therapy are usual y observed after 6 months from completion of therapy. Some examples include radiation myelitis, brain necrosis, and bowel obstruction.

Question 8.18 The answer is A.

Immobilization is critical y important because it adds to the accuracy of daily setup and treatment. A planning computed tomography (CT) scan is obtained after immobilization has been completed. At the time of image acquisition for planning, tumor motion caused by respiration must be determined. The planning volume must account for respiratory movement and uncertainty of tumor position. Three-dimensional dose distribution in each patient is not easily measured and it must be predicted from computer calculation.

Intensity-modulated radiation therapy can have a high degree of control on the shaping of the dose distribution. The computer determines the intensity profiles to achieve the desired dose distribution.

Question 8.19 The answer is C.

Charged particles include protons and carbons. These particles differ from photons in that they interact only modestly with tissue until they reach the end of their path where they then deposit majority of their energy and stops (Bragg peak). This ability to stop at given depth gives them the potential advantage of treating tumors that are close to critical structures. While proton therapy may have potential use in clinical settings demanding such characteristics, it’s widespread use for al cancer is not yet warranted.

Furthermore, in the era of IMRT (Intensity-Modulated Radiation Therapy) and IGRT

(Image-Guided Radiation Therapy), despite theoretical and dosimetric advantages 110

conferred by charged particles, whether this wil al ow higher dose to be delivered more safely, and yield a clinical advantage over highly conformal photon techniques is not yet ful y determined. The high cost of development and operation of charged particle therapy facilities has also limited its widespread development and use.

Corresponding chapter in Cancer: Principles & Practice of Oncology, Tenth Edition: 13

(Essentials of Radiation Therapy).

111





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case, unless instructed otherwise.

Question 9.1 Interindividual pharmacokinetic/pharmacodynamic variability can be a result of which of the fol owing principles?

A. Dose proportionality

B. Feedback-control ed dosing

C. Therapeutic drug monitoring

D. Sex dependence

Question 9.2 A 35-year-old female is currently being treated with pazopanib (CYP3A4

substrate). She is admitted for seizure management and the consult team recommends initiation of phenytoin. What e ect may concurrent administration have on pazopanib concentrations?

A. Decrease pazopanib concentration

B. Increase pazopanib concentration

C. No change in pazopanib concentration

D. None, if the pazopanib is taken with food

Question 9.3 Which of the fol owing scenarios best identifies a prognostic marker?

A. KRAS mutation testing in setting of colon cancer

B. Dihydropyrimidine dehydrogenase (DPD) deficiency in the setting of 5-FU therapy C. MMR protein expression deficiency in setting of colon cancer D. UGT1A1*28 polymorphism in setting of irinotecan therapy Question 9.4 HG is a 55-year-old patient with BRAF mutation positive, metastatic melanoma on vemurafenib therapy. Despite an initial dramatic response, his disease relapsed after roughly 6 month of treatment. Which of the fol owing explanations describes the most likely mechanism of resistance?

A. KRAS mutation

B. MEK mutation

C. T790M mutation

D. T315I mutation

112

Question 9.5 Which of the fol owing medication:pharmacogenomic assay pairs are correctly matched (select two correct responses)?

A. 6-mercaptopurine:thiopurine methyltransferase (TPMT) activity B. Tamoxifen:uridine diphosphate glucuronosyltransferase (UGT) 1A1 activity C. 5-fluorouracil:dihydropyrimidine dehydrogenase (DPD) activity D. Afatinib:anaplastic lymphoma kinase (ALK) gene rearrangement Question 9.6 Which of the fol owing is CORRECT regarding hemorrhagic cystitis?

A. Bladder protection with mesna is required for al patients receiving cyclophosphamide B. Hemorrhagic cystitis is caused by indirect damage to the bladder wal by either cyclophosphamide or ifosfamide

C. Mesna works by providing a free sulfhydryl group that binds to toxic metabolites D. Mesna should be given in divided doses to total 100% of the total alkylating agent dose

Question 9.7 RT is a 50-year-old female with progressive disease fol owing two cycles of carboplatin and paclitaxel for advanced ovarian cancer. Based on our current understanding, which of the fol owing mechanisms may best explain platinum-resistant tumor cel s (select two correct responses)?

A. Decreased damage tolerance

B. Reduced cel ular accumulation

C. Inactivation of autophagy

D. Intracel ular detoxification

Question 9.8 PL is a-65 year-old patient with newly diagnosed metastatic non–smal cel lung adenocarcinoma scheduled to begin treatment with cisplatin and pemetrexed in 1

week. Which of the fol owing medications should be started today to help minimize hematologic toxicities with pemetrexed?

A. Vitamin B6 and Vitamin B12

B. Folic acid and dexamethasone

C. Folinic acid and Vitamin B6

D. Vitamin B12 and folic acid

Question 9.9 Which of the fol owing statements is CORRECT regarding anthracycline cardiotoxicity?

A. Acute doxorubicin cardiotoxicity is irreversible, and its incidence can be reduced by increasing infusion rates.

B. Chronic and delayed anthracycline cardiotoxicity is more common and severe because it is irreversible.

113

C. The incidence of cardiomyopathy secondary to anthracyclines is only related to the cumulative dose.

D. Available evidence suggests the superiority of β-blocker use to prevent anthracycline cardiotoxicity.

Question 9.10 NB is a 68-year-old patient with hormone-refractory metastatic prostate cancer with progressive disease, including brain metastases, after docetaxel treatment. In discussing the possible role for cabazitaxel in this situation with the patient, which of the fol owing statements are CORRECT (select two correct responses)?

A. Cabazitaxel penetrates the blood–brain barrier

B. Cabazitaxel is an excel ent substrate for the multidrug resistance P-glycoprotein pump C. Cabazitaxel binds to and stabilized the α-tubulin subunit causing cel -cycle arrest D. Cabazitaxel is active against prostate cancers that are sensitive and resistant to docetaxel

Question 9.11 Which of the fol owing kinase inhibitors were original y developed as a direct inhibitor of a mutated/amplified tyrosine kinase (select two correct responses)?

A. Imatinib for the treatment of GIST

B. Erlotinib for the treatment of non–smal cel lung cancer C. Lapatinib for the treatment of HER2-positive breast cancer D. Vandetanib in the treatment of medul ary thyroid cancer Question 9.12 Which of the fol owing is a CORRECT statement regarding the role of VEGF

inhibition in the treatment of kidney cancer?

A. VEGF inhibitors like pazopanib or sunitinib are effective in the treatment of kidney cancer due to known kinase mutations in VEGF.

B. The mechanism in which mTOR inhibitors are effective in the treatment of kidney cancer is solely based on the antiproliferative impact against endothelial cel s resulting in anti-angiogensis.

C. The increase activation of the hypoxia inducible factor (HIF) pathway results in activation of downstream target genes such as VEGF.

D. Inhibition of VEGF via bevacizumab has resulted in greater disease response than inhibition of VEGF via multikinase inhibitors such as sunitinib or sorafenib.

Question 9.13 LB is a 63-year-old patient with newly diagnosed metastatic melanoma. His tumor was sent for mutational analysis and was found to be BRAF V600E mutation positive.

Which of the fol owing is a CORRECT statement regarding treatment of his tumor?

A. Due to sorafenib’s inhibition of RAF, it can be used as initial therapy.

B. BRAF inhibition is the most important part of his therapy and treatment with a MEK

inhibitor should not be considered.

C. BRAF inhibitors are only approved in the second-line setting and LB should be 114

initiated on either cytotoxic chemotherapy or immunotherapy with ipilimumab.

D. High serum levels of BRAF inhibitors are important to al ow for achieving adequate pathway inhibition.

Question 9.14 Which of the fol owing is a principle of epigenetic therapy?

A. Epigenetic changes cause alterations in the sequencing of targeted genes.

B. Epigenetic therapy is mostly utilized and has the greatest efficacy in solid tumors.

C. The impact of epigenetic therapy is not seen immediately due to efficacy being based on cel ular reprogramming.

D. Combination therapy with HDAC inhibitors and demethylating agents should not be pursued due overlapping toxicities.

Question 9.15 PM is an 82-year-old male with newly diagnosed multiple myeloma who presents for discussion of management of his disease. Past medical history is signi cant for diabetes, peripheral neuropathy, hyperthyroidism, and hypertension. Which of the fol owing would be the most appropriate management of his cancer?

A. Bortezomib 1.3 mg/m2 subcutaneously on days 1, 4, 8, and 11 and dexamethasone.

B. Carfilzomib 20 mg/m2 IV on days 1, 2, 8, 9, 15, and 16 and dexamethasone.

C. Bortezomib 1.3 mg/m2 IV on days 1, 4, 8 and 11 and dexamethasone.

D. Carfilzomib 27 mg/m2 IV on days 1, 2, 8, 9, 15, and 16 and dexamethasone.

Question 9.16 Poly (ADP-ribose) polymerase (PARP) signals the presence of DNA damage and facilitates DNA repair. Which of the fol owing is a role for PARP inhibition? (Select two correct responses).

A. Chemopotentiation

B. Serine/threonine kinase inhibition

C. Synthetic lethality with BRCA 1/2 mutations

D. Increased hypoxia-inducible factor-1 function

Question 9.17 Asparaginase is commonly used in combination with methotrexate as part of acute lymphoblastic leukemia treatment protocols. Which of the fol owing statements regarding administration of these drugs is TRUE?

A. Asparaginase should be given concurrently with methotrexate in order to inhibit methotrexate’s clearance and increase its cytotoxicity.

B. Asparaginase should be given immediately before methotrexate in order to decrease the risk of methotrexate neurotoxicity.

C. Asparaginase should be given 12 hours before methotrexate in order to prime cancer cel s for methotrexate’s antimetabolite activity.

D. Asparaginase and methotrexate should be given sequential y at least 24 hours apart 115

secondary to methotrexate antagonism.

Question 9.18 SB is a patient with metastatic prostate cancer who presents to the clinic with hypokalemia and peripheral edema. He recently started on abiraterone 1,000 mg po daily after disease progression on docetaxel. Which of the fol owing would be the most appropriate treatment options?

A. Switch the patient to enzalutamide therapy.

B. Decrease the dose of abiraterone to 750 mg po daily.

C. Initiate prednisone 5 mg po twice daily.

D. Initiate spironolactone 50 mg po daily.

Question 9.19 Which of the fol owing statements regarding antiangiogenesis agents is CORRECT?

A. Lenalidomide was the first angiogenesis inhibitor approved by the FDA for cancer treatment.

B. Vorinostat, celecoxib, and bortezomib may al be referred to as exclusive angiogenesis inhibitors.

C. Proangiogenic factors include endostatin, angiostatin, and thrombospondin.

D. Resistance to vascular endothelial growth factor inhibitors has been seen secondary to increased expression of proangiogenic factors.

Question 9.20 TB is a 72-year-old male with progressive CLL who is about to initiate therapy with ofatumumab. Which of the fol owing are considered advantages to ofatumumab over rituximab therapy?

A. Ofatumumab induces more antibody-dependent cel -mediated toxicity (ADCC) than rituximab.

B. Ofatumumab causes more complement activation than rituximab.

C. Ofatumumab is a humanized monoclonal antibody whereas rituximab is chimeric.

D. Ofatumumab demonstrated about an 80% response rate in treatment refractory disease.

116

Question 9.1 The answer is D.

A number of analyses have suggested that many anticancer drugs exhibit significant pharmacokinetic sexual dimorphism. Dose proportionality is when drug concentrations change in strict proportionality to the dose of drug administered. In this scenario, pharmacokinetic parameters are constant. Therapeutic drug monitoring and feedback-control ed dosing are both dose-adaptation principles developed to overcome interindividual pharmacokinetic variability.

Question 9.2 The answer is A.

Anticonvulsant drugs such as phenytoin and carbamazepine can induce drug-metabolizing enzymes (e.g., CYP450 isoenzymes) and thereby increase anticancer agent clearance. Suppression of CYP activity, with agents such as ketoconazole, may lead to a rise in plasma concentrations. It is not advisable to attempt to manipulate the extent of drug absorption, by way of ingesting food, to overcome drug–drug interactions.

Question 9.3 The answer is C.

A prognostic biomarker identifies subpopulations of patients with different disease outcomes, independent of treatment. In stage II colon cancer patients, MMR protein expression deficiency leads to a more favorable natural disease course. The remaining options represent predictive biomarkers, which identify subpopulations of patients most (or least) likely to have a response to a given therapy.

Question 9.4 The answer is B.

KRAS is a downstream effector of the EGFR pathway, and colorectal cancer patients with a KRAS mutation do not receive benefit from cetuximab or panitumumab therapy.

Activating BRAF mutations result in uncontrol ed activity of the MAPK pathway via MEK activation. Secondary MEK mutations have been implicated in acquired resistance to vemurafenib. T790M and T315I point mutations, respectively, are associated with acquired resistance to EGFR and BCR-ABL tyrosine kinase inhibitors.

Question 9.5 The answers are A and C.

TPMT deficiency results in higher intracel ular activation of 6MP to form active thioguanine nucleotides, resulting in severe, possibly fatal hematologic toxicity from standard doses of therapy. DPD deficiency may result in higher 5-FU blood levels leading to severe, possibly fatal toxicities. UGT1A1 is an essential enzyme involved in irinotecan metabolism. Polymorphisms, notably the *28 al ele, have been associated with reduced expression of UGT1A1 and greater rates of irinotecan toxicity. ALK-positive NSCLC patients are highly sensitive to therapy with ALK-targeted inhibitors, including 117

crizotinib and ceritinib.

Question 9.6 The answer is C.

Bladder protection with mesna is required for al patients receiving ifosfamide, and only those select patients receiving high-dose cyclophosphamide. Mesna prevents hemorrhagic cystitis by providing a free sulfhydryl group that conjugates with toxic metabolites (particularly acrolein) of ifosfamide and cyclophosphamide. The dose of mesna should be 60% of the alkylating agent dose, given in divided doses every 4 hours.

Question 9.7 The answers are B and D.

Inhibition of transport mechanisms has a marked effect on intracel ular platinum accumulation, which may also be affected by enhanced efflux. Inactivation of the platinum compounds may occur through cel ular thiols and heavy metal binding via metal othionein. Increased DNA damage tolerance may permit persistence of cancer cel s and autophagy reversal has been shown to sensitize tumors to the effects of cytotoxic drugs.

Question 9.8 The answer is D.

Supplementation with Vitamin B12 and folic acid is required to minimize hematologic toxicities with both pemetrexed and pralatrexate. Other side effects reduced by supplementation include: mucositis, skin rash, reversible transaminasemia, anorexia and fatigue, and GI toxicity. Vitamin B12 and folic acid supplementation should start at least 1 week prior to chemotherapy and be continued for at least 21 days after therapy.

Question 9.9 The answer is B.

Acute doxorubicin cardiotoxicity is reversible, and its incidence can be significantly reduced by decreasing doxorubicin infusion rates. The incidence of anthracycline cardiotoxicity is dependent on both cumulative dose and the schedule of drug administration. Recent meta-analytic data has shown relatively similar efficacy in preventing anthracycline cardiotoxicity regardless of which prophylactic treatment was used (e.g., β-blockers, dexrazoxane, statins, angiotensin antagonists).

Question 9.10 The answers are A and D.

Cabazitaxel is a very poor substrate for the multidrug resistance P-glycoprotein efflux pump, which makes it useful for treatment of docetaxel-resistant prostate cancer. It is a semisynthetic taxoid derivative which binds to and stabilized the β-tubulin subunit causing inhibition of microtubule depolymerization and cel cycle arrest in the G2/M

phase.

118

Question 9.11 The answers are A and C.

Imatinib and lapatinib were both developed based on their direct inhibition of KIT/PDGFR mutations and HER2 kinase gene amplification, respectively. Erlotinib was developed in more of cytotoxic approach in NSCLC where an al comer approach was taken. It was not until after FDA approval where the EGFR mutation status was taken into consideration when prescribing erlotinib to NSCLC patients. It is known that many medul ary thyroid cancers have activating mutations targeting RET, but there are no direct RET inhibitors available. Vandetanib does have off-target activity against RET, but it is unknown if this is driving the response rate or if the VEGF receptor inhibitor is the main driver.

Question 9.12 The answer is C.

There are no known driver mutations in VEGF that have been shown in kidney cancer.

The loss of function in the Von Hippel–Lindau (VHL) tumor suppressor gene results in activation of oncogenes within the hypoxia-inducible factor (HIF) pathway. HIF

activation results in downstream activation of VEGF which is why it is thought that anti-VEGF drugs have activity in kidney cancer. The mechanism of mTOR inhibitors in kidney cancer is poorly understood. The antiproliferative activity against endothelial cel s suggests an antiangiogenic mechanism, but mTOR inhibitors have also shown to inhibit the growth of kidney cel lines without tumor angiogenesis impact.

Question 9.13 The answer is D.

Since sorafenib is a multikinase inhibitor the drug concentration needed for complete inhibition of RAF resulted in intolerable adverse events. This was an initial chal enge as wel with an older formulation of vemurafenib. Approved BRAF inhibitors have high enough serum concentrations to inhibit the BRAF pathway. Since MEK is part of the RAS/RAF pathway, inhibition of MEK can be utilized as monotherapy or in combination with a BRAF inhibitor. Patients with BRAF V600 mutations should be treated with targeted therapy initial y and chemotherapy or immunotherapy should be reserved for progression of disease.

Question 9.14 The answer is C.

Epigenetic therapy is based on restoring normal function of the affected genes and proteins and not targeting specific genetic alterations. Thus far, the majority of research and clinical efficacy has been in the treatment of hematologic malignancies. Since many of the epigenetic therapies do not have overlapping toxicity profiles, combination therapies are being explored. An immediate response is typical y not seen with epigenetic therapy since it takes time for cel ular restoration to occur.

Question 9.15 The answer is A.

119

Bortezomib is approved for first-line therapy for multiple myeloma either as a single agent or in combination. Carfilzomib is only indicated for relapsed or refractory disease; thus, would not be appropriate initial therapy. The patient already has a history of peripheral neuropathy. Carfilzomib is associated with a lower incidence of neuropathy than bortezomib, but this toxicity can be minimized when bortezomib is given subcutaneously instead of intravenously.

Question 9.16 The answers are A and C.

Preclinical studies have shown that combining PARP inhibitors with anticancer treatment modalities that result in DNA instability (e.g., radiation therapy and platinum chemotherapy agents) potentiates their cytotoxicity. In the presence of BRCA mutations, PARP inhibitors cause impaired homologous recombination, loss of repair mechanisms, and cel death via synthetic lethality. PARP inhibition has also been implicated in decreased production of hypoxia-inducible factor-1 function that may contribute to cancer cel death.

Question 9.17 The answer is D.

Asparaginase has been shown to antagonize the cytotoxic antimetabolite activity of methotrexate when administered either concurrently with or immediately before the drug. The proposed mechanism is via decreased methotrexate polyglutamation leading to lower levels of unbound intracel ular drug. It is recommended, therefore, that the two drugs be given sequential y at least 24 hours apart.

Question 9.18 The answer is C.

Abiraterone is a potent and irreversible inhibitor of CYP17. This blockage can result in raising adrenocorticotrophic hormone (ACTH) levels including corticosterone and deoxycorticosterone. Administration of corticosteroids such as prednisone should always be given with abiraterone to reduce the toxicity of mineralocorticoid excess.

Question 9.19 The answer is D.

Bevacizumab was the first angiogenesis inhibitor to be approved by the FDA for cancer treatment fol owing a phase III trial showing a survival benefit. Drugs that only exhibit antiangiogenic properties are known as exclusive inhibitors. Drugs such as vorinostat, celecoxib, and bortezomib al inhibit angiogenesis as a secondary function and thus are known as inclusive inhibitors. Proangiogenic factors include, but are not limited to, vascular endothelial growth factor, platelet-derived growth factor, placental growth factor, and transforming growth factor-β.

Question 9.20 The answer is B.

Ofatumumab is a ful y human monoclonal antibody that binds to a different epitope on 120

CD20 than rituximab leading to increases in complement activation, but less antibody-dependent cel -mediated toxicity (ADCC) than rituximab. Treatment for refractory CLL

resulted in about a 50% overal response with the majority of patients having bulky disease.

Corresponding chapters in Cancer: Principles & Practice of Oncology, Tenth Edition: 15

(Pharmacokinetics and Pharmacodynamics), 16 (Pharmacogenomics), 17 (Alkylating Agents), 18 (Platinum Analogs), 19 (Antimetabolites), 20 (Topoisomerase-Interacting Agents), 21 (Antimicrotubule Agents), 22 (Kinase Inhibitors as Anticancer Drugs), 23

(Histone Deacetylase Inhibitors and Demethylating Agents), 24 (Proteasome Inhibitors), 25

(Poly[ADP-Ribose] Polymerase Inhibitors), 26 (Miscel aneous Chemotherapeutic Agents), 27 (Hormonal Agents) and 28(Antiangiogenesis Agents), 29 (Monoclonal Antibodies).

121





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 10.1 Which of the fol owing types of immunity is most responsible for the host response to tumor development?

A. Humoral immunity

B. B-cel –mediated immunity

C. T-cel –mediated immunity

D. Antibody-mediated immunity

Question 10.2 Currently, what is the proposed mechanism for using immunotherapy to destroy cancer cel s?

A. Develop antibodies to target growth factors on cancer cel s B. Increase levels of immune lymphocytes

C. Develop antibodies to directly destroy the cancer cel s D. Increase levels of antigen-presenting cel s

Question 10.3 A 55-year-old woman with metastatic melanoma enters a clinical trial with a cancer vaccine. Approximately 4 weeks after starting treatment she develops abdominal pain and watery diarrhea. Which of the fol owing is the most likely diagnosis and the etiology?

A. Autoimmune colitis from activation of T cel s against antigen found in cel s lining the gastrointestinal tract

B. Autoimmune colitis from antibody production targeting antigen found in cel s lining the gastrointestinal tract

C. Infectious colitis from immunosuppression due to aberrant T-cel production D. Infectious colitis from contamination of the vaccine product with a virus capable of infecting the gastrointestinal tract

Question 10.4 Expression of the Epstein–Barr virus (EBV) latent gene EBNA is seen in which of the fol owing cancers?

A. Nasopharyngeal carcinoma

B. Burkitt lymphoma

C. T-cel lymphoma

122

D. Al of the above

Question 10.5 A 20-year-old sexual y active woman inquires about the role of the human papil oma virus (HPV) vaccine in relation to cervical cancer. Which of the fol owing statements regarding the HPV vaccine is CORRECT?

A. It prevents the development of cervical cancer in al patients B. It induces regression of cervical cancer tumors

C. It prevents infection with HPV 16 and 18

D. It prevents the development of cervical cancer in patients infected with HPV 16 and 18

Question 10.6 Which of the fol owing is an approach to cancer immunotherapy?

A. Passive transfer of activated immune cel s with antitumor activity B. Active immunization to enhance antitumor reactions

C. Nonspecific stimulation of immune reactions

D. Al of the above

Question 10.7 Which of the fol owing is an example of an immunotherapy that works by nonspeci c stimulation of immune reactions, and in which disease has it shown to be effective?

A. Cancer vaccine in hepatocel ular carcinoma

B. Adoptive immunotherapy in lung cancer

C. IL-2 in melanoma

D. Anti-CTLA4 in pancreatic cancer

Question 10.8 A 48-year-old man presents with hematuria, and CT imaging reveals a 5-cm kidney mass. Imaging of his chest shows multiple smal bilateral lung nodules consistent with metastatic renal cel cancer. He is asymptomatic and in otherwise good health. You discuss treatment options with him including the use of IL-2 therapy. Which of the fol owing statements is TRUE regarding the use of IL-2 in this situation?

A. IL-2 is very wel -tolerated with minimal side effects in the majority of patients B. IL-2 is FDA-approved for multiple cancer types given the excel ent outcomes, including kidney cancer, melanoma, and lung cancer.

C. The chance of tumor regression with the use of IL-2 in kidney cancer is approximately 75%.

D. Although tumor response is seen in approximately 20% of patients with kidney cancer treated with IL-2, some patients can have durable benefit without tumor progression for several years.

Question 10.9 Which of the fol owing results in inhibition of T cel s?

123

A. CTLA-4

B. CD28

C. B7-1

D. B7-2

Question 10.10 Of over 1,000 vaccine treatments that have been studied, what is the approximate overal objective response rate to vaccines for cancer treatment?

A. <5%

B. 10%

C. 30%

D. 50%

Question 10.11 The purpose of checkpoint molecules such as CTLA-4 and PD-1 are to: A. Enhance the immune response against infectious agents by activating T cel s.

B. Enhance the immune response against cancer by activating T cel s.

C. Protect normal tissues against autoimmunity by inhibiting T cel s.

D. Protect normal tissues from tumorigenesis by stimulating the immune system.

Question 10.12 A 67-year-old man presents with abdominal pain and weight loss and is found to have multiple liver masses and di use lymphadenopathy. Biopsy of a liver lesion con rms metastatic melanoma. He is otherwise healthy with no other signi cant medical problems. Which of the fol owing is accurate regarding the use of immunotherapeutic agents in metastatic melanoma?

A. Nivolumab is an inhibitor of the checkpoint molecule CTLA-4, and its use can result in significant tumor regression

B. Nivolumab often results in autoimmune toxicity while ipilimumab is rarely associated with side effects

C. Both nivolumab and ipilimumab can result in durable tumor regression D. The combination of nivolumab and ipilimumab does not appear to result in additional toxicity than either agent alone

Question 10.13 Which of the fol owing has been associated with death in trials of nivolumab for lung cancer?

A. Neutropenia

B. Pneumonitis

C. Hepatitis

D. Hypophysitis

Question 10.14 Which is TRUE regarding cancer vaccines?

A. Cancer vaccines have a high rate of efficacy but their use is limited due to toxicity 124

B. Cancer vaccines have a high rate of efficacy and are currently used in multiple tumor types to induce tumor regression.

C. Cancer vaccines have a low rate of efficacy because of their inability to generate antitumor T cel s

D. Cancer vaccines have a low rate of efficacy despite their ability to generate antitumor T cel s

Question 10.15 Which of the fol owing is TRUE regarding sipuleucel-T?

A. Sipuleucel-T is a vaccine loaded with prostatic acid phosphatase linked to GM-CSF.

B. The response rate to sipuleucel-T is approximately 50%.

C. Sipuleucel-T significant prolongs time to disease progression and overal survival in men with prostate cancer.

D. Al of the above.

Question 10.16 What is the purpose of adoptive cel transfer therapies?

A. Decreasing the number of reactive T cel s ex vivo and transfer back to the patient B. Increasing the number of cytokines ex vivo and transfer back to the patient C. Activating and expanding tumor-reactive T cel s and transfer back to the patient D. Modulating CD4+ tumor-specific T cel s before transferring back to the patient Question 10.17 Which of the fol owing is CORRECT regarding adoptive cel therapy?

A. Adoptive cel therapy is only effective if the lymphocytes are genetical y modified prior to infusing them into the patient.

B. Both nonviral- and viral-based gene delivery platforms have been used to genetical y modify cel s for use in adoptive cel therapy

C. Targeting antigens that are expressed only on tumor cel s and not on normal tissue can decrease the toxicity associated with on-target, off-tumor effects of the lymphocytes

D. B and C only

Question 10.18 Which of the fol owing indicates the potential utility of anti-CD19 CAR T

cel s?

A. They have been used in many types of solid tumors because of the high prevalence of CD19 on solid tumor cel s.

B. Because they are found on almost al malignant B cel s, they have been tested in patients with hematologic malignancies.

C. Toxicity associated with this therapy is typical y long term due to graft-versus-host disease.

D. B and C only

125

Question 10.1 The answer is C.

Initial y, it was thought that the action of antibodies or humoral immunity was mainly responsible for the response to malignant cel development. However, it has been discovered that malignant cel development is closely related to the cel ular arm of the immune response, specifical y a response to T cel s. B cel s do not play a major role in the immune response to tumor cel s.

Question 10.2 The answer is B.

For existing malignancies, the main mechanism for immunotherapy is to try to increase the level of immune lymphocytes. These immune lymphocytes would be responsible for recognizing the cancer antigens and destroying the cancer cel s. Although the development of antibodies that target growth factors on cancer cel s may help in reducing the overal tumor burden, this does not work by directly destroying the cancer cel s.

Question 10.3 The answer is A.

Autoimmune adverse events are the typical toxicities associated with immunotherapy including vaccine therapy. Colitis occurs from T-cel activation against antigen that is found in both the tumor and the intestinal lining. Infectious colitis is possible, however vaccine therapy does not result in immunosuppression and vaccines are not made with live virus that can infect the host.

Question 10.4 The answer is D.

Expression of the Epstein–Barr virus latent gene EBNA is seen in Burkitt lymphoma, nasopharyngeal carcinoma, and T-cel lymphoma.

Question 10.5 The answer is C.

HPV vaccines protect women from contracting the strains of HPV that are commonly associated with the development of cervical cancer: HPV 16 and 18. The quadrivalent HPV vaccine (Gardasil) also offers protection against HPV 6 and 11, which cause genital warts in 90% of cases. HPV vaccination does not prevent cervical cancer in everyone, since only 70% of cervical cancer is related to HPV. If a patient already has cervical cancer, it wil not provide a tumor response, and if the patient has already contracted HPV16 or 18, it wil not offer any additional protection to the patient.

Question 10.6 The answer is D.

Three main approaches to cancer immunotherapy include nonspecific stimulation of immune reactions through stimulation of effector cel s and/or inhibition of regulatory 126

cel s, active immunization using cancer vaccines, and adoptive immunotherapy, defined as the passive transfer of activated immune cel s with antitumor activity.

Question 10.7 The answer is C.

IL-2 is glycoprotein produced by activated peripheral blood lymphocytes and recombinant IL-2 in high doses can result in tumor cel regression. The FDA-approved IL-2 for the treatment of melanoma and renal cel carcinoma given the activity that has been shown in clinical trials. Its activity stems from the nonspecific stimulation of the immune system. Although anti-CTLA-4 therapies also work by nonspecific stimulation of immune reactions, they have not been shown to be effective in pancreatic cancer.

Cancer vaccines and adoptive immunotherapy have not been shown to be effective in lung cancer or hepatocel ular carcinoma.

Question 10.8 The answer is D.

IL-2 has a fairly low response rate of 20%, however it can result in durable responses in some patients with renal cel cancer; in fact, it is the only known curative treatment for this patient population. It also has efficacy in melanoma, but has not proven to be effective in other cancers. It does carry a high rate of toxicity due to an inflammatory response mediated by cytokine release, with symptoms including fever, hypotension, renal insufficiency, hepatic dysfunction, and pulmonary edema.

Question 10.9 The answer is A.

When CTLA-4 is engaged on the T cel , the T-cel function is impaired. When CD28 is engaged, T cel s are stimulated. B7-1 and B7-2 are ligands that are costimulatory on the T cel s.

Question 10.10 The answer is A.

The results of treatment with cancer vaccines have been overal poor. Of over a 1,000

vaccine treatments studied in cancer, the objective response rate is only 3.4%. The objective response rate used has been criticized by many, suggesting that the response rate may be even lower.

Question 10.11 The answer is C.

Both CTLA-4 and PD-1 are receptors on T cel s that inhibit T cel s in order to prevent overstimulation of the immune system and autoimmunity. Inhibiting their function with therapeutic antibodies (i.e., ipilimumab and nivolumab) can activate the immune system against cancer but can also lead to autoimmune side effects.

Question 10.12 The answer is C.

The CTLA-4 inhibitor ipilimumab and the PD-1 inhibitor nivolumab both can result in 127

significant and durable tumor regression in patients with metastatic melanoma.

However, they can both also cause autoimmune toxicity, and the combination of the two drugs appears to have a higher rate of toxicity, with one trial showing a 53% rate of grade 3 or 4 adverse events.

Question 10.13 The answer is B.

Because of the activation and proliferation of T-cel s achieved by inhibition of PD-1, nivolumab is associated with many immune-mediated toxicities. In the early studies with nivolumab in lung cancer, there were several patients who died from pneumonitis.

Hepatitis and hypophysitis (as wel as many other immune-mediate adverse reactions) can also be seen with PD-1 inhibitors, however these have not been shown to be fatal.

Cytopenias (including neutropenia) are rare with immunotherapeutics.

Question 10.14 The answer is D.

Cancer vaccines have shown the ability to generate antitumor T cel s, however they have not proven the ability to reduce tumor size or improve cancer survival, except in a few rare instances. Therefore they are not used in most tumor types, although they continue to be studied particularly in combination with other immunotherapeutics.

Question 10.15 The answer is A.

Sipuleucel-T is a cancer vaccine that is FDA-approved for use in metastatic prostate cancer. It consists of a prostatic acid phosphatase linked to GM-CSF. Interestingly, it has been shown in a randomized trial to improve survival in men with prostate cancer, however the response rate is extremely low and it does not improve time to disease progression compared to placebo.

Question 10.16 The answer is C.

Adoptive cel transfer therapies function by stimulating T cel s ex vivo by activating and expanding self/tumor-reactive T cel s before transfer back to the patient. CD8+ T cel s have been subject to much research because they are potent effectors of the adaptive tumor response. CD4+ T cel s are more controversial, because they can either help or hinder antitumor immune responses.

Question 10.17 The answer is D.

Adoptive cel therapy involves the transfer of lymphocytes with anticancer activity to a patient with cancer. It has been shown to have activity in patients with some types of metastatic cancer (particularly melanoma) in studies using genetical y modified and nongenetical y modified lymphocytes. Genetic modification of lymphocytes can be performed using nonviral- or viral-based gene delivery platforms, although the viral-based platforms are more common. Toxicity increases if the antigen targeted is found on 128

both tumor and normal tissue, making the ideal target one that is found exclusively on tumor cel s.

Question 10.18 The answer is B.

CARs are fusion proteins that contain an antigen recognition domain linked to a T-cel activation domain. Because CD19 is found on most malignant B cel s but not on normal cel s (except for B cel s), it is a good target for treating many B-cel hematologic malignancies. Therefore, immunotherapy with anti-CD19 CAR T cel s has been tested in patients with B-cel hematologic malignancies. CD19 is not typical y found on solid tumors so its utility is limited in that patient population. Toxicity seen in trials with this therapy has been transient and has included hypotension and neurologic toxicity. Long-term toxicity such as GVHD has not been observed.

Corresponding chapter in Cancer: Principles & Practice of Oncology, Tenth edition: 14 (Cancer Immunotherapy).

129





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 11.1 Which of the fol owing drug acts on a targeted mutation?

A. Docetaxel

B. Navelbine

C. Erlotinib

D. Pemetrexed

Question 11.2 In children with lymphoblastic leukemia, folic acid was observed to: A. Cause disease proliferation.

B. Cause disease regression.

C. Have no effect.

D. Improve survival.

Question 11.3 Which of the fol owing drug is an antimetabolite chemotherapeutic agent?

A. Gemcitabine

B. Temozolomide

C. Mitoxantrone

D. Bevacizumab

Question 11.4 In patients with advanced or metastatic disease, which of the fol owing has curative potential with primary induction chemotherapy?

A. Germ cel cancer

B. Non–smal cel lung cancer

C. Gastric cancer

D. Colorectal cancer

Question 11.5 The goals of therapy in incurable, advanced, metastatic disease include: A. Obtain a complete response

B. Pal iate tumor-related symptoms

C. Deliver higher doses of chemotherapy

D. Never offer therapy

130

Question 11.6 Neoadjuvant chemotherapy can be utilized in which of the fol owing cancers?

A. Burkitt lymphoma

B. Hodgkin lymphoma

C. Multiple Myeloma

D. Lung cancer

Question 11.7 Which of the fol owing is TRUE regarding the purpose of administering adjuvant chemotherapy?

A. To increase quality of life.

B. To reduce local and distant recurrence.

C. To use as primary therapy instead of surgery.

D. To use as primary therapy instead of radiation.

Question 11.8 Which of the fol owing play essential role in activating apoptosis?

A. Bcl-2

B. NF-κB

C. Caspases

D. Bcl-xL

Question 11.9 The most important indicator of the effectiveness of chemotherapy is: A. Achievement of a minor response.

B. Achievement of a partial response.

C. Achievement of a complete response.

D. Achievement of stable disease.

Question 11.10 According to RECIST criteria 1.1, a partial response is defined as: A. At least a 30% reduction in measurable tumor mass.

B. At least a 10% reduction in measurable tumor mass.

C. Improvement in quality of life.

D. Improvement in survival.

Question 11.11 Anticancer activity of bortezomib is due to the inhibition of: A. Proteasome.

B. Bcl-2.

C. Thymidylate synthase.

D. MDM2.

Question 11.12 In early-stage colon cancer treated with adjuvant chemotherapy, the majority of relapses occur:

131

A. Within the first 5 years.

B. Within the first 3 years.

C. Within the first 2 years.

D. Within the first year.

Question 11.13 Gompertzian kinetics are characterized by: A. Clinical y undetectable tumors are at their lowest growth fraction.

B. The growth fraction is stable over time.

C. The growth fraction increases exponential y with time.

D. The growth fraction decreases exponential y with time.

Question 11.14 Which of the fol owing is the most common genetic change associated with development of resistance to tyrosine kinase inhibitors (TKI) in patients with epidermal growth factor receptor (EGFR) mutation?

A. T790M mutation

B. PTEN overexpression

C. D761Y mutation

D. MET gene mutation

Question 11.15 Which of the fol owing is TRUE regarding intention to treat (ITT) analysis?

A. Increases the risk of bias

B. Should not be used in a randomized control trial

C. Smal effect on overal survival and progression-free survival D. Al patients randomized to a group wil be analyzed

Question 11.16 In patients with colorectal cancer the genetic change associated with resistance to cetuximab is:

A. BRAF mutation.

B. Wild-type KRAS.

C. EGFR-TK mutation.

D. NFκB activation.

Question 11.17 Dose-dense chemotherapy was developed after the observation that: A. The growth of cel s is significantly lower in the early part of the growth curve.

B. The log cel kil is higher in smal er volume tumors, resulting in more rapid growth between chemotherapy cycles.

C. Growth between chemotherapy cycles is halted.

D. More frequent administration of chemotherapy led to less toxicity.

Question 11.18 In most cases, normal bone marrow and gastrointestinal (GI) precursor 132

cel s are able to counteract the effects of cytotoxic chemotherapy because: A. They are not exposed to the chemotherapeutic agent.

B. They have intact mechanisms for apoptosis and cel -cycle arrest.

C. They have rapid turnover.

D. They possess resistance mechanisms.

Question 11.19 Which of the fol owing is TRUE concerning p53?

A. It is a targetable mutation for therapy

B. It is a potent inducer of apoptosis.

C. It causes S-phase arrest in the cel cycle.

D. It can decrease the activity of cytotoxic chemotherapy.

Question 11.20 The final stage of the programmed-cel death pathway is mediated by: A. Bcl-2.

B. p53.

C. Tumor necrosis factor.

D. Caspase cascade.

Question 11.21 Which of the fol owing is inhibited by imatinib?

A. EGFR

B. BRAF

C. KRAS

D. Bcr-abl

Question 11.22 Cetuximab use in colorectal cancer is characterized by: A. Approval in the first-line setting.

B. Limited utility as monotherapy.

C. High toxicity.

D. Response rates of 21% to 23% when used with irinotecan.

Question 11.23 Which of the fol owing is characteristic of a randomized discontinuation trial design?

A. Phase 1 study design

B. Phase 2 study design

C. Phase 3 study design

D. Preferred for drugs with preexisting predictive biomarker Question 11.24 Palbociclib is an inhibitor of :

A. CDK4 and CDK6.

B. FGFR.

133

C. C KIT.

D. VEGFR2.

Question 11.25 Which of the fol owing is a nonmeasurable lesion, according to RECIST

criteria?

A. 3.5 cm × 2.0 cm pancreatic adenocarcinoma

B. 1.7 cm × 1.5 cm invasive ductal carcinoma of the breast C. 0.8 cm × 0.7 cm right paratracheal lymph node

D. 5.5 cm × 4.0 cm rectal adenocarcinoma

Question 11.26 Computed tomography contrast perfusion and dynamic-contrast magnetic resonance imaging may be useful in evaluating:

A. Response to alkylating agents.

B. Response to antiangiogenic agents.

C. Degree of tumor necrosis.

D. Overal survival.

Question 11.27 Which of the fol owing is TRUE regarding the use of time to progression as an end point in clinical trials?

A. Uses a smal er sample size when compared with using overal survival as an end point.

B. Not confounded by subsequent therapies.

C. The study can be completed in a shorter amount of time.

D. Al of the above.

134

Question 11.1 The answer is C.

Erlotinib is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).

Question 11.2 The answer is A.

Folic acid has been observed to have a significant proliferative effect in children with lymphoblastic leukemia. This led to the development of folic acid analogues as antineoplastic agents.

Question 11.3 The answer is A.

Gemcitabine is considered an antimetabolite because of the ability to inhibit the normal pathways involved in purine and pyrimidine synthesis. Temozolomide is an alkylating agent. Mitoxantrone is an anthracycline. Bevacizumab is an angiogenesis inhibitor.

Question 11.4 The answer is A.

Germ cel cancers are curable with primary induction chemotherapy in a subset of patients presenting with advanced or metastatic disease. In the metastatic setting, non–

smal cel lung cancer, gastric cancer, and colorectal cancer are not considered curable with conventional chemotherapy alone.

Question 11.5 The answer is B.

In most cases, the goals of chemotherapy in patients with advanced or metastatic malignancies include pal iation of tumor-related symptoms, improvement in quality of life, and prolongation of time to tumor progression. Eradication of al evidence of disease, although it may occur, is not general y achievable in this setting.

Question 11.6 The answer is D.

Neoadjuvant chemotherapy is used in a variety of local y advanced solid tumors in an effort to confer possible future surgical resectability. Chemotherapy is the primary treatment modality in patients with hematologic malignancies.

Question 11.7 The answer is B.

Adjuvant chemotherapy is used as an adjunct to surgery and/or radiation to reduce the risk of local or distant recurrence from occult micrometastatic disease. Randomized phase III data support the use of adjuvant chemotherapy in breast cancer, colorectal cancer, non–smal cel lung cancer, gastric cancer, Wilms tumor, and osteogenic sarcoma.

135

Question 11.8 The answer is C.

Activation of caspases leads to cel death, whereas activation of Bcl-2, Bcl-xL, and NF-

κB lead to inhibition of apoptosis.

Question 11.9 The answer is C.

The most important indicator of the effectiveness of chemotherapy is the rate of complete response. Despite improvements in response rates and overal survival in certain metastatic diseases, unless a complete response is achieved with chemotherapy, the patient is not considered cured.

Question 11.10 The answer is A.

A partial response is defined as at least a 30% improvement in measurable tumor mass.

Although there are data to suggest that quality of life and survival may improve when a partial response is achieved, it is not consistently applicable across diseases.

Question 11.11 The answer is A.

Bortezomib exerts its anticancer activity by inhibiting the 26S proteasome. The proteasome–ubiquitin complex degrades several intracel ular regulatory proteins including IκB that is an inhibitor of NFκB. Activation of NFκB promotes cel proliferation and inhibition of apoptosis.

Question 11.12 The answer is B.

The majority of relapses in early-stage colon cancer treated with adjuvant chemotherapy occur within the first 3 years. Therefore, adjuvant trials may use 3-year disease-free survival as the primary end point.

Question 11.13 The answer is D.

Gompertzian kinetics provides a model of tumor growth whereby the growth fraction of a tumor decreases exponential y over time. Clinical y undetectable tumors are at their highest growth fraction. Therefore, chemotherapy would result in a significantly higher fractional cel kil .

Question 11.14 The answer is A.

T790M mutation is the most common cause for development of resistance to EGFR

TKIs such as gefitinib and erlotinib in patients with activating mutations in the TK

domain of the EGFR gene. In addition, MET gene amplification, loss of PTEN expression and D761Y mutation has been implicated in the development of resistance to EGFR

TKI.

136

Question 11.15 The answer is D.

ITT analysis includes al patients assigned to a group at the time of randomization regardless of what occurred subsequently. When evaluating a randomized control ed trial, it is important that the OS as wel as the PFS analyses are always by intention to treat (ITT). It avoids the bias introduced by omitting dropouts and noncompliant patients.

Question 11.16 The answer is A.

Both KRAS and BRAF V600E mutations are associated with development of resistance to cetuximab in the treatment of patients with colorectal cancer. EGFR-TK mutations are uncommon in patients with colorectal cancer, and NFκB activation results in pro-apoptotic signaling; however, it has not been shown to be associated with development of resistance to cetuximab in patients with colorectal cancer.

Question 11.17 The answer is B.

The growth of cel s is significantly faster in the early part of the growth curve enabling chemotherapy to cause a greater log cel kil . Dose-dense chemotherapy, by administering cytotoxic drugs more frequently, can produce greater effects on smal er-volume tumors.

Question 11.18 The answer is B.

Normal bone marrow and GI precursor cel s possess intact genetic machinery to undergo apoptosis, repair DNA damage, and halt cel -cycle progression. Therefore, cel s that have been damaged by chemotherapy undergo programmed cel death and are not al owed to continue on through the cel cycle.

Question 11.19 The answer is B.

p53 is a tumor-suppressor gene that mediates apoptosis in cel s with DNA damage. It plays a role in G1 and G2 arrest of the cel cycle after exposure to cytotoxic agents.

Question 11.20 The answer is D.

Caspase activation occurs through the activity of the intrinsic and extrinsic pathways of apoptosis. Bcl-2 is involved in the intrinsic pathway, and tumor necrosis factor mediates the extrinsic pathway. p53 is a tumor suppressor gene involved in the early activation of the programmed-cel death pathway.

Question 11.21 The answer is D.

Imatinib inhibits bcr-abl, platelet-derived growth factor, and c-kit. It is used to treat chronic myeloid leukemia and GI stromal tumors.

137

Question 11.22 The answer is D.

Cetuximab is a chimeric antibody with promising activity in colorectal cancer and other solid tumors. Currently, it is used in the second- or third-line setting, either alone or in combination with chemotherapy. In irinotecan-resistant patients, reported overal response rates with the cetuximab/irinotecan combination are 21% to 23%. Toxicity is usual y manageable and is mostly related to rash.

Question 11.23 The answer is B.

Randomized discontinuation design is a novel phase 2 study design and is useful in identifying the target population for a drug. For a drug with an established predictive biomarker, there is no benefit to using this study design since the target population is already defined by the biomarker.

Question 11.24 The answer is A.

Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. It has been approved for the treatment of ER positive and HER2 negative advanced metastatic cancer in combination with letrozole.

Question 11.25 The answer is C.

The RECIST criteria use evaluation of tumor size to define a response. Measurable disease is a lesion with longest diameter ≥10 mm on CT or on skin if using calipers and nodes with a short axis of ≥15 mm.

Question 11.26 The answer is B.

Computed tomography contrast perfusion has been studied in assessing blood flow to rectal tumors treated with bevacizumab. The functionality of vascular endothelial growth factor receptor blockers has also been studied using dynamic-contrast magnetic resonance imaging. The utility of these tests in assessing response to alkylating agents, tumor necrosis, or effect on overal survival is not known.

Question 11.27 The answer is D.

Time to tumor progression as an end point for studies involving metastatic cancer has certain advantages over using overal survival: Sample size can be smal er, subsequent therapies do not confound the data, and the study may be able to be completed in a shorter amount of time.

Corresponding chapter in Cancer: Principles & Practice of Oncology, Tenth Edition: 30

(Assessment of Clinical Response).

138





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 12.1 Which of the fol owing is TRUE concerning a clinical trial?

A. The sample size of a clinical trial is fixed and determined before the trial begins.

B. Clinical trials are prospectively planned experiments involving only animals.

C. Using tumor registry data to compare the survival rates of prostate cancer patients treated with surgery to those of patients who received radiotherapy is an example of clinical trial.

D. Clinical trials test a clearly stated hypothesis using a predefined analysis plan.

Question 12.2 Phase I trials of cytotoxic agents are designed to determine a dose that is appropriate for use in phase II trials. Which of the fol owing statements is TRUE about phase I trials?

A. Phase I trials involve the first use of a drug, device, or procedure in humans in a new disease setting or a new combination of therapies.

B. Patients for phase I trials are usual y not chosen on the basis of their likelihood of having a favorable response to the experimental treatment.

C. Phase I trials do not require statistical justification because the sample sizes are usual y smal .

D. A and B.

Question 12.3 Which of the fol owing regarding the conventional 3 + 3 phase I designs is TRUE?

A. Participants are often those with end-stage disease who have many treatment options.

B. Such studies are usual y performed by starting with a high dose.

C. Cohorts of three to six patients are treated at each dose level, and the initial dose is chosen to cause little or no toxicity.

D. The optimal dose recommended for phase I is chosen using a dose-toxicity curve generated from a statistical model fitted to the ful data.

Question 12.4 Traditional phase I trials are designed to determine a dose that is appropriate for use in phase II trials. Which of the fol owing statement on traditional phase I trials is TRUE?

139

A. Many patients may receive subtherapeutic doses and it does not al ow for dose escalation in the individual patient.

B. Al phase I trials are completed in a short time period.

C. Dose escalation in the individual patient is al owed.

D. Phase I trial provides substantial information regarding cumulative toxicity from the study drug

Question 12.5 A drug, device, or other treatment may be considered for phase II testing when:

A. The maximum tolerable dose is known but there is genuine doubt about efficacy and patients with the condition of interest and a likely favorable outcome can be recruited as study participants.

B. A standard treatment exists for comparison.

C. Accrual is rapid enough to al ow recruitment of 20 to 30 patients.

D. An appropriate control group can be recruited at the same time as the experimental group.

Question 12.6 which of the fol owing statements regarding phase II trials is CORRECT?

A. Phase II trials are traditional y performed in patients with a wide variety of tumor types.

B. Two-stage designs al ow for early elimination of ineffective drugs.

C. Patient eligibility should not be restricted by biomarker testing.

D. Phase II trials cannot help develop predictive biomarker assays for the study drug.

Question 12.7 Phase II trials of a single agent are designed to determine whether the experimental drug has any antitumor activity against a given type of tumor and the antitumor e ect is often measured as an objective response based on tumor shrinkage.

However, such a trial is NOT appropriate for the question of patient welfare because: A. The welfare of patients with cancer is often measured by survival or symptom control, but there is no necessary relationship between such beneficial end points and tumor response.

B. Survival is inherently a comparative end point that should be assessed in a prognostical y comparable set of patients.

C. Comparing the survival times of responders and nonresponders is not a valid means of showing a treatment is beneficial to patients because responders may have more favorable prognostic factors than nonresponders.

D. Al of the above.

Question 12.8 Patients in a phase II trial are often recruited in a two-stage manner that al ows early stopping if the nul hypothesis is unlikely to be rejected, thus saving patients from unnecessary exposure to inactive agents. Which of the fol owing is TRUE of a two-140

stage design?

A. The optimal two-stage design minimizes the average sample size and thus optimizes the protection of patients given an inactive agent.

B. Simon two-stage designs are often applied in phase II trials on molecularly targeted drugs and therapeutic cancer vaccines.

C. If both stages are completed, the minimax design usual y enrol s more patients compared with the optimal design.

D. Simon two-stage designs are often used in phase II trials comparing treatment groups to an internal control group to draw conclusions about survival.

Question 12.9 Unlike cytotoxic agents that work by kil ing tumor cel s, cytostatic agents work via biologic e ects that modify the environment of tumor growth; that is, inhibition of a molecular target. Which of the fol owing is TRUE regarding early-phase trials of cytostatic agents such as molecularly targeted drugs and cancer therapeutic vaccines?

A. Phase I trials on cytostatic agents are often designed to identify maximum tolerated dose.

B. Heavily treated patients with end-stage disease greatly benefit from a cancer vaccine.

C. The response rate based on tumor shrinkage is the best primary end point measuring treatment efficacy in phase II trials on cytostatic agents.

D. Because of the nature of low toxicity profiles in cytostatic agents, factorial designs and randomized studies have appealing features and are used to evaluate multiple drugs in a single trial.

Question 12.10 Which of the fol owing best describes Simon phase 2.5 design on molecularly targeted drugs and cancer therapeutic vaccines?

A. The design compares progression-free survival times of the same patient from the current trial with his/her previous trial.

B. The design first treats al eligible patients with two to four courses of the experimental drugs. Patients are then evaluated, and the experimental drug is either continued or discontinued, depending on their response to the initial treatment.

C. The design is similar to a phase III trial except that it al ows a relatively large type I (false positive) error and aims to identify a relatively large difference, thus requiring fewer patients.

D. The design wil compare time to progression of patients in the study with a prospectively identified and prognostical y comparable historical control.

Question 12.11 Which of the fol owing is TRUE of phase III trials?

A. The primary end points should be demonstrably related to patient benefit such as tumor shrinkage.

B. Eligibility criteria should be limited to a group of patients with certain conditions.

C. Conditions of treatment should be suited to community patient care.

141

D. A quality-of-life measure should be included to measure benefit to patients.

Question 12.12 Which of the fol owing is TRUE of randomized treatment assignment?

A. Trial participants are a representative sample of patients with the disease of interest.

B. Randomization may fail to balance unknown prognostic factors in smal studies.

C. Randomization is unnecessary if controls can be matched closely enough to trial participants.

D. Randomization is effective only if patients and treating physicians are unaware of treatment assignment for the duration of the study.

Question 12.13 Randomization is general y unnecessary in which of the fol owing scenarios?

A. Study of patients with a disease that wil uniformly and rapidly progress to an end stage.

B. Phase III trial

C. Screening study on multiple cytostatic agents, such as molecularly targeted drugs or cancer therapeutic vaccines

D. Phase II trial on cytotoxic agents using time to progression as the primary efficacy end point

Question 12.14 Which of the fol owing is TRUE of power and hypothesis testing in clinical trials?

A. Statistical power mainly depends on the anticipated size of treatment effect. Trials designed to detect a large effect wil demand smal sample sizes.

B. Statistical power is also heavily influenced by the prespecified type I error (probability of erroneously claiming a “positive” result), and a two-sided type I error of 0.05 has been widely accepted, especial y in phase III trials.

C. Confidence intervals do not provide information about the size and direction of treatment effect, and it is less informative than significance testing.

D. Because data from smal randomized trials can be pooled for meta-analysis, the calculation of sample size for a randomized clinical trial is no longer critical.

Question 12.15 Which of the fol owing is TRUE for therapeutic equivalence (or noninferiority) trials?

A. Therapeutic equivalence trials are designed to test similarity, as measured by a clinical end point, between the experimental drugs and the standard treatment.

B. Because it is impossible to prove equivalence in true sense, in practice therapeutic equivalence wil be accepted if the difference in efficacy is larger than or smal er than a prespecified amount δ.

C. The traditional superiority trials can be used to prove equivalence D. A trial designed to demonstrate therapeutic equivalence requires fewer patients 142

because it usual y al ows a relatively large type I error.

Question 12.16 Therapeutic equivalence trials often express results as an estimate of difference between two treatments with a 95% confidence interval. Which of the fol owing statements about the 95% confidence interval is CORRECT?

A. The confidence interval is a range of values consistent with the hypothesized difference, given the precision with which the trial can measure that difference.

B. The trial estimates that in 5 of 100 cases the true difference wil fal outside the 95%

confidence interval.

C. It is unlikely that the true difference is larger than the lower limit or smal er than the upper limit of the confidence interval.

D. If the confidence interval includes 0, then the trial has shown that the two treatments do not differ.

Question 12.17 Which one of the fol owing describing the pros and cons of Bayesian methods in planning clinical trials is TRUE?

A. In the traditional statistical (frequentist) methods, the treatment effect is regarded as a fixed but unknown parameter, and the likelihood of the parameter is described using a probability derived from observed frequencies in a defined distribution. In contrast, a Bayesian statistical method assumes that the treatment effect itself is a random quantity drawn from a prior distribution.

B. Bayesian methods are more widely applied in planning phase III trials than phase I or phase II trials.

C. Bayes’ theorem can be considered as a substitute for randomization.

D. Bayesian clinical trials require fewer patients than frequentist trials.

Question 12.18 The intention-to-treat analysis is considered the primary analysis of data from a clinical trial. Which of the fol owing describes an intention-to-treat analysis?

A. An ineligible patient is not included in an intention-to-treat analysis because the study treatment is not appropriate for that patient.

B. Al patients who give consent and are randomized are included in the intention-to-treat analysis in the study arm to which they were randomized.

C. Data from patients who are ineligible or who die or withdraw from the study before completion should be analyzed separately from data from eligible patients who complete the trial.

D. Lack of compliance can distort the results from patients who fail to complete the trial, so these data should be dropped from an intention-to-treat analysis.

Question 12.19 An interim analysis is any assessment of data performed during patient enrol ment or fol ow-up period of a trial. Which of the fol owing is TRUE for planning clinical trials with interim analyses?

143

A. Multiple looks at outcome data over the course of a trial wil alter type I and II errors.

Unless they are included in the design, multiple looks wil cause the operating characteristics of the trial to deviate from the planned values.

B. Interim outcome information is general y available to participating physicians and study leaders.

C. The method of stochastic curtailment is designed to calculate conditional power (the projected probability of rejecting the nul hypothesis at the end of study), conditional on the accumulated information, and to stop the trial if the conditional power is smal (e.g., 0.2). In such a “futility” analysis, the number of interim analyses does not need to be fixed in advance.

D. A data-safety committee is usual y put in charge of the interpretation of interim analyses. The committee also includes the study leaders to notify the patients and medical community in a timely manner.

Question 12.20 One of the most important features that make survival data di erent from other kinds of data is the presence of censoring. That is, the actual survival times for some patients cannot be observed during the study. Which of the fol owing is TRUE for the analysis of survival data?

A. The usual statistical methods are appropriate for analyzing survival data.

B. Two methods are most frequently used for the estimation of survival curves. The life table method requires relatively large sample size, and the Kaplan–Meier product limit method is appropriate for any sample size.

C. Traditional summary statistics, such as means and standard deviations, can provide a sufficient summary for survival data without censoring.

D. The statistical power of clinical trials using survival as a primary end point wil be mainly determined by the total number of patients rather than the actual number of events including death or tumor progression.

Question 12.21 An important assumption in the analysis of survival data is noninformative censoring. That is, censoring is not related to the outcome of interest. For a clinical trial with cancer-speci c survival as the primary end point, which of the fol owing patients is more likely to suffer from informative censoring?

A. Alive at the time of study closeout

B. Withdrew from the trial because of disease progression C. Died of accident

D. Moved out of the region

Question 12.22 Which of the fol owing is characteristic of phase 0 trials?

A. Phase 0 trials do not require an assay for measuring the pharmacodynamic endpoint.

B. Patients receive multiple doses of the experimental drug.

C. Phase 0 trials identify whether the experimental drug has inhibitory effect against its 144

specified molecular target.

D. Drug doses used in these trials are expected to cause significant toxicity.

Question 12.23 Which of the fol owing is TRUE regarding meta-analysis?

A. Meta-analysis combines the results of several studies that address a set of related research hypothesis.

B. Meta-analysis on therapeutic studies usual y includes both randomized and nonrandomized trials.

C. Meta-analysis based on summarized p-values is more precise than meta-analysis based on individual patient data.

D. Meta-analysis is an alternative to properly designed and sized randomized clinical trials.

145

Question 12.1 The answer is D.

Sample size may be altered during the course of a trial of any phase on the basis of outcomes observed during the trial. Clinical trials are prospectively planned experiments involving human subjects. Using tumor registry data to compare the survival rates of prostate cancer patients treated with surgery to those of patients who received radiotherapy is an example of observational study.

Question 12.2 The answer is D.

Statistical power is not the focus of phase I trial design, but the issues (e.g., patient safety) are major, and long-term consequences (e.g., loss of patient benefit and waste of resources) are severe if resources are incorrectly directed toward ineffective treatments or away from effective treatments. Therefore, careful statistical design is needed if sound and sufficient information is to be drawn from smal and often heterogeneous patient samples.

Question 12.3 The answer is C.

Participants are often those with end-stage disease whose treatment options have been exhausted. Patients with advanced disease that is resistant to standard therapy are often included in such trials. Such studies are usual y performed by starting with a low dose that is not expected to produce serious toxicity in any patients. The conventional 3+3 phase I design is total y algorithm based, and the dose recommended for phase II trials is chosen among the fixed and prespecified levels. The recommended dose, commonly referred to as the maximum tolerated dose, is usual y taken as the highest level for which the dose-limiting toxicity rate is less than 33%.

Question 12.4 The answer is A.

Traditional phase I study design has several inherent limitations. Many patients may receive subtherapeutic doses and it does not al ow for dose escalation in the individual patient. Furthermore, it may require longer period of time to complete than some of the newer trial designs and may not be effective in determining cumulative toxicity.

Question 12.5 The answer is A.

Phase II trials may be single-arm trials testing a single treatment, so no direct comparison of treatments may be involved. The ideal sample size depends on many factors, including the nature and variability of the primary outcome, the expected effect size, and the procedures to be used to test hypotheses. An appropriate primary outcome is determined by the nature of the treatment being tested and the goals of the study.

146

Question 12.6 The answer is B.

Phase II trials are traditional y restricted to a particular tumor type because the biologic response of interest is that of the tumor itself. Phase II trials are designed to establish the experimental drug’s activity in a broad population of unselected patients. The two-stage study design is useful in eliminating ineffective drugs at an early stage. With the entry of molecularly targeted drugs, it is important to identify and develop assays for predictive biomarkers. Furthermore, phase II trials in which patient selection is driven by biomarker testing wil have to be designed to identify the target patient population.

Question 12.7 The answer is D.

There is no biological y inherent relationship between response and survival. For example, a meta-analysis on randomized clinical trials by Torri and col eagues showed that a large improvement in response rate only corresponded to a minor increase in survival. In addition, survival end points are comparative in nature and require taking the distribution of potential prognostic factors into consideration.

Question 12.8 The answer is A.

The optimal two-stage design minimizes the average sample size and thus optimizes the protection of patients given an inactive agent. In some cases molecularly targeted drugs and therapeutic cancer vaccines are not expected to be toxic to normal tissue. Simon and col eagues have suggested that some therapeutic cancer vaccines do not require a toxicity trial. For some molecularly targeted drugs, preclinical studies provide a target serum concentration, in such cases the phase I trial can be designed to estimate the relationship between the dose administered and serum concentration. The minimax design have somewhat larger average sample size compared to the optimal design, but in some cases it is preferable because the smal increase in average sample size is more than compensated for by a large reduction in maximum sample size. Trials of cytostatic agents often choose time to progression as the primary end point. When testing cytotoxic agents, the use of Simon two-stage designs is limited to situations where outcome assessment can be made shortly after patients are treated. These designs usual y are not practical for end points requiring a long period of fol ow-up. Phase II trials usual y do not have an internal control group.

Question 12.9 The answer is D.

Because cytostatic agents usual y have a good safety profile, phase I trials on such drugs are often designed to identify a biological y active dose rather than maximum tolerated dose. Because therapeutic cancer vaccines work via stimulation of tumor reactive T

cel s, heavily treated patients with end-stage disease are less likely to benefit from a cancer vaccine. Cytostatic agents, such as antiangiogenesis factors, growth modulators, or cancer vaccines, usual y selectively work on molecular targets to modulate tumor environment. They may prolong patient survival without causing tumor shrinkage.

147

Therefore, time to progression is often used as the primary end point for such trials.

Question 12.10 The answer is C.

Option A represents a design that used growth modulation index for the assessment of efficacy, option B describes a randomized discontinuation design, and option D is frequently used for trials on the combination of cytotoxic agents. Simon phase 2.5

designs are similar to phase III trials except that they al ow a relatively large type I error and are able to identify only a relatively large difference.

Question 12.11 The answer is C.

The primary end points for evaluating effectiveness of a treatment should be direct measures of patient welfare. Thus tumor shrinkage is usual y not an appropriate end point for phase III trials because it may have little or no relation to patient benefit.

Eligibility criteria should be broad to enhance generalizability of results. Validated quality-of-life instruments are useful parts of phase III trials, especial y if they are directly related to areas of concern to patients. Many areas of patient benefit (e.g., longer survival, lower risk of relapse, accessibility, or lower cost) may not be readily measured by these instruments.

Question 12.12 The answer is B.

A random sample helps to provide a fair, unbiased comparison of the treatments within the population of patients from whom participants are recruited, although this population may not be representative of al patients with the disease. Randomization may not result in equal, or nearly equal, numbers of patients with a particular characteristic in each treatment group, but it does distribute biasing characteristics according to a known probability distribution so that they do not obscure identification of treatment effects, if any, by statistical tests. Matching is not a substitute for randomization; in fact, matching too closely can mask real treatment effects. Blinding of participants or treating physicians to treatment assignment can reduce bias introduced in the process of treatment, whereas randomization reduces bias in patient selection. Randomized assignment to treatment can be used with or without blinding.

Question 12.13 The answer is A.

Randomization is unnecessary for patients with a disease that wil uniformly and rapidly progress to an end stage. In such a setting of homogeneity, a historical control usual y is sufficient. In phase III trials, screening studies of multiple cytostatic agents and phase II trials, including those of cytotoxic agents, randomization al ows the investigators to conclude with confidence that any observed differences between study groups are due to the treatment being studied.

Question 12.14 The answer is B.

148

Statistical power depends on the anticipated size and the variability of the treatment effect. Trials designed to detect a large effect that varies substantial y from patient to patient may demand large sample sizes. Because a confidence interval provides information about the size and direction of treatment effect, it is more informative than significance testing, especial y for “negative” trials. It is true that meta-analysis can combine the results of smal randomized studies and may address questions that cannot be answered by any individual study alone. However, by no means can meta-analyses replace careful y designed and adequately powered randomized trials. This is because different trials can be heterogeneous in terms of diagnostic and staging procedures, supportive care, and methods of patient evaluation and fol ow-up. Such heterogeneity may obscure smal -to-moderate therapeutic effects and undermine the ground for any pooled analyses.

Question 12.15 The answer is A.

Because it is impossible to prove equivalence in true sense, in practice therapeutic equivalence wil be accepted if the difference in efficacy is within a prespecified level δ.

The traditional superiority trials cannot be used to prove equivalence because a

“negative” finding may be simply due to inadequate sample size. Claim D may be true for bioequivalence studies but not for therapeutic equivalence trials. In the former, for example, the objective is to show biologic equivalence of two proprietary preparations of a drug, and a relatively large type I error or large tolerable difference δ is acceptable.

For trials targeting equivalence in therapeutic effect (e.g., mortality rate), however, usual y a much smal er δ is of interest, and this wil require a very large sample size.

Question 12.16 The answer is B.

The confidence interval is a range of values consistent with the observed difference, not the hypothesized difference, given the precision with which the trial can measure that difference. It is likely that the true difference is smal er than the lower limit or larger than the upper limit of the confidence interval. If the confidence interval includes 0, then the trial has failed to show difference.

Question 12.17 The answer is A.

Because Bayesian methods can incorporate information from preclinical studies and sources outside of the trial, they are appealing in planning phase I and II trials. In these trials, information regarding the experimental treatment is sparse, and study design is based on various (usual y subjective) assumptions. However, phase III trials intend to provide reliable and objective guidance for decision making in a given disease, so the subjective nature of prior distributions in Bayesian methods limits their popularity in planning phase III trials. Bayes theorem cannot be considered as a substitute for randomization. Randomization is just as important for the validity of Bayesian methods as for frequentist methods. Bayesian sample size calculation depends on the prior 149

distribution used. If the prior distribution for the treatment effect is a skeptical prior, then the sample size for Bayesian methods may be much larger than the conventional sample size.

Question 12.18 The answer is B.

Omitting patients who die or withdraw without completing the study is a serious source of bias, as is dropping patients for noncompliance or deviation from protocol. These may be patients for whom the treatment does not work or is associated with serious adverse consequences. There is no sound way to identify and eliminate this bias in the context of the trial, so the intention-to-treat analysis includes al consenting, randomized patients in the study arm to which they were randomized.

Question 12.19 The answer is C.

Multiple looks at outcome data over the course of a trial wil not alter type I and II errors and are useful for directing decisions during the trial. Interim outcome information is general y available only to data-monitoring committee. For phase III trials, it is mandatory to have an independent data-safety committee that has the power to recommend termination of the study based on safety concerns, outstanding benefit, or futility. Because the study leaders have a conflict of interest with respect to the decision to continue the study, they are not part of the committee.

Question 12.20 The answer is B.

The usual statistical methods are not appropriate for analyzing survival data because they ignore the censored observations. Even if survival data have no censoring, a survival curve stil provides a better approach for data summary because it takes the length of fol ow-up time into consideration. In addition, survival times are usual y skewed to the right, and the conventional means and standard deviations may not be adequate for data description. The statistical power of clinical trials using survival as a primary end point wil be mainly determined by the actual number of events (i.e., death or progression) rather than the total number of patients.

Question 12.21 The answer is B.

For this study, noninformative censoring means that the probability distributions of cancer-specific survival are similar for both censored and noncensored patients.

However, patients who have experienced disease progression are more likely to have a poor prognosis.

Question 12.22 The answer is C.

Phase 0 trials are first in human trials that help eliminate ineffective and toxic drugs at a very early stage of clinical development. A smal sample of patients receive a single, low 150

dose of the study drug at which it is not expected to cause toxic adverse effects. These trials provide preliminary pharmacokinetic and pharmacodynamic information to inform decisions concerning further evaluation of the study drug. These studies do require the prior development of an assay to measure the pharmacodynamics end point for the study drug.

Question 12.23 The answer is A.

Meta-analysis combines and summarizes the results from several therapeutic trials. To achieve meaningful results and avoid bias, meta-analysis includes only randomized clinical trials including unpublished studies. Studies are not restricted to any particular geographic region. Col aboration of the individual study investigators is required for meta-analysis. Meta-analysis based on individual patient data is more precise than meta-analysis based on summarized p-values. Meta-analysis is not an alternative to properly designed and sized randomized clinical trials.

Corresponding chapter in Cancer: Principles & Practice of Oncology, Tenth edition: 36 (Design and Analysis of Clinical Trials).

151





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 13.1 A 65-year-old man with a 40 pack-year history of smoking presented with hoarseness and a neck mass. The patient did not aspirate and had not lost weight. The patient was found to have T4N2cM0 squamous cel carcinoma (SCC) of the glottic larynx.

T4 classi cation was based on limited cortical erosion of the thyroid cartilage. A total laryngectomy and bilateral neck dissections fol owed by adjuvant radiation therapy was recommended by the otolaryngologist. However, the patient preferred a chance to preserve the larynx. Which treatment approach o ers the best chance to preserve the patient’s larynx and prevent disease recurrence?

A. Radiation therapy alone

B. Induction chemotherapy fol owed by radiation therapy

C. Concurrent chemotherapy and radiation therapy

D. Chemotherapy alone

Question 13.2 Which of the fol owing statements about the epidermal growth factor receptor (EGFR) in head and neck SCC (HNSCC) is TRUE?

A. Randomized trials demonstrated that oral tyrosine kinase inhibitors (TKI) of EGFR

such as erlotinib and monoclonal antibody inhibitors of EGFR such as cetuximab resulted in similar tumor control.

B. Activating EGFR mutations are frequent in HNSCC.

C. The EGFR inhibitor cetuximab improved overal survival when added to definitive radiation therapy or to pal iative platin-based chemotherapy in HNSCC.

D. High EGFR expression is associated with sensitivity to radiation therapy.

Question 13.3 Which of the fol owing are risk factors for HNSCC?

A. Tobacco use

B. Alcohol use

C. Fanconi anemia

D. Al of the above

Question 13.4 Which of the fol owing characteristics are typical features of human papil oma virus (HPV)-related HNSCC?

152

A. Most patients have limited or no smoking history and most have primary tumors that involve the oropharynx (base of tongue or palatine tonsils).

B. Survival outcomes are substantial y better than in patients with smoking-associated HNSCC.

C. The role of the HPV in subsites other than the oropharynx is not clear.

D. Al of the above.

Question 13.5 A 56-year-old man presented to his primary care physician with a 3-month history of right ear pain and two masses on the right side of his neck. On examination, he was found to have a 3-cm right palatine tonsil mass and two enlarged lymph nodes under the upper part of the right sternocleidomastoid muscle. One lymph node was 2 cm, and the other was 1 cm in diameter. A ne-needle aspiration (FNA) of one of the neck lymph nodes was performed and it was consistent with p16+ SCC. Neck and chest computed tomography (CT) showed no additional lymphadenopathy or distant metastasis. What is the stage of his disease?

A. Stage II

B. Stage III

C. Stage IVA

D. Stage IVC

Question 13.6 Which of the fol owing statements is TRUE?

A. Radical neck dissections should be performed for the management of al local y advanced HNSCC.

B. Complications from neck dissections may include hematoma, seroma, lymphedema, wound infections and dehiscence, carotid artery exposure and rupture, and damage to the VII, X, XI, and XII cranial nerves.

C. In a surgical y treated tumor without radiographic evidence of lymph node metastasis, an elective neck dissection should be performed if the risk of occult metastasis to the neck nodes is greater than 50%.

D. For patients who have had a neck dissection for HNSCC, there is no benefit from postoperative adjuvant radiation therapy.

Question 13.7 Which of the fol owing statements is TRUE?

A. The combination of cisplatin and 5FU improves overal survival in comparison to single-agent methotrexate in patients with metastatic HNSCC.

B. Cetuximab has no activity in metastatic or recurrent HNSCC.

C. The combination of cisplatin and 5FU results in a higher tumor response rate than single-agent methotrexate in patients with metastatic HNSCC.

D. Higher chemotherapy doses improve overal survival.

Question 13.8 A 66-year-old man presented to his otolaryngologist with a 4-cm left oor 153

of mouth SCC. A 3-cm left neck node was felt on examination. CT of the neck also showed that the primary tumor invaded into the mandible. There was no evidence of distant metastasis on CT of the chest. What is the most appropriate initial therapy for this patient?

A. Surgery

B. Radiation therapy

C. Concurrent chemotherapy and radiation therapy

D. Chemotherapy

Question 13.9 A 54-year-old woman recently underwent resection of a SCC of the supraglottis with bilateral neck dissections. The pathology showed a T2 lesion completely excised to negative margins but lymphovascular and perineural invasion were present. Two of the 28 lymph nodes contained SCC with extracapsular extension on the right. What is the most appropriate adjuvant therapy for this patient?

A. Observation

B. Radiation alone.

C. Concurrent chemotherapy and radiation therapy.

D. Chemotherapy alone.

Question 13.10 What is the benefit of cetuximab in patients with HNSCC?

A. Concurrent cetuximab and radiation therapy resulted in improved overal survival compared to radiation therapy alone in stage I to IV disease.

B. Cetuximab is equal y effective as cisplatin when given concurrently with radiation therapy.

C. Addition of cetuximab to concurrent cisplatin and radiation therapy improved overal survival and reduced relapse risk.

D. Concurrent cetuximab and radiation therapy resulted in improved overal survival compared to radiation therapy alone in nonmetastatic stage III to IV HNSCC.

Question 13.11 Which of the fol owing statements about the treatment of laryngeal SCC is TRUE?

A. Radiation therapy alone resulted in worse overal survival compared with concurrent chemotherapy and radiation therapy in patients with local y advanced laryngeal SCC.

B. Concurrent chemotherapy and radiation therapy resulted in better local tumor control and laryngeal preservation rate than radiation therapy alone for local y advanced SCC of the larynx.

C. A total laryngectomy is required for the treatment of local y advanced SCC of the larynx.

D. Large-volume laryngeal SCC is defined as tumor that extends more than 1 cm onto the base of tongue and/or extension through the thyroid cartilage into adjacent soft tissue and is best treated with nonsurgical therapy.

154

Question 13.12 True or False: There is an overal survival bene t with adjuvant chemotherapy given after resection of a SCC of the larynx.

A. True

B. False

Question 13.13 Which of the fol owing statements are TRUE? (Select two correct responses)

A. The three subtypes of nasopharyngeal carcinoma are World Health Organization (WHO) type I keratinizing SCC; WHO type II nonkeratinizing SCC; and WHO type III undifferentiated carcinoma or lymphoepithelioma. Type III nasopharyngeal SCC is due to EBV infection and has a much better prognosis than Type I nasopharyngeal SCC.

B. Nasopharyngeal carcinoma is usual y treated with chemotherapy and radiation.

C. Common presenting symptoms of nasopharyngeal carcinomas include hoarseness, painful lower neck mass, and weight loss.

D. The majority of nasopharyngeal carcinomas present with distant metastatic disease.

Question 13.14 A 56-year-old woman presented to her primary care physician with left-sided facial swel ing and facial drooping. The patient had weakness of the lower portion of her face and a palpable left parotid mass. A biopsy was performed and showed high-grade mucoepidermoid carcinoma. There were no palpable neck lymph nodes. What is the best treatment for this patient?

A. Radiation alone

B. Concurrent chemotherapy and radiation therapy

C. Surgery alone

D. Surgery fol owed by adjuvant radiation therapy

Question 13.15 Which of the fol owing statements is TRUE about local y advanced HNSCC? (Select two correct responses)

A. The most common long-term complication of radiation therapy is xerostomia.

B. Once the patient is able to receive nutrition via a G-tube, there is no benefit from having the patient continue to swal ow during radiation therapy.

C. Intensity-modulated radiation therapy (IMRT) decreases the risk of xerostomia.

D. The severity of the acute side effects of radiation therapy is similar when chemotherapy is given concurrently.

Question 13.16 Which of the fol owing statements are TRUE regarding second primary cancers in patients with HNSCC?

A. Patients with HPV-related oropharyngeal SCC have a similar risk of second primary cancers as do patients with smoking-induced HNSCC.

155

B. Patients with resected HNSCC who quit smoking have a lower risk of second primary cancers than those who continue to smoke.

C. Treatment with α-tocopherol decreases the incidence of second primary cancers.

D. Treatment with isotretinoin decreases the incidence of second primary cancers.

Question 13.17 Which of the fol owing statements regarding induction chemotherapy in the treatment of HNSCC is TRUE?

A. Treatment with concurrent chemotherapy and radiation therapy resulted in improved overal survival compared to induction chemotherapy fol owed by radiation therapy for local y advanced laryngeal SCC.

B. Addition of docetaxel to cisplatin and 5FU was associated with similar overal survival when compared to cisplatin and 5FU in patients with local y advanced HNSCC

subsequently treated with radiation therapy alone or concurrent carboplatin and radiation therapy.

C. Induction chemotherapy may facilitate organ preservation in patients with local y advanced laryngeal or hypopharyngeal SCC.

D. Induction chemotherapy fol owed by concurrent cisplatin and radiation therapy results in improved overal survival compared to concurrent cisplatin and radiation therapy.

Question 13.18 A 35-year-old nonsmoking female with a history of chronic oral lichen planus presented with a painful right oral tongue lesion measuring 2.5 cm. Biopsy revealed wel -di erentiated SCC. Ultrasound revealed that the oral tongue lesion was 0.6 cm thick.

CT showed no abnormal neck nodes. The lesion was widely excised and a right selective neck dissection (SND) was performed. Pathology revealed a 2.6 cm SCC, negative surgical margins, no perineural or lymphovascular invasion, and al 15 lymph nodes without SCC.

The pathologic stage was II (T2N0M0). The most appropriate next therapy is: A. Postoperative adjuvant radiation therapy.

B. Postoperative adjuvant concurrent chemotherapy and radiation therapy.

C. Close monitoring.

D. Left selective neck dissection.

Question 13.19 A 58-year-old male with stage IVA SCC of the larynx was treated with concurrent chemotherapy and radiation therapy 12 months ago. On routine surveil ance CT, multiple new bilateral pulmonary nodules were noted. A biopsy of one of the pulmonary nodules showed SCC consistent with metastases from the laryngeal cancer. The patient has an ECOG performance status of 0 and has no serious comorbidities. What is the most effective treatment for this patient’s cancer?

A. Weekly administration of cetuximab

B. Weekly paclitaxel

C. Carboplatin, docetaxel, and cetuximab with peg-filgrastim 156

D. Carboplatin, 5FU, and cetuximab

Question 13.20 A 65-year-old male presented with a large hard palate mass. Biopsy showed a salivary ductal adenocarcinoma. The mass was completely excised and pathology revealed a 4 cm tumor with positive surgical margins. Postoperative adjuvant radiation therapy was given. Nine months later, a surveil ance CT showed several pulmonary nodules.

A biopsy of one of the pulmonary nodules showed metastatic salivary ductal adenocarcinoma. The patient was referred to medical oncology for management. The most appropriate next step in the management of this patient is: A. Weekly cetuximab.

B. Platin, 5FU, and cetuximab.

C. Taxane.

D. Perform immunohistochemistry stain for the androgen receptor.

157

Question 13.1 The answer is C.

RTOG 91-11 was a three-arm randomized trial of patients with laryngeal SCC who were candidates for total laryngectomy but wanted to preserve their larynx. These patients were randomly assigned to receive radiation alone, induction chemotherapy fol owed by radiation, or concurrent chemotherapy and radiation therapy. Concurrent chemotherapy and radiation therapy resulted in the highest chance for laryngeal preservation and disease control. However, overal survival was similar in the three treatment arms.

Question 13.2 The answer is C.

EGFR plays a key role in the development of HNSCC. EGFR overexpression leads to activation of multiple signaling pathways that lead to cel growth and resistance to apoptosis. Activating EGFR mutations are infrequent in HNSCC. Randomized trials demonstrated improved overal survival with the addition of cetuximab to pal iative platin-based chemotherapy (EXTREME Trial) and with the addition of cetuximab to definitive radiation therapy (Bonner et al. Trial). Analysis of EGFR expression in archived tumor tissue from a prospective RTOG clinical trial demonstrated that EGFR

overexpression is associated with resistance to radiation therapy. In contrast to monoclonal antibody inhibitors of EGFR such as cetuximab, no randomized trial has been performed to show clinical benefit of an oral tyrosine kinase inhibitors (TKI) of EGFR such as erlotinib in HNSCC.

Question 13.3 The answer is D.

Several risk factors for the development of HNSCC have been identified. The two most important are tobacco and alcohol use. They seem to be synergistic. Other risk factors include occupational exposure to chemicals and irritants, such as aromatic hydrocarbons and wood dust, and viruses, such as HPV and EBV. In addition, patients with Fanconi anemia are also at increased risk.

Question 13.4 The answer is D.

It has been recognized over the last decade that HPV is the cause of an increasing proportion of SCC of the oropharynx. Today, most cases of oropharyngeal SCC is due to HPV; however, smoking can also contribute to the biology of HPV-related SCC. These tumors are often described as having a basal cel -like or poorly differentiated appearance and are frequently nonkeratinizing. These tumors are more commonly found in never smokers or those patients with a limited smoking history. HPV-related oropharyngeal SCC has a much better prognosis than other oral mucosal HNSCC. The overal survival is higher, and the risks of primary cancer relapse and secondary cancer development are much lower in comparison to HPV-unrelated HNSCC. Patients with HPV-related HNSCC

158

have a better tumor response to chemotherapy and radiation therapy than patients with smoking-associated HNSCC.

Question 13.5 The answer is C.

The patient has a tonsil mass that is between 2 and 4 cm, making the primary tumor T2

classification. He has multiple ipsilateral regional lymph nodes with the largest lymph node being smal er than 6 cm, which is N2b classification. CT found no evidence of distant metastasis. The patient’s disease is classified as T2N2bM0, which is within stage IVA.

Question 13.6 The answer is B.

Control of neck nodal disease is very important in the management of HNSCC. Both neck node dissection and radiation therapy can be used. When HNSCC is treated surgical y, a neck dissection is recommended even in a clinical y negative neck if the risk of occult metastasis exceeds 10% to 15%. A radical neck dissection (RND) removes al neck nodal groups, the internal jugular vein, the eleventh cranial nerve and the sternocleidomastoid muscle. A RND is rarely performed today. A modified radical neck dissection (MRND) preserves one or more of the fol owing structures: cranial nerve XI, internal jugular vein, and sternocleidomastoid. A MRND does not compromise neck nodal disease control. A selective neck dissection (SND) removes selected neck nodal groups only and are the most common type of neck dissection performed today. Most patients with neck nodes involved by SCC should be treated with postoperative adjuvant radiation therapy to reduce the risk of disease recurrence. Postoperative adjuvant concurrent chemotherapy and radiation therapy should be offered to patients with positive surgical margins at the primary tumor site and/or extracapsular nodal extension.

Complications from neck dissections may include hematoma; seroma; lymphedema; wound infections and dehiscence; damage to the VII, X, XI, and XII cranial nerves; carotid exposure; and carotid rupture.

Question 13.7 The answer is C.

Many chemotherapeutic agents including cisplatin, carboplatin, 5FU, taxanes, and methotrexate have activity against metastatic HNSCC. Combinations of conventional cytotoxic chemotherapy and higher doses of chemotherapy result in higher tumor response rates but have not shown an overal survival benefit in comparison to single agent cytotoxic chemotherapy. The anti-EGFR antibody cetuximab has shown significant, albeit modest, activity against HNSCC. The EXTREME trial demonstrated that the addition of cetuximab to platin-based chemotherapy improved overal survival in patients with incurable HNSCC. Also, cetuximab is approved for the treatment of platin-refractory incurable HNSCC.

Question 13.8 The answer is A.

159

This patient has a stage IVA (T4aN1M0) SCC of the oral cavity. The primary therapy that is most effective in most cases of oral cavity SCC is surgery. Primary radiation therapy alone, chemotherapy alone, or concurrent chemotherapy would not be considered to be as effective, particularly with invasion of the mandible. The patient wil likely require postoperative adjuvant radiation therapy alone or with chemotherapy, depending on the pathologic findings.

Question 13.9 The answer is C.

After gross tumor resection, adjuvant therapy with either radiation or concurrent chemotherapy and radiation therapy is recommended for most cases of local y advanced HNSCC. Pathologic findings determine which adjuvant therapy is to be recommended. Major adverse pathologic risk factors for local recurrence are positive surgical margins or extracapsular nodal extension. Minor adverse pathologic risk factors for recurrence include T3 or T4 primary tumors, N2 or N3 nodal disease, and perineural or lymphovascular invasion. If the patient has any major risk factor, adjuvant concurrent chemotherapy and radiation therapy is recommended based on the results of two randomized trials. If the patient has any minor risk factor, adjuvant radiation therapy is recommended. If the patient has no adverse risk factors, observation is recommended.

Question 13.10 The answer is D.

Cetuximab is an EGFR inhibitory antibody that has been used alone or combined with chemotherapy for treatment of metastatic disease, and combined with radiation therapy to treat local y advanced stage III to IV HNSCC. In a randomized phase III trial that compared concurrent radiation therapy with cetuximab to radiation therapy alone for nonmetastatic stage III to IV HNSCC of the oropharynx, larynx, and hypopharynx, cetuximab improved both local disease control and overal survival. In patients receiving cetuximab with radiation therapy, the incidence of acne and infusion reactions were increased but the incidence of mucositis was similar. Concurrent cetuximab with radiation therapy has not been compared with cisplatin and radiation therapy. RTOG

0522 showed the lack of benefit and increased acute toxicity with the addition of cetuximab to concurrent cisplatin and radiation therapy.

Question 13.11 The answer is B.

The treatment of larynx cancers has changed significantly over the last 30 years.

Historical y, the traditional treatment approach for local y advanced SCC of the larynx was a total laryngectomy and neck dissection fol owed by adjuvant radiation therapy.

This resulted in loss of speech, even if the quality of the speech was acceptable before therapy. The Veterans Administration Laryngeal Study Group Trial was a randomized trial that compared total laryngectomy fol owed by adjuvant radiation therapy to induction chemotherapy fol owed by radiation therapy. In the latter treatment arm, 160

salvage total laryngectomy was performed in patients with persistent or recurrent local disease. This pivotal trial established that overal survival was similar between the two treatment arms; however, approximately two-thirds of patients had laryngeal preservation with the nonsurgical treatment approach. Subsequently, RTOG 91-11 was a three-arm randomized trial that compared radiation therapy alone, induction chemotherapy fol owed by radiation therapy, and concurrent chemotherapy with radiation therapy for treatment of patients with local y advanced laryngeal SCC. This trial excluded patients with large volume primary tumors who were felt to benefit from a primary surgical approach. RTOG 91-11 demonstrated that the best chance for laryngeal preservation was when patients were treated with concurrent chemotherapy and radiation therapy, even though overal survival was the same in each of the three treatment arms. However, subsequent improvements in surgical techniques including trans-oral endoscopic laser resection and transoral robotic surgery have also provided surgical approaches to preserve the larynx.

Question 13.12 The answer is B.

Adjuvant chemotherapy has been tested in several trials of HNSCC without resulting in survival improvement. Currently, adjuvant chemotherapy is only used in the treatment of patients with local y advanced nasopharyngeal SCC fol owing concurrent chemotherapy and radiation therapy based on the result of the Intergroup 0099 trial.

Even in this setting, the benefit of adjuvant chemotherapy is unclear.

Question 13.13 The answers are A and B.

Nasopharyngeal carcinomas are unusual in the United States but are much more common in China and Southeast Asia. On the basis of pathology, there are three subtypes of nasopharyngeal carcinoma: WHO type I keratinizing SCC; WHO type II nonkeratinizing SCC; and WHO type III, undifferentiated carcinoma or lymphoepithelioma. The WHO type III is associated with EBV and has a much more favorable prognosis than type I disease. Nasopharyngeal SCC usual y presents with a painless upper neck mass, nasal stuffiness, facial pain, and headache. Cranial nerve involvement occurs in 25% of the patients. Cranial nerves II, III, IV, V, and VI can be affected by the tumor extending into the cavernous sinus. Involvement of the sixth (abducens) cranial nerve is most common, resulting in diplopia. Lateral pharyngeal space extension of the tumor affects cranial nerves IX through XII. Approximately, 80% to 90% of the patients have neck lymph node involvement at presentation and half of the patients having bilateral neck nodal disease. Nasopharyngeal SCC is almost exclusively treated with radiation therapy because of the chal enges of performing effective surgery in the skul base. Concurrent chemotherapy and radiation therapy fol owed by adjuvant chemotherapy is the current standard treatment for patients with stage II to IV SCC of the nasopharynx; however, a recent randomized trial did not show a benefit of adjuvant chemotherapy for patients with EBV-related nasopharyngeal SCC. Definitive radiation 161

therapy alone is effective treatment for stage I nasopharyngeal SCC.

Question 13.14 The answer is D.

The treatment of choice for malignant tumors of the parotid gland is surgery. High grade tumors and tumors with perineural invasion are also treated with adjuvant radiation therapy. There is no clear role for chemotherapy in salivary gland cancers that have been resected or in those treated with definitive or postoperative radiation therapy.

Question 13.15 The answers are A and C.

Xerostomia is the most common long-term complication of radiation therapy for treatment of HNSCC. Xerostomia impairs swal owing function and sleeping and results in poor dentition. Radiation to the head and neck can cause acute and late toxicities.

The degree of toxicity from radiation varies from patient to patient and depends on the dose of radiation, the radiation port, the radiation technique, and whether chemotherapy is given concurrently. The addition of chemotherapy to radiation therapy increases the acute toxicity. IMRT al ows varying doses of radiation to be given to different parts of a radiation field. IMRT permits the parotid gland and other major salivary glands to be spared from treatment, resulting in a lower risk of xerostomia. To decrease the risk of long-term swal owing dysfunction, patients should be strongly encouraged to continue to swal ow to exercise the pharyngeal muscles even if they are receiving the majority of nutrition via a G-tube.

Question 13.16 The answer is B.

Prospective trials on secondary chemoprevention with isotretinoin and α-tocopherol have shown no significant benefit in preventing second primary cancers in patients with resected HNSCC. Smoking status is an important risk factor for the development of second primaries and never smokers have lower risk for second primaries compared to former and current smokers. Those patients who quit smoking have a lower risk of second primary cancers than those patients who continue to smoke. The risk of second cancers is lower in patients with HPV-related oropharyngeal SCC than those with smoking-induced HNSCC.

Question 13.17 The answer is C.

Induction chemotherapy fol owed by definitive radiation therapy has the potential for organ preservation in patients with local y advanced SCC of the larynx or hypopharynx, based on RTOG 91-11 and the European randomized trials, respectively. In the RTOG

91-11 randomized trial, overal survival was similar with induction chemotherapy fol owed by definitive radiation therapy compared with concurrent chemotherapy and radiation therapy. However, there was a significant organ preservation advantage with the concurrent chemotherapy and radiation therapy approach. The addition of docetaxel to cisplatin and 5FU was associated with improved overal survival when 162

compared to cisplatin and 5FU in patients with local y advanced HNSCC subsequently treated with radiation therapy alone (TAX 323 trial) or concurrent carboplatin and radiation therapy (TAX 324 trial). The recent results of the PARADIGM and DeCIDE

randomized trials failed to demonstrate an overal survival benefit of induction chemotherapy added to concurrent chemotherapy and radiation therapy; however, these trials had several limitations complicating trial interpretation.

Question 13.18 The answer is C.

The most appropriate management of a patient with pathologic stage II (T2N0M0) oral cavity SCC is close monitoring. Approximately 80% of these patients wil be cured with appropriate surgery alone. Appropriate surgery in such patients includes resection of the primary tumor site to achieve wide negative margins, and a selective ipsilateral neck dissection if the tumor thickness exceeds 4 to 6 mm. There is no established role for adjuvant radiation therapy or concurrent chemotherapy and radiation therapy in such patients. Also, a lateralized oral tongue SCC would not require a contralateral neck dissection since the risk of contralateral nodal involvement by SCC would be low (<15%). This patient should be fol owed closely by an experienced otolaryngologist for the possibility of a local-regional recurrence. Also, patients with lichen planus are at risk for development of oral mucosal SCC and must be fol owed to monitor for this potential problem.

Question 13.19 The answer is D.

The EXTREME trial showed that the addition of cetuximab to platin and 5FU improved overal survival over platin and 5FU alone in patients with incurable HNSCC. While single agent cetuximab or paclitaxel and the three-drug regimen of carboplatin, docetaxel, and cetuximab have antitumor activity in incurable HNSCC, neither has been compared to platin, 5FU, and cetuximab. The current standard-of-care first-line therapy for patients with incurable HNSCC with good performance status and adequate organ function is the combination of platin, 5FU, and cetuximab.

Question 13.20 The answer is D.

Salivary gland cancers are rare and heterogeneous in pathology, prognosis, and treatment. The most common histologic types include adenoid cystic carcinoma, mucoepidermoid carcinoma, adenocarcinoma, and salivary ductal carcinoma. Salivary ductal carcinomas are aggressive cancers that are treated with surgery and adjuvant radiation therapy. Incurable salivary ductal carcinoma often spreads to the lungs and bone and cytotoxic chemotherapy has limited activity. Several recent reports demonstrated frequent expression of the androgen receptor in salivary ductal carcinomas and, in these patients, high tumor response to androgen blockade. Androgen blockade can include GNRH agonists (leuprolide) with or without androgen receptor blockade (bicalutamide), similar to strategies used to treat prostate cancer. Other 163

potential y effective agents in these patients include enzalutamide and abiraterone.

Corresponding chapters in Cancer: Principles & Practice of Oncology, Tenth Edition: 37

(Molecular Biology of Head and Neck Cancers), 38 (Cancer of the Head and Neck), and 39

(Rehabilitation after Treatment of Head and Neck Cancer).

164





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered response that is BEST in each case.

Question 14.1 A 40-year-old never-smoker woman was diagnosed with adenocarcinoma of the lung a year ago. Molecular testing of her tumor revealed an exon 19 deletion in EGFR. She was started on erlotinib and had a partial response. However, her most recent scan suggested signi cant progression in her disease burden with multiple new liver and lung metastases. Her tumor was rebiopsied. Which of the fol owing alterations is most likely to explain the tumor’s resistance to erlotinib?

A. L858R

B. MET amplification

C. T790M

D. The biopsy is likely to reveal transdifferentiation to smal cel lung cancer (SCLC).

Question 14.2 Sequencing the lung adenocarcinoma of a 54-year-old man with a 60

pack-year smoking history is likely to reveal which of the fol owing features?

A. EML4-ALK translocation

B. An excess of C>T transitions

C. Co-mutation of TP53 and RB1

D. An excess of G>T transversions

Question 14.3 A 55-year-old man with a 30 pack-year history of smoking, presents to the emergency room with shortness of breath. Chest radiograph demonstrates a right upper lobe opacity. Computed tomography (CT) scan reveals a 3.5-cm spiculated mass in the peripheral right upper lobe, which is suspicious for malignancy, without any hilar or mediastinal lymphadenopathy. What is the next best step in management?

A. Bronchoscopy and biopsy of the mass

B. CT-guided biopsy of the mass

C. Brain MRI

D. Refer to thoracic surgeon for resection.

Question 14.4 A 65-year-old man with a 40 pack-year history of smoking, presents to the emergency room with shortness of breath. Chest radiograph demonstrates a left lower lobe mass and left pleural e usion. CT reveals a 3-cm left lower lobe mass, left hilar ful ness, and 165

a moderate left pleural e usion. Biopsy of the mass and thoracentesis are both positive for adenocarcinoma. Staging studies do not reveal any distant metastases. Which of the fol owing is the next best step in his management?

A. Referral to a thoracic surgeon

B. Radiation to the chest

C. Concurrent chemotherapy and radiation

D. Platinum-based doublet therapy

Question 14.5 A 66-year-old man, with a 30 pack-year history of smoking, presents to your o ce for consultation regarding chemotherapy options for metastatic non–smal cel lung cancer (NSCLC), squamous histology. He has no signi cant medical problems and the performance status (PS) is 1. Laboratory studies reveal normal blood counts, liver enzymes, and kidney function. Which of the fol owing treatment regimens would you recommend?

A. Cisplatin and pemetrexed

B. Carboplatin, paclitaxel, and bevacizumab

C. Carboplatin and paclitaxel

D. Carboplatin and erlotinib

Question 14.6 A 55-year-old Asian woman, who is a never smoker, completed four cycles of front-line carboplatin and paclitaxel, for metastatic NSCLC. Imaging studies done after completion of therapy show stable disease. She is very active and has continued to work as a nurse throughout her treatment. Her PS is 0 and she has tolerated the treatment wel , other than grade I neuropathy. Her tumor EGFR status is wild type. She wants “the best treatment possible” and desires further treatment. What would you recommend?

A. Treatment break, erlotinib at the time of disease progression B. Stopping carboplatin, continuing paclitaxel til disease progression C. Continuing carboplatin and paclitaxel for four additional cycles D. Pemetrexed maintenance therapy

Question 14.7 A 58-year-old man, with a 40 pack-year history of smoking is referred to you by a radiation oncologist for management of limited-stage SCLC. What treatment would you recommend?

A. Cisplatin and etoposide chemotherapy

B. Cisplatin and etoposide chemotherapy with concurrent thoracic radiation C. Cisplatin and etoposide chemotherapy, fol owed by PCI if response to chemotherapy D. Cisplatin and etoposide chemotherapy with concurrent thoracic radiation, fol owed by PCI if response to treatment

Question 14.8 Which of the fol owing statement(s) is/are CORRECT regarding the role of adjuvant chemotherapy after resection for NSCLC?

166

A. Adjuvant chemotherapy benefits patients with stage IA disease.

B. Adjuvant chemotherapy benefits patients with node-positive disease.

C. Adjuvant chemotherapy may benefit patients with stage IB disease, who have primary tumors less than 4 cm in size.

D. Al of the above.

Question 14.9 Which of the fol owing statements is CORRECT regarding pulmonary carcinoid tumors?

A. Patients usual y present with carcinoid syndrome.

B. Surgery has a curative potential for resectable localized tumors.

C. Adjuvant chemotherapy is the standard of care fol owing complete surgical resection.

D. Most pulmonary carcinoids are atypical carcinoids.

Question 14.10 Which of the fol owing statement is TRUE regarding rst-line therapy with EGFR tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutated lung adenocarcinoma?

A. Response rates with TKIs are similar to that achieved with chemotherapy, although they are more durable.

B. TKIs have consistently shown superior overal survival compared to chemotherapy.

C. TKIs when combined with chemotherapy yield better outcomes than treatment with either modality alone.

D. TKIs show better response rates and progression-free survival compared to chemotherapy.

Question 14.11 A 60-year-old man with a 45 pack-year history of smoking, presents with chest pain. Chest x-ray reveals a right upper lobe mass. CT scan of the chest demonstrates a 4-cm right upper lobe lung mass, with right hilar and multiple ipsilateral enlarged mediastinal lymph nodes. Bronchoscopy and biopsy of the mass reveals NSCLC. PET scan demonstrates increased FDG-uptake in the lung mass, right hilar and mediastinal lymph nodes, but no other site of metastatic disease. CT of the abdomen and brain MRI are unremarkable. Mediastinoscopy and biopsy reveals NSCLC. His cancer is staged as T2aN2M0, stage IIIA NSCLC. His PS is 1 and he is otherwise in good health. Which of the fol owing is the best management for this patient?

A. Definitive radiation to the chest

B. Radiation to the chest, fol owed by platinum-based chemotherapy C. Concurrent radiation to the chest and platinum-based chemotherapy D. Platinum-based chemotherapy

Question 14.12 When treating a patient with metastatic ALK rearranged adenocarcinoma of the lung, disease progression was noted after 9 months of treatment with crizotinib.

Which of the fol owing is/are valid treatment option(s) for this patient?

167

A. Treatment with a second-generation ALK inhibitor such a ceritinib B. Treatment with chemotherapy

C. Treatment with local ablative techniques for oligo-progression D. Al of the above

Question 14.13 A 45-year-old Asian woman, who is a never smoker, presents to your office for consultation regarding systemic therapy for metastatic adenocarcinoma of the lung. Her tumor has an activating EGFR mutation. Which of the fol owing is a valid rst-line treatment option for this patient?

A. Cetuximab

B. Afatinib

C. Necitumumab

D. Crizotinib

Question 14.14 A 65-year-old Caucasian man, who is a never smoker, presents to your o ce for consultation regarding therapy for metastatic adenocarcinoma of the lung.

Genotyping of his tumor revealed a gene fusion involving ROS1. The patient is interested in knowing more about this alteration and if he would qualify for treatment with any of the currently approved TKIs. Which of the fol owing response is CORRECT?

A. While ROS1 alterations are seen in nearly 15% of adenocarcinomas, but there are no TKIs known to be active in this setting

B. ROS1 rearrangements are seen in 5% of adenocarcinomas, and these tumors respond wel to treatment with erlotinib.

C. ROS1 rearrangements are seen in nearly 2% of adenocarcinomas, and these tumors respond wel to treatment with crizotinib.

D. ROS1 rearrangements are seen in 15% of al adenocarcinomas, and these tumors can respond to crizotinib.

Question 14.15 A 65-year-old man, who is a former smoker presents for consultation regarding management of unresectable stage IIIB adenocarcinoma of the lung. He has a PS

of 0 and adequate blood counts, hepatic, and renal function. Which of the fol owing would you recommend?

A. Concurrent definitive cisplatin and etoposide therapy, no consolidation therapy, no PCI

B. Concurrent definitive cisplatin and etoposide therapy, consolidation docetaxel therapy, no PCI

C. Concurrent definitive cisplatin and etoposide therapy, consolidation gefitinib therapy, no PCI

D. Concurrent definitive cisplatin and etoposide therapy, consolidation gefitinib therapy, fol owed by PCI

168

Question 14.16 A 44-year-old woman presents with a newly diagnosed adenocarcinoma of the lung located at the apex of the left lung and involving the brachial plexus and rst rib. She undergoes a PET scan that reveals no other nodal involvement or distant sites of FDG uptake. The preferred treatment strategy in this situation would be?

A. Definitive treatment with concurrent chemoradiation

B. Surgical resection fol owed by adjuvant chemotherapy

C. Pal iative chemotherapy

D. Concurrent chemoradiation fol owed by surgical resection Question 14.17 Which of the fol owing is a characteristic genomic feature of smal cel lung cancer?

A. Recurrent alterations in EGFR and ALK

B. Recurrent alterations in TP53 and RB1

C. Recurrent mutations in DDR2

D. Recurrent KRAS mutations.

Question 14.18 A 45-year-old male was diagnosed with stage II adenocarcinoma of the right lung. Staging revealed ipsilateral hilar lymph-node involvement and no distant metastatic disease. Patient underwent a sleeve resection of the tumor and his postoperative recovery was uneventful. Which is the next preferred step in the management of his disease?

A. No further treatment, observation only.

B. Adjuvant chemotherapy with a doublet containing cisplatin C. Adjuvant chemotherapy with a doublet containing carboplatin D. Prophylactic cranial irradiation

Question 14.19 What is the most common histologic subtype of malignant mesotheliomas?

A. Epithelial

B. Sarcomatoid

C. Poorly differentiated

D. Biphasic

Question 14.20 Which of the fol owing immunohistochemistry markers is present in malignant mesotheliomas?

A. CEA

B. TTF-1

C. Moc-31

D. Calretinin

Question 14.21 Which of the fol owing is an indicator of poor prognosis in malignant 169

mesothelioma?

A. Anemia

B. Epithelial histology

C. Female gender

D. Thrombocytopenia

Question 14.22 Which of the fol owing nding(s) indicate an unresectable pleural mesothelioma?

A. Direct extension into the spine

B. Extension into the internal surface of the pericardium without pleural effusion C. Direct transdiaphragmatic extension to the peritoneum D. Al of the above

Question 14.23 Frequent alteration of which of the fol owing novel tumor suppressor genes is seen in mesothelioma?

A. RBL1

B. APC

C. RB1

D. BAP1

Question 14.24 Which of the fol owing statements is applicable to peritoneal mesotheliomas?

A. It is not associated with airborne asbestos fiber exposure.

B. Median age of presentation is 50 years.

C. Pleural plaques are observed in approximately 50% of patients.

D. It is more common in females.

Question 14.25 A 60-year-old man was recently diagnosed with metastatic pleural mesothelioma. Assuming that this patient has no other signi cant comorbidities, which of the fol owing chemotherapy regimens would be most preferable in the first-line setting?

A. Cisplatin and gemcitabine

B. Carboplatin and gemcitabine

C. Single agent pemetrexed

D. Cisplatin and pemetrexed

170

Question 14.1 The answer is C.

EGFR mutations occur in nearly 10% of NSCLCs among North American and European patients. These mutations are found more frequently in Asian populations (50%), women and never smokers. EGFR mutations predict response to EGFR–tyrosine kinase inhibitors (TKIs). The most common mutations observed are an in-frame deletion in exon 19 and a point mutation in exon 21 (L858R). These mutations result in prolonged EGFR activation and downstream signaling. Patients treated with EGFR TKIs eventual y develop resistance to these drugs. Acquisition of a secondary EGFR T790M gatekeeper mutation is the most common mechanism of resistance and is seen in about 50% of al cases. MET amplification, activation of other bypass signaling pathways and transdifferentiation to smal cel lung cancer (SCLC) represent other, less prevalent, mechanisms of acquired resistance.

Question 14.2 The answer is D.

Data from several studies that have characterized the genomic profile of lung cancers through next-generation sequencing have offered a valuable insight into the molecular heterogeneity of lung cancers. Tumors from smokers are enriched for G>T

transversions while tumors obtained from never smokers show C>T transitions. EML4-ALK translocations are frequently seen in never or former light smokers. Co-mutation of TP53 and RB1 is predominantly seen in SCLC, not adenocarcinoma.

Question 14.3 The answer is B.

The right upper lobe mass is suspicious for malignancy, however, a tissue diagnosis is needed. Since the location of the mass is peripheral, the best way to approach it would be through CT-guided biopsy, rather than bronchoscopy and biopsy. Once a diagnosis of lung cancer is established, staging studies, such as CT of the abdomen, MRI of the brain, PET, or bone scan may be performed. If the diagnosis is NSCLC, and there is no evidence of distant metastases on staging studies, then he should be referred to a thoracic surgeon for discussion regarding surgical interventions.

Question 14.4 The answer is D.

The seventh edition of the TNM staging system includes several changes to the T

descriptors and reclassification of malignant pleural nodules, pleural effusions and pericardial effusions as M1 disease. He has stage IV disease due to the presence of malignant pleural effusion and should receive treatment with platinum-based doublet chemotherapy for metastatic disease. Surgery would be appropriate only for early-stage disease, while chemoradiation would be the treatment of choice for local y advanced, stage III disease, in patients with good PS and no significant weight loss.

171

Question 14.5 The answer is C.

Cisplatin, pemetrexed and carboplatin, paclitaxel, bevacizumab are possible combinations to consider for patients with advanced NSCLC with nonsquamous histology. For patients with squamous histology, carboplatin and paclitaxel is a reasonable treatment option.

The addition of erlotinib to chemotherapy does not appear to improve survival, compared to chemotherapy alone, in patients with advanced NSCLC.

Question 14.6 The answer is D.

Several randomized studies have demonstrated that there is no survival advantage to continuing platinum doublet therapy beyond four to six cycles. If patients experience significant toxicities fol owing upfront therapy, delaying further treatment til disease progression is a reasonable option. Agents used in the second-line setting for the treatment of NSCLC include docetaxel, erlotinib, and pemetrexed. Patients whose tumors have an activating mutation in the EGFR–tyrosine kinase domain, have the most durable benefit from erlotinib. Maintenance chemotherapy is an option for patients with good PS and stable disease fol owing front-line chemotherapy, who do not experience significant treatment-related toxicities. Maintenance chemotherapy (either pemetrexed or bevacizumab) has been shown to improve overal survival in patients with NSCLC.

Pemetrexed maintenance would be an appropriate option for this patient.

Question 14.7 The answer is D.

In a patient with limited-stage SCLC, the optimal treatment would comprise concurrent chemotherapy and radiotherapy including cisplatin and etoposide, fol owed by prophylactic cranial irradiation (PCI).

Question 14.8 The answer is B.

Adjuvant platinum-based chemotherapy has been shown to improve survival in patients with stage II and III NSCLC who undergo surgical resection. Patients with stage I disease do not benefit from chemotherapy and a subset analysis of the JBR-10 study suggested that patients with tumor size greater than 4 cm may benefit from adjuvant chemotherapy.

Question 14.9 The answer is B.

Only 2% of patients with pulmonary carcinoid present with carcinoid syndrome.

Approximately 30% of patients are asymptomatic at presentation. Ninety percent of pulmonary carcinoids are typical, while 10% are atypical. Surgery is the treatment of choice for carcinoid tumors. There is no role for adjuvant chemotherapy, fol owing complete resection for carcinoid tumors.

Question 14.10 The answer is D.

172

Several prospective randomized clinical trials have shown better response rates and progression-free survival in patients treated with EGFR TKIs, when activating mutations in the tyrosine kinase domain of EGFR (exon 19 deletion or exon 21 point mutation L858R) are present in their tumors. The lack of significant overal survival benefit in these trials has been attributed to a high rate of crossover in the control arm (chemotherapy arm). There is no benefit in combining TKIs with chemotherapy.

Question 14.11 The answer is C.

This patient has local y advanced NSCLC. In this setting, concurrent chemoradiation is better than radiation therapy alone or sequential chemotherapy fol owed by radiation.

Chemotherapy alone would be indicated for pal iation of metastatic disease and is not appropriate in this setting.

Question 14.12 The answer is D.

Acquired crizotinib resistance in adenocarcinomas of the lung can be due to secondary mutations in ALK, ALK amplifications, or activation of bypass signaling pathways through EGFR, KIT etc. Treatment with a second-generation TKI such as ceritinib has been shown to be active and safe in crizotinib resistant tumors, irrespective of the mechanism of resistance. As of early 2015, there have been no clinical trials that have compared ceritinib to chemotherapy in this setting. Treatments with chemotherapy or local ablative therapies are also valid treatment options in this setting, depending on the tempo of progression.

Question 14.13 The answer is B.

In patients with EGFR mutations, initial therapy with an EGFR TKI results in better response rates and longer time to tumor progression compared with chemotherapy.

Erlotinib and afatinib are currently approved EGFR TKIs. Cetuximab and necitumumab are EGFR directed monoclonal antibodies that have been studied in NSCLC. However, they have no established role in the management of patients with EGFR mutated NSCLC at the current time. Crizotinib is a TKI that is active against ALK, ROS1, and MET

altered tumors.

Question 14.14 The answer is B.

The frequency of ROS1 translocations in al patients with NSCLC is approximately 1% to 2%. Crizotinib has shown to be active in this subset of lung cancers with a response rate of 72%.

Question 14.15 The answer is A.

The standard of care for local y advanced unresectable NSCLC is concurrent definitive chemoradiation with cisplatin and etoposide. The role of consolidation docetaxel was 173

investigated in a phase III study conducted by the Hoosier Oncology Group (HOG), where it was associated with increased toxicity and no survival improvement compared to concurrent chemoradiation without consolidation therapy. The Southwest Oncology Group (SWOG) conducted another study in which patients who completed chemoradiation and did not experience progressive disease were randomized to receive gefitinib or placebo. The gefitinib arm had a shorter survival than the placebo arm.

Prophylactic cranial radiation decreases the incidence of brain metastases in patients with stage III disease, but does not improve overal survival. At present, there is no sufficient evidence to recommend PCI in patients with stage III disease.

Question 14.16 The answer is D.

This patient has a pancoast tumor of the lung. Based on data from multiple phase II studies, the preferred management approach in these patients is trimodality therapy with concurrent chemoradiation (typical y with a platinum doublet such as cisplatin-etoposide) fol owed by surgical resection. R0 (complete) resection and pathologic complete response rates as high as 90% and 50%, respectively, have been reported with this approach (Intergroup trial 0160). Curative intent concurrent chemoradiation alone is recommended in patients not deemed to be surgical candidates. Radiotherapy for symptom relief is an option in patients treated with a pal iative intent.

Question 14.17 The answer is B

Genomic characterization of SCLCs has consistently revealed co-alteration of TP53 and RB1 across several different studies. Recurrent EGFR and ALK alterations are more prevalent among patients with adenocarcinoma of the lung, particularly never or former smokers. KRAS mutations are present in nearly a third of al lung adenocarcinomas, and DDR2 mutations in roughly 4% of squamous cel lung cancers.

Question 14.18 The answer is B.

The Lung Adjuvant Cisplatin Evaluation (LACE) meta-analysis indicated an absolute 5-year overal survival benefit of 5% with adjuvant cisplatin based chemotherapy regimens. The analysis included approximately 4,500 patients treated on five large clinical trials. Significant survival benefit was seen in patients with stage II and III NSCLC.

Question 14.19 The answer is A.

Epithelial is the most common subtype of malignant mesotheliomas, comprising approximately 50% to 60% of cases. Biphasic and sarcomatoid mesotheliomas are less frequent. Uncommon tumors that cannot be categorized morphological y are considered to be poorly differentiated.

Question 14.20 The answer is D.

174

Mesothelioma cel s are diffusely positive for pankeratin, keratin 5/6, calretinin, and WT1. CEA, a nonspecific marker, Moc-31, which is commonly seen in adenocarcinomas, and TTF-1, which is seen in primary tumors of the lung and thyroid, are negative in mesotheliomas.

Question 14.21 The answer is A.

The established poor prognostic factors in malignant mesothelioma are poor performance status, male gender, anemia, thrombocytosis, leukocytosis, elevated LDH, and nonepithelial histology including sarcomatoid and biphasic subtypes.

Question 14.22 The answer is D.

Local y advanced and technical y unresectable tumor (T4) is defined by a tumor involving al the ipsilateral pleural surfaces and extension of the tumor to the peritoneum, contralateral pleura, mediastinal organs, spine, chest wal , or internal surface of the pericardium with or without effusion. Involvement of the endothoracic fascia describes a local y advanced but potential y resectable disease.

Question 14.23 The answer is D.

Mutations in the BRCA associated protein 1 ( BAP1) tumor suppressor gene have been described in nearly 20% of mesotheliomas. These mutations are more frequent among smokers. Germline mutations in BAP1 have also been reported in families with a high incidence of mesotheliomas.

Question 14.24 The answer is C.

The incidence of peritoneal mesothelioma is increasing and it currently accounts for 25% to 33% of al mesotheliomas. This disease has a median age at presentation of 60

years and is more common in men with a ratio of three to one. There is a clear relationship between peritoneal mesothelioma and heavy exposure to airborne asbestos fibers, and approximately 50% of patients have pleural plaques.

Question 14.25 The answer is D.

The standard therapy for mesothelioma is the combination of cisplatin and pemetrexed, which is associated with increased overal survival compared to cisplatin alone (12.1 vs.

9.3 months). Patients that are unlikely to tolerate cisplatin may be treated with carboplatin while gemcitabine regimens may be used in patients unable to be treated with pemetrexed.

Corresponding chapters in Cancer: Principles & Practice of Oncology, Tenth Edition: 40

(Molecular Biology of Lung Cancer), 41 (Non–Smal Cel Lung Cancer), 42 (Smal Cel and Neuroendocrine Tumors of the Lung), and 114 (Benign and Malignant Mesothelioma).

175





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 15.1 A 46-year-old woman presents with dul anterior chest pain. She is a lifelong nonsmoker. Her medical history is signi cant for Hashimoto thyroiditis, for which she has been taking levothyroxine for 1 year. Examination is unremarkable. Chest radiograph reveals clear lung elds with a retrosternal density. Computed tomography (CT) scan shows a 4-cm, smooth, anterior mediastinal mass. Laboratory studies show normal blood counts, blood chemistry, lactate dehydrogenase (LDH), α-fetoprotein (AFP), and β-

human chorionic gonadotropin (β-hCG). What is the most likely diagnosis?

A. Smal cel lung cancer (SCLC)

B. Thymoma

C. Pericardial cyst

D. Nonseminomatous germ cel tumor (NSGCT)

Question 15.2 Which of the fol owing statements regarding thymoma is TRUE?

A. The incidence of thymoma is higher in women than in men.

B. Thymoma is most commonly seen in people under 30 years old.

C. The most common site of metastatic spread for thymoma is bone.

D. Complete surgical resection is the most important predictor of long-term survival for patients with thymoma.

Question 15.3 Which of the fol owing statements regarding myasthenia gravis are TRUE?

(Select three correct responses).

A. Myasthenia gravis occurs in 30% to 50% of people with thymoma.

B. Ocular symptoms are the most common initial manifestation of myasthenia gravis.

C. Myasthenia gravis is caused by autoantibodies against presynaptic muscarinic acetylcholine receptors.

D. Thymoma is diagnosed in 15% of people with myasthenia gravis.

Question 15.4 A 32-year-old man presents with an anterior mediastinal mass that was identi ed incidental y on a chest radiograph done as part of an employment examination.

He is asymptomatic and a lifelong nonsmoker, with no signi cant medical history.

Examination is unremarkable. CT scan shows a 4-cm, smooth, lobulated, anterior 176

mediastinal mass without local invasion. Resection of the mass reveals an encapsulated, lymphocyte-rich thymoma (World Health Organization [WHO] type B1) with no capsular invasion. He recovers from surgery without complications. What is the most appropriate next step in the management of this patient?

A. Clinical surveil ance

B. Adjuvant radiotherapy alone

C. Adjuvant chemotherapy alone

D. Adjuvant chemotherapy plus radiotherapy

Question 15.5 Which of the fol owing are the most appropriate systemic therapy options for the treatment of advanced, stage IV thymoma? (Select two correct responses) A. Gemcitabine and docetaxel

B. Cyclophosphamide, doxorubicin, and cisplatin

C. Cisplatin plus etoposide

D. Carboplatin plus paclitaxel

Question 15.6 Which of the fol owing paraneoplastic syndromes are associated with thymoma? Select al that apply.

A. Myasthenia gravis and pure red cel aplasia

B. Subacute cerebel ar degeneration and gynecomastia

C. Polymyositis and hypothyroidism

D. Opsoclonus/myoclonus syndrome and Pel–Ebstein fever

Question 15.7 Which of the fol owing molecularly targeted therapies has meaningful clinical activity in advanced thymoma?

A. Octreotide, a somatostatin analog

B. Erlotinib, an EGFR inhibitor

C. Imatinib, a c-kit inhibitor

D. Sorafenib, a multitargeted kinase inhibitor

Question 15.8 A previously healthy 51-year-old man presents with facial and bilateral upper extremity edema that has progressed over the past 2 weeks. Examination reveals moderate facial, cervical, and bilateral upper extremity edema and prominent anterior chest wal vasculature. He is tachycardic, but his heart sounds are regular and his lungs are clear. There is no lower extremity edema. CT scan of the chest shows a large anterior mediastinal mass encasing and narrowing the superior vena cava, and invading the pericardium and upper lobe of the left lung. There are numerous dilated, intrathoracic col ateral vessels. An experienced thoracic surgeon deems that the lesion is primarily unresectable. Mediastinotomy with biopsy of the mass reveals wel -di erentiated thymic carcinoma (WHO type B3). PET scan shows the large FDG-avid mediastinal mass with no evidence of metastatic disease. What is the most appropriate management of this patient?

177

A. Pal iative radiotherapy fol owed by chemotherapy B. Definitive radiotherapy with concurrent chemotherapy

C. Neoadjuvant chemotherapy fol owed by surgical resection and postoperative radiotherapy

D. Pal iative chemotherapy alone

Question 15.9 Which of the fol owing histologic subtypes is associated with a more favorable outcome in patients with thymic carcinoma?

A. Clear cel carcinoma

B. Wel -differentiated squamous cel carcinoma

C. Sarcomatoid differentiation

D. Smal cel carcinoma

Question 15.10 Thymic carcinoid is associated with which genetic predisposition syndrome?

A. Multiple endocrine neoplasia type 1 (MEN 1)

B. Louis–Bar syndrome

C. Li–Fraumeni syndrome

D. Cowden syndrome

Question 15.11 A 21-year-old man presents with anterior chest pain and cough. Physical examination is unremarkable and his performance status is excel ent. Chest radiography shows widening of the superior mediastinum. CT scan shows a 6-cm anterior mediastinal mass encasing the trachea and great vessels and three 1-cm pulmonary nodules. CT scan of the abdomen and pelvis and a testicular ultrasound examination are normal. Laboratory studies reveal normal blood counts and blood chemistry, LDH of 880 IU/L (normal, 120 to 240 IU/L), AFP of 1,800 ng/mL (normal, <8 ng/mL), and β-hCG of 1.2 mIU/mL (normal,

<5 mIU/mL). What is the most likely diagnosis?

A. Hodgkin lymphoma

B. Benign teratoma

C. Nonseminomatous germ cel tumor (NSGCT)

D. Seminoma

Question 15.12 Which of the fol owing statements is TRUE regarding mediastinal germ cel tumors?

A. The incidence of malignant mediastinal germ cel tumors is the same in men and women.

B. Seminoma is the most common mediastinal germ cel tumor.

C. An elevated serum AFP in a patient with biopsy-proven seminoma indicates the presence of a nonseminomatous component.

D. Mediastinal NSGCTs are associated with better overal survival than testicular 178

NSGCTs.

Question 15.13 A 33-year-old woman presents with a cough and dyspnea on moderate exertion. Physical examination shows an anxious woman with a pulse of 110 beats/min, a respiratory rate of 24 breaths/min, and mild stridor. Lungs are otherwise clear to auscultation, and heart sounds are regular. Chest radiography shows a large anterior mediastinal mass with narrowing of the midtrachea. CT scan shows a 10-cm, heterogeneous, anterior mediastinal mass with foci of dense calci cation that compresses the trachea and narrows, but does not obstruct, the superior vena cava. Laboratory studies reveal normal blood counts, blood chemistry, LDH, carcinoembryonic antigen (CEA), AFP, and β-hCG. She undergoes complete resection of the mass. Pathologic evaluation reveals a multicystic mass with foci of mature gland formation, respiratory epithelium, cartilage, and bone. There is no invasion into adjacent structures, and surgical margins are negative. What is the most appropriate management of this patient?

A. Clinical surveil ance

B. Adjuvant radiotherapy

C. Cisplatin plus etoposide × 4 cycles

D. Doxorubicin plus ifosfamide × 6 cycles

Question 15.14 A 23-year-old man presents with hoarseness, cough, and anterior chest pain. He has a 10 pack-year smoking history. Physical examination is normal. Chest radiography shows a large left mediastinal mass and clear lung elds. CT scan of the chest shows a 5-cm irregular left paratracheal mass. Serum CEA, β-hCG, and AFP are normal. Left mediastinotomy with biopsy of the anterior mediastinal mass reveals a poorly di erentiated malignant neoplasm that is immunohistochemical y negative for leukocyte common antigen, vimentin, S100, TTF1 and chromogranin, but positive for low–molecular-weight cytokeratin. Genetic studies reveal no B- or T-cel rearrangements, and karyotypic analysis shows aneuploidy and isochromosome 12p. Which of the fol owing is the most appropriate therapy for this patient?

A. Cisplatin plus etoposide

B. Cisplatin, etoposide, and bleomycin (BEP)

C. Concurrent chemotherapy and radiation therapy

D. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) Question 15.15 A previously healthy 28-year-old man presents with fatigue and vague chest discomfort. A chest radiograph shows a widened mediastinum, and a CT scan con rms a 9-cm anterior mediastinal mass with focal hemorrhage that l s the substernal space and invades into the upper lobe of the left lung. Laboratory studies show LDH of 850

IU/L (normal, 120 to 240 IU/L), AFP of 8,700 ng/mL (normal, <8 ng/mL), and β-hCG of 220 mIU/mL (normal, <5 mIU/mL). Biopsy con rms embryonal carcinoma with elements of choriocarcinoma. After four cycles of cisplatin, etoposide, and bleomycin (BEP), a CT

scan shows marked shrinkage of the mediastinal mass, now 3 cm in maximal diameter. One 179

month after completion of therapy, LDH is 150 IU/L, AFP is 5 ng/mL, and β-hCG is 2.4

mIU/mL. Which of the fol owing is the most appropriate management of this patient?

A. Clinical surveil ance

B. Cisplatin, ifosfamide, and vinblastine (VIP)

C. Two additional cycles of cisplatin, etoposide, and bleomycin (BEP) D. Resection of the residual mediastinal mass

Question 15.16 A 22-year-old man has a retrosternal mass identi ed on a chest radiograph done during his enlistment into military service. He is an asymptomatic nonsmoker with no signi cant medical history. CT scan shows a 2.5-cm smooth anterior mediastinal mass without local invasion. Serum LDH, β-hCG, and AFP are normal.

Testicular ultrasound is normal. He refuses primary surgical resection. A percutaneous core biopsy shows pure seminoma. Which of the fol owing is the most appropriate management of this patient?

A. Surgical resection

B. Radiotherapy

C. Cisplatin, etoposide, and bleomycin (BEP)

D. Cisplatin plus etoposide fol owed by surgical resection Question 15.17 Mediastinal nonseminomatous germ cel tumors are associated with which of the fol owing? (Select two correct responses)

A. Myasthenia gravis

B. Acute megakaryocytic leukemia

C. Klinefelter syndrome

D. Thymic carcinoid

Question 15.18 A 30-year-old man presents with chest tightness and shortness of breath.

A chest radiograph shows a large mediastinal mass. CT scan shows a 9-cm, lobulated, anterior mediastinal mass invading the left lung and the pericardium with a smal pericardial e usion, a 3-cm right paratracheal lymph node, and a 5-cm subcarinal lymph node. Echocardiogram shows no tamponade. Serum LDH is 440 IU/L (normal, 120 to 240

IU/L), but AFP and β-hCG are normal. Testicular ultrasound is normal. Bronchoscopic core biopsy of the subcarinal mass reveals seminoma. Which of the fol owing is the most appropriate initial management of this patient?

A. Carboplatin plus etoposide

B. Radiotherapy

C. Surgical resection

D. Cisplatin plus etoposide

Question 15.19 A previously healthy 45-year-old man presents with hoarseness and vague chest discomfort. A chest radiograph shows a widened mediastinum, and a CT scan 180

con rms a large anterior mediastinal mass encasing the trachea and abutting the superior vena cava, left pleura, and superior pericardium. Serum AFP is normal, but β-hCG is 10

mIU/mL (normal, <5 mIU/mL). Biopsy shows seminoma. He is treated with cisplatin, etoposide, and bleomycin (BEP). CT scan after treatment shows marked shrinkage of the mediastinal mass, now 2 cm in maximal diameter. β-hCG is 1.2 mIU/mL. Which of the fol owing is the most appropriate management of this patient?

A. Clinical surveil ance

B. Cisplatin, ifosfamide, and vinblastine (VIP)

C. Resection of the residual mediastinal mass

D. Involved-field radiotherapy

Question 15.20 Which of the fol owing is TRUE for mediastinal germ cel tumors according to the International Germ Cel Consensus Classification (IGCCC)?

A. Al pure mediastinal seminomas are good risk

B. Al mediastinal nonseminomatous germ cel tumors are poor risk C. Pure mediastinal seminomas with nonpulmonary visceral metastases are poor risk D. Mediastinal nonseminomatous germ cel tumors without visceral metastases are intermediate risk

181

Question 15.1 The answer is B.

This middle-aged woman has a localized anterior mediastinal mass with mild symptoms.

Thymoma is the most common tumor arising in the anterior mediastinum.

Approximately one-half of patients are symptomatic because of compression of mediastinal structures (e.g., pain, cough, superior vena cava syndrome) or associated paraneoplastic syndromes. Paraneoplastic syndromes can be identified in up to 70% of patients with thymoma, but are uncommon in patients with thymic carcinoma. Patients with smal cel lung cancer are typical y very symptomatic with a central lung mass and bulky mediastinal lymphadenopathy, and nearly al have a history of tobacco use.

Pericardial cysts occur primarily in the middle mediastinum and are usual y asymptomatic. NSGCTs occur predominantly in young men, and 80% to 85% are associated with elevations of AFP and/or β-hCG.

Question 15.2 The answer is D.

The incidence of thymoma is slightly greater in men than in women. Although thymoma can occur in people of al ages, the incidence does increase in the elderly. The most common site of metastasis is the pleura through direct invasion of the pleural space by the primary anterior mediastinal mass resulting in “drop metastases.” Thymoma can metastasize to regional lymph nodes or to distant sites, including lung nodules, but hematogenous metastases tend to occur very late in the course of the disease. The best predictor of long-term prognosis for people with thymoma is the completeness of surgical resection. Other prognostic factors include histologic grade (defined by the World Health Organization [WHO] classification system) and anatomic stage of disease (defined by the TNM or Masaoka staging systems). The presence of a paraneoplastic syndrome, such as myasthenia gravis, may be associated with a better prognosis due to earlier diagnosis of thymoma.

Question 15.3 The answers are A, B, and D.

Myasthenia gravis is the most common paraneoplastic syndrome associated with thymoma, occurring in 30% to 50% of patients. The most common initial manifestation of myasthenia is ocular symptoms, such as diplopia, which progress on to generalized muscle weakness in 80% of patients. Myasthenia gravis is caused by the production of autoantibodies targeting the postsynaptic nicotinic acetylcholine receptor within the myoneural junction. Although pathologic thymic changes, mainly lymphoid hyperplasia, are seen in most patients with myasthenia gravis, only 15% have actual thymoma. In patients with thymoma, thymectomy usual y results in partial improvement in myasthenic symptoms, though most continue to require treatment with immunosuppressive drugs and/or anticholinesterase-mimetic agents (e.g., pyridostigmine).

182

Question 15.4 The answer is A.

This young man has undergone complete resection of a noninvasive, low-grade thymoma. Several histologic classification schemes and staging systems have been developed for thymic neoplasms. The WHO histologic classification is most commonly used and includes both thymomas (types A, AB, B1, and B2) and thymic carcinomas (types B3 and C) with varying degrees of pathologic atypia and aggressiveness. The most commonly used staging system was developed by Masaoka: stage I, no microscopic capsular invasion (noninvasive); stage II, microscopic capsular invasion or gross invasion into perithymic fat; stage III, gross invasion into adjacent organs; stage IVa, pleural or pericardial dissemination; and stage IVb, lymphogenous or hematogenous metastases.

Complete resection of Masaoka stage I, low-grade thymoma is associated with 5- and 10-year overal survival rates of 90% to 100% and 70% to 80%, respectively. Neither adjuvant radiotherapy nor chemotherapy has been shown to benefit patients who have undergone complete resection of Masaoka stage I, or noninvasive, thymoma.

Question 15.5 The answers are B and C.

Systemic treatment for stage IV thymoma is given with pal iative intent, with the goals of shrinking tumor, improving symptoms, and prolonging survival. Due to the rarity of metastatic thymoma, few randomized trials have been performed. However, data from phase II studies suggest that the combinations of cyclophosphamide, doxorubicin, and cisplatin (CAP) and cisplatin plus etoposide (PE) yield similar favorable outcomes, with response rates of 50% to 64% and median overal survivals of 38 to 52 months. In a single-arm, phase II study, the combination of carboplatin plus paclitaxel resulted in an apparently less favorable response rate of 33%. Most other regimens, such as gemcitabine plus docetaxel, have not been adequately studied.

Question 15.6 The answers are A and C.

A wide variety of paraneoplastic syndromes, primarily due to autoimmune dysregulation, have been associated with thymoma. These include connective tissue disorders (polymyositis, systemic lupus erythematosus, Sjogren syndrome, scleroderma), endocrine disorders (Addison disease, hypothyroidism, panhypopituitarism), neuromuscular syndromes (myasthenia gravis, Eaton–Lambert myasthenic syndrome, myotonic dystrophy), hematologic disorders (pure red cel aplasia, hypogammaglobinemia, T-cel deficiency syndrome, amegakaryocytic thrombocytopenia), and miscel aneous disorders (hypertrophic pulmonary osteoarthropathy, nephrotic syndrome, paraneoplastic pemphigus). Subacute cerebel ar degeneration is associated with smal cel lung cancer (SCLC), while opsoclonus/myoclonus syndrome occurs primarily with both SCLC and neuroblastoma. Gynecomastia is associated with HCG secretion by germ cel tumors.

Pel–Ebstein fever is a classic sign of Hodgkin disease.

Question 15.7 The answer is A.

183

A growing number of potential y oncogenic molecular abnormalities have been identified in both thymoma and thymic carcinoma. The most promising clinical results for molecularly targeted agents in thymoma come from a phase II study of the somatostatin analog, octreotide, that reported an objective response rate of 13% when given alone and 32% when used in conjunction with prednisone in patients with tumors that were positive on octreotide scan. Despite the expression of EGFR in many thymic tumors, trials of the EGFR inhibitors gefitinib and erlotinib have reported minimal clinical activity. Imatinib may have activity in the smal subset of patients with thymic carcinoma whose tumors harbor mutations of c-kit, though clinical trials have been largely disappointing. Other multikinase inhibitors, such as sunitinib or dasatinib, are currently undergoing clinical study in patients with thymic malignancy.

Question 15.8 The answer is C.

This middle-aged man presents with superior vena cava syndrome caused by a local y advanced, primarily unresectable thymic carcinoma. Symptoms caused by compression or invasion of mediastinal structures, including anterior chest pain, cough, dyspnea, and superior vena cava syndrome, occur in up to 70% of patients with thymic carcinoma, whereas paraneoplastic syndromes are rare. Because completeness of resection is the most important predictor of outcome, multimodality therapy should be recommended for al patients with thymic neoplasms, both thymoma and thymic carcinoma, whose tumors are judged to be primarily unresectable because of the extent of local invasion.

The most commonly studied combined modality approach is neoadjuvant cisplatin-based chemotherapy fol owed by surgical resection and postoperative radiotherapy.

Cumulative results of studies including patients with both thymoma and thymic carcinoma reveal that neoadjuvant chemotherapy results in an objective response rate of 89% and a complete response rate of 31%. Long-term survival remains the goal of therapy for patients with local y advanced disease, with one trial noting a 7-year disease-free survival rate of 83% after trimodality therapy. Therefore, purely pal iative approaches are only justifiable in patients whose performance status or comorbidities preclude potential y curative combined modality therapy. Although there are some data supporting the use of definitive chemotherapy plus radiotherapy without surgical resection, further studies are needed to define the long-term utility of this approach.

Question 15.9 The answer is B.

In patients with thymic carcinoma, improved survival has been correlated with the fol owing histologic features: negative margins/complete resection, encapsulated tumor, lobular growth pattern, low mitotic activity, and low histologic grade. Low-grade tumors include wel -differentiated squamous cel carcinoma, wel -differentiated mucoepidermoid carcinoma, and basaloid carcinoma. High-grade tumors include smal cel carcinoma, poorly differentiated lymphoepithelioma-like carcinoma, sarcomatoid carcinoma, anaplastic carcinoma, and clear cel carcinoma.

184

Question 15.10 The answer is A.

Thymic carcinoid is a rare tumor that is associated with MEN I. Thymic carcinoids rarely cause serotonin-mediated carcinoid syndrome, but can produce adrenocorticotropic hormone (ACTH), leading to Cushing syndrome. The primary treatment of thymic carcinoid tumors is complete surgical resection, which results in a 5-year survival rate of 60%, although late recurrences and mortality are not uncommon. Adjuvant radiotherapy is reserved for patients with incomplete resections, and the role of adjuvant systemic therapy is unclear.

Question 15.11 The answer is C.

This young man presents with an anterior mediastinal mass and an elevated AFP, a combination of findings that is pathognomonic for NSGCT. Approximately 10% of germ cel tumors originate in extragonadal sites, with 50% to 70% of these arising in the anterior mediastinum. Mediastinal germ cel tumors account for 10% to 15% of al mediastinal tumors in adults and 6% in children. The serum tumor markers LDH, AFP, and β-hCG, are helpful in the diagnosis and management of germ cel tumors. Benign teratomas, the most common mediastinal germ cel tumors (60% to 70%), are not associated with significant tumor marker elevations. Pure seminoma can cause modest elevations of β-hCG, but not AFP. AFP is produced by yolk sac elements present only in NSGCTs. Although serum LDH levels are commonly elevated in Hodgkin and non-Hodgkin lymphoma, AFP levels are not affected.

Question 15.12 The answer is C.

Although benign teratoma occurs with equal frequency in men and women, approximately 90% of malignant germ cel tumors occur in men. Benign teratoma is the most common mediastinal germ cel tumor, accounting for 60% of such tumors in adults. Mediastinal NSGCT is more common that primary pure mediastinal seminoma, which accounts for about 35% of malignant mediastinal germ cel tumors. Patients with pure seminoma may have modest elevations of serum β-hCG, but an elevated serum AFP indicates the presence of a NSGCT component, even in a patient with biopsy-proven seminoma. The overal 5-year survival rate of patients with mediastinal NSGCT is about 50%, which is significantly worse than the prognosis of those with testicular NSGCT.

Question 15.13 The answer is A.

This woman has undergone complete resection of a benign, noninvasive teratoma, the most common mediastinal germ cel tumor. Unlike malignant germ cel tumors, benign teratoma occurs with equal incidence in both men and women, usual y 20 to 40 years of age. Benign teratoma typical y presents as a large anterior mediastinal mass with normal serum tumor markers and symptoms that are due to compression of mediastinal structures. Although they may be adherent to adjacent structures, they are typical y noninvasive. Histological y, both benign and malignant teratomas contain elements from 185

al three germ cel layers: ectoderm (skin, hair, sweat glands, teeth); mesoderm (fat, muscle, bone, cartilage); and endoderm (bronchial or intestinal epithelium). Malignant teratoma, in which one or more of these elements have an invasive or metastatic phenotype, is an aggressive tumor that responds poorly to therapy and is associated with an unfavorable prognosis. In contrast, surgical resection of benign teratoma results in an excel ent long-term survival rate with a low risk of recurrence. Neither adjuvant radiotherapy nor chemotherapy is indicated in the management of patients with benign teratoma.

Question 15.14 The answer is B.

This young man presents with a mediastinal, poorly differentiated carcinoma of unknown primary site that is clinical y and molecularly consistent with an extragonadal germ cel tumor. Poorly differentiated carcinoma arising in the midline structures of a young man is highly suggestive of an unrecognized extragonadal germ cel tumor, even in the face of normal tumor markers. In this patient, immunohistochemical analysis is consistent with carcinoma (positive cytokeratin), and argues against lymphoma (common leukocyte antigen), neuroendocrine tumor (chromogranin), sarcoma (vimentin), lung cancer (TTF1), and melanoma (S100). Genetic analysis can frequently be useful in clarifying histogenesis in such situations. Isochromosome 12p (i[12p]) is pathognomonic of germ cel tumors and is found in approximately 30% of patients in this setting. A long-term survival rate of 16% has been reported for patients with midline, poorly differentiated carcinoma of unknown primary site treated with cisplatin-based chemotherapy appropriate for NSGCT. The presence of i(12p) has been favorably associated with response and survival. Because the International Germ Cel Cancer Col aborative Group considers mediastinal NSGCT a poor-risk tumor, the treatment should consist of four cycles of cisplatin, etoposide, and bleomycin (BEP). Treatment aimed at good-risk NSGCT (answer A), stage III NSCLC (answer C), or lymphoma (answer D) is not appropriate.

Question 15.15 The answer is D.

This young man has had an excel ent response to initial chemotherapy for mediastinal NSGCT with normalization of tumor markers and a smal residual mediastinal mass.

Mediastinal NSGSTs commonly arise in the anterior compartment, and most patients are symptomatic at diagnosis. Elevations of β-hCG and AFP are found in 30% to 50% and 60% to 80% of patients, respectively. NSGCTs frequently consist of a mixture of histologic subtypes, including choriocarcinoma, embryonal carcinoma, endodermal sinus (yolk sac) elements, and teratoma. Primary treatment of mediastinal NSGCTs is cisplatin, etoposide, and bleomycin, as per the guidelines for poor-risk nonseminomatous testicular cancer. Such treatment yields a complete response rate of 40% to 64% and a long-term survival rate of 45%. Surgical resection is recommended for patients with residual masses after completion of initial chemotherapy and normalization of tumor 186

markers. If viable, NSGCT is identified in the resected specimen, then two further cycles of cisplatin-based therapy are indicated. If the residual mass reveals only mature teratoma or necrosis, then clinical surveil ance without further treatment is indicated.

The role of surgical resection in patients with incomplete tumor marker responses has not been clearly defined, but such patients would typical y proceed to salvage chemotherapy with a regimen such as VIP.

Question 15.16 The answer is B.

This young man presents with a localized mediastinal seminoma. Pure mediastinal seminoma is a rare disease that occurs mainly in men 20 to 40 years of age and accounts for 35% of malignant mediastinal germ cel tumors. Despite a slow growth rate, mediastinal seminoma tends to present as a large tumor that causes symptoms due to compression of mediastinal structures. Serum β-hCG and LDH levels may be modestly elevated in patients with pure seminoma, but an elevated AFP level would be indicative of a nonseminomatous germ cel component. Radiotherapy is the treatment of choice for localized mediastinal seminoma, yielding long-term survival rates of 60% to 80%.

The total radiation dose should be ≥45 Gy, and the field should include the mediastinum and bilateral supraclavicular fossae. Although surgery fol owed by adjuvant therapy also yields high long-term survival rates, resection is not general y indicated in the management of mediastinal seminoma. Because of the exquisite sensitivity of seminoma to radiotherapy, the relatively low rates of recurrence after radiotherapy and the high cure rates associated with salvage chemotherapy, systemic treatment is not recommended for patients with localized disease.

Question 15.17 The answers are B and C.

A number of hematologic malignancies occur in association with mediastinal NSGCT, including acute megakaryocytic leukemia, acute myeloid leukemia, erythroleukemia, malignant histiocytosis, and myelodysplastic syndrome. These may be diagnosed either before or at the same time as the NSGCT. In addition, mediastinal NSGCTs can develop malignant, nongerm cel components, such as adenocarcinoma, squamous cel carcinoma, or sarcoma. Klinefelter syndrome (47XXY) is found in up to 20% of patients with mediastinal NSGSTs. Myasthenia gravis is associated with thymoma, not NSGCT.

Thymic carcinoid is associated with MEN1 syndrome.

Question 15.18 The answer is D.

This man presents with local y advanced, mediastinal seminoma that invades adjacent structures and involves regional lymph nodes. More than half of patients with mediastinal seminoma wil have metastases at diagnosis, primarily to the intrathoracic lymph nodes, lung, or bone. Patients with local y advanced disease are usual y treated with cisplatin-based chemotherapy with or without radiotherapy, whereas those with distant disease are treated with chemotherapy alone. Cisplatin-based treatment results 187

in a response rate that approaches 95% and a complete response rate of up to 85%, with a long-term disease-free survival rate of 80% to 85%. Carboplatin-based therapy is known to be inferior to cisplatin-based regimens. For patients with bulky, local y advanced mediastinal seminoma, the large radiation fields required to encompass al disease can result in excessive pulmonary or cardiac toxicity. In addition, despite high rates of local control, 20% to 40% of patients with local y advanced disease who are treated with radiotherapy alone wil develop distant metastases, leading to the recommendation for primary systemic chemotherapy in such patients. Surgery is not indicated in the primary treatment of mediastinal seminoma.

Question 15.19 The answer is A.

This man has had an excel ent response to initial chemotherapy for local y advanced mediastinal seminoma with normalization of β-hCG and a smal residual mediastinal mass. The optimal management of patients with a residual mass after initial chemotherapy or radiotherapy for seminoma remains controversial. Most studies have demonstrated that viable seminoma is rarely found in resected residual masses and that about 85% of such specimens consist entirely of scar tissue. Other studies have shown that up to 25% of residual masses more than 3 cm in size contain viable seminoma.

Nevertheless, resection of a residual mass is not recommended unless the mass enlarges during clinical surveil ance. Similarly, the addition of radiotherapy after chemotherapy has not been shown to be of significant benefit. Salvage chemotherapy with a regimen such as VIP, with or without aggressive local therapy, is indicated for recurrent disease.

Question 15.20 The answer is B.

Al patients with mediastinal NSGCT are considered poor risk per the International Germ Cel Consensus Classification (IGCCC) regardless of serum tumor marker levels, the extent of local/regional disease, or the presence/absence of distant metastases. As such, al patients with mediastinal NSGCT who require primary chemotherapy should receive four cycles of cisplatin, etoposide, and bleomycin (BEP) or vinblastine, ifosfamide, and cisplatin (VIP). For mediastinal seminoma, patients without nonpulmonary visceral metastases are categorized as good risk, while those with nonpulmonary visceral metastases are intermediate risk. Patients with good-risk disease who require chemotherapy may receive either three cycles of cisplatin, etoposide, and bleomycin (BEP) or four cycles of cisplatin plus etoposide, whereas those with intermediate-risk disease should receive four cycles of cisplatin, etoposide, and bleomycin (BEP).

Corresponding chapter in Cancer: Principles & Practice of Oncology, Tenth Edition: 43

(Neoplasms of the Mediastinum).

188





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 16.1 Which of the fol owing statements about the incidence of esophageal cancer is TRUE?

A. Esophageal cancer is relatively uncommon in the United States, and the lifetime risk of being diagnosed with the disease is less than 1%.

B. Incidence rates among white men continue to increase and now exceed 8 per 100,000 person-years, and reflect the marked increase in the incidence of adenocarcinoma of the esophagus of more than 400% in the past 2 decades.

C. Although the incidence of adenocarcinoma in white women (2 per 100,000) is lower than that in white men, rates of adenocarcinoma have increased in women by more than 300% during the past 20 years.

D. Only A and B

E. Al of the above

Question 16.2 Which of the fol owing statements are TRUE? (Select two correct responses)

A. Blood group B has been associated with gastric cancers.

B. Most of the patients with Helicobacter pylori infection wil develop gastric cancer.

C. Epstein–Barr virus infection has been noted in a certain type of gastric carcinoma.

D. WHO classifies H. pylori infection as class I carcinogen.

Question 16.3 Which of the fol owing are risk factors for development of esophageal adenocarcinoma? (Select two correct responses)

A. Gastroesophageal reflux disease

B. Low BMI

C. Barrett esophagus

D. H. Pylori infection

Question 16.4 Which of the fol owing is TRUE for cancer of the esophagus?

A. Adenocarcinoma has a better outcome compared to squamous cel carcinoma of the esophagus.

B. HER2+ overexpression is an adverse prognostic factor similar to breast cancer.

189

C. The incidence of esophageal cancer is higher in African-American compared to Caucasian men.

D. The lifetime risk of being diagnosed with esophageal cancer is 1%.

Question 16.5 Which of the fol owing statement(s) about the molecular biology of esophageal cancer is/are TRUE?

A. EGFR overexpression correlates with poor prognosis including poor response to chemotherapy.

B. Presence of p53 point mutation correlates with response to induction chemotherapy and predicts survival after esophagectomy.

C. Reduced expression of E-cadherin correlates with progression from Barrett esophagus to dysplasia and final y to adenocarcinoma.

D. Al of above

Question 16.6 Which of the fol owing is TRUE about Barrett esophagus with high-grade dysplasia?

A. Esophageal cancer incidence per year is 30%.

B. Esophagectomy is the only available treatment option.

C. Endoscopic mucosal resection can be used as a therapeutic option in this case.

D. Surveil ance with annual endoscopy

Question 16.7 A 57-year-old Caucasian woman with long-standing re ux symptoms presented with hematemesis to a local emergency department. Endoscopy revealed a distal esophageal malignant ulcer with involvement of the gastroesophageal (GE) junction and 5

cm of the gastric cardia. Biopsy revealed intestinal metaplasia at the GE junction and con rmed a diagnosis of adenocarcinoma. CT shows thickened distal esophagus and proximal stomach, hiatal hernia, and enlarged celiac nodes. Which statement most accurately describes her cancer?

A. She has a Siewert type I cancer: adenocarcinoma of the distal esophagus, which usual y arises from an area with specialized intestinal metaplasia of the esophagus (i.e., Barrett esophagus) and may infiltrate the esophagogastric junction from above.

B. She has a Siewert type II cancer: adenocarcinoma of the cardia, which arises from the epithelium of the cardia or from short segments with intestinal metaplasia at the esophagogastric junction.

C. She has a Siewert type III cancer: adenocarcinoma of the subcardial stomach, which may infiltrate the esophagogastric junction or distal esophagus from below.

Question 16.8 A 48-year-old man with a long-standing history of GERD presented to the clinic with dysphagia and weight loss. The patient had EGD with biopsies that showed a friable circumferential lesion in the lower part of the esophagus. EUS revealed a cT3 lesion with one regional lymph node. CT and PET scan for evaluation did not show any distant 190

sites of metastasis. Initial treatment with preoperative chemoradiation using weekly carboplatin and paclitaxel was suggested for the patient. Which of the fol owing is TRUE for this treatment modality?

A. The rate of pathologic complete response is 5%.

B. Chemoradiation fol owed by surgery can be used only for localized esophageal adenocarcinoma but not squamous cel carcinoma.

C. Chemoradiation fol owed by surgery improves PFS but not OS compared to surgery alone.

D. Chemoradiation fol owed by surgery improves both PFS and OS compared to surgery alone.

Question 16.9 A 54-year-old male has a 10-year history of untreated GERD. He presents to his primary care physician with melena. The patient underwent EGD which revealed a mass in the GEJ junction that is biopsy proven to be adenocarcinoma. EUS and PET-CT

scan showed a mass that is abutting the diaphragm, but no evidence of distant metastasis.

The patient has no comorbid conditions and has very good performance status. What of the fol owing responses are TRUE about using perioperative chemotherapy ECF? (Select two correct responses)

A. The lesion is not resectable and hence only chemotherapy should be offered.

B. There was a 6-month improvement in progression-free survival, a 4-month improvement in median survival.

C. There was 25% pathologic complete response seen.

D. The use of ECF in this setting did not increase the rate of curative resection though it improves survival.

Question 16.10 A 49-year-old female with a long-standard history of GERD presents to her gastroenterologist with worsening abdominal pain, weight loss, and heart burn. EGD

with biopsy shows a tumor in the lower third of the esophagus. Biopsy reveals high-grade adenocarcinoma. EUS shows cT3 and one paraesophageal lymph node. CT scan and PET

scan done for staging shows multiple liver lesions consistent with metastasis. The patient has no comorbidities and her performance status is 0. Which of the fol owing is the most appropriate next step?

A. Chemotherapy with cisplatin and 5FU

B. Docetaxel, cisplatin, and 5FU

C. Epirubicin, cisplatin, and 5FU

D. Check for HER2 overexpression on the esophageal tumor tissue Question 16.11 In the question above, HER2 was overexpressed on the tumor tissue.

Which treatment do you offer?

A. Chemotherapy

B. Chemotherapy plus cetuximab

191

C. Chemotherapy plus trastuzumab

D. Supportive care

Question 16.12 Which of the fol owing cases would be sent for genetic testing? (Select two correct responses)

A. A patient with gastric cancer histopathological y confirmed as diffuse and older than 50 years with a first-degree relative with stomach cancer at the age of 55.

B. A patient with diffuse gastric cancer, who has an uncle with stomach cancer diagnosed at the age of 45 years with an aunt with lobular breast cancer.

C. A 37-year-old man diagnosed with diffuse gastric cancer, and no family history of gastric cancer.

D. A 62-year-old male smoker diagnosed with gastric cancer and history of nasopharyngeal cancer.

Question 16.13 Which of the fol owing syndrome is usual y associated with intestinal type of gastric cancer?

A. Lynch syndrome

B. Li–Fraumeni syndrome

C. Familial adenomatous polyposis syndrome

D. Peutz–Jeghers syndrome

Question 16.14 Which of the fol owing gene mutations is associated with the highest gastric cancer risks?

A. BRCA1/2

B. P53

C. CDH1

D. APC

Question 16.15 A 22-year-old woman is diagnosed with metastatic gastric cancer, with di use involvement of the stomach and linitis plastica. Her father died of the same cancer at an age of 42 years. Her mother is concerned about familial gastric cancer and is asking for information about hereditary gastric cancer and appropriate screening for her other children. Which of the fol owing would be the most appropriate recommendation to this family?

A. Hereditary gastric cancer is rare and unlikely. She may just have some environmental exposures or DNA mismatch repair gene mutations that cannot be screened for.

B. She may very wel have hereditary early onset diffuse gastric cancer, but no surveil ance or workup is recommended because this has yet to be confirmed in larger studies.

C. E-cadherin mutation testing should be considered here, and, in fact, prophylactic gastrectomy should be considered strongly for her siblings if a germline E-cadherin 192

mutation is confirmed and mucosal abnormality can be documented by endoscopic examination of the stomach.

D. E-cadherin mutation testing should be considered, and, in fact, prophylactic gastrectomy should be considered strongly for her siblings if a germline E-cadherin mutation is confirmed even if no mucosal abnormalities are seen by endoscopic examination of the stomach.

Question 16.16 Which of the fol owing is TRUE about the use of diagnostic modalities in patients with gastric cancer?

A. PET scan is less useful in assessing metastasis of signet cel subtype.

B. The accuracy rate of CT scan for staging of advanced gastric cancer was 96%.

C. There is no role for laparoscopy if staging CT scan was negative.

D. Brain MRI should be routinely done as part of the initial work up.

Question 16.17 A 48-year-old male who was diagnosed with adenocarcinoma of the stomach underwent partial gastrectomy. PET-CT prior to surgery shows no evidence of distant disease. He had 1 of 18 lymph nodes removed involved with cancer. Margins were negative for cancer. The pathologic stage is IIB (T3 N1 tumor). He was referred to you to discuss adjuvant treatment options. He has an ECOG performance status of 1. What is the best treatment modality?

A. Chemotherapy with Carboplatin and Paclitaxel

B. There is no evidence for benefit from adjuvant treatment in this case.

C. 5FU and leucovorin, fol owed by 45 Gy in 25 fractions plus concurrent 5FU and leucovorin.

D. Check for HER2 over expression and if positive, treat with cisplatin/5FU plus trastuzumab.

Question 16.18 A 48-year-old gentleman presents to the clinic with abdominal pain and weight loss. CT scan of the abdomen and pelvis showed di use gastric wal thickening as wel as liver lesions suspicious for metastasis. CT-guided biopsy of one of the lesions con rmed metastatic adenocarcinoma of the stomach. HER2 was not overexpressed on the tumor tissue. Which of the fol owing are TRUE regarding combination chemotherapy for the treatment of metastatic gastric cancer? (Select two correct responses) A. Cisplatin is superior to oxaliplatin with a better OS.

B. 5FU is superior to capecitabine with better OS.

C. Oxaliplatin is noninferior to cisplatin in terms of OS.

D. Capecitabine is noninferior to 5FU in terms of OS.

Question 16.19 57-year-old man presented to your clinic for a second opinion on treatment of metastatic HER2 negative gastric cancer. The patient has received rst-line treatment with epirubicin/cisplatin/5FU. On his last evaluation, his CT scan of the chest, 193

abdomen, and pelvis showed progression of the disease in the lungs and liver. The patient remains asymptomatic except for fatigue. His weight is stable and his performance status is 1. Blood work included CBC that showed mild anemia and his chemistry panel including liver function test and bilirubin was normal. Which of the fol owing is the best recommendation for this patient?

A. Refer to hospice

B. Erlotinib single agent

C. Ramucirumab single agent

D. Trastuzumab/cisplatin/capecitabine

Question 16.20 Which of the fol owing is TRUE about ramucirumab?

A. It is used only in combination with chemotherapy as a second-line for advanced gastric cancer.

B. It prolongs only progression-free survival but not overal survival.

C. It prolongs overal survival when used as a single agent in the second line.

D. It is a murine monoclonal antibody targeting VEGF.

194

Question 16.1 The answer is E.

Esophageal cancer is relatively uncommon in the United States and the lifetime risk of being diagnosed with the disease remains less than 1%. Incidence rates among Caucasian men increased up until the year 2000, reflecting the marked increase in the incidence of adenocarcinoma of the esophagus of more than 400% in the past two decades, but now have stabilized between 7 and 8 per 100,000 person-years. Although the incidence of esophageal cancer in Caucasian females (1.6 per 100,000) is lower than that in Caucasian males, rates of adenocarcinoma have increased in white women by more than 300% during the past 20 years.

Question 16.2 The answers are C and D.

As a commensal organism, H. pylori infection is widely prevalent throughout the world.

Despite its classification by the World Health Organization as a class I carcinogen, infection with H. Pylori does not typical y lead to gastric cancer. This underscores the importance of other factors, such as virulence, environmental factors, and host factors, as wel as genetic polymorphisms (e.g., interleukin-1β, a potent inhibitor of acid secretion). The blood group A phenotype has been reported to be associated with gastric cancers. Epstein–Barr virus infection has been noted in a certain type of gastric carcinoma (lymphoepithelioid type), although the importance of this is unclear.

Question 16.3 The answers are A and C.

GERD has been implicated as one of the strongest risk factors for the development of adenocarcinoma of the esophagus. Chronic reflux is associated with Barrett esophagus, the premalignant precursor of esophageal adenocarcinoma. Population-based case-control studies that examined the relationship between symptomatic reflux and risk of adenocarcinoma of the esophagus have demonstrated that increased frequency, severity, and chronicity of reflux symptoms are associated with a 2- to 16-fold increased risk of adenocarcinoma of the esophagus, regardless of the presence of Barrett esophagus. Increased body mass index (BMI) is a risk factor for adenocarcinoma of the esophagus, and individuals with the highest BMI have up to a sevenfold greater risk of esophageal cancer than those with a low body mass index. Barrett esophagus remains the single most important risk factor for developing esophageal adenocarcinoma; patients with Barrett esophagus are 11-fold more likely to develop esophageal adenocarcinoma than individuals without Barrett esophagus. Infection with Helicobacter pylori, and particularly with cagA+ strains, is inversely associated with the risk of adenocarcinoma of the esophagus. The mechanism of action is unclear, although an H.

pylori infection can result in chronic atrophic gastritis, leading to decreased acid production and potential y reducing the development of Barrett esophagus.

195

Question 16.4 The answer is D.

In patients with localized esophageal adenocarcinoma, HER2+ disease was associated with a significantly lower tumor grade, earlier stage of disease with fewer malignant lymph nodes, and the presence of Barrett’s esophagus. These features of HER2+

localized esophageal cancer led to an independent improvement in disease-specific survival (HR, 0.54; 95% CI, 0.35–0.84) and overal survival ( p = 0.0022), suggesting that HER2+ is a favorable prognostic feature in localized esophageal adenocarcinoma.

Esophageal cancer is relatively uncommon in the United States, and the lifetime risk of being diagnosed with the disease remains less than 1%. It was estimated that 17,990

new cases would be identified in 2013, with 15,210 patients expected to die of the disease. Age-adjusted incidence rates are essential y equivalent among African-American and Caucasian men.

Question 16.5 The answer is D.

Al of these molecular mechanisms are involved in the pathogenesis of esophageal cancer.

Question 16.6 The answer is C.

High-grade dysplasia in Barrett esophagus is the most powerful predictor of subsequent invasive adenocarcinoma and is associated with a per-year cancer incidence of 6%, thereby warranting therapeutic intervention. The rationale for esophagectomy is that resection completely eradicates the mucosa at risk, which prevents progression to invasive carcinoma. This is supported by older surgical series reporting previously unidentified invasive cancer, which was present in up to 40% of resected specimens.

The argument against esophagectomies is that most patients with high-grade dysplasia do not develop invasive carcinoma in their lifetimes and, in the era of endoscopic resection, that early cancers can be effectively addressed without an esophagectomy.

Those supporting endoscopic methods, ranging from surveil ance to mucosal ablative and resection techniques, argue that this al ows for the identification of patients with an early invasive lesion that is readily amenable to cure or elimination of the mucosa at risk, thus preventing progression. Endoscopic mucosal resection (EMR) is now considered an essential diagnostic, staging, and therapeutic option available for patients with either high-grade dysplasia or superficial esophageal cancers (T1a). Annual endoscopy is recommended for those patients with low-grade dysplasia, whereas more frequent screening (every 3 months) is recommended for those patients with high-grade dysplasia if eradication therapy has not been instituted.

Question 16.7 The answer is B.

Adenocarcinomas of the GEJ present a unique chal enge because appropriate management of these tumors as either esophageal or gastric cancers has been uncertain.

Siewert et al. have offered a classification system based on demographics, 196

histopathologic variables, and patterns of lymphatic spread that provides clarity, which is wel established, and has been general y accepted worldwide. In this classification scheme, type I tumors are considered adenocarcinomas of the distal esophagus and type II and III lesions are classified as gastric cancers (cardia and subcardia). This classification system al ows for a tailored and consistent surgical approach to these tumors as wel as consistency in reporting outcome results associated with therapeutic interventions. However, it should be noted that in the most recent guidelines established by the American Joint Committee on Cancer, GEJ tumors are included under the esophageal cancer staging classification.

Question 16.8 The answer is D.

The CROSS trial, has for many practitioners established a new standard or care for preoperative chemoradiotherapy. The rate of pathologic complete response was 25%.

This study randomized 366 patients with squamous cel carcinoma or adenocarcinoma of the esophagus or GEJ to treatment with (1) preoperative carboplatin at an area under the curve of 2 mg/mL per minute and paclitaxel 50 mg/m2 once weekly for 5 weeks, and concurrent radiotherapy (1.8 Gy daily to 41.4 Gy) in 23 fractions, fol owed by transthoracic esophagectomy or transhiatal esophagectomy for GEJ cancers, or (2) immediate surgery. Unlike earlier trials, this more modern trial staged al patients by endoscopic ultrasound and CT scan, and patients were required to have either node positive or T2–3N any disease. The majority of patients treated had adenocarcinoma (75%) and most tumors involved the distal third of the esophagus (58%). The majority of patients were node positive (65%), and slightly more patients on the chemoradiotherapy arm had T3 tumors (84%) compared to the surgery-alone arm (78%). At a median fol ow-up of 45 months, the trial showed a significant survival benefit for chemoradiotherapy added to surgery, with a median survival increased from 24 months to 49 months (HR, 0.0657; p = 0.003), and improvement in 2- and 5-year overal survival (67% and 47% vs. 50% and 34%; HR, 0.665).

Question 16.9 The answers are B and D.

Positive results of a recent trial of perioperative chemotherapy in gastric and distal esophagus or GEJ cancer have been reported. In a trial by Cunningham et al., 503

patients were assigned to three cycles of preoperative and three cycles of postoperative epirubicin/cisplatin/5FU or surgery alone. Preoperative chemotherapy resulted in significant improvement in patient survival, with a 6-month improvement in progression-free survival, a 4-month improvement in median survival, and a 13%

improvement in 5-year overal survival (23% to 36%), al of which are statistical y significant. Despite the survival improvement with pre- and postoperative chemotherapy, there was no improvement in the rate of curative resection in patients treated with preoperative chemotherapy compared with surgery alone (66% to 69%), and there were no cases of pathologic complete response to preoperative chemotherapy.

197

Downstaging was also observed with preoperative chemotherapy, with a shift to earlier T

and N stage tumors with preoperative chemotherapy compared to surgery alone.

Because 26% of patients on this trial had tumors in the GEJ and lower esophagus, the results may apply to local y advanced esophageal cancer. The median fol ow-up was 47

months in the surgery-alone arm, and 49 months in the chemotherapy arm.

Question 16.10 The answer is D.

HER2 testing is now recommended for al patients with metastatic EGJ

adenocarcinoma at the time of diagnosis.

Question 16.11 The answer is C.

Validation of the activity of a growth factor receptor-targeted agent, trastuzumab, was recently achieved in esophagogastric cancer. Over 3,800 patients with gastric or GEJ

adenocarcinoma were screened for overexpression of the HER2 receptor by fluorescence in situ hybridization (FISH) and immunohistochemistry; 22.1% tested positive. Five hundred ninety-four patients were ultimately randomized to chemotherapy alone with (1) capecitabine 1,000 mg/m2 twice a day for 14 days or (2) infusional 5FU 800

mg/m2 per day for 5 days, combined with cisplatin 80 mg/m2 on day 1, cycled every 3

weeks, or to chemotherapy plus trastuzumab 6 mg/kg once every 3 weeks. The majority of patients received capecitabine plus cisplatin as the chemotherapy regimen. Al end points were improved with the addition of trastuzumab to chemotherapy, including antitumor response (47.3% vs. 34.5%), progression-free survival (6.7 months vs. 5.5

months), and overal survival (13.8 months vs. 11.1 months) (HR, 0.74; p = 0.0046).

Toxicity was comparable for the two.

Question 16.12 The answers are B and C.

At the second meeting of The International Gastric Cancer Linkage Consortium (IGCLC) in 2010, hereditary diffuse gastric cancer (HDGC) guidelines were extended to recommend CDH1 genetic testing to families with the fol owing:

• Cases of gastric cancer in which one case is histopathological y confirmed as diffuse and younger than 50 years

• Families with both lobular breast cancer and diffuse gastric cancer, with one diagnosed younger than 50 years

• Probands diagnosed with diffuse gastric cancer younger than 40 years, with no family history of gastric cancer

Question 16.13 The answer is A.

Lynch syndrome-associated gastric cancers predominantly show intestinal histology (more than 90% of the cases). This correlation echoes the strong association between MSI tumor phenotype and intestinal gastric cancer.

198

Question 16.14 The answer is C.

Mutations in CDH1 gene are associated with hereditary diffuse gastric cancer, which carries a more than 80% risk of developing gastric cancer.

Question 16.15 The answer is D.

Large families with an autosomal-dominant, highly penetrant inherited predisposition for the development of gastric cancer are rare. However, early-onset diffuse gastric cancers have been described and linked to the E-cadherin/ CDH1 locus on 16q and associated with mutations in this gene, which may be the case in this family. This seminal finding has been confirmed in other studies with gastric cancers at a relatively high (67% to 83%) penetrance rate. Thus, E-cadherin mutation testing should be considered in the appropriate clinical setting. In fact, prophylactic gastrectomy should be considered strongly in families with germline E-cadherin mutation even without gross mucosal abnormalities on endoscopic examination of the stomach. Hereditary nonpolyposis colon cancer (HNPCC) involves germline mutations of DNA mismatch repair genes. Gastric adenocarcinoma may be observed in families with HNaPCC.

Question 16.16 The answer is B.

Whole-body 2-[18F]-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) is being applied increasingly in the evaluation of gastrointestinal malignancies. In gastric cancer, approximately half of the primary tumors are FDG-negative; the diffuse (signet cel ) subtype was most likely to be non-FDG avid, likely because of decreased expression of the glucose transporter-1 (Glut-1). Although laparoscopic staging is thought to detect CT-occult metastatic disease in approximately 40% of patients and spares nontherapeutic operations in approximately one-third of patients with gastric cancer, one needs to remember that tumor biology, not staging, wil eventual y guide outcomes.

Clearly, not al patients benefit from preoperative laparoscopic staging; therefore, future studies should address the issue of selective laparoscopy based on noninvasive staging (i.e., patients with T1 tumors). Staging laparoscopy with or without cytology should be considered only if therapy wil be altered consequent to information obtained by laparoscopy.

Question 16.17 The answer is C.

The Intergroup Trial (INT 0116) randomized patients to receive surgery alone or surgery plus postoperative 5FU-based chemotherapy and radiation. The trial included patients with stages IB–IVA nonmetastatic adenocarcinoma of the stomach or GEJ.

After en bloc resection, 556 patients were randomized to either observation alone or postoperative combined-modality therapy consisting of one monthly 5-day cycle of 5-FU

and leucovorin, fol owed by 45 Gy in 25 fractions plus concurrent 5-FU and leucovorin (4 days in week 1, 3 days in week 5) fol owed by two monthly 5-day cycles of 5FU and leucovorin. Nodal metastases were present in 85% of the cases. With 5 years of median 199

fol ow-up, 3-year relapse-free survival was 48% for adjuvant treatment and 31% for observation ( p = 0.001); 3-year OS was 50% for treatment and 41% for observation ( p

= 0.005). The median OS in the surgery-only group was 27 months, compared with 36

months in the chemoradiotherapy group; the HR for death was 1.35 (95% CI = 1.09 to 1.66; p = 0.005). The hazard ratio for relapse in the surgery-only group as compared with the chemo-radiotherapy group was 1.52 (95% CI = 1.23 to 1.86; p <0.001). The median duration of relapse-free survival was 30 months in the chemoradiotherapy group and 19 months in the surgery-only group. Patterns of failure were based on the site of first relapse only and were categorized as local, regional, or distant. Local recurrence occurred in 29% of the patients who relapsed in the surgery-only group and 19% of those who relapsed in the chemoradiotherapy group. Regional relapse, typical y abdominal carcinomatosis, was reported in 72% of those who relapsed in the surgery-only group and 65% of those who relapsed in the chemoradiotherapy group.

Question 16.18 The answers are C and D.

Cunningham et al. in the REAL-2 trial studied 1,002 patients who were randomized to one of four treatment groups: a control arm of ECF and three investigational arms. The central question in this study was: Can capecitabine be substituted for 5FU and/or oxaliplatin substituted for cisplatin? The four arms were ECF, epirubicin–oxaliplatin–

5FU, epirubicin–cisplatin–capecitabine, and epirubicin–oxaliplatin–capecitabine (EOX).

The four regimens are shown in Table 46.9. Patients were stratified for performance status and extent of disease. The primary end point was in OS. The study was powered to show noninferiority for capecitabine compared with 5FU, and oxaliplatin compared with cisplatin. There were approximately 250 patients per arm. The study design was a two-by-two comparison. A total of 40% of patients had primary gastric cancer, and the remainder had either EGJ or esophageal cancers, with 10% of patients having squamous cel cancer of the esophagus. There was no difference in median OS between the arms (ECF, 9.9 months; epirubicin–oxaliplatin–5FU, 9.3 months; epirubicin–

cisplatin–capecitabine, 9.9 months; and EOX, 11.2 months). The 1-year OS was also similar and ranged from 38% to 47%, the best outcome evident with EOX and the lowest with the control arm of ECF. The authors concluded the oxaliplatin could be substituted for cisplatin, and capecitabine could be substituted for 5FU in the pal iative setting.

Question 16.19 The answer is C.

The REGARD study was a placebo-control ed, double blind, phase 3 international trial conducted in the second-line setting in patients with metastatic gastric or EGJ

adenocarcinoma. Median OS was 5.2 months for ramucirumab and 3.8 months for placebo (HR = 0.776; 95% CI = 0.603 to 0.998; p = 0.0473). The significance of this study is that it provides a proof-of-principal that antiangiogenic therapy does have activity in gastroesophageal malignancies.

200

Question 16.20 The answer is C.

Ramucirumab is a ful y human IgG1 monoclonal antibody targeting VEGFR2. The REGARD study showed that single agent ramucirumab prolonged the median OS

compared to placebo (median OS 5.2 months for ramucirumab and 3.8 months with placebo; HR 0.776, 95% CI 0.60-0.99, p = 0.04).

Corresponding chapters in Cancer: Principles & Practice of Oncology, Tenth Edition: 44

(Molecular Biology of the Esophagus and Stomach), 45 (Cancer of the Esophagus), 46

(Cancer of the Stomach), and 47 (Genetic Testing in Stomach Cancer).

201





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 17.1 Which of the fol owing factors are associated with an increased risk of pancreatic cancer?

A. Cigarette smoke

B. Chronic pancreatitis

C. Prior cholecystectomy

D. African-American ethnicity

E. Al of the above

Question 17.2 Which of the fol owing statements regarding pancreatic cancer is TRUE?

A. At diagnosis, 31% have evidence of distant metastases.

B. Pancreatic cancer decreases in incidence later in life.

C. Activation of the KRAS oncogene plus inactivation of tumor suppressor genes ( TP53, DPC4, p16, and BRCA2) are associated with the development of pancreatic cancer.

D. Pancreatic intraepithelial neoplasms (PanINs) are intraductal proliferative epithelial lesions that wil not progress to pancreatic cancer.

E. Patients with advanced pancreatic cancer wil have high levels of CA 19-9 if they are Lewis antigen-a or -b negative.

Question 17.3 A 56-year-old man is evaluated for a 1-month history of gradual y worsening painless jaundice and a 10-lb weight loss. Computed tomography (CT) scan of the abdomen and pelvis revealed a 3.3-cm pancreatic head mass adjacent to the superior mesenteric vein with no intervening fat plane and encasing both the superior mesenteric vein and artery. The common bile duct was dilated and the pancreatic body and tail were atrophied with dilatation of the pancreatic duct. Portal lymphadenopathy measuring 2 cm was present. The patient underwent endoscopic retrograde cholangiopancreatography and a biliary stent was placed. Biopsy tissue of the mass was consistent with moderately di erentiated pancreatic adenocarcinoma. What stage is this patient’s cancer per the TNM

staging system?

A. Stage I

B. Stage II

C. Stage III

202

D. Stage IV

Question 17.4 A 67-year-old woman presents to her local emergency department with a 2-month history of right upper quadrant pain, jaundice, and 20-lb weight loss. CT of the abdomen with contrast reveals a 2.5-cm, il -de ned soft tissue density within the head of the pancreas and mild celiac axis, porta hepatis, and portacaval adenopathy, with the largest being within the celiac axis region measuring 2.0 × 1.8 cm. Fol owing admission endoscopic retrograde cholangiopancreatography with biliary stent placement and biopsy is done. Pathology reports poorly differentiated adenocarcinoma. What test should be ordered at this point to help establish her stage?

A. Multiphase multidetector helical computerized tomography B. Magnetic resonance imaging

C. Ultrasonography

D. Serum CA 19-9 measurement

E. Endoscopic ultrasonography

Question 17.5 A 71-year-old woman undergoes Whipple resection for a T3N1M0

pancreatic adenocarcinoma. Postoperative recovery was uneventful, and she starts adjuvant therapy 7 weeks later with gemcitabine given intravenously weekly for 3 weeks, fol owed by a 1-week break. In a fol ow-up visit after her first cycle, she reports a 5-lb weight loss, nausea, decreased appetite, and diarrhea with oating stools. What should be done next?

A. Increase pancreatic enzyme supplementation

B. Admit the patient for smal bowel obstruction

C. Hold chemotherapy for 1 week and fol ow up on symptoms D. CT scan of the chest, abdomen, and pelvis to rule out metastatic disease Question 17.6 Which of the fol owing statements regarding adjuvant therapy of pancreatic adenocarcinoma is TRUE?

A. In RTOG 9704 administering gemcitabine before and after adjuvant 5-FU based CRT

for resected pancreatic head adenocarcinoma demonstrated a trend toward improved median OS compared with 5-FU before and after 5-FU CRT.

B. CONKO-001 demonstrated gemcitabine when compared with observation improves disease free survival but not overal survival.

C. GITSG 9173 clearly showed no benefit with 5-FU based chemoradiation fol owed by chemotherapy compared with observation.

D. ESPAC-1 showed that those who received CRT did better than those treated with chemotherapy alone.

Question 17.7 A 64-year-old woman is diagnosed with local y advanced unresectable pancreatic cancer. After 2 months of a gemcitabine-based chemotherapy regimen, CT scans 203

demonstrate a decrease in the size of the lesion and her CA19-9 decreased from 854 to 201. What should be done now?

A. Switch to 5FU-based chemoradiation

B. Continue current gemcitabine-based chemotherapy for another 2 months C. Add radiation to her current regimen

D. Add 5FU to her chemotherapy regimen

Question 17.8 A 52-year-old woman is evaluated for chronic right upper quadrant abdominal pain and is diagnosed with pancreatic adenocarcinoma with metastasis to the liver. She is distraught and wants to do everything possible to prolong her life. Which of the fol owing regimens has been shown to prolong overal survival compared with gemcitabine alone?

A. Gemcitabine and oxaliplatin

B. Gemcitabine and capecitabine

C. Gemcitabine and nab-paclitaxel

D. Gemcitabine, cisplatin, and bevacizumab

E. Gemcitabine and cetuximab

Question 17.9 A 45-year-old man with unintentional weight loss is diagnosed with metastatic adenocarcinoma of the pancreas. Which of the fol owing chemotherapy regimens would be appropriate rst-line treatment choice in this otherwise healthy patient with normal organ function?

A. Gemcitabine

B. FOLFIRINOX (5FU, leucovorin, irinotecan, and oxaliplatin) C. 5FU with radiation

D. FOLFOX (5FU + leucovorin + oxaliplatin)

Question 17.10 Mutation of which tumor suppressor gene is most frequently associated with familial pancreatic cancer?

A. BRCA2

B. PALB2

C. KRAS

D. TP53

Question 17.11 Which one of the fol owing statements regarding risk factors for pancreatic cancer is CORRECT?

A. People with blood types A, B, and AB are more likely than type O to develop pancreatic cancer.

B. Testing for KRAS mutations in the pancreatic juice of patients is an effective screening test for pancreatic cancer.

204

C. Patients with hereditary nonpolyposis colorectal cancer syndrome do not have an increased risk for pancreatic cancer.

D. Hereditary pancreatitis is not a significant risk factor for pancreatic cancer.

Question 17.12 A 65-year-old male diagnosed with metastatic pancreatic cancer received treatment with single-agent gemcitabine. He now has disease progression and is interested in pursuing further systemic therapy. Which one of the fol owing should be o ered as a second-line treatment choice?

A. OFF (oxaliplatin, 5FU, and leucovorin)

B. Erlotinib

C. Paclitaxel

D. Supportive care alone

Question 17.13 Which of the fol owing is/are TRUE about pancreatic cancer?

A. Most pancreatic cancers have mutations in KRAS, TP53, SMAD4, p16/CDKN2A.

B. Telomere shortening is the earliest and prevalent genetic change identified in the precursor lesions.

C. Underexpression of TGF-β is observed in some pancreatic cancers.

D. p16-mediated CDK inhibition is a protective mechanism against pancreatic cancer.

E. Al of the above.

Question 17.14 A 52-year-old man is found to have mildly abnormal liver function and an elevated serum α-fetoprotein (AFP). Workup reveals prior hepatitis B viral (HBV) infection. Ultrasound reveals a 4-cm lesion in the left hepatic lobe, and a computed tomography (CT) scan reveals no evidence of metastatic disease or vascular involvement.

MRI demonstrates features consistent with hepatocel ular carcinoma (HCC). The patient undergoes partial hepatectomy, surgical margins are clear. The pathology report con rms the diagnosis of HCC. Which of the fol owing approaches should be fol owed?

A. Adjuvant sorafenib

B. Combination chemotherapy that is doxorubicin based

C. Adjuvant external beam radiation to surgical bed

D. Routine surveil ance

Question 17.15 Which of the fol owing criteria help(s) guide selection of patients with HCC appropriate for potential liver transplantation?

A. Patients with solitary tumors ≤5 cm, or patients with multifocal disease with ≤3

tumor nodules each ≤3 cm in size

B. Patients with Child–Pugh B or C cirrhosis

C. Tumors without evidence of macrovascular invasion and distant metastasis D. Al of the above

205

Question 17.16 Which of the fol owing statements about staging systems for hepatocel ular carcinoma is TRUE?

A. The Okuda system takes into account several clinical features that include tumor size (>50% of liver), ascites (positive or negative), hypoalbuminemia (<3 g/dL), and hyperbilirubinemia (>3 mg/dL).

B. The Cancer of the Liver Italian Program system uses hepatic tumor morphology and extent of liver replacement, Child–Pugh score, portal vein thrombosis, and serum AFP

levels.

C. The Barcelona Clinic Liver Cancer scoring system combines assessment of tumor stage, liver function, and patient symptoms with a treatment algorithm and has been shown to correlate wel with patient outcomes.

D. Al of the above.

Question 17.17 Which of the fol owing abnormalities is both a paraneoplastic syndrome associated with HCC, and may also be caused by end-stage liver failure?

A. Hypoglycemia

B. Erythrocytosis

C. Hypercalcemia

D. Hypercholesterolemia

Question 17.18 An increased risk of developing HCC is associated with which of the fol owing?

A. Wilson disease

B. Hereditary tyrosinemia

C. Porphyria cutanea tarda

D. Primary biliary cirrhosis

E. Al of the above

Question 17.19 Which of the fol owing statements about screening and prevention is CORRECT?

A. The advent of vaccination for hepatitis B is unlikely to reduce HCC in endemic areas.

B. A combination of AFP and ultrasound screening is used in high-risk populations.

C. Aggressive screening programs for HCC have been shown to improve survival.

D. Detection of HCC, through surveil ance of patients awaiting liver transplantation, does not increase priority for orthotopic liver transplantation.

Question 17.20 Which of the fol owing increase(s) the risk of developing cholangiocarcinoma?

A. Primary sclerosing cholangitis

B. Clonorchis sinensis infestation

206

C. Chronic portal bacteremia and portal phlebitis D. Al of the above

Question 17.21 A 66-year-old man is noted to have painless jaundice on a routine fol ow-up at his primary care physician’s office. Workup reveals a mass causing biliary obstruction at the hilum. Endoscopic retrograde cholangiopancreatography con rms a high-grade stricture predominantly involving the left hepatic duct; however, brushings reveal atypical cel s and no malignancy. He is seen at a tertiary care center and o ered surgical management, an en bloc resection of the left hepatic lobe and extrahepatic bile duct, and a complete periportal lymphadenectomy. Which of the fol owing statements about management/natural history of hilar cholangiocarcinoma is/are TRUE?

A. Surgical resection is associated with an operative mortality rate of 30%.

B. Recurrences occur most commonly at the bed of resection, fol owed by retroperitoneal lymph nodes. Distant metastases occur in one-third of cases.

C. Less than 10% of patients have resectable cancer at the time of diagnosis.

D. Al of the above.

Question 17.22 A 70-year-old man presents with 16-lb weight loss and persistent right upper quadrant pain. CT scan reveals a gal bladder stone and thickening of the anterior wal of the gal bladder. He undergoes a laparoscopic cholecystectomy. Pathology reveals a moderately di erentiated 2-cm gal bladder adenocarcinoma invading the perimuscular connective tissue. Margins of resection are negative for tumor. Based on the available information, what is the stage of this cancer?

A. Stage IA

B. Stage IB

C. Stage II

D. Stage IIIA

Question 17.23 The patient in Question 17.22 recovers from surgery and seeks a second opinion at a tertiary care center 5 weeks after his cholecystectomy. A CT scan 2 weeks after surgery shows mild periportal ful ness. What is the most appropriate next step in management?

A. Perform en bloc resection of the gal bladder, resection of segments IVb and V of the liver, and regional lymph node dissection.

B. No further therapy is warranted; surveil ance with CT scans and laboratories done every 3 months.

C. He requires a second laparotomy to assess the extent of remaining disease to guide further therapy.

D. Perform ultrasound-guided biopsy of the periportal nodes; if positive, then fluoropyrimidine-based chemoradiation is indicated.

207

Question 17.24 Which one of the fol owing statements about adjuvant therapy for biliary cancers is TRUE?

A. Based on retrospective data it appears patients may benefit from adjuvant chemotherapy.

B. Adjuvant radiation is superior to chemotherapy alone.

C. Adjuvant therapy can improve overal survival for patients with R0 resections.

D. Fluoropyrimidine-based chemoradiation is standard because it is superior to radiation alone.

Question 17.25 Which of the fol owing statements regarding brolamel ar HCC is CORRECT?

A. Fibrolamel ar HCC occurs more frequently in men compared with women.

B. This variant of HCC is associated with viral hepatitis but not cirrhosis.

C. Lymph node metastases at the time of presentation is common.

D. Most patients with fibrolamel ar HCC present in their sixth decade of life.

Question 17.26 A 50-year-old man with a history of chronic hepatitis B infection and Child–Pugh A cirrhosis presents with abdominal pain. He is otherwise in good health. CT of the abdomen reveals a cirrhotic liver with a 2.5-cm liver mass that rapidly enhances during the arterial phase of contrast administration and “washout” during the later venous phases.

There is no involvement of the portal vein. AFP is 300 ng/mL. What is the next best step in his management?

A. Biopsy to obtain a histologic diagnosis.

B. Refer him to a hepatobiliary surgeon.

C. Start him on sorafenib.

D. Refer him to a radiation oncologist.

Question 17.27 Which of the fol owing statements is CORRECT regarding hepatoblastoma?

A. This is the most common primary cancer of the liver in adults.

B. Hepatoblastoma is a chemoresistant tumor.

C. Patients with this tumor have a poor outcome after liver transplantation, with a 5-year survival rate of 20%.

D. The peak incidence of hepatoblastoma is within the first 2 years of life.

Question 17.28 Which of the fol owing statements is CORRECT?

A. The hepatitis B x gene product has no known role in causing HCC.

B. NS5A protein product of hepatitis C viral (HCV) genome inactivates p53.

C. Level of HBV replication is inversely related to the risk of liver cancer.

D. Hepatitis B virus genotype C is associated with decreased risk of HCC.

208

Question 17.29 Which of the fol owing statement(s) regarding hepatitis C infection is/are CORRECT?

A. Sixty percent to 80% HCV infections become chronic in contrast to 10% HBV

infections.

B. HBV genome integrates into hepatocyte DNA while HCV genome does not.

C. The average interval from HCV infection to HCC is 30 years in contrast to 40 to 50

years for HBV infection.

D. Al of the above.

Question 17.30 A 45-year-old man with a history of alcoholic cirrhosis was found by screening ultrasound to have two new lesions in hepatic segments 7 and 3, measuring 3 cm and 2 cm, respectively. MRI findings were consistent with hepatocel ular carcinoma. He has been abstinent from alcohol use for the past 2 years. His total bilirubin is 1.5 mg/dL, serum albumin 3 g/dL and INR is 1.6. He does not have ascites or encephalopathy. There is no evidence of metastatic disease and he is referred for orthotopic liver transplantation evaluation. He is deemed to be an acceptable candidate. While waiting for a donor organ, what should be done next?

A. Refer to interventional radiology for ablative therapy B. Sorafenib to prevent disease progression while waiting for donor organ C. Cisplatin, IFNα-2b, doxorubicin, and 5FU as neoadjuvant therapy D. Observation

Question 17.31 A 45-year-old woman presents with painless jaundice and weight loss. Her total bilirubin is 17.6 mg/dL, alkaline phosphatase is 568 units/L and alanine transaminase (ALT) is 138 units/L. Viral hepatitis serology is negative. CT chest abdomen and pelvis with contrast is performed and reveals an il -de ned, in ltrative, hypoattenuating lesion at the hepatic hilum with marked intrahepatic biliary ductal dilatation. MRI of the liver characterizes the lesion as compatible with cholangiocarcinoma centered in the hepatic hilum extending to the con uence of the left medial and lateral hepatic ducts, involving the cystic duct, proximal extrahepatic duct, and abutting the undersurface of the portal vein and right hepatic artery. ERCP is performed with common bile duct stenting.

Pathology reports atypical epithelial cel s in the brushing. Hepatobiliary surgery is consulted and determines that her tumor is unresectable and she is not a liver transplant candidate due to psychosocial issues. What is the next step in management once hyperbilirubinemia resolves?

A. FOLFOX

B. Gemcitabine and cisplatin

C. External beam radiation therapy with concurrent 5FU

D. Pal iative care alone including routine stent exchange Question 17.32 Which of the fol owing individuals would meet criteria to have 209

surveil ance for HCC?

A. A 28-year-old African woman who is a hepatitis B carrier.

B. A 47-year-old Indian woman who is hepatitis B carrier and has a brother with HCC.

C. A 62-year-old Hispanic male with alcoholic cirrhosis.

D. A 42-year-old Chinese man who is a hepatitis B carrier.

E. Al of the above

Question 17.33 A 52-year-old man is admitted to the hospital due to new onset of symptomatic ascites and jaundice. He is an alcoholic and has no history of medical care prior to this encounter. He is mildly encephalopathic. Serum total bilirubin is 5.6 mg/dL and INR is 2.1. He is diagnosed with unresectable metastatic hepatocel ular carcinoma and alcoholic cirrhosis after an extensive work up. The patient’s family arrives and would like to discuss treatment options. Your recommendation wil be:

A. Gemcitabine and oxaliplatin.

B. Sorafenib.

C. Sunitinib.

D. Hospice or supportive care alone

210

Question 17.1 The answer is E.

Tobacco smoke exposure plays a significant role in the development of pancreatic adenocarcinoma. It has been estimated that tobacco smoking contributes to the development of 20% to 30% of pancreatic cancers. The strongest associations between cigarette smoking and pancreatic cancer have been observed when the smoking occurred within the previous 10 years. Smoking cessation can reduce this risk.

Environmental tobacco smoke contains the same toxins, irritants, and carcinogens, such as carbon monoxide, nicotine, cyanide, ammonia, benzene, nitrosamines, vinyl chloride, arsenic, and hydrocarbons, as primary cigarette smoke. Host etiologic factors associated with an increased risk of pancreatic cancer include a history of diabetes mel itus (DM), chronic cirrhosis, pancreatitis, a high-fat and high-cholesterol diet, and prior cholecystectomy. Although not al studies have supported a relationship between DM

and pancreatic cancer, a meta-analysis of 20 epidemiologic studies confirms that the pooled relative risk of pancreatic cancer in persons with DM for 5 years is double (relative risk, 2.0; 95% confidence interval [CI], 1.2 to 3.2) the risk of persons without DM. There is no association with a high-protein diet. People of African-American descent experience a higher rate of pancreatic cancer than those of European ancestry in the United States, with an annual incidence of 16.7 per 100,000 versus 10.9 per 100,000, respectively. Death from pancreatic cancer is similarly elevated, with an annual rate of 14.6 per 100,000 versus 10.6 per 100,000. The diagnosis is slightly but significantly earlier in African-Americans compared with Caucasians, with a median age of diagnosis of 68 and 73 years, respectively. In developed countries, the incidence and mortality rates range from 7 to 9 per 100,000 for men and 4.5 to 6 per 100,000 for women.

Question 17.2 The answer is C.

CA 19-9 is a clinical y useful tumor marker. The epitope of this antibody is a sialylated lacto-N-fucopentaose II related to the Lewis-a blood group antigen. Limitations of CA 19-9 are that it is not specific for pancreatic cancer and has been found to be elevated in other tumor types, such as biliary tract, colon, and stomach cancers. Ten percent of patients are Lewis antigen-a or b negative and unable to synthesize this antigen, and therefore may have undetectable levels of CA 19-9, even in the setting of advanced pancreatic cancer. Cholestasis can falsely elevate serum CA 19-9 levels. Therefore, in patients who present with obstructive jaundice, an elevated CA 19-9 is not specific for the presence of pancreatic malignancy. Despite these caveats, serum CA 19-9 levels seem to have prognostic utility, particularly when measured either preoperatively or postoperatively in patients with resectable pancreatic cancer. Pancreatic ductal adenocarcinoma arises from ductal epithelial cel s. Neoplasia arising from these cel s progresses from initial pancreatic intraepithelial neoplasms (PanINs) to invasive 211

carcinomas. The evidence that these lesions are precancerous includes the observation that after segmental resection of pancreas with PanINs in the resected tissue, pancreatic cancer can develop in the pancreatic remnant. The strongest evidence that PanINs are precancerous lesions is the stepwise progression of genetic mutational events that correlates with the stepwise progression of worsening PanINs culminating in adenocarcinoma. PanIN-1 lesions show a predominance of KRAS mutations and overexpression of HER2/neu. In PanIN-2 lesions, p16 mutations are the typical mutational event, and in PanIN-3 lesions, TP53, DPC4, and BRCA2 mutations predominate. The mutational pattern of PanIN-3 lesions is equivalent to mutations found in pancreatic adenocarcinoma. These events are the basis of a current progression model for pancreatic cancer in which point mutation of KRAS and overexpression of HER2/neu are initiating early events, p16 inactivation is an intermediate event, and TP53, DPC4, BRCA2 inactivation fol ows just before invasion outside of the duct.

Approximately 95% of al cases have KRAS mutation, 90% have p16 mutations, 75%

have TP53 mutations, and 55% have DPC4 mutations. It is estimated that 5% to 10%

of pancreatic cancers are hereditary or have a familial link. Of patients with available data in the United States who were diagnosed with pancreatic cancer from 1996 to 2002, 8% presented with local disease, 31% presented with regional disease, and 61%

had distant metastases. Therefore, the majority of patients are metastatic at diagnosis.

Five-year survival from al stages of disease is 5%. Pancreatic cancer tends to occur later in life. Only 10% of patients in Europe present before the age of 50 years, whereas those aged 50 to 54 years, experience an incidence of 9.8 per 100,000, and those aged 70 to 74 years, experience an incidence of 57 per 100,000. The median age of diagnosis with pancreatic cancer in the United States is 72 years.

Question 17.3 The answer is C.

The patient has a stage III, T4N1M0 pancreatic cancer. As per the seventh edition of the American Joint Committee on Cancer staging system, this represents unresectable disease. The T-stage designation classifies T1 to T3 tumors as potential y resectable and T4 tumors as local y advanced (unresectable). Tumors with any involvement of the superior mesenteric or celiac arteries are classified as T4. However, tumors that involve the superior mesenteric, splenic, or portal veins are classified as T3 because these veins can be resected and reconstructed, provided that they are patent.

Question 17.4 The answer is A.

Laparoscopy and multiphase CT have evolved concurrently as methods to evaluate a pancreatic mass. Both have emerged as highly effective in evaluating the tumors, but CT as a noninvasive modality supplants the use of routine laparoscopy. Currently, routine use of laparoscopy is not warranted. The cornerstone of diagnostic evaluation of a pancreatic tumor is the multiphase CT scan, coordinating intravenous contrast administration with subsequent rapid thin-cut CT through the pancreas during arterial, 212

portal venous and parenchymal phases of enhancement. With this type of CT, extension of the tumor to the superior mesenteric artery, celiac axis, superior mesenteric vein/portal vein complex, and contiguous structures can be clearly determined, as wel as an assessment of distant metastasis. Optimal y, CT imaging should precede stent placement and biopsy because of the possibility of postprocedure inflammation from the biopsy and artifact from the stent that can confound interpretation of the images.

Magnetic resonance imaging has not been widely used to assess pancreatic cancer.

Endoscopic ultrasound can image the primary cancer and be a means of obtaining a fine-needle aspiration of pancreatic adenocarcinoma, but in general, the procedure is noncontributory when CT scan characterizes the tumor. When a mass cannot be visualized on CT scan, sonography through the wal of the stomach or duodenum can image tumors in the body/tail and head of the pancreas, respectively. Although preoperative ultrasonography is useful in assessing tumor characteristics and resectability of pancreatic adenocarcinoma, it is particularly operator dependent. Serum CA 19-9 is not a component of the TNM staging system for pancreatic cancer.

Question 17.5 The answer is A.

Malabsorption is a frequent complication seen in patients after Whipple surgery because of pancreatic enzyme insufficiency. Most patients require adjustment of the pancreatic enzyme supplement for adequate control of this symptomatology. Although smal bowel obstruction and metastatic disease can be seen, the patient’s clinical picture does not go along with these diagnoses. The aim during adjuvant therapy is to administer the chemotherapy with minimal delays to obtain the ful benefit from therapy.

Question 17.6 The answer is A.

The Radiation Therapy Oncology Group (RTOG) performed a prospective randomized trial (RTOG 9704) comparing gemcitabine with infusional 5FU as the systemic component of therapy with al patients also receiving 5FU-based chemoradiation. There was no survival difference between patients randomized to gemcitabine and those who received infusional 5FU. However, among the 380 patients with resected pancreatic head lesions, survival was superior for patients randomized to gemcitabine compared with those who received infusional 5FU (20.6 months vs. 15.9 months; hazard ratio

[HR] for death 0.79; 95% CI, 0.63 to 0.99; p = 0.033). In CONKO-001, patients randomized to receive gemcitabine had a median disease-free survival of 13.9 months (95% CI, 11.4 to 15.3), whereas those patients who underwent surgery alone had a median disease-free survival of only 6.9 months (95% CI, 6.1 to 7.8; p = 0.001).

However, there was no statistical y significant difference in overal survival when the initial results of the study were reported in 2007. The long-term survival outcomes of this trial were reported in 2013, and the median overal survival of 22.8 months was seen in the gemcitabine group, compared with 20.2 months in the observation group (HR, 0.76; p = 0.01). Additional y, 10-year survival rate was superior in the 213

gemcitabine group (12.2% vs. 7.7%), compared with the observation group. In the GITSG 9173 trial 5FU-based chemoradiation fol owed by up to 2 years of weekly bolus 5FU was evaluated against observation alone. A preliminary analysis of survival was reported after only 43 patients had completed treatment and showed a striking survival advantage for patients receiving combined modality therapy compared with survival of patients who underwent surgery alone (median 21.0 months vs. 10.9 months, respectively; one-tailed p = 0.03). In ESPAC-1, patients receiving chemoradiation did worse (median survival of 15.9 months; HR for death 1.28; 95% CI, 0.99 to 1.66) than those not receiving chemoradiation (median survival of 17.9 months; p = 0.05).

Conversely, patients who received chemotherapy had a median survival of 20.6 months (HR for death 0.71; 95% CI, 0.55 to 0.92) versus 15.5 months for those patients who did not receive chemotherapy, a statistical y significant result ( p = 0.009).

Question 17.7 The answer is B.

The optimal treatment of local y advanced pancreatic cancer remains controversial.

Local y advanced disease is general y incurable, and al therapies have significant limitations. Systemic therapy for 2 to 4 months fol owed by 5FU- or capecitabine-based chemoradiation is a reasonable approach for some patients with local y advanced disease. However, concurrent chemoradiotherapy approaches has not impact the survival, compared with patients with chemotherapy alone. If patients are responding to chemotherapy (objective radiographic response or CA 19-9 level decline) after 2 months and tolerating therapy wel , it is reasonable to continue for 2 more months.

Question 17.8 The answer is C.

The combination of nab-paclitaxel and gemcitabine is the only gemcitabine combination that showed overal survival benefit in patients with advanced pancreatic cancer by a large randomized study. The overal survival was superior in patients who received the combination regimen (8.5 months vs. 6.7 months; HR 0.72; p <0.001), compared with the gemcitabine only group.

Question 17.9 The answer is B.

Results from of the phase III randomized trial reported significant improvement in overal survival for patients receiving FOLFIRINOX compared to single-agent gemcitabine alone (11.6 months vs. 6.8 months; HR 0.57; p <0.0001). Therefore, FOLFIRINOX should be considered for first-line treatment in patient with good performance status and normal serum bilirubin level. FOLFOX has shown activity in patients with pancreatic cancer in the second-line setting, but further evaluation of clinical benefit in the front line has not been validated.

Question 17.10 The answer is A.

BRCA2 is the most commonly mutated tumor suppressor gene in familial pancreatic 214

cancer fol owed by PALB2. KRAS is an oncogene and not a tumor suppressor gene. TP53

gene mutation is found in more than 70% of al pancreatic cancers, but there is no evidence to link this mutation with familial pancreatic cancer.

Question 17.11 The answer is A.

Non type O blood type has been long known to be associated with increased risk for lung cancer. A genome-wide association study identified high-risk single nucleotide polymorphism for pancreatic cancer in the gene encoding for the ABO blood type.

Patients with nonpolyposis colorectal cancer syndrome or Lynch syndrome are at higher risk for gastrointestinal malignancies including pancreatic cancer. KRAS mutation testing has so far not proven to be effective in differentiating between pancreatic cancer and other conditions such as pancreatitis and pancreatic adenoma.

Question 17.12 The answer is A.

Data on second-line treatment of patients with pancreatic cancer who failed first-line gemcitabine are limited. Based on the CONKO-003 study, patients with pancreatic cancer experienced progression during the first-line gemcitabine had better overal survival in the OFF (oxaliplatin plus FF) group compared with the FF group (5FU and folinic acid) (5.9 months vs. 3.3 months, HR, 0.66; p = 0.01). Hence, an OFF

chemotherapy regimen would be an appropriate second-line option in patients progressed on the first-line gemcitabine therapy. Single-agent erlotinib has not shown significant treatment benefit for patients with metastatic pancreatic cancer. Raltitrexed is a thymidylate synthase inhibitor currently unavailable in the United States that has shown activity in the second-line setting in combination with irinotecan or oxaliplatin.

Supportive care alone is a reasonable choice in those with progressive metastatic disease in the absence of evidenced-based treatment options or patients unwil ing or unable to tolerate more antineoplastic therapy.

Question 17.13 The answer is E.

Telomere shortening is thought to predispose to chromosome fusion (translocation) and missegregation of genetic material during the mitosis and later during tumor genesis, telomerase is reactivated. SMAD4 (DPC4) pathway mediates signals initiated on the binding of the extracel ular proteins TGF-β. The underexpression of TGF-β receptors results in cel ular resistance to the usual suppressive effects of the TGF-β ligand. The cyclin D oncogene complexes with CDKs and phosphorylates the retinoblastoma protein (tumor suppressive protein) that results in loss of negative regulatory effect of retinoblastoma protein.

Question 17.14 The answer is D.

There is no treatment demonstrating a consistent survival advantage to support adjuvant therapy for hepatocel ular carcinoma. The phase III STORM trial of adjuvant 215

sorafenib compared with placebo failed to demonstrate a significant difference in the primary endpoint of recurrence-free survival or the secondary endpoints of time to relapse and overal survival.

Question 17.15 The answer is D.

The Milan criteria for selection of patients appropriate for liver transplantation include patients with solitary tumors less than or equal to 5 cm, patients with multifocal disease with less than or equal to three tumor nodules each less than or equal to 3 cm in size, patients with Child–Pugh B or C cirrhosis, patients who are not candidates for primary liver resection, and patients who have tumors with no evidence of macrovascular invasion.

Question 17.16 The answer is D.

Multiple clinical staging systems for hepatic tumors have been described. The most widely used is the American Joint Committee on Cancer/Tumor-Node-Metastasis (TNM). A staging system based entirely on clinical grounds that incorporate the contribution of the underlying liver disease was original y developed by Okuda et al.

Adverse prognostic signs are as listed. Patients with Okuda stage III (advanced), namely, with three or more positive features, have a dire prognosis because they usual y cannot be curatively resected and the condition of their liver typical y precludes chemotherapy.

The American Association for the Study of Liver Diseases has endorsed the use of the Barcelona Clinic Liver Cancer system for staging of HCC. This has now been validated both internal y and external y in several studies.

Question 17.17 The answer is A.

Various paraneoplastic syndromes have been described to occur in patients with hepatocel ular cancer. Most of these are biochemical abnormalities without associated clinical consequences. The most important ones include hypoglycemia (also caused by end-stage liver failure), erythrocytosis, hypercalcemia, hypercholesterolemia, dysfibrinogenemia, carcinoid syndrome, increased thyroxin-binding globulin, sexual changes (gynecomastia, testicular atrophy, and precocious puberty), and porphyria cutanea tarda. The pathogenesis of hypoglycemia is unclear but may be related to production of insulin-like growth factor I by the tumor.

Question 17.18 The answer is E.

Chronic viral hepatitis due to both hepatitis B and C account for 75% of HCC cases worldwide. Primary biliary cirrhosis is associated with an increased risk of cholangiocarcinoma as wel as hepatocel ular carcinoma. Conditions causing cirrhosis such as Wilson disease, chronic alcohol abuse, autoimmune hepatitis and cryptogenic cirrhosis are risk factors for HCC. Hereditary hemochromatosis and α-1-antitrypsin deficiency also place a patient at high risk. Noncirrhotic conditions such as hereditary 216

tyrosinemia, porphyria cutanea tarda, galactosemia, hereditary hemorrhagic telangiectasia, and cigarette smoking are also associated with HCC.

Question 17.19 The answer is B.

A combination of ultrasonography and serum AFP levels is used for the screening of high-risk populations for HCC. Although screening programs are in place in endemic areas of HCC and in high-risk populations, it is unclear whether screening identifies patients at an earlier stage or improves patient survival. Detection of HCC, through surveil ance of patients awaiting liver transplantation, results in increased priority for orthotopic liver transplantation.

Question 17.20 The answer is D.

In most patients, cholangiocarcinoma is sporadic and no precipitating factor can be identified. Risk factors that have been associated with the development of cholangiocarcinoma can be divided into congenital (choledochal cysts, anomalous pancreatic-biliary tree junction), autoimmune (primary biliary cirrhosis), infectious ( Clonorchis sinensis and Opisthorchis viverrini infestation, chronic portal bacteremia, and portal phlebitis), and final y environmental exposures (the radiocontrast agent thorotrast and possibly cigarette smoking).

Question 17.21 The answer is B.

Approximately one-third of patients presenting with the suspected diagnosis of cholangiocarcinoma wil have resectable disease. Operative mortality averages approximately 8%, indicating the high-risk population that this tumor affects and the complexity of the procedure. Approximately 10% to 35% of patients survive 5 years after surgical resection. Recurrences occur most commonly at the bed of resection, fol owed by retroperitoneal lymph nodes. Distant metastases occur in one-third of cases.

The most common sites of metastases are the lung and mediastinum, fol owed by liver and peritoneum. Comparisons of outcome over time suggest improved outcome in more recent series as a result of routine inclusion of liver resection. Prognostic factors for survival include negative microscopic margin status, lymph node metastases, tumor size, tumor grade, preoperative serum albumin, hepatic resection, and postoperative sepsis.

Question 17.22 The answer is C.

The pathologic stage is T2 NX (stage II) gal bladder cancer. Tumor invading the perimuscular connective tissue but not extending through the serosa is classified as T2

per the seventh edition of the AJCC Cancer Staging Manual.

Question 17.23 The answer is A.

Numerous studies have demonstrated that simple cholecystectomy is curative for stage 217

I disease (T1, N0). Recent studies have suggested that the prognosis is different for pT1a and pT1b tumors after simple cholecystectomy. Invasion of the muscular layer al ows access to lymphatics and vessels, providing the rationale for extended cholecystectomy in this population. When an extended cholecystectomy is performed for T2 disease, the 5-year survival has been reported to be as high as 100%, but probably fal s in the range of 70% to 90%. Simple cholecystectomy alone is associated with a 5-year survival rate of 20% to 40.5%. Lymph node metastases are seen in 46% of patients with T2 primary tumors, providing another reason in favor of radical repeat resection after simple cholecystectomy. In series of extended cholecystectomies, the operative morbidity ranges from 5% to 46%, and the mortality ranges from 0% to 21%. The risk of resection for each patient and each type of resection needs to be weighed against the chance of benefiting from the procedure on the basis of the tumor stage.

Question 17.24 The answer is A.

Balachandran et al. reported on 117 patients with gal bladder cancer, of whom 80

underwent simple cholecystectomy and 37 underwent extended resections. Seventy-three patients received adjuvant chemoradiotherapy and 44 patients did not. The median survival of al 117 patients was 16 months. On multivariate analysis, the T stage and use of adjuvant therapy were the only statistical y significant independent predictors of survival. Median survival was 24 months and 11 months, in patients with or without adjuvant chemoradiotherapy ( p = 0.001), respectively, and this difference was most pronounced for patients with T3, node-positive disease, or after a simple cholecystectomy. Ben-David et al. reported on 14 patients with gal bladder cancer treated at the University of Michigan with resection fol owed by radiotherapy or chemoradiotherapy. The median radiation dose was 54 Gy, and approximately half the patients received concurrent chemotherapy. The median survival was 23 months.

Interestingly, there was no difference in survival between patients with R0 or R1

resection. No differences were observed in survival or pattern of failure between patients with gal bladder cancer and bile duct cancer (distal or hilar). The high risk of systemic spread and locoregional failure associated with gal bladder cancer that extends beyond the mucosa has led most cancer centers in the United States to recommend consideration of adjuvant chemotherapy and radiotherapy. For external beam radiation therapy, the target volume should include the gal bladder fossa and adjacent liver, as wel as the regional nodal areas.

Question 17.25 The answer is C.

Fibrolamel ar HCC is a rare histologic variant of HCC. Most patients present in the third decade of life, and it affects men and women equal y. This variant of HCC is uncommonly associated with prior cirrhosis or viral hepatitis. In addition, a higher proportion of patients with fibrolamel ar HCC have lymph node metastases at presentation than the usual HCC.

218

Question 17.26 The answer is B.

This man has a hepatic mass within a cirrhotic liver, which is very suspicious for HCC.

The radiologic features are also highly suggestive of HCC. If the mass is larger than 2 cm in size with characteristic appearance of HCC on imaging and AFP is higher than 200

ng/mL, a biopsy is not essential for management. Patients with a high clinical suspicion for HCC who are deemed appropriate surgical candidates should be taken to surgery without a preoperative biopsy.

Question 17.27 The answer is D.

Hepatoblastoma is the most common primary cancer of the liver in children. The peak incidence is within the first 2 years of life. Surgical resection is the first line of therapy.

However, these tumors are very chemosensitive, and neoadjuvant chemotherapy can render unresectable tumors operable. Five-year survival after liver transplantation is excel ent (83%).

Question 17.28 The answer is B.

The NS5A protein product of HCV genome has been demonstrated to inactivate p53 by sequestration. The hepatitis B x gene product has been implicated in causing HCC

because it is a transcriptional activator of various cel ular genes associated with growth control. The elevated serum level of HBV DNA (a marker of higher levels of HBV

replication) is associated with a higher risk of HCC. The HBV genotype C is general y thought to increase the risk of HCC because these individuals are likely to remain seropositive for hepatitis B e antigen and thus have higher serum levels of HBV DNA for a longer time.

Question 17.29 The answer is D.

Hepatitis B virus is a DNA virus and it may become integrated within the chromosomes of infected hepatocyte. On the other hand, hepatitis C virus is an RNA virus without a DNA intermediate form, and therefore cannot integrate into hepatocyte DNA.

Question 17.30 The answer is A.

This patient is an ideal candidate for locoregional therapy while waiting for liver transplantation. Due to donor organ shortages, patients may wait for months prior to surgery. Transarterial chemoembolization (TACE) has been shown to reduce dropout from the wait list, reduce posttransplant recurrence, and occasional y downstage tumors that are initial y beyond transplant criteria. Radiofrequency ablation or TACE may be used for definitive therapy in patients, not candidates, for surgical resection or transplantation. Contraindications to TACE include portal vein thrombus, poorly compensated cirrhosis. Ascites is a relative contraindication as it indicates elevated portal vein pressure portending a higher risk of worsening liver function with TACE.

219

Sorafenib would not be a good choice for a patient on the wait list for surgery because of its VEGF inhibition. Neoadjuvant chemotherapy with PIAF (cisplatin, IFNα-2b, doxorubicin, and 5FU) has been shown in a phase II trial in patients with advanced HCC

to have a 26% response rate and some patients who achieved a partial response went on to have surgery. This patient is already a candidate for surgery and the toxicity of this regimen may complicate plans for transplantation. Observation alone would not be appropriate given the wait time for transplantation and the available therapies for locoregional control including surgery and intravascular procedures.

Question 17.31 The answer is B.

The UK-ABC-02 trial was a large phase III randomized control trial conducted after the phase II portion demonstrated an improvement in progression-free survival (PFS) in patients with local y advanced or metastatic biliary tract cancers treated with either gemcitabine and cisplatin or gemcitabine alone. The trial redemonstrated the PFS

advantage (8 months vs. 5 months, p <0.001) and met its primary endpoint of overal survival (OS) with a median OS of 11.7 months in the gemcitabine and cisplatin arm and 8.1 months in the gemcitabine-alone arm (HR, 0.64; 95% CI, 0.52 to 0.8; p

<0.001). This combination was tolerated without substantial y increased toxicity.

There is no high-quality evidence for second-line therapy and in fact only 17% of patients in the UK-ABC-02 trial went on to receive second-line therapy. 5FU containing regimens as second-line therapy is supported by a smal series of patients who received FOLFOX4 (four of eighteen patients responded) but high-quality evidence is lacking to guide second line and beyond therapy and clinical trial enrol ment is encouraged. There is mixed literature for radiation therapy used in the pal iative setting for cholangiocarcinoma. The risk of toxicity is substantial but a smal phase II trial suggested the median OS may be superior to chemotherapy with stereotactic body radiotherapy.

Larger comparative trials are needed. Given the survival benefit with gemcitabine and cisplatin, pal iative care alone would not be appropriate unless requested by the patient or the patient is medical y unfit.

Question 17.32 The answer is E.

The fol owing groups should undergo surveil ance for HCC.

Hepatitis B carrier—Asian men more than 40 years old, Asian women more than 50

years old, Africans more than 20 years old, al cirrhotic hepatitis B carriers, family history of HCC and patients with high hepatitis B virus DNA with ongoing hepatic injury.

Nonhepatitis B cirrhosis—hepatitis C, alcoholic cirrhosis, genetic hemochromatosis, and primary biliary cirrhosis

Tests that have been used for surveil ance for HCC include serologic tests (measurement of serum AFP) and radiologic tests (such as ultrasonography). Although the ideal surveil ance interval is not known, a surveil ance interval of 6 to 12 months 220

has been proposed based on estimates of tumor doubling time.

Question 17.33 The answer is D.

This patient has Child–Pugh C cirrhosis at presentation and unresectable HCC. He would not have qualified for enrol ment in the SHARP study as only patients with Child–Pugh A were enrol ed. In clinical practice, patients with Child–Pugh B cirrhosis are often offered sorafenib therapy if no viable alternatives such as clinical trial enrol ment are available. However, survival is markedly shorter than patients with preserved hepatic function and there is no evidence that sorafenib has a meaningful impact on survival in this population. A phase III trial compared sunitinib with sorafenib in patients with Child–Pugh A cirrhosis and was stopped early due to poorer survival in the sunitinib arm. This patient should be offered hospice services or supportive medical care given his poor prognosis and lack of evidence-based treatment options.

Corresponding chapters in Cancer: Principles & Practice of Oncology, Tenth Edition: 48

(Molecular Biology of Pancreas Cancer), 49 (Cancer of the Pancreas), 51 (Molecular Biology of Liver Cancer), 52 (Cancer of the Liver), and 53 (Cancer of the Biliary Tree).

221





Each of the numbered items below is fol owed by let ered answers. Select the BEST answer(s).

Question 18.1 A 60-year-old previously healthy woman noted abdominal distension and discomfort for 6 months, associated with nausea and vomiting. Computed tomography (CT) scan shows a 20 × 25-cm abdominal mass, and exploratory laparotomy demonstrated a pedunculated mass arising from the stomach. No other metastases were found. A partial gastrectomy was done, and pathology revealed a gastrointestinal stromal tumor (GIST) which strongly stains for CD117 and CD34. Sixty mitoses were seen per 50 high-power field (HPF). Which of the fol owing is TRUE regarding GISTs?

A. The most common mutation associated with GIST involves the inactivation of a tumor suppressor gene.

B. Both tumor size and mitotic index predict response to imatinib therapy.

C. Gastric GISTs are associated with relatively worse outcomes compared with smal intestinal GISTs.

D. Patients with metastatic GIST tumors harboring exon 9 mutations have a better prognosis and response to imatinib compared with those with exon 11 mutation.

E. None of the above.

Question 18.2 After the patient in Question 18.1 has recovered from surgery, what would you recommend for this patient on the basis of current data?

A. Observation with serial scans

B. Imatinib 400 mg per os (PO) daily for 1 year

C. Imatinib 400 mg PO daily for at least 3 years

D. Sunitinib 50 mg 4 weeks on/2 weeks off therapy for 5 years Question 18.3 A 52-year-old woman with metastatic gastric GIST had an initial complete response to daily imatinib 400 mg with resolution of her hepatic and peritoneal metastases after 6 months of therapy. Imatinib was continued for 18 months when her CT scan showed recurrent hepatic lesions. Imatinib was increased to 800 mg daily. However, subsequent scans revealed progressive disease. You recommend starting sunitinib for this patient. Which of the fol owing statements are TRUE? (Select two correct responses) A. Acquired resistance to imatinib therapy may be associated with the development of secondary KIT or PDGFRA mutations.

B. Sunitinib therapy for patients with imatinib-resistant GIST improved progression-free 222

survival compared with placebo.

C. Patients with GIST harboring exon 11 mutation have a higher response to sunitinib than those with exon 9 mutation.

D. Patients with the wild-type GIST are resistant to both imatinib and sunitinib therapy.

Question 18.4 The patient in Question 18.3 started sunitinib 50 mg daily for 28 days fol owed by a 2-week break. After two cycles, repeated CT scans showed a decrease in the measurable lesions. In addition to hypopigmentation of her hair, she also noted progressive generalized fatigue. Patient denies any dyspnea on exertion, diarrhea, or pedal edema.

Physical examination reveals an erythematous rash in the hands, clear lungs, no cardiac gal ops or rubs, and no focal neurologic deficits. Pertinent laboratory tests are as fol ows: White blood cel 5.6 × 103 cel s/μL

Hemoglobin 11.8 g/dL

Sodium 145 mmol/L

Potassium 4.5 mmol/L

Creatinine 0.8 mg/dL

Total bilirubin 0.5 mg/dL

Alkaline phosphatase 118 μ/L

What would you order next?

A. Magnesium level

B. Magnetic resonance imaging of the brain

C. Thyroid function tests

D. 25-Hydroxycholecalciferol level

Question 18.5 After 6 months of sunitinib therapy, the patient in Question 18.4 was noted to have progression of her liver and omental lesions. Her Karnofsky performance status is 90% and hematologic, renal, and hepatic functions are al adequate. She is interested in further therapy. What would be your best recommendation?

A. No further therapy and proceed with hospice because there is no standard therapy after second-line sunitinib.

B. Sorafenib

C. Regorafenib

D. Bevacizumab

Question 18.6 Familial and genetic syndromes associated with GIST are: (Select two correct responses)

A. Cowden syndrome

B. Li–Fraumeni syndrome

C. Carney triad

D. Neurofibromatosis

223

Question 18.7 What is the most common type of smal bowel malignancy?

A. Adenocarcinoma

B. Lymphoma

C. Carcinoid

D. Schwannoma

Question 18.8 Which of the fol owing are characteristic of primary intestinal mucosal-associated lymphoid tissue (MALT) lymphoma? (Select two correct responses) A. Association with Hashimoto thyroiditis

B. The majority of patients present with stages I and II C. Most common in women

D. Associated with the translocation t(11;14)

Question 18.9 A 50-year-old male presented with bloating, and tarry stools. Upper endoscopy revealed a mass in the third portion of the duodenum, with the biopsy showing moderately di erentiated adenocarcinoma. Resection demonstrated three periduodenal lymph nodes involved with carcinoma. CT scan showed no distant metastases. Which of the fol owing statements regarding smal bowel adenocarcinoma is TRUE?

A. The duodenum is the most common location for adenocarcinoma.

B. Jejunal and ileal tumors are associated with worse outcomes compared to duodenal adenocarcinoma.

C. Stage III smal bowel adenocarcinoma is associated with a 63% survival.

D. Adjuvant therapy with irinotecan, 5-fluorouracil, and leucovorin is standard for stage III duodenal adenocarcinoma.

Question 18.10 Which of the fol owing is a criterion to di erentiate between primary intestinal and secondary lymphomas?

A. No superficial adenopathy

B. No evidence of splenic involvement except through direct extension of the primary tumor

C. No evidence of peripheral blood or bone marrow involvement D. Al the above

Question 18.11 The risk for progressive disease for a patient with smal intestinal GIST

measuring less than 2 cm with more than five mitoses/50 hpf is: A. 0%

B. 4.3%

C. 24%

D. 50%

E. 85%

224

Question 18.12 A 20-year-old student presented to the emergency department with a 2-day history of right lower abdominal pain associated with fever. His abdomen was slightly distended with di use tenderness but without guarding or rebound tenderness. Rectal examination showed no masses and was negative for occult blood. Complete blood count showed a slightly elevated white blood cel at 11,000. CT scan showed a mass in the terminal ileum with no evidence of free peritoneal air. Colonoscopy revealed a terminal ileum mass, the biopsy of which showed sheets of monotonous round nucleated cel s with abundant basophilic cytoplasm with numerous macrophages. Ki-67 index was 100%. What is your diagnosis?

A. MALT lymphoma

B. Burkitt lymphoma

C. Peripheral T-cel lymphoma

D. Medul ary carcinoma of the smal intestine

225

Question 18.1 The answer is E.

In the majority of malignant GISTs, a gain-of-function mutation results in the constitutive activation of the KIT proto-oncogene. Approximately 80% of GISTs harbor KIT mutations, whereas another 5% to 7% have activating PDGFRA mutations. The most common mutation is identified in the KIT juxtamembrane domain, exon 11.

Other mutations in exon 9, 13, 17, and 18 have been described. In the Intergroup US–

Finland study, higher response rates and better outcomes were observed among patients with GIST with the exon 11 mutation compared with those with exon 9 mutation.

Objective responses to imatinib therapy among patients with GIST with exon 11 and exon 9 mutations are approximately 70% and 40%, respectively. Patients with wild-type GIST have a response rate of approximately 30%. Median time to progression also is longer for those with exon 11 compared with other genotypes. The higher prevalence of a specific exon 9 mutation among GISTs originating in the smal intestine may explain in part the observation of worse prognosis of these tumors compared with gastric GISTs.

Although tumor size and mitotic index carry prognostic significance for patients with GIST, neither has been associated with response to tyrosine kinase inhibition.

Question 18.2 The answer is C.

Based on the tumor size and mitotic rate, this patient is at high risk for recurrence.

Thus, observation and serial scans wil not be appropriate. Adjuvant imatinib for 3 years is associated with increased recurrence-free and overal survival compared to 1 year.

There are no randomized studies on the use of sunitinib in the adjuvant setting.

Question 18.3 The answers are A and B.

Primary resistance to imatinib, manifested by continued tumor growth within the first 6

months of imatinib therapy, occurs in a minority of GISTs. Secondary resistance general y occurs after a median of 24 months of continued tyrosine kinase inhibition.

Acquired mutations in KIT or PDGFRA have been implicated in the development of drug resistance to imatinib. The emergence of KIT-independent genotypes may also result in imatinib resistance. Sunitinib was approved by the Food and Drug Administration for the treatment of GIST after disease progression or intolerance to imatinib. The pivotal Phase III study demonstrated a superior time to progression of 27.3 weeks for patients treated with sunitinib compared with 6.4 weeks for patients treated with placebo. Six-month survival rates also favor sunitinib at 79.4% compared with 56.9% for placebo. With the crossover design, the advantage for survival benefit on longer fol ow-up diminished. A subset analysis showed improvement in response rates and outcomes for patients with GIST harboring exon 9 mutation compared with those harboring exon 11 mutations.

Responses were also observed among patients with wild-type genotype.

226

Question 18.4 The answer is C.

Biochemical and clinical hypothyroidism has been associated with sunitinib therapy.

Routine monitoring of thyroid function test is warranted and thyroid hormone replacement therapy may al eviate the symptoms. The precise mechanism for sunitinib-associated hypothyroidism is unclear. Destructive thyroiditis through fol icular apoptosis has been postulated for sunitinib-associated thyroid dysfunction based on the observation of transient thyroid-stimulating hormone suppression and subsequent absence of visualized thyroid tissue. Other causes of fatigue associated with sunitinib include adrenal insufficiency or congestive heart failure.

Question 18.5 The answer is C.

Regorafenib, a tyrosine kinase inhibitor targeting KIT, PDGFR, and VEGFR1,2 and 3, is the standard third-line treatment for GIST refractory to imatinib and sunitinib.

Although sorafenib appears to have activity against GIST, it is not approved as a standard third-line therapy for GIST due to lack of confirmatory Phase III studies. There are no current data on the use of bevacizumab, an anti-VEGF monoclonal antibody for the treatment of GIST.

Question 18.6 The answers are C and D.

Both familial paraganglioma and neurofibromatosis type 1 are associated with GIST.

These syndromes, along with pediatric GIST, can be characterized by the wild-type KIT

gene. Carney triad, which encompasses multifocal GIST with pulmonary chondromas and extra-adrenal paraganglioma is another syndrome associated with GIST. Cowden syndrome is an autosomal dominant subtype of the PTEN hamartoma syndrome associated with a lifetime increased risk for various cancers including breast, colorectal, endometrial, renal cancers, and melanoma. Li–Fraumeni syndrome is an autosomal dominant hereditary disorder characterized by TP53 mutation and the development of multiple malignancies including sarcoma, breast cancer, colorectal and pancreatic cancers, lymphoma, melanoma, and germ cel tumors.

Question 18.7 The answer is C.

According the National cancer database, the most common tumors of the smal bowel are carcinoids. Carcinoids arise from the neuroendocrine cel s of Kulchitsky and have increased fourfold in incidence during the last two decades. Carcinoids are fol owed by adenocarcinomas and lymphomas as the most common smal intestinal malignancies.

Sarcomas are less likely and schwannomas are rare.

Question 18.8 The answers are A and B.

MALT lymphomas are predominantly seen in men, with a peak incidence in the sixth decade. These malignancies may be associated with chronic inflammatory disorders 227

such as Hashimoto thyroiditis and Sjögren disease. The majority of patients present with stages I or II. The translocation t(11;14) causing overexpression of cyclin D1 is characteristic of mantle cel lymphoma.

Question 18.9 The answer is A.

Smal bowel adenocarcinomas are rare malignancies which are slightly more common in men. The duodenum represents with most common location, accounting for approximately half of the cases. Compared to more distal lesions, tumors of the duodenum tend to occur in older patients and are associated with worse outcomes.

Overal survival for patients with smal bowel adenocarcinomas for patients with stage I, II, III, and IV disease are as fol ows: 63%, 48%, 32% and approximately 4%. Despite the high risk of recurrence for patients with stage II and III disease, there are no standard adjuvant therapy regimens.

Question 18.10 The answer is D.

The main criteria to distinguish between primary intestinal lymphomas and secondary involvement include no superficial palpable lymphadenopathy, no mediastinal adenopathy, no evidence of peripheral blood or bone marrow involvement, no involvement of the liver or spleen unless by direct extension of the primary tumor, and disease confined to the affected smal bowel and regional draining mesenteric lymph nodes.

Question 18.11 The answer is D.

GISTs arising from the smal intestine appear to have a more malignant behavior at a smal er size compared with those found in the stomach or in the colon. For smal tumors less than 2 cm, those with less than 5 mitoses per 50 hpf have a 0% risk of progression according to one study, whereas those with more than 5 mitoses per 50 hpf have a 50%

risk for progression. GISTs larger than 10 cm with more than 10 mitoses per 50 hpf have a 90% risk of progression.

Question 18.12 The answer is B.

This patient has Burkitt lymphoma arising from the terminal ileum presenting with appendicitis-like symptoms. This type of lymphoma accounts for less than 5% of al lymphomas in the smal intestine. A “starry-eyed” pattern interspersed throughout monomorphic cel s with abundant basophilic cytoplasm is characteristic and related to numerous macrophages with ingested apoptotic tumors within. A high proliferative index is also characteristic of this malignancy. Treatment consists primarily of aggressive chemotherapy.

Corresponding chapters in Cancer: Principles & Practice of Oncology, Tenth Edition: 54

228

(Cancer of the Smal Bowel) and 55 (Gastrointestinal Stromal Tumor).

229





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 19.1 A 30-year-old multigravid woman presents with a large abdominal mass associated with abdominal pain. She underwent a total proctocolectomy for colon cancer secondary to familial adenomatous polyposis (FAP) 4 years ago fol owed by adjuvant chemotherapy for node-positive disease. A recent esophagogastric endoscopy revealed only a tubulovil ous adenoma in the duodenum but the computed tomography (CT) scan revealed a 10-cm mass l ing the pelvis. Biopsy showed desmoid tumor. A TRUE statement regarding desmoid tumors is:

A. Desmoid tumors represent the second most common cause of death for patients with FAP.

B. Desmoid tumors are uniformly aggressive and local y invasive.

C. Adjuvant radiation is recommended.

D. Adjuvant chemotherapy is recommended.

Question 19.2 A 55-year-old woman underwent a right hemicolectomy for a cecal mass, 15 years ago. Four years later, she was found to have a hepatic flexure adenocarcinoma and a total colectomy was performed. Four years ago, she presented with postmenopausal bleeding and was found to have endometrial adenocarcinoma. She also had multiple skin malignancies, including sebaceous adenomas and keratoacanthomas. One year ago, she underwent a Whipple procedure for a duodenal adenocarcinoma invading into the pancreas. She has three siblings and a paternal uncle with colorectal cancer al diagnosed in their late 30s. What is the most probable primary genetic explanation for her inherited colorectal cancer syndrome?

A. Chromosomal instability characterized by the deletion or mutation of a tumor suppressor gene

B. Chromosomal instability characterized by activation of an oncogene C. Microsatel ite instability (MSI) caused by germline mutations in a DNA mismatch repair ( MMR) gene

D. MSI caused by epigenetic changes associated with hypermethylation in CpG islands Question 19.3 Other than genetic counseling, which test would you order to con rm the diagnosis in the patient in Question 19.2?

230

A. TP53 mutation and loss of heterozygosity of chromosome 18q B. APC mutation, including the I1307K al ele

C. MSI testing and methylation of CpG islands

D. MSI test and MMR gene mutation including MLH1, MSH2, and MSH6

Question 19.4 The patient in Question 19.3 had a positive test result. What screening

tests and surveil ance program would you recommend to her three daughters aged 24, 22,

and 20 years?

A. Colonoscopy now and repeat every 1 to 2 years and transvaginal ultrasound for her

daughters starting at age 30 to 35 years

B. Colonoscopy for al and transvaginal ultrasound for her daughters starting at age 30 to

35 years

C. Colonoscopy now and repeat every 1 to 2 years with transvaginal ultrasound at age 30

to 35 years only for her children confirmed to have the same genetic mutation as the

patient; colonoscopy at age 40 to 50 years for those with no mutation D. Colonoscopy and transvaginal ultrasound at age 30 to 35 years only for those confirmed with the same mutation as the patient; colonoscopy at age 40 to 50 years

for those with no mutation

Question 19.5 Which gene is associated with hereditary nonpolyposis colorectal cancer

(HNPCC)?

A. APC

B. MYH

C. STK11

D. MSH2

Question 19.6 A 65-year-old woman presented with intermittent constipation and

diarrhea associated with abdominal cramping. A colonoscopy revealed a near-obstructing

mass and biopsy showed a vil oglandular polyp. She underwent an exploratory laparotomy

and resection of a 5 × 5-cm circumferential necrotic and fungating mass. Pathology

revealed a moderately di erentiated adenocarcinoma invading into the pericolonic fat

with 2 of 30 positive lymph nodes. Margins were negative. CT scan showed no evidence of

metastatic disease. After recovery from her surgery, based on current evidence, you would

recommend:

A. 5FU with leucovorin × 6 months

B. Capecitabine × 6 months

C. Irinotecan with 5FU (FOLFIRI) × 6 months

D. Oxaliplatin with 5FU (FOLFOX) × 6 months

E. Oxaliplatin with 5FU (FOLFOX) and bevacizumab × 6 months Question 19.7 One week after the rst dose of chemotherapy, the patient in Question

231

19.6 developed a fever of 102°F associated with chil s. She also developed diarrhea, mucositis, confusion, and ataxia. Repeat complete blood count showed a white blood cel count of 0.5 × 103 cel s/ L with an absolute neutrophil count of 100, hemoglobin of 11.7 g/dL, and platelet count of 42,000. Which one of the fol owing pharmacogenetic conditions would best explain her clinical course?

A. The patient is homozygous for the thymidylate synthase ( TYMS) *3/*3 polymorphism.

B. The patient is homozygous for UGT1A1*28 polymorphism.

C. The patient is heterozygous for the IVS14 + 1 G>A DPYD*2A mutation.

D. The patient is heterozygous for the ERCC2 Lys751Gln polymorphism.

Question 19.8 A 62-year-old engineer was diagnosed with metastatic cecal adenocarcinoma to the lung and liver. He was initial y treated with oxaliplatin plus infusional 5FU (FOLFOX6) and bevacizumab. After four cycles (2 months), his CT scan showed progressive disease. You discussed irinotecan 180 mg/m2 every 2 weeks plus weekly cetuximab based on the results of the EPIC study. A test for UGT1A1 polymorphism was done, and results revealed him to be homozygous for UGT1A1*28/*28. Which of the fol owing statements is/are TRUE?

A. Patients homozygous for the UGT1A1*28 polymorphism glucuronidate SN38 more efficiently than those with the wild-type *1 genotype.

B. Patients homozygous for the UGT1A1 *28 polymorphism glucuronidate SN38 less efficiently than those with the wild-type *1 genotype.

C. Patients homozygous for UGT1A1*28 polymorphism are at greater risk for severe neutropenia with irinotecan compared with those with the wild-type *1 genotype.

D. A and C are true.

E. B and C are true.

Question 19.9 A 52-year-old teacher presents with a 2-month history of rectal bleeding. A rectal examination revealed a palpable nonobstructing mass 5 cm from the anal verge.

Subsequent colonoscopy con rmed a friable, tethered mass biopsy that showed moderately di erentiated adenocarcinoma. Transrectal ultrasound revealed a T3N1 cancer. CT scans of the chest, abdomen, and pelvis revealed no metastatic sites. Which of the fol owing treatment strategies would you recommend?

A. Total mesorectal excision (TME) alone

B. TME fol owed by chemotherapy

C. TME fol owed by chemoradiation

D. Neoadjuvant 5FU-based chemoradiation fol owed by TME and adjuvant 232

chemotherapy

Question 19.10 Which of the fol owing appropriately staged patients with rectal cancer would be the best candidate for transanal excision?

A. A 48-year-old woman with a 2.5-cm T1 moderately differentiated rectal adenocarcinoma 4 cm from the anal verge.

B. A 65-year-old man with a 4.5-cm T2 wel -differentiated circumferential rectal mass 6 cm from the anal verge.

C. A 30-year-old man with a 2-cm wel -differentiated T1 mucinous adenocarcinoma 12

cm from the anal verge.

D. A 52-year-old woman with a 3-cm wel -differentiated T1N1 adenocarcinoma 5 cm from the anal verge.

E. None of the above.

Question 19.11 For the patient you have selected for transanal resection in Question

19.10, pathologic review of the excised specimen showed no lymphovascular invasion and

al margins were negative. Which of the fol owing options would you recommend?

A. No further therapy

B. Short-course (25 Gy/5 fractions) radiation

C. Intracavitary radiation

D. Adjuvant chemotherapy without radiation

E. Adjuvant chemotherapy with radiation

Question 19.12 Which of the fol owing are TRUE statements regarding MYH-associated polyposis? (Select two correct responses)

A. Inheritance is autosomal dominant.

B. Clinical features of MYH-related polyposis may be similar to FAP.

C. The MYH gene is a base-excision repair gene.

D. A deficiency in MYH leads to accumulation of germline mutations in the APC gene.

Question 19.13 A 49-year-old woman noted rectal bleeding for 2 months. She denied any pain, diarrhea, constipation, or weight loss. A colonoscopy was done that revealed a 2-cm low-lying mass 1 cm from the anal verge. A transrectal ultrasound revealed no lymph nodes. Biopsy showed basaloid squamous cel carcinoma. CT scans of the abdomen and pelvis did not reveal any metastatic disease. The BEST curative treatment option for this patient is:

A. APR

B. Short-course (25 Gy/5 fractions) radiation fol owed by APR

C. Neoadjuvant chemoradiation with 5FU fol owed by APR

D. Chemoradiation alone with 5FU and mitomycin

233

Question 19.14 A 58-year-old man presented with a 6-month history of anorexia, fatigue, and a vague right-sided abdominal discomfort. His physical examination was unremarkable except for mild pal or. Initial laboratory test revealed a hemoglobin level of 10.7 g/dL with a mean corpuscular volume of 73. He also had mildly elevated alkaline phosphatase and hepatic transaminases. Colonoscopy revealed a nonobstructing transverse colon mass. Biopsy demonstrated moderately di erentiated adenocarcinoma. CT scan revealed a 3-cm lesion in the left lobe of the liver and two other lesions measuring 1.5 to 2 cm in the right lobe of the liver. Positron emission tomography revealed uptake in the transverse colon and al three known hepatic lesions. Among the fol owing options, what would be the best option for this patient based on current studies?

A. Curative-intent resection of the transverse colon primary and al three hepatic lesions fol owed by active surveil ance

B. Pal iative-intent front-line chemotherapy with bevacizumab for metastatic colon cancer until progression, fol owed by pal iative second-line chemotherapy C. Curative-intent resection of the transverse colon primary and al three hepatic lesions with perioperative chemotherapy

D. Curative-intent resection of the transverse colon primary and al three hepatic lesions with radiotherapy

Question 19.15 Which genetic change is associated with resistance to treatment with cetuximab?

A. KRAS mutation

B. EGFR over expression

C. KRAS wild type

D. MLH1 inactivation

Question 19.16 A 54-year-old woman has completed six cycles of rst-line therapy for metastatic KRAS codon 12 mutated colon cancer with FOLFOX and bevacizumab, and was shown to have stable disease on restaging scans. Her CEA has also decreased from 135

ng/mL at initial diagnosis to 4.5 ng/mL. She is asking about taking a break from chemotherapy altogether for the next few months given the stable disease. When considering observation versus maintenance chemotherapy in metastatic colorectal cancer, you inform her that:

A. There is no benefit in maintenance therapy with capecitabine and bevacizumab and observation is preferred.

B. She should switch to FOLFIRI–panitumumab given no response noted on imaging.

C. Maintenance therapy with capecitabine and bevacizumab wil lengthen the time to progression and is preferred

D. She needs to complete a total of 12 cycles of oxaliplatin-based regimen before she can consider observation.

234

Question 19.17 Common clinical characteristics for BRAF V600E colorectal tumors include al of the fol owing: (Select two correct responses)

A. Male

B. Right-sided tumors

C. Low-grade features

D. MSI-H

Question 19.18 High-risk features for stage II colon cancers include which TWO of the fol owing characteristics?

A. T4 perforated tumor

B. Moderately differentiated

C. Sampling of 0/8 lymph nodes

D. No lymphovascular invasion

235

Question 19.1 The answer is A.

Desmoid disease is second only to colorectal cancer as a common cause of death among patients with FAP. There is heterogeneity in the clinical presentation of desmoid tumors from asymptomatic abdominal mass to bowel or ureteral obstruction. Sporadic desmoid tumors may also occur. Retrospective studies have not confirmed the role of adjuvant radiation or chemotherapy for desmoid tumors. For unresectable tumors, chemotherapy, hormonal therapy, and targeted agents such as imatinib have been reported in literature as possible pal iative options.

Question 19.2 The answer is C.

This patient meets the Amsterdam criteria for HNPCC with at least three affected relatives in at least two successive-generation relatives and one first-degree relative diagnosed with colorectal cancer before age 50 years. Unlike FAP, which is characterized by chromosomal instability caused by mutations in the APC tumor suppressor gene, HNPCC is characterized by MSI caused by mutations in the DNA MMR

genes. HNPCC is the most common hereditary syndrome predisposing one to colorectal cancers, accounting for approximately 2% to 3% of al colorectal cancer cases. The lifetime risk for developing colon cancer among patients with HNPCC approaches 80%.

HNPCC is also associated with other malignancies, including endometrial, gastric, ampul ary, biliary, and urinary tract cancers. This patient has Muir–Torre syndrome characterized by multiple colon cancers and multiple cutaneous neoplasias, including sebaceous adenomas.

Question 19.3 The answer is D.

HNPCC can be confirmed by the demonstration of the MSI-H phenotype and germline mutation in any of the DNA MMR genes, such as MLH1 on chromosome 3p, MSH2 on chromosome 2p, MSH6 on chromosome 2p, PMS1 on 2q, and PMS2 on 7q. Germline mutations involving MSH2 and MLH1 genes account for more than 60% of the known mutations present in patients with HNPCC. The National Comprehensive Cancer Network guidelines recommend the use of tumor screening with MSI and lack of expression of MMR protein expression by immunohistochemistry initial y, fol owed by MMR mutation testing, although proceeding directly to MMR mutation testing is also acceptable. A negative MMR mutation test result does not rule out Lynch syndrome or HNPCC.

Question 19.4 The answer is C.

Once a germline MMR mutation is identified in a patient, genetic counseling and testing of at-risk family members are essential. The patient’s three daughters, along with al her first-degree relatives, have a 50% probability of being a carrier of the mutant 236

gene. In general, for family members who do not carry the known mutation, there is no need for intensive surveil ance, and routine colorectal screening according to national guidelines is recommended. For family members who carry the germline MMR

mutation, the National Comprehensive Cancer Network recommends colonoscopies every 1 to 2 years beginning at age 20 to 25 years or 5 to 10 years younger than the earliest age of diagnosis in the family, whichever comes first. For women with the MMR

mutation, screening for endometrial cancer with transvaginal ultrasound with or without CA 125 for ovarian cancer screening is recommended at age 30 to 35 years.

Women who have completed childbearing could opt for prophylactic hysterectomy and bilateral salpingo-oophorectomy to reduce their risks for developing endometrial and ovarian cancers.

Question 19.5 The answer is D.

Germline mutations in the MMR genes MSH2, MLH1, and MSH6 account for 90% of al patients with HNPCC. APC gene mutation is commonly associated with FAP. MYH-

associated polyposis is a rare inherited syndrome with increased for colorectal cancer.

Question 19.6 The answer is D.

The standard adjuvant therapy for patients with stage III colon cancer involves the combination of oxaliplatin and 5FU based on the MOSAIC and the NSABP-C07 studies.

Recent updates of the MOSAIC study demonstrated a significant improvement in 6-year overal survival among patients with stage III colorectal cancer treated with FOLFOX compared with those treated with infusional 5FU and leucovorin. Irinotecan-based regimens are not recommended for adjuvant therapy for patients with stage III according to the negative results of three large randomized studies. Current studies on adding bevacizumab and cetuximab to oxaliplatin regimens are ongoing.

Question 19.7 The answer is C.

More than 80% of the administered dose of 5FU is eliminated via the dihydropyrimidine dehydrogenase (DPD) enzyme. Patients with DPD deficiency are at high risk for 5FU toxicities, such as severe neutropenia, neutropenic fever, diarrhea, mucositis, cerebel ar ataxia, neurotoxicity, and even death. The most common mutation associated with DPD deficiency is the IVS14 + 1 G>A DPYD*2A mutation. Complete DPD deficiency has been reported in patients homozygous for this al ele, whereas partial DPD deficiency occurs in patients heterozygous for this al ele. More than 40 other mutations and polymorphism have been identified in the DPD gene, although their functional significance is not clear. Moreover, instances of low DPD activity have been reported in patients without any identified DPD mutation or polymorphism. The TSER*3/ *3 genotype is associated with higher levels of thymidine synthase and lower tumor response to 5FU therapy. Although it is possible that this patient is homozygous 237

for the UGT1A1*28 gene resulting in severe neutropenia and diarrhea, the constel ation of the patient’s symptoms, including cerebel ar ataxia and mucositis, is more consistent with 5FU-related toxicities. Furthermore, irinotecan therapy would not have been given to this patient with stage III colon cancer.

Question 19.8 The answer is E.

SN-38 is the active metabolite of irinotecan and is 100- to 1,000-fold more potent than irinotecan as a topoisomerase I inhibitor. Glucuronidation is the principal elimination pathway for SN-38. UDP-glucuronosyltransferase 1 family polypeptide A1 mediates this glucuronidation of irinotecan encoded by the UGT1A1 gene. Patients who are homozygous for the UGT1A1*28 al ele glucuronidate SN-38 less efficiently than patients who have one or two wild-type al eles; therefore, homozygous patients are exposed to higher plasma concentrations of SN-38 and are thus at a greater risk for severe neutropenia.

Question 19.9 The answer is D.

The results of the German Rectal Cancer Study confirmed the benefit of neoadjuvant prolonged course RT with 5FU-based chemotherapy for patients with T3+/N0–2 rectal cancer. Although overal survival was similar for patients treated with neoadjuvant chemoradiotherapy compared with those treated with postoperative chemoradiotherapy, local recurrence rates and toxicities were more favorable with the neoadjuvant approach.

Question 19.10 The answer is A.

Transanal excision should only be considered for select patients with early stage rectal cancer with the fol owing characteristics: smal rectal cancers less than 3 cm; wel -to-moderately differentiated T1 tumors within 8 cm from the anal verge and limited to less than 30% of the rectal circumference with no evidence of nodal metastases. Only patient A meets al of these criteria.

Question 19.11 The answer is A.

After transanal resection of appropriately selected patients with early stage rectal cancer, no further therapy is recommended.

Question 19.12 The answers are B and C.

MYH-associated polyposis is an autosomal-recessive disease affecting the MYH gene, a base-excision repair gene. A deficiency in MYH leads to somatic, not germline, mutations in the APC gene. Thus, clinical features of patients with MYH-associated polyposis are similar to FAP.

238

Question 19.13 The answer is D.

The standard therapy for early localized squamous carcinoma of the anus is chemoradiation with 5FU and mitomycin, which is associated with excel ent cure rates.

Salvage APR is reserved for recurrent anal cancer.

Question 19.14 The answer is C.

This patient is potential y curable with an aggressive multidisciplinary approach.

Resection of al tumor sites with close surveil ance certainly is an option for this patient.

However, the results of the recently published study, EORTC 40983, showed an improvement in progression-free survival for patients treated with perioperative chemotherapy with resection. Historical y, cure rates of up to 35% have been observed even in patients with metastatic disease, as long as al tumor sites are resected. Thus, pal iative chemotherapy would not be the best option for this patient. There is currently no role for radiotherapy for this patient.

Question 19.15 The answer is A.

Patients with colorectal cancer who test positive for the KRAS, NRAS, or BRAF V600E

mutations are resistant to treatment with cetuximab.

Question 19.16 The answer is C.

Based on the phase III CAIRO3 data, after completion of 6 cycles of capecitabine +

oxaliplatin (CAPOX) and bevacizumab, the patients who transitioned to maintenance therapy with capecitabine and bevacizumab had a significantly longer time for progression than those on observation (8.5 months vs. 4.1 months). This study also reported the patients placed back on CAPOX/bevacizumab after progression on maintenance therapy were noted to have continued improved time to second progression of 19.8 months versus 15.0 months. Complete treatment break at this point would not be preferred, but the patient could make an informed decision based on this information. Changing to second-line therapy with FOLFIRI plus panitumumab at this point is an incorrect treatment option since anti-EGFR therapy is not beneficial for patients with KRAS-mutated colorectal cancer. There is no need to go through al 12

cycles of oxaliplatin at this time (if the patient is able to tolerate the side effects) based on the OPTIMOX-1 data, since the original chemotherapy may be restarted at the time of tumor progression.

Question 19.17 The answers are B and D.

BRAF V600E is the most frequent BRAF mutation in colorectal cancers. It is most commonly associated in older women, right-side location, high-grade features and presence of microsatel ite instability (MSI-high). Nevertheless, this mutation is uncommon, occurring in approximately 5% to 10% of the colon cancer population. The 239

prognosis is worse than in those with wild-type BRAF.

Question 19.18 The answers are A and C.

High-risk features for stage II colon cancers include: bowel obstruction, perforated T4

tumors, poorly differentiated, signet ring or mucinous tumors, inadequate lymph node sampling (at least 10 is considered adequate), and positive lymphovascular invasion.

Corresponding chapters in Cancer: Principles & Practice of Oncology, Tenth Edition: 56

(Molecular Biology of Colorectal Cancer), 57 (Cancer of the Colon), 60 (Cancer of the Rectum), and 61 (Cancer of the Anal Region).

240





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 20.1 Activating mutations in which of the fol owing genes is seen in patients with hereditary papil ary renal cel carcinoma?

A. VHL

B. MET

C. FLCN

D. SDHB

Question 20.2 A 56-year-old moderately obese woman with a medical history of chronic hypertension wel control ed on a thiazide diuretic presents to the emergency department with a 1-day history of abdominal pain, diarrhea, nausea, and fever. General physical examination is signi cant only for some mild abdominal tenderness; negative stool guaiac; a white blood cel count of 14.2/ L; hemoglobin of 14.5 g/dL; a normal platelet count; normal electrolytes, amylase, lipase, and transaminases; and a creatinine of 0.9 mg/dL.

Workup includes an abdominal computed tomography (CT) scan, which is remarkable for a 1.5-cm enhancing left renal mass in the left lower pole that is interpreted by the radiologist as a “probable renal cel carcinoma” without evidence of other metastases. The patient undergoes a laparoscopic partial nephrectomy. There are no postoperative complications, and she is back to work 3 weeks later. Postoperative creatinine is 1.3 and pathology reveals a 2.5-cm renal cel carcinoma, granular cel type, that is con ned to the renal parenchyma.

No lymph nodes were recovered. The next appropriate step is: A. Open retroperitoneal lymph node dissection.

B. Adjuvant sunitinib.

C. Adjuvant local radiotherapy.

D. Submission of pathology specimen for second review.

Question 20.3 A 55-year-old woman undergoes partial nephrectomy for clear cel carcinoma of the kidney, Fuhrman grade IV. The patient does wel for 10 years, at which time she develops a pathologic intratrochanteric fracture of her left hip. CT scanning of the chest, abdomen, pelvis, and brain and bone scan reveals no other sites of disease. The most appropriate next step is:

A. Radiation alone.

241

B. High-dose interleukin-2 alone.

C. Orthopedic resection of the tumor with reconstruction fol owed by radiation.

D. Temsirolimus.

Questions 20.4–5 A 76-year-old man with chronic obstructive pulmonary disorder and diabetes mel itus presents with back pain and confusion. Workup reveals extensive metastatic disease in the lungs, bones, and liver and a 6-cm tumor in the kidney. There is no evidence of cord compression. Laboratory studies reveal a calcium level of 11.5 mg/dL, lactate dehydrogenase (LDH) of 600, and a creatinine level of 2.0 mg/dL. After hydration and zoledronate, his calcium normalizes, hemoglobin is 9.5, creatinine decreases to 1.7, and Eastern Cooperative Oncology Group performance status is 2.

Question 20.4 Based on MSKCC risk factors, this patient would be considered: A. No risk.

B. Low risk.

C. Intermediate risk.

D. Poor risk.

Question 20.5 The most appropriate therapy in this case is: A. Interferon-α.

B. Temsirolimus.

C. Sunitinib.

D. Sorafenib.

Question 20.6 A 25-year-old Caucasian man without a medical history presents with hematuria. Workup reveals bilateral renal cysts, at least one of them suspicious for malignancy. Family history is signi cant for a pheochromocytoma in his father and a pancreatic islet cel tumor and early death from kidney cancer in a paternal aunt. The most likely familial cancer syndrome is:

A. Von Hippel–Lindau disease.

B. Birt–Hogg–Dubé syndrome.

C. Hereditary papil ary renal cancer.

D. Hereditary leiomyomatosis and renal cancer.

Question 20.7 Which of the fol owing associated with loss of VHL function is most likely to lead to tumor angiogenesis?

A. Modulation of NF-kB activity and downregulation of JUNB

B. Increase in matrix metal oproteinases

C. Increase in hypoxia inducible factor (HIF)

D. Destabilization of microtubule formation

242

Question 20.8 Inactivation or alteration in which of the fol owing tumor suppressor genes is implicated in the pathogenesis of invasive bladder cancer?

A. TP53

B. RB1

C. PTEN

D. Al of the above

Question 20.9 A patient with hematuria is taken to the operating room, where an examination under general anesthesia reveals a mobile bladder. Resection of the papil ary lesion reveals grade III urothelial papil ary carcinoma, and multiple biopsies of the erythematous areas of the bladder al reveal di use carcinoma in situ. Muscle is present in the pathologic specimens, and there is no evidence for invasive tumor. The appropriate therapy is:

A. Intravesical Bacil us Calmette–Guérin (BCG) vaccine.

B. Intravesical cyclophosphamide.

C. Radiation.

D. Cystectomy.

Question 20.10 The patient receives de nitive treatment, as wel as with a fol ow-up maintenance program; however, 4 months after initiating the maintenance BCG program, the urologist notes multiple recurrent papil ary lesions. Repeat biopsy reveals urothelial cancer invasive into muscle. CT scans of the chest, abdomen, and pelvis are unremarkable, creatinine remains normal at 1.2 mg/dL, and his performance status is excel ent.

Appropriate initial therapy at this point is:

A. Reinduction with intravesical BCG.

B. Intravesical chemotherapy with mitomycin-C.

C. Partial cystectomy.

D. Cisplatin-based multiagent chemotherapy.

Question 20.11 Which of the fol owing is the most common molecular abnormality seen in patients with prostate cancer?

A. KRAS mutation

B. BRAF mutation

C. p53 mutation

D. Chromosomal translocations involving TMPRSS2

Question 20.12 Which of the fol owing are risk factors for cancer of the male urethra?

A. HPV-16

B. Chronic irritation

C. Infection

243

D. Caucasian race

Questions 20.13–14 A 62-year-old woman is newly diagnosed with muscle-invasive bladder cancer. She quit smoking 10 years ago, had a non–ST-elevated myocardial infarction 4 years ago, underwent coronary artery bypass surgery and has had no residual cardiac symptoms, takes only a beta-blocker and a thiazide for hypertension, and has normal laboratory test results, including a creatinine of 0.9. Cystoscopic biopsy revealed a muscle-invasive bladder cancer without associated carcinoma in situ (Tcis), and CT of the chest, abdomen, and pelvis is unremarkable.

Question 20.13 Which of the fol owing statements about radical cystectomy is most CORRECT?

A. An orthotopic neobladder is less effective in women than in men.

B. An abdominal wal diversion wil require a urostomy bag.

C. An orthotopic neobladder wil require the patient to be wil ing and able to perform self-catheterization.

D. Metabolic acidosis is not a significant problem with continent diversions.

Question 20.14 Which of the fol owing statements about combined radiation and chemotherapy is most CORRECT?

A. Toxicity profile and tolerability of combined radiation and chemotherapy are significantly better than that of radical cystectomy.

B. Long-term cancer outcome is similar to cystectomy.

C. It is preferred over cystectomy because of her cardiac history.

D. It wil obviate the need for cystectomy.

Question 20.15 Which of the fol owing is CORRECT about neoadjuvant chemotherapy?

A. Three cycles of methotrexate, vinblastine, doxorubicin, and cisplatin before cystectomy are a standard of care.

B. Gemcitabine/carboplatin should be considered to decrease the risk of renal failure with cystectomy.

C. It increases the risk of surgical complications of cystectomy.

D. It should always be used with an organ preservation approach but is optional if cystectomy is chosen.

Question 20.16 Which of the fol owing genes is most commonly found to be abnormal y altered in invasive (≥T2) urothelial carcinoma of the bladder?

A. ERBB2

B. TP53

C. MDM2

D. FGFR3

244

Question 20.17 A 71-year-old man without signi cant medical history presents with hematuria and ank pain. CT scan reveals a mass at the pelvic–ureteral junction with associated hydronephrosis, but no associated lymphadenopathy. Cystoscopy and ureteroscopy reveal an obstructing mass at the pelvic–ureteral junction, and cytology is diagnostic for urothelial cancer. Which of the fol owing is the most appropriate therapy?

A. Open nephroureterectomy and bladder cuff resection

B. Open radical nephrectomy with retroperitoneal lymph node dissection C. Laparoscopic radical nephrectomy without retroperitoneal lymph node dissection D. Definitive radiation and combined chemotherapy

Question 20.18 A 51-year-old man with a strong family history of prostate cancer, a normal digital rectal examination, no signi cant comorbid medical problems, and a PSA of 2.9 seeks advice on prostate cancer prevention. He is sexual y active in a monogamous relationship and denies any urinary or rectal symptoms. Which is the most likely to reduce his risk of developing prostate cancer?

A. Reducing his alcohol intake.

B. Taking supplemental high dose vitamin E.

C. Avoiding high fat intake, reducing his BMI (avoiding obesity), and increasing his physical activity.

D. Increasing his calcium/vitamin D intake.

Questions 20.19–20 A 71-year-old white man with a history of hypertension, hyperlipidemia, coronary artery disease, and prior angioplasty with stent placement, but no prior myocardial infarction, is noted to have an increase in his PSA from 3.0 to 3.9 ng/mL

and then to 4.6 ng/mL over 19 months. He is a semiretired accountant, swims actively three times per week, and helps care for his mildly demented 95-year-old father. General physical examination is unremarkable; a rectal examination reveals a mildly enlarged prostate gland without any palpable nodules.

Question 20.19 The most CORRECT statement about this case is: A. Biopsy should be discussed because the PSA increase is >0.75 ng/ mL/year.

B. Biopsy should not be discussed because PSA is normal for his age.

C. Biopsy should not be discussed because his expected survival makes treatment not worthwhile, even if prostate cancer is discovered.

D. Biopsy should be discussed because the PSA is >4 ng/mL.

E. The free-to-total PSA ratio wil determine the need for biopsy.

Question 20.20 Biopsy reveals Gleason 8 prostate cancer in six of six cores. CT scan of the abdomen and pelvis and bone scan are unremarkable. The most appropriate therapy is: A. Radical retropubic prostatectomy.

B. Three-dimensional conformal radiotherapy with concomitant androgen ablation.

245

C. Interstitial radiotherapy with 125I.

D. Al of the above.

Question 20.21 After discussion with a radiation oncologist and a urologist, the patient elects to undergo combined androgen ablation and external beam radiation therapy. The androgen ablation is administered before the radiation therapy and continued for 3

months thereafter. Radiotherapy is complicated only by a mild diarrhea that resolves once the radiation therapy is complete. The PSA nadirs at 1.2 ng/mL; however, 9 months after his last dose of the luteinizing hormone–releasing hormone (LHRH) agonist, the PSA increases to 2.4 ng/mL and then to 3.6 ng/mL 1 month later. Testosterone level is normal at 350 ng/mL. The most appropriate next therapeutic and/or diagnostic maneuver is: A. Perform MRI of the pelvis to assess for local recurrence.

B. Reinitiate androgen ablation.

C. Refer the patient to a urologist for salvage prostatectomy.

D. Initiate docetaxel-based chemotherapy.

Question 20.22 The patient is treated with an LHRH agonist along with the antiandrogen bicalutamide. PSA declines to 0.8 ng/mL, but after 10 months, the PSA begins to slowly increase to a value of 3.7. He continues to feel wel and has minimal urinary symptoms, no bone pain, and no weight loss. The most appropriate therapy at this point is: A. Docetaxel-based chemotherapy.

B. Discontinuing the antiandrogen bicalutamide.

C. Hospice care.

D. Radionuclide therapy with strontium-98 (Metastron).

Question 20.23 Infestation with which of the fol owing parasites is a risk factor for developing bladder cancer?

A. Clonorchis sinensis

B. Opisthorchis viverrini

C. Schistosoma haematobium

D. None of the above

Question 24–25 A 51-year-old black male executive with no medical history undergoes a routine PSA screening evaluation and is found to have a PSA of 5.5 ng/mL. Biopsy reveals a Gleason 3 + 3 prostate cancer in two of six biopsy cores. After discussion with a radiation oncologist and urologist, he elects to receive treatment with a radical retropubic prostatectomy.

Question 20.24 Which of the fol owing statements about the surgery is TRUE?

A. Robotic laparoscopic prostatectomy is associated with a lower incidence of impotence than open retropubic prostatectomy.

246

B. The incidence of impotence under the assumption that a bilateral nerve sparing procedure can be performed is <10%.

C. Problems with incontinence persist in approximately 20% of patients.

D. Surgical experience has only a minimal impact on the positive margin rate.

Question 20.25 Surgical pathology con rms a Gleason score 6 tumor in both lobes of the prostate. There is a focal surgical positive margin. There is no evidence of seminal vesicle or lymph node invasion. His postoperative PSA is undetectable, and he has good continence.

The most appropriate next step is:

A. Adjuvant radiotherapy.

B. Repeat surgical exploration with possible reexcision of the prostatic bed.

C. Pelvic CT scan.

D. Prostascint scan.

Question 20.26 The patient maintains an undetectable PSA until 8 years later (at the age of 59 years), recurrent biochemical disease is noted. After appropriate discussion, androgen ablation with an LHRH agonist alone is initiated, and the PSA once again becomes undetectable. The patient maintains an undetectable PSA while on androgen ablation for 3

years, when he develops sudden midback pain after lifting his grandson. There are no associated neurologic signs or symptoms. Bone scan shows marked uptake at the T8

vertebra and PSA remains undetectable. The most appropriate therapeutic or diagnostic maneuver is:

A. Immediate radiotherapy to T8.

B. Therapy with ketoconazole, 400 mg three times daily with hydrocortisone replacement.

C. Spinal MRI to rule out cord compression.

D. Bone densitometry to assess for osteoporosis.

Question 20.27 A 75-year-old man with diabetes, hypertension, and coronary artery disease who is receiving atorvastatin, glyburide, and an angiotensin-converting enzyme inhibitor is under surveil ance after external beam radiotherapy for a Gleason 3 + 3

prostate cancer that was diagnosed and treated 10 years earlier when he was found to have a PSA of 4.3 on routine screening. His PSA level, which had been 0.2 ng/mL, has increased to 0.3, 0.35, and then 0.40 over the period of 18 months. The most appropriate therapy at this time is:

A. Androgen ablation with an LHRH agonist.

B. Continued active surveil ance.

C. High-intensity focused ultrasound to his prostate.

D. High-dose (150 mg) bicalutamide.

Question 20.28 A 65-year-old man has been receiving combined androgen ablation with 247

leuprolide and bicalutamide for 4 years for biochemical recurrence after radical prostatectomy. His PSA has increased from an undetectable nadir to 1.1 ng/mL on serial measurement over the period of 6 months. The PSA then continues to increase 2 months later to 2.5, with serum testosterone of 10 ng/mL. Bone scan and CT of the abdomen/pelvis do not reveal any metastatic disease, and he remains asymptomatic. The most appropriate therapy option is:

A. Continue current treatment regimen and active surveil ance.

B. Docetaxel-based chemotherapy.

C. Start enzalutamide.

D. Discontinue bicalutamide.

Question 20.29 Which of the fol owing has the highest risk of developing prostate cancer?

A. A 60-year-old Caucasian male with no family history of cancer.

B. A 60-year-old African-American male with a father with prostate cancer.

C. A 40-year-old Asian male.

D. A 40-year-old obese Caucasian male.

Question 20.30 Genetic alterations in which of the fol owing is most common in prostate adenocarcinoma?

A. NRIP1

B. FOXA1

C. PTEN

D. CDK2

Question 20.31 Which of the fol owing statements about the androgen receptor is most CORRECT?

A. The majority of its activity in prostate cancer is due to its cytoplasmic effects.

B. Upregulation of androgen receptor expression has been linked to prostate cancer development.

C. Castration leads to complete inactivation of al androgen receptor-mediated pathways.

D. Castrate-resistant prostate cancer (CRPC) is associated with upregulation of androgen receptor expression.

Question 20.32 A 63-year-old uncircumcised man without any signi cant medical history presents to his physician with an inability to retract the foreskin. Examination reveals phimosis, with an underlying painless ulcerated mass of 1 × 2 cm. A 2.5-cm hard node is palpated in the left inguinal region. Biopsy of the penile lesion reveals squamous cel cancer. In addition to wide surgical resection of the primary lesion, other appropriate therapeutic and/or diagnostic maneuvers at this time include: A. Four-week course of a broad-spectrum antibiotic.

248

B. Left inguinal lymph node dissection.

C. Bilateral inguinal radiotherapy.

D. Taxane-based chemotherapy.

249

Question 20.1 The answer is B.

Hereditary papil ary renal cel carcinoma is an autosomal-dominant hereditary cancer syndrome characterized by mutations in the MET protooncogene, which encodes the hepatocyte growth factor/scatter factor receptor tyrosine kinase. Although MET

overexpression has been demonstrated in a number of epithelial cancers, HRPC is the first cancer syndrome for which germline MET mutations have been identified.

Individuals with this syndrome are at risk for developing multifocal, bilateral papil ary type 1 kidney cancer in their fifth and sixth decades of life, with age-dependent penetrance of 67% by 60 years of age.

Question 20.2 The answer is D.

Renal cel cancer is currently divided into clear cel and non–clear cel subtypes. The non–clear cel subtypes have been further divided into papil ary, chromophobe, and col ecting duct tumors. Several renal cancers cannot be accurately subtyped, often because of poor histologic differentiation such that the originating subtype cannot be easily recognized. Such tumors are often classified as “sarcomatoid.” Granular cel carcinoma has been used in the past but is not currently an accepted pathologic classification. Thus, a second opinion and pathologic review should be requested. The risk of recurrence in this case is low, and adjuvant sunitinib has not been shown to decrease the risk of recurrence. Patients who do have recurrence after nephrectomy almost always recur systemical y, and thus additional local radiotherapy is not indicated.

Likewise, the role of extensive lymph node dissection is highly controversial and general y not recommended. In any case, formal retroperitoneal lymph node dissection as is carried out in testes cancer would certainly not be standard in patients with localized renal cel carcinoma.

Question 20.3 The answer is C.

Patients with renal cancer can develop recurrent disease more than 5 years after initial definitive therapy. Development of a single metastatic site is not unusual. Patients with a single site of metastatic disease and a long interval between initial diagnosis and recurrent metastatic disease typical y have a good prognosis. Thus, aggressive surgical resection including orthopedic stabilization is indicated. Because orthopedic surgery such as this often leaves microscopic tumors behind in the surgical field, additional radiotherapy to the site is appropriate. Radiation alone is insufficient to completely eradicate metastatic renal cancer and does not repair the underlying structural bony abnormality. High-dose interleukin-2 is approved for metastatic renal cancer but is less effective than aggressive local surgery for complete eradication of disease when possible.

Temsirolimus improves survival in patients with poor prognosis metastatic disease, which does not apply here. In addition, it is not curative.

250

Question 20.4 The answer is D.

Several prognostic factors have been identified that can help explain the highly heterogeneous natural history of metastatic renal cancer. Hypercalcemia, poor performance status, elevated LDH, and anemia are significant prognostic factors in most studies, and the most widely used prognostic factor model is from the Memorial Sloan Kettering Cancer Center (MSKCC). Age, in and of itself, is not a prognostic factor. The presence of one to two factors is considered intermediate risk, while three or more factors is considered poor risk.

Question 20.5 The answer is B.

Of the choices, phase III data supportive of a survival benefit in a patient with poor prognosis such as this are available only for temsirolimus. The available data suggest that sunitinib or sorafenib could be considered. However, data suggest that interferon is not effective in patients with poor prognosis, and phase III data show that sunitinib is more effective than interferon for metastatic disease in patients with a good and intermediate prognosis.

Question 20.6 The answer is A.

Von Hippel–Lindau disease, caused by mutation of the VHL gene, is an autosomal-dominant cancer syndrome characterized by multiple renal cysts, early onset and multiple renal tumors, retinal angiomas and central nervous system hemangioblastomas, pheochromocytomas, and pancreatic islet cel tumors. The Birt–Hogg–Dubé syndrome, caused by mutations of the BHD gene, is characterized by early onset chromophobe cancers, benign hair fol icle tumors (fibrofol iculomas), and pulmonary cysts. Hereditary papil ary renal cancer, caused by mutations of the MET gene, is characterized by multiple type I papil ary cancers. The hereditary leiomyomatosis and renal cancer syndrome, caused by mutation of the fumarate hydratase gene, is characterized by cutaneous and uterine leiomyomas and aggressive type II papil ary cancers.

Question 20.7 The answer is C.

VHL is part of the normal oxygen sensing and response system in al cel s and is mutated or altered in greater than 60% of sporadic clear cel carcinomas of the kidney. Under normoxic conditions, VHL is part of a multiprotein complex that recognizes the hydroxylated HIF transcription factor, acts as a ubiquitin ligase, and thus targets it for proteasomal degradation. Under hypoxic conditions, HIF is not hydroxylated, not targeted to VHL and thus not degraded leading to upregulation of multiple genes critical for the hypoxic response including vascular endothelial growth factor and ultimately increased angiogenesis. The VHL gene is expressed constitutively.

Question 20.8 The answer is D.

251

The tumor suppressor genes TP53, RB1 CDKN2A, and PTEN are implicated in the pathogenesis of invasive bladder cancer.

Question 20.9 The answer is A.

Indications for intravesical therapy are multiple recurrent Ta lesions, especial y if they are high grade, or Tcis. It is critical that the pathologic specimen in patients diagnosed with superficial bladder cancer contains muscle to determine whether there is an noninvasive component. Most, but not al , studies have suggested that intravesical BCG

is more effective than intravesical chemotherapy. Although other chemotherapeutic agents are being investigated, cyclophosphamide needs to be activated to 4-hydroxy-cyclosphosphamide in the liver to act as an alkylating agent, and thus bladder instil ation of the parent compound is not expected to be effective. Radiation or cystectomy, although potential y useful for invasive carcinoma or refractory bladder cancer, is not appropriate as initial therapy in this patient.

Question 20.10 The answer is D.

Patients with muscle-invasive bladder cancer require definitive local therapy. Additional intravesical therapy is inappropriate. Partial cystectomies are only rarely indicated and should be performed in only a very highly select group, which does not include patients with a history of Tcis or patients with multiple tumors. The standard definitive therapy for bladder cancer is cystectomy. Multiagent cisplatin-based neoadjuvant chemotherapy improves survival for patients with invasive urothelial bladder cancer and is considered a standard of care.

Question 20.11 The answer is D.

Chromosomal translocations fusing the TMPRSS2 androgen-responsive gene to various ETS family transcription factors, of which ERG is the most common, occur in approximately 60% of patients. Prostate cancer is characterized by a relatively low rate of mutations in KRAS, BRAF, and p53, unlike most other tumors.

Question 20.12 The answer is A, B, and C.

Risk factors for male urethral cancers include HPV-16, chronic irritation, and infection.

The incidence of urethral cancer in men with urethral strictures ranges from 24% to 76%. No racial predisposition has been noted for urethral cancers.

Question 20.13 The answer is C.

There are several options for urinary diversion after cystectomy, and no clear evidence has emerged that any is more or less desirable or effective based on patient gender.

Diversion to the abdominal wal with a urostomy can be performed as a conduit, requiring a urine col ection device, or as a continent diversion, requiring regular 252

catheterization. Metabolic complications, including metabolic acidosis, can occur with both conduits and continent diversions. Complications of orthotopic continent diversions, or neobladders, include intermittent urethral obstruction and frequent requirement for intermittent or temporary self-catheterization.

Question 20.14 The answer is B.

Organ preservation with combined radiation and chemotherapy has been investigated in numerous trials, and long-term outcomes are similar to those observed in cystectomy series. The therapy is, however, an aggressive and potential y toxic approach in which approximately 30% of patients wil require cystectomy for incomplete response. It is thus not more tolerable than cystectomy. The patient’s cardiac history does not preclude major surgery, and in fact wil ingness to accept a cystectomy has been an inclusion criterion for most organ preservation trials.

Question 20.15 The answer is A.

Randomized studies have demonstrated that cisplatin-based combination chemotherapy provides a survival advantage. The largest phase III studies used methotrexate, vinblastine, doxorubicin, and cisplatin or a similar regimen in which the doxorubicin was eliminated (MVC). The strongest data supporting neoadjuvant chemotherapy are in the surgical setting, with no survival advantage demonstrated in modest-sized trials using combined chemotherapy and radiation for primary tumor treatment. The randomized data further demonstrate that there is no increase in surgical morbidity or complications after neoadjuvant chemotherapy. There are no data on the neoadjuvant use of carboplatin-based regimens, and data in the metastatic setting strongly suggest that carboplatin is an inferior agent in comparison with cisplatin for this disease.

Question 20.16 The answer is B.

Alterations (deletion/mutation) in the tumor suppressor gene p53 are most common (∼50% to 70%) in invasive disease and are markers of poor prognosis. Activating mutations of FGFR3 are common in papil ary noninvasive cancers, though less commonly found in T2 tumors (0% to 20%). MDM2 and ERBB2 are also less commonly amplified (∼10%), although ERBB2 overexpression can be 10% to 50%.

Question 20.17 The answer is A.

The standard definitive treatment for renal pelvis urothelial cancers is radical nephroureterectomy with resection of the bladder cuff at the ureteral insertion site.

Radical nephrectomy without ureter resection is inappropriate because of the high incidence of undiagnosed or recurrent disease in the ureter. Definitive radiotherapy would also be inappropriate because this would be expected to lead to kidney necrosis.

253

Question 20.18 The answer is C.

High-fat diet has been associated with increased prostate cancer incidence and mortality, and obesity and increased BMI have an increased risk of death from prostate cancer. There is evidence to suggest that diet and exercise may slow the course of the disease once diagnosed. Although dietary studies have suggested that vitamin E

correlates with a decreased incidence of prostate cancer, data from the phase III intervention study (SELECT) of selenium and vitamin E to prevent prostate cancer demonstrates that vitamin E use is actual y associated with an increased risk of developing prostate cancer (JAMA 2011;306:1549). Alcohol use and calcium/vitamin D intake are not associated with an increased risk of prostate cancer.

Question 20.19 The answer is A.

The decision to screen for and diagnose prostate cancer always needs to be accompanied by a discussion between the physician and the patient regarding risks and benefits of screening. To this end, it should be recognized that the median survival of an average 70-year-old man without significant comorbidities is more than 10 years, and that such a patient could benefit from the treatment of localized disease.

Nonetheless, there is a risk of treating disease that wil never become clinical y significant within the patient’s lifetime. It also needs to be recal ed that the sensitivity and specificity of al PSA-based screening methods are limited, and there are no absolute “normal” criteria. Therefore, no single test can determine the absolute need for a biopsy. Predictors of cancer on biopsy include PSA greater than 4.0 ng/mL, PSA greater than age-adjusted PSA norms (based on normal increasing PSA with age), free-to-total PSA ratio, and PSA velocity. Of these, and in this case, the rapid increase in the PSA is most predictive of malignancy, and this is also predictive of aggressive disease.

Question 20.20 The answer is D.

On the basis of the high Gleason score, the aforementioned rapid PSA doubling time, and the tumor in al cores, this patient is at a high risk for local y advanced disease and systemic recurrence. As such, staging CT scan and bone scan are reasonable, although not general y necessary in patients with lower-risk disease. Because of the presence of high-risk features and the general good health of the patient, watchful waiting is probably not an appropriate option in this case. Radiotherapy, with external beam radiotherapy or interstitial brachytherapy, or surgical prostatectomy is equal y appropriate for patients with clinical y localized disease. The choice is dependent on a discussion of expected risks and benefits.

Question 20.21 The answer is B.

Rapidly increasing PSA before diagnosis, high Gleason score, PSA nadir of greater than 1.0 after radiotherapy, short interval between definitive local therapy and biochemical recurrence, and rapid PSA increase once recurrence is identified are al associated with 254

a poor prognosis. The probability of local y recurrent disease alone is extremely low, and there is not much value to pelvic MRI for assessing local recurrence. Despite the poor prognosis, the role of chemotherapy in patients whose testosterone axis is intact is controversial. Although timing of androgen ablation is not clearly defined, some retrospective data suggest that “early” ablation in high-risk patients such as this provides a long-term survival advantage over “later” ablation.

Question 20.22 The answer is B.

Approximately 10% to 15% of patients receiving treatment with an antiandrogen wil experience an antiandrogen withdrawal response. Although the majority of these responses are of brief duration, it is obviously the easiest therapeutic maneuver.

Docetaxel-based chemotherapy leads to improved survival in castrate-resistant prostate cancer (CRPC), which is general y defined as a progressive disease after androgen ablation, an antiandrogen, and antiandrogen withdrawal. Radioactive nuclides are occasional y useful for the pal iation of diffuse bone pain but have not been shown to have an impact on survival.

Question 20.23 The answer is C.

Over 90% of bladder cancers in Western countries are urothelial carcinomas. In areas where the parasite Schistosoma haematobium is endemic, squamous cel bladder carcinomas are more common. Opisthorchis viverrini and Clonorchis sinensis are associated with cholangiocarcinoma, and not bladder cancer.

Question 20.24 The answer is C.

Although robotic laparoscopic prostatectomy has been touted as a less-invasive and potential y more effective approach, there is no reliable evidence that the risk of long-term complications, including impotence, is different than that observed in patients undergoing an open procedure with an experienced surgeon. In both groups, the incidence of impotence is at least 25%, even in young men with good erectile function before surgery. The risk of incontinence, when assessed by anonymized, validated quality of life instruments, is on the order of 20%. One of the most important variables for both pathologic outcome and complications is the surgeon’s experience.

Question 20.25 The answer is A.

Adjuvant radiotherapy has been shown to decrease the risk of recurrence in patients with T3 disease. However, overal survival and clinical metastases-free survival have not been affected by this approach. Some have thus argued for close monitoring and salvage radiotherapy on biochemical recurrence in patients such as this. Imaging tests have not been shown to be helpful in identifying patients most likely to benefit from adjuvant therapy, and surgical reexploration is not indicated either.

255

Question 20.26 The answer is D.

Patients on long-term androgen ablation are at high risk for the development of osteoporosis and its complications, and an osteoporotic fracture must be considered in this patient before initiating any therapy for progressive metastatic disease. If progressive disease were to be diagnosed, ketoconazole is not an unreasonable second-line hormonal therapy, but the addition of an antiandrogen would likely be more appropriate. In the absence of neurologic signs or symptoms, an MRI is not necessary.

Question 20.27 The answer is B.

Patients with a slowly increasing PSA after definitive local therapy may have a very long natural history, with only a minority of patients having cancer-related mortality within 10 years. Androgen ablation, especial y in elderly patients, is associated with osteoporosis, muscle loss, and changes in lipid metabolism that may have significant impact on cardiovascular comorbidities. High-intensity focused ultrasound for treatment of possible localized recurrence is stil investigational. Single-agent antiandrogen therapy is not approved and may lead to higher mortality in these patients.

Question 20.28 The answer is D.

The patient has nonmetastatic CRPC. The initial diagnostic test to perform is to confirm the patient is truly at castrate levels of testosterone (<50 ng/mL), as a very smal percentage of patients (∼1%) do not achieve complete testosterone suppression with LHRH agonists. The patient’s imaging is negative for metastatic disease, so he would not be an appropriate candidate for therapies approved for metastatic CRPC (e.g., enzalutamide, abiraterone, docetaxel, sipuleucel-T). His PSA doubling time (PSADT) is short (<2 months), indicating aggressive disease kinetics, so continued surveil ance would be less desirable. Antiandrogen withdrawal (AAW) – for example, discontinuation of bicalutamide – is based on the observation of antiandrogen conversion to an agonist, thus stimulating tumor growth. Upon discontinuation of the antiandrogen, AAW can occur in up to 30% of patients, although the timing of response is variable and can take up to 8 weeks before response is seen, which is dependent on the half-life of the drug (earlier for flutamide, later for bicalutamide). There are several other treatment options for nonmetastatic CRPC (e.g., high dose ketoconazole, estrogens, flutamide, nilutamide), with varying PSA responses, but none has shown an improvement in overal survival.

Question 20.29 The answer is B.

Prostate cancer is rare before the age of 40, and thus additional risk factors would likely be involved in the etiology of prostate cancer in younger males. Incidence and mortality rates are significantly lower for Asian-American descent, and somewhat lower for Mexican Americans and other Latinos. African-American males have the highest incidence of prostate cancer, with almost twofold compared with American men of 256

European descent. African-American men are diagnosed at a younger age with more aggressive disease and worsened clinical outcomes. There is now also confirmation of a genetic risk component because genetic polymorphisms, including several on 8q24, have been found to be closely associated with prostate cancer. In fact, the large difference in prostate cancer mortality between African Americans and Caucasian Americans cannot be explained by socioeconomic factors alone. Men with a first-degree relative with prostate cancer have approximately two- to threefold increased risk of developing prostate cancer.

Question 20.30 The answer is C.

PTEN is a tumor suppressor that deactivates PI3K signaling and its deletion is seen in

∼30% of primary prostate cancers, and more commonly in advanced disease (∼50% to 55%). PTEN plays a prominent role in tumorigenesis and is used in preclinical models of prostate cancer. FOXA1 is a transcription factor that is involved in AR and steroid receptor function, and can promote progression to CRPC, but is altered in ∼5% of cases.

CDK2 is a cyclin dependent kinase involved in the RB pathway, and NRIP1 is an AR

corepressor; these are also less commonly altered.

Question 20.31 The answer is D.

Although the androgen receptor does have cytoplasmic effects, some of which may be important to prostate cancer oncogenesis, the majority of its effects occur in the nucleus where it modifies expression of genes with an androgen-responsive promoter.

Upregulation of androgen receptor expression has been reported to be both necessary and sufficient for the castrate-resistant state, which is likely an adaptation to prolonged exposure to a low androgen environment. Such upregulation is not general y observed de novo and has not been linked to the development of prostate cancer. Castration dramatical y lowers testosterone, but the levels of other androgenic steroids are sufficient to cause partial activation of androgen receptor-mediated pathways.

Question 20.32 The answer is A.

Penile carcinoma is a rare malignancy that presents most commonly with phimosis in an uncircumcised patient. Metastatic spread of penile carcinoma is via superficial inguinal lymphatics, fol owed by deep inguinal lymphatics, and then to the pelvic lymphatics.

Systemic metastatic disease almost never develops in the absence of pelvic lymphadenopathy. Therefore, surgery and occasional y radiotherapy form the cornerstone of treatment for lymph node-positive patients; however, half of the patients with clinical y palpable nodes wil have inflammatory lesions only. Thus, a course of antibiotics before any further therapy is indicated. If the nodes persist after a course of antibiotics, biopsy and surgical dissection are indicated. Management of patients with clinical N0 is more controversial, with some authors recommending immediate lymph node dissection and others recommending a watchful waiting approach. Pathologic risk 257

factors as assessed in the primary lesion may assist in decision making.

Lymphangiography before a course of antibiotics is general y not considered helpful.

Corresponding chapters in Cancer: Principles & Practice of Oncology, Tenth Edition: 62

(Molecular Biology of Kidney Cancer), 63 (Cancer of the Kidney), 64 (Molecular Biology of Bladder Cancer), 65 (Cancer of the Bladder, Ureter, and Renal Pelvis), 66 (Genetic Testing in Urinary Tract Cancers), 67 (Molecular Biology of Prostate Cancer), and 68 (Cancer of the Prostate).

258





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 21.1 A 24-year-old man has, for the past week, experienced dyspnea on climbing two ights of stairs. In the ED arterial blood gas on room air demonstrates PO2 66 mm Hg, PCO2 34 mm Hg, and pH 7.42. On examination he is in no acute distress at rest. Lungs are clear to auscultation, there is a no organomegaly but a rm enlargement of the right testis.

Chest x-ray reveals multiple bilateral pulmonary nodules. Pathology from the orchiectomy specimen demonstrates embryonal carcinoma. hCG level is 1,024 mIU/mL, alpha-fetoprotein (AFP) is 248 ng/mL. While in the hospital he develops headaches and a CAT

scan of his brain shows multiple smal hemispheral metastases. Which of the fol owing is the most appropriate next step in management?

A. Begin whole brain radiotherapy, and after its completion in 2 weeks, start chemotherapy.

B. Begin chemotherapy immediately.

C. Begin whole brain radiotherapy and whole lung radiotherapy to be fol owed in 3 weeks by chemotherapy.

D. Begin concomitant whole brain radiotherapy and chemotherapy.

E. Use CCNU in high dose because it wil cross the blood brain barrier and thus be effective against both lung and brain metastases.

Question 21.2 23-year-old male presents to his physician with a 3-week history of back pain. Physical examination demonstrates a 3-cm hard mass in the left testis and an easily palpable mass is noted in the left upper quadrant. Chest x-ray is negative. Abdominal imaging reveals a 10-cm retroperitoneal mass only. AFP is within normal limits, beta-hCG is 3,000 mIU/mL. Which one of the fol owing statements is most accurate?

A. Initial diagnostic procedure should include percutaneous biopsy of the testis.

B. Histology is likely to be nonseminomatous germ cel cancer.

C. The patient should undergo debulking retroperitoneal lymphadenectomy.

D. The probability of cure with combination chemotherapy is approximately 60%.

E. The patient should receive radiation therapy to the abdomen.

Question 21.3 A 30-year-old man has multiple pulmonary lesions detected at the time of 259

diagnosis of an embryonal carcinoma of the right testis. After orchiectomy and three cycles of BEP chemotherapy, chest x-ray demonstrates a persistent 2-cm nodule in the right mid lung eld; the other lesions have disappeared. Computed tomography con rms this nding; the mediastinum and retroperitoneum appear normal. The serum level of beta-human chorionic gonadotropin, previously elevated, is now undetectable. The most appropriate management of this patient is:

A. Needle biopsy of the nodule

B. Surgical resection of the nodule

C. Continuation of chemotherapy, without bleomycin

D. Radiotherapy to the residual nodule

E. Obtain PET scan

Question 21.4 A 26-year-old man presents with cough and a left testicular mass. Work-up reveals multiple retroperitoneal lymph nodes and several lung nodules. Serum hCG is 80

mIU/mL, AFP is normal. Pathologic diagnosis of the testicular mass is pure seminoma. What is the best management decision?

A. Two cycles of BEP (bleomycin, etoposide, cisplatin)

B. Three cycles of BEP

C. Four cycles of BEP

D. Three cycles of EP

Question 21.5 A 28-year-old man with a history of Klinefelter syndrome presents to his physician with a complaint of cough and hoarseness of 3 months duration. A chest x-ray reveals a widened mediastinum. CT con rms the presence of an 8-cm superior mediastinal mass, Serum AFP is 1,500 ng/mL, beta-hCG 20,000 mIU/mL. A diagnosis of germ cel tumor of mediastinal origin is made. Which is the most appropriate next step in management?

A. Surgical resection of the mass

B. Three cycles of BEP

C. Four cycles of BEP

D. Radiation therapy

E. Testicular ultrasound

Question 21.6 A 23-year-old male presents with painless enlargement of the testis and cough. Ultrasound reveals an intratesticular mass. CT scan of the chest, abdomen, and pelvis reveals multiple retroperitoneal nodes, liver metastases, and multiple pulmonary nodules, AFP is 16,000 ng/mL, beta-hCG is 200 mIU/mL. At the start of the third cycle of BEP, the patient is asymptomatic. AFP has decreased to 200, beta-hCG is undetectable.

What is the next step in management?

A. Complete four cycles of BEP

B. Change treatment to salvage therapy with TIP

260

C. Repeat CT scans for assessment of disease response D. Consider tandem high-dose therapy with stem cel rescue E. Obtain PET scan

Question 21.7 A 29-year-old male presents to his physician with left supraclavicular adenopathy. Examination reveals a hard left testicle. Further workup includes CT imaging, which demonstrates a 7-cm retroperitoneal mass without parenchymal pulmonary nodules.

AFP is 16,534 ng/mL, beta-hCG 333 mIU/mL. Pathology of the orchiectomy specimen con rms a mixed germ cel tumor with elements of seminoma, embryonal carcinoma, and yolk sac tumor. At the completion of the fourth cycle of chemotherapy, repeat CAT scans reveal a large residual retroperitoneal mass with both solid and cystic components. Tumor markers have normalized. The patient undergoes retroperitoneal exploration and removal of the large mass. Pathology reveals mature teratoma. Three years after surgery, the AFP is now elevated to 33.5. Serial assays con rm increase to 243.6. Repeat scans reveal only a new retroperitoneal density at the site of previous disease. What is the next best step in the management of this patient?

A. Initiate salvage chemotherapy with ifosfamide-based chemotherapy B. Refer for resection of the abdominal mass

C. Prepare for high-dose chemotherapy and stem cel rescue.

D. Any of the above

Question 21.8 A 26-year-old man presents with cough and a left testicular mass. Work-up reveals a palpable abdominal mass and several lung nodules, Serum AFP is 11,000 ng/mL, beta-hCG is 450 mIU/mL. Pathologic diagnosis of the testicular mass is pure seminoma.

What is the next best step in the optimal management of this patient?

A. Two cycles of BEP

B. Three cycles of BEP

C. Four cycles of BEP

D. Three cycles of EP

Question 21.9 A 32-year-old man previously treated for testicular cancer 3 years ago with four cycles of BEP now presents with pancytopenia. Evaluation reveals acute myelogenous leukemia (AML). What is the likely chromosome abnormality associated with this leukemia?

A. 47XXY

B. t(9:22)

C. 5q-

D. 13q deletion

E. 11q23 translocation

Question 21.10 A 24-year-old man presents with a left testicular mass and undergoes a radical orchiectomy. Pathologic evaluation of the resected specimen reveals embryonal 261



carcinoma with vascular invasion. The preoperative level of human chorionic gonadotropin (hCG) is 950 mIU/mL. The AFP level is within normal limits. CT imaging demonstrates no evidence of metastatic disease. The marker normalizes postsurgery, but 3 months later on surveil ance the hCG is elevated to 110 mIU/mL, con rmed on repeat. Repeat imaging demonstrates no pulmonary, liver, or retroperitoneal abnormalities. Which one of the fol owing would you advise?

A. Four cycles of BEP (bleomycin, etoposide, and cisplatin) B. Three cycles of BEP

C. Three cycles of etoposide and cisplatin

D. Radiation therapy to the abdomen

E. Observation

Question 21.11 A 27-year-old man is hospitalized with respiratory symptoms. His physical examination is noncontributory. Plane x-ray of the chest shows several 2-cm nodular pulmonary lesions bilateral y and a large mediastinal mass. A computed tomographic (CT) scan of the chest, abdomen, and pelvis con rms a large anterior mediastinal mass and pulmonary nodules. Fine-needle biopsy of the lung reveals anaplastic carcinoma.

Laboratory studies reveal:

The most appropriate therapeutic option is:

A. Systemic chemotherapy with a cisplatin-based combination B. Irradiation of the thorax

C. Bilateral thoracotomy and wedge resections of tumors

D. Combination chemotherapy with ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine)

E. Surgical resection of gross disease fol owed by systemic chemotherapy Question 21.12 Risk factors for germ cel tumors includes which one(s) of the fol owing?

(Select three correct responses)

A. Cryptorchidism

B. Intratubular germ cel neoplasia (ITGCN)

C. Father with history of testicular cancer

D. Turcot syndrome

262

Question 21.13 Germ cel tumors may express which of the fol owing immunohistochemical proteins? (Select four correct responses) A. Cytokeratin

B. Placental alkaline phosphatase (PLAP)

C. CD 20

D. CD 30

E. CD 10

F. OCT3/4

Question 21.14 For patients with clinical stage I testis cancer which factor(s) predict for risk of recurrence after orchiectomy? (Select two correct responses) A. Presence of lymphovascular invasion and embryonal carcinoma histology B. Presence of choriocarcinoma as an element in mixed germ cel tumors C. Seminoma ≥4 cm

D. Degree of elevation of the preorchiectomy markers

E. Seminoma with presence of syncytiotrophoblasts

Question 21.15 Adjuvant chemotherapy for patients with pathologic stage II disease after RPLND is recommended for patients with:

A. Three positive lymph nodes.

B. Extranodal extension of tumor.

C. Pure embryonal carcinoma histology.

D. Microscopic disease with no lymph node greater than 2 cm.

Question 21.16 According to the International Germ Cel Consensus Classi cation, which patient vignette is consistent with poor risk seminoma?

A. Multiple pulmonary metastases with hCG 10,000

B. Disseminated disease with a solitary brain metastasis C. Multiple liver metastases associated with enlarged retroperitoneal nodes D. None of the above

Question 21.17 Which of the fol owing is a TRUE statement regarding hCG in germ cel tumors?

A. The presence of elevated hCG is indicative of nonseminomatous histology B. The half-life of hCG is 5 to 7 days

C. Very high levels of hCG can produce symptoms of hyperthyroidism D. Very high levels of hCG are common in patients with disseminated yolk sac tumor Question 21.18 Which one of the fol owing statements is TRUE regarding NSGCT in rst relapse?

263

A. Such patients are incurable with standard-dose chemotherapy.

B. EP chemotherapy can be repeated if the patient achieved a complete remission with first-line BEP therapy.

C. High-dose chemotherapy and autologous stem cel rescue should be considered in the treatment paradigm.

D. Three cycles of ifosfamide-based chemotherapy should be administered.

Question 21.19 Long-term sequelae of cisplatin-based chemotherapy treatment of germ cel tumors include:

A. A one- to twofold risk of cardiovascular events.

B. A greater than 50% risk of infertility after primary therapy.

C. Peripheral neuropathy in more than half of the patients treated.

D. Single-digit risk of acute leukemia proportional to the dose of etoposide.

E. Risk of contralateral testis cancer of 5%.

Question 21.20 A 55-year-old male patient presents to his physician because of scrotal swel ing. An ultrasound demonstrates an intratesticular mass. What is the most likely histology of the lesion?

A. Leydig cel tumor

B. Liposarcoma of the spermatic cord

C. Large B-cel lymphoma

D. Granulosa cel tumor

E. Metastatic carcinoma

264

Question 21.1 The answer is B.

The diagnosis of poor risk nonseminomatous germ cel tumor has been established. The presence of CNS metastases is increased in patients with extensive pulmonary involvement. The patient has significant tumor burden as indicated by hypoxemia and immediate therapy for pulmonary disease is warranted. CNS disease can respond rapidly to chemotherapy. Thus there is no need for prechemotherapy radiotherapy. The appropriate chemotherapy is the combination of bleomycin, etoposide, and cisplatin (BEP).

Question 21.2 The answer is B.

The patient has a tumor of the testis with large volume metastatic disease to the retroperitoneum at presentation. The appropriate diagnostic procedure would include orchiectomy, not biopsy of the testis which could lead to the incorrect diagnosis due to sampling and would not remove the primary site which would be necessary in the course of the disease. 70% of patients with seminoma, while a much smal er percentage of nonseminoma patients, present with localized, stage I disease; thus on the basis of probability, the patient should have nonseminomatous disease since metastases at presentation for seminoma are much less common than for NSGCT. As described the patient has bulky stage IIC disease and should be treated with chemotherapy. There is no role in germ cel tumors for debulking. The probability of cure with chemotherapy for good risk NSGCT is >90%, the outcome is higher for seminoma. Even if the diagnosis were seminoma, the large volume retroperitoneal disease would best be treated with chemotherapy not radiation therapy.

Question 21.3 The answer is B.

The presence of residual x-ray findings after chemotherapy for disseminated NSGCT

requires decision regarding intervention versus observation. The likelihood of persistent cancer after the response described is smal , but since the initial path identified nonseminomatous disease there is a risk of residual teratoma even though this histology was not described in the original tumor. Needle biopsy of the lesion is insufficient to identify tumor versus fibrosis based on sampling error. Chemotherapy without documentation of persistent disease is not warranted and radiotherapy is not indicated for NSGCT. Likewise PET scanning in nonseminomatous disease does not have a high positive or negative predictive value to discriminate between viable tumor, fibrosis, or teratoma. The best answer is to proceed to surgery to remove the lesion to confirm complete remission and remove a possible site of residual teratoma.

Question 21.4 The answer is B.

The patient has good risk metastatic seminoma (no visceral disease). Thus the standard 265

of care would include three cycles of BEP. In an attempt to avoid bleomycin exposure, potential equivalent therapy would include four cycles of EP, not three. Two cycles of BEP would be insufficient and four, excessive for good risk disease.

Question 21.5 The answer is C.

Klinefelter syndrome is a known risk factor for germ cel tumor involving the mediastinum. The elevation of AFP identifies the tumor as nonseminomatous. NSGCT

of the mediastinum by definition is poor risk. Therefore the appropriate treatment is four cycles of BEP. Surgical resection should not be undertaken as primary therapy, radiation therapy is inadequate for nonseminomatous histology, and testicular pathology is unlikely. These tumors originate in the mediastinum.

Question 21.6 The answer is A.

The degree of elevation of the AFP at initiation of treatment for NSGCT defines poor risk disease. After 6 weeks of therapy the marker although lower remains abnormal. The interpretation of this requires knowledge of the half-life of AFP. At 5 to 7 days, six to eight half-lives wil have transpired in 6 weeks (42 days). Thus the marker should be between (1/2)6 = 1/64 and (1/2)8 = 1/256 of the original value or between 62.5

and 250. At 200 the value is as predicted and there is no need to change therapy for lack of response. Likewise there is no indication for transplant strategy. Assessment of response by imaging in the middle of treatment when the patient demonstrates evidence of response by markers should not change management. PET scanning is not useful in nonseminomatous histology. Since this is poor risk disease four cycles of therapy are indicated.

Question 21.7 The answer is B.

The recurrence of nonseminomatous disease 2 years after complete remission is the definition of late relapse. This situation is almost always heralded by AFP elevation. Late relapse is considered relatively chemoresistant. Thus surgical resection should be considered in those situations in which the tumor appears to be resectable. High-dose chemotherapy and stem cel rescue is not indicated as primary treatment but consolidation of patients identified to have chemosensitive disease at relapse.

Question 21.8 The answer is C.

While the pathology of the surgical specimen identifies seminoma only, this histology is inconsistent with the marked elevation of the AFP. Patients with seminoma and elevated AFP who do not have another cause for elevation such as chronic liver disease or congenital neural tube defects should be treated along the algorithm of NSGCT. Thus this patient has poor risk disease by definition since the AFP is >10,000 (S3) and the best treatment includes four cycles of chemotherapy.

266

Question 21.9 The anwser is E.

The long-term risk of leukemia in patients treated with BEP is smal , related to the cumulative dose of etoposide, and is less than 1% for doses included in three or four cycles of BEP. The characteristic genetic alteration is 11q23 three cycles of BEP.

Question 21.10 The answer is B.

The elevation of a tumor marker while on surveil ance is unequivocal evidence of recurrence. Thus observation at this point is inappropriate. The treatment paradigm for non seminomatous germ cel tumor depends on the presence of visceral (liver, bone, CNS) versus nonvisceral disease and the level of the markers. The elevation of the hCG

qualifies as S1; there is no evidence of visceral disease. Thus the patient has good risk disease and should be treated with three cycles of BEP.

Question 21.11 The answer is A.

Although the histology of the biopsy material does not specifical y identify a germ cel element, the presence of both AFP and beta-hCG elevation is consistent with a germ cel neoplasm, nonseminomatous type. Thus the treatment for Hodgkin disease with ABVD

is inappropriate. There is no indication for surgery with multiple sites of disease.

Irradiation is not an option for nonseminomatous disease. The best answer is to begin chemotherapy immediately for poor risk germ cel tumor.

Question 21.12 The answers are A, B, and C.

Cryptorchidism, ITGCN, and first-degree relatives with testis cancer are al risk factors for the development of testicular cancer. Turcot syndrome is a genetic disorder associated with polyposis, colorectal cancer, glioblastoma, and medul oblastoma, but not testicular cancer. Klinefelter’s, a rare genetic disorder, is associated with increased risk of germ cel neoplasm, usual y mediastinal presentation.

Question 21.13 The answers are A, B, D, and F.

Embryonal carcinoma may express CD30 and cytokeratin. Seminoma may express PLAP, while cytokeratin expression may be weak or negative. Yolk sac tumor, embryonal carcinoma, and seminomas may express PLAP. OCT3/4 may be expressed in classic seminoma, yolk sac, and embryonal carcinomas. CD 20 is a marker for mature B cel s, while CD10 is expressed in early B-cel development.

Question 21.14 The answers are A and C.

The major risk factor for recurrence of nonseminomatous testis cancer in stage I patients is evidence of lymphovascular invasion which predicts a risk of relapse of 50+%

for patients on surveil ance. For seminoma the size of the lesion ≥4 cm is a risk factor for relapse. While pure choriocarcinoma is associated with poor outcome because of the 267

likely presence of metastatic disease at presentation, the presence of choriocarcinoma as a component of a mixed germ cel tumor does not of itself predict for a poor outcome.

Elevated markers preop which normalize postorchiectomy, which is required for stage I classification, do not have predictive value. Syncytiotrophoblasts seen on the histologic tumor specimen in patients with seminoma may be associated with the measurement of hCG, but have no predictive or prognostic significance.

Question 21.15 The answer is B.

While primary RPLND is infrequently performed because of the overal excel ent outcome of patients with stage I disease on surveil ance, compliance is a major factor in observation strategies. Those patients who do undergo surgical intervention are at higher risk for recurrence if there are more than six involved lymph nodes, nodes larger than 2 cm or of any size with extranodal extension. These patients should be considered for adjuvant chemotherapy. Patients with embryonal histology can be effectively managed with surveil ance and treatment at the time of relapse.

Question 21.16 The answer is D.

While each of these patient vignettes would constitute poor risk disease in a patient with nonseminomatous histology, there is no category of poor risk disease for seminoma.

These clinical situations would al be classified as intermediate risk.

Question 21.17 The answer is C.

While elevated hCG is more commonly seen in patients with nonseminomatous histology, a smal proportion of patients with seminoma can express hCG. The half-life of hCG is 2 to 3 days, whereas the half-life of AFP is 5 to 7 days. Yolk sac tumors express AFP, not hCG. Hyperthyroidism can be associated with very high levels of hCG in patients with NSGCT especial y disseminated choriocarcinoma since there is homology between hCG and TSH which results in excess thyroid hormone production.

Question 21.18 The answer is C.

Patients who relapse after initial therapy for germ cel malignancy can achieve a second durable remission with ifosfamide-based chemotherapy. However these patients are general y considered “poor risk” and are given four cycles of therapy. There is no precedent for repeating EP after BEP. In general patients who relapse should be considered for high-dose chemotherapy and stem cel rescue strategies.

Question 21.19 The answer is D.

Long-term sequelae of patients treated with chemotherapy include increased risk of cardiovascular events, peripheral neurotoxicity, ototoxicity, second malignancies, infertility, and contralateral testis cancer among others. The risk of cardiovascular 268

events for survivors is estimated at two to seven times that of an age adjusted cohort.

Paternity occurs in >60% patients treated with first-line chemotherapy. 20% to 40%

of patients have chemotherapy-induced neurotoxicity. The risk of contralateral testis cancer is approximately 2% of survivors. Leukemia can occur within a few years after exposure to etoposide with incidence proportional to the dose received. For patients receiving 1,500 to 2,000 mg/m2, the risk is less than 1%. The highest risk is noted for patients with >3,000 mg/m2 which is 6%.

Question 21.20 The answer is C.

The most common tumor of the testis in men older than 50 is lymphoma. Spermatic cord liposarcomas are usual y identified by an extratesticular mass on ultrasound.

Granulosa cel tumors in general are rare and seen in very young patients. The testicle is a very rare site for a metastatic carcinoma as wel . Leydig cel tumors can occur in this age population but are less frequent in incidence than lymphomas.

Corresponding chapter in Cancer: Principles & Practice of Oncology, Tenth Edition: 70 (Cancer of the Testis).

269





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 22.1 Which of the fol owing feature is most characteristic of type I endometrial cancers?

A. Most of these cancers have serous or clear cel histology.

B. Risk factors include unopposed estrogen, anovulation, and obesity.

C. They are rarely (less than 5% of cases) associated with microsatel ite instability.

D. The precursor lesion is preneoplastic atrophic endometrium.

Question 22.2 Type II endometrial cancers have which of the fol owing features?

A. The precursor lesion is atypical hyperplasia.

B. The majority of tumors are slow growing.

C. These cancers are unrelated to estrogen exposure.

D. Al of the above.

Question 22.3 Genetic changes commonly seen in type I endometrial cancers include: A. KRAS mutation

B. PTEN mutation

C. β-Catenin mutation

D. Al of the above

Question 22.4 Which of the fol owing genetic change(s) is/are most characteristic of type II endometrial cancers (select three correct answers)?

A. Microsatel ite instability (MSI)

B. HER2/neu amplification

C. BCL2 overexpression

D. p53 mutations

Question 22.5 Risk factors for endometrial cancer include: (Select two correct responses) A. Increasing age.

B. Black race.

C. Family history of endometrial cancer.

270

D. Combination oral contraceptives (contain estrogen and progestogen).

Question 22.6 The majority of cervical, vaginal, and vulvar cancers appear to have a common cause, which is:

A. Increased exposure to exogenous estrogen.

B. Chronic bacterial and parasitic infections.

C. Multiple prior herpes simplex virus (HSV) infections.

D. Human papil omavirus (HPV) infection with high-risk types.

Question 22.7 In patients with gestational trophoblastic disease (GTD) with a complete mole, molecular features include which of the fol owing?

A. Mutations in p53.

B. Most are diploid with duplication of a haploid maternal genome.

C. Predominance of maternal chromosomes is common.

D. Several genes, including CMYC, ERBB2, CFMS, and BCL2, have been implicated in the pathogenesis of complete moles.

Question 22.8 A 39-year-old married woman is seeing you in the o ce after recently having a cervical biopsy that demonstrated cervical cancer. She has no prior medical problems other than anemia and one prior uncomplicated child birth. You tel her which of the fol owing epidemiologic factors are TRUE?

A. During the past 80 years, death rates from cervical cancer have decreased primarily because of improved treatment of STDs such as gonorrhea, chlamydia, and syphil is.

B. Delayed childbearing is associated with an increased risk of cervical cancer.

C. HSV is thought to be the causative agent for the majority of patients.

D. The incidence of cervical cancer is 30% and 100% higher in Black and Hispanic women, respectively, compared with Whites in the United States.

Question 22.9 The patient asks about prevention and treatment of HPV infections, and you advise her:

A. The viral infections are rare.

B. Treatments for HPV infections with antiviral therapy are effective if taken within 4

days of exposure.

C. HPV vaccines have been approved by the Food and Drug Administration (FDA) to help prevent infection from the most common HPV types.

D. She should receive the HPV vaccine now to help treat her cancer.

Question 22.10 You counsel her about HPV and human immunode ciency virus (HIV).

After extensive discussion, you decide to proceed with testing for HIV with which of the fol owing justifications? (Select three correct responses) 271

A. HIV immunosuppression is correlated with an increased risk of cervical HPV

infections.

B. Patients with HIV appear to have a faster rate of progression to high-grade dysplasia (cervical intraepithelial neoplasia [CIN]).

C. Antiretroviral therapy to manage HIV has demonstrated direct activity against HPV.

D. Cervical cancers in HIV-positive women may be more aggressive than in HIV-negative women.

Question 22.11 She has done extensive reading about cervical cancer and asks you about factors that are associated with metastatic disease. You advise her that the fol owing are associated with extracervical disease:

A. Tumor size and histologic subtype

B. Presence of microinvasion and lymphovascular space invasion C. Depth of invasion and presence of microinvasion

D. Presence of lymphovascular space invasion and history of pelvic surgery Question 22.12 If her initial biopsy returned with invasive squamous cel carcinoma with 2 mm of invasion and no lymphovascular space involvement (LVSI), you recommend: A. Simple hysterectomy.

B. Radiation therapy with possible chemotherapy.

C. Chemotherapy with cisplatin 40 mg/m2 weekly for six cycles.

D. Cervical conization.

Question 22.13 The patient has a 3-cm visible tumor found on her cervix that is biopsied and is frankly invasive squamous cel carcinoma. She has several questions regarding staging of her cancer. You advise the fol owing:

A. If enlarged lymph nodes are seen on her computed tomography (CT) scan, her cancer would be staged appropriately as at least stage III.

B. Staging for cervical cancer is clinical, involving pelvic examination.

C. If hydronephrosis is demonstrated on her CT scan, her cancer would be staged appropriately as at least stage II.

D. Positron emission tomography (PET) scanning is used in staging to determine nodal involvement.

Question 22.14 The patient’s 3-cm visible tumor appears con ned to the cervix and is staged as IB1. Which of the fol owing therapies is most appropriate?

A. Radiation and chemotherapy with weekly cisplatin dosed at 40 mg/m2

B. Simple hysterectomy with removal of fal opian tubes and ovaries C. Radiation therapy or radical hysterectomy with lymphadenectomy D. Brachytherapy radiation with a dose of 75 Gy

272

Question 22.15 A 40-year-old woman is diagnosed with invasive cervical cancer. She has a 5-cm cervical tumor with parametrial involvement, and evidence of hydronephrosis on imaging. Her cancer is stage IIIB. You elect to treat her with combined chemotherapy and radiation. Which of the fol owing applies to the treatment of locoregional y advanced cervical cancer?

A. Randomized trials involving patients with local y advanced cervical cancer have failed to demonstrate a benefit of chemotherapy in addition to standard radiation therapy.

B. Carboplatin appears to be the most appropriate agent to combine with radiation therapy for cervical cancer and this should be fol owed by hysterectomy.

C. Paclitaxel with cisplatin is an acceptable regimen to combine with radiation therapy and has demonstrated improved survival.

D. Weekly cisplatin with radiation therapy appears as active as other regimen with manageable toxicity.

Question 22.16 After receiving de nitive concurrent chemoradiotherapy for her stage IIIB cervical cancer, the patient develops a recurrence in the cervix, 18 months from the completion of therapy. Imaging studies suggest no extrapelvic disease. You recommend the fol owing:

A. Referral back to the radiation oncologist for consideration of further radiation B. Chemotherapy with combined cisplatin and topotecan

C. Chemotherapy with combined cisplatin and paclitaxel

D. Referral for consideration of further surgery

Question 22.17 A 67-year-old woman presents for evaluation of a cancer found in the vagina. Before any examination or evaluation, you review with her that which of the fol owing are TRUE? (Select two correct responses)

A. Prior in utero exposure to the synthetic estrogen diethylstilbestrol (DES) places a woman at an increased risk for development of vaginal clear cel adenocarcinoma.

B. Most cancers found in the vagina are actual y metastases or direct extensions from other gynecologic tumors.

C. Vaginal squamous cel carcinoma is thought to be unrelated to the HPV.

D. Staging for primary vaginal cancers includes surgical exploration.

Question 22.18 The patient is found to have had a prior hysterectomy for mild dysplasia.

Her apparent primary vaginal cancer extends to the subvaginal tissues and is appropriately staged as a stage II cancer. You recommend:

A. Referral for total radical vaginectomy

B. Chemotherapy with a cisplatin-based regimen

C. Referral for radiation therapy

D. Local excision fol owed by close observation

273

Question 22.19 Which of the fol owing statement(s) applies to invasive vulvar cancer?

(Select two correct responses)

A. There are three distinct types of invasive squamous vulvar cancer.

B. HPV-associated vulvar cancer tends to occur in younger women (age <55 years) and is associated with prior cervical precancerous abnormalities.

C. Melanoma of the vulva is caused by exposure to HPV.

D. Non–HPV-associated invasive squamous vulvar cancer is associated with lichen sclerosis.

Question 22.20 A 55-year-old patient with a history of abnormal Pap smears presents for evaluation of a 3-cm vulvar mass. The mass is located 1 cm lateral to the clitoris on the right and has an ulcerated appearance. She states she noticed it 2 years ago and has tried many di erent ointments to help control the itching and irritation. This was recently biopsied to reveal invasive squamous cel carcinoma. What treatment would you recommend?

A. Neoadjuvant chemoradiation fol owed by local resection B. Concurrent chemoradiation

C. Radical vulvectomy with bilateral inguinal lymphadenectomy D. Local resection fol owed by radiation and/or chemotherapy Question 22.21 Which of the fol owing histologic feature(s) is/are most signi cant in predicting the outcome for a patient with vulvar cancer? (Select two correct responses) A. Presence of lymphovascular invasion

B. Tumor grade

C. Depth of invasion and tumor diameter

D. Presence and number of positive lymph nodes

Question 22.22 The nal pathology reveals a 3.3-cm invasive squamous cel carcinoma with 2 involved (positive) lymph nodes larger than 1.0 cm, without extracapsular spread, in the right inguinal/femoral lymph node dissection out of 12 removed. The contralateral node dissection was negative. Margins around the primary tumor were negative and greater than 1 cm. Her appropriate International Federation of Gynecology and Obstetrics (FIGO) and TNM stage are:

A. II and T2N2M0.

B. IIIA and T3N1M0.

C. IIIB and T2N1M0.

D. IVA and T2N1M0.

Question 22.23 The most appropriate therapy for this patient after she recovers from surgery is:

274

A. Close observation.

B. Chemotherapy with cisplatin plus 5FU.

C. Referral for consideration of radiation therapy.

D. Exploration with dissection of the pelvic lymph nodes.

Question 22.24 Unfortunately, despite the use of adjuvant therapy, this patient’s cancer recurs local y on the vulva with a 2-cm lesion. Which of the fol owing would you advise?

A. Repeat resection

B. Chemotherapy with bleomycin

C. Best supportive care

D. Chemotherapy with cisplatin plus 5FU

Question 22.25 A 62-year-old woman has been diagnosed with a uterine corpus (body) cancer. You have not received her records for review, but she is seen in your o ce for consultation and asks many general questions. Which of the fol owing would you tel her?

A. Approximately 90% of these cancers arise from the endometrial lining and are typical y managed with hysterectomy and staging.

B. Most of these cancers are caused by exogenous estrogen use.

C. Uterine sarcomas are more common than endometrial cancers and represent approximately 90% of corpus cancers.

D. Endometrial cancer typical y presents at late stage with patients having abnormal uterine bleeding.

Question 22.26 This patient’s records arrive in the o ce, and the pathology veri es the diagnosis of a grade 2 endometrioid-type endometrial cancer from an o ce endometrial biopsy. She asks what has caused her cancer to develop. Which of the fol owing are considered to be independent risk factors for the development of endometrial cancer?

(Select three correct responses)

A. Obesity

B. Diabetes mel itus

C. Premature ovarian failure with early menopause

D. Presence of an estrogen-producing tumor

Question 22.27 For this patient with an o ce biopsy demonstrating grade 2 endometrioid endometrial cancer who is of apparent good heath with no other medical comorbidities, you recommend:

A. Further evaluation with CT scan and PET scan to evaluate for metastatic disease.

B. A formal dilation and curettage (D&C) to obtain a more accurate pathologic diagnosis.

C. Hysterectomy with removal of the tubes and ovaries with consideration of pelvic and para-aortic lymphadenectomy.

D. Referral for radiation therapy with possible chemoradiation.

275

Question 22.28 During the patient’s initial visit, she reports that her mother was diagnosed with endometrial cancer at age 42, her maternal aunt with colon cancer at age 51, and her sister with endometrial cancer at age 38. You are concerned her cancer may be hereditary. You advise that:

A. She undergoes colon assessment if she is not up to date with age-appropriate screening and considers counseling and possible testing for hereditary nonpolyposis colorectal cancer (Lynch II syndrome).

B. She undergo breast MRI and be tested for BRCA1 and BRCA2.

C. Colon and endometrial cancers are common, and no further evaluation is necessary at this time.

D. The maternal side of her family very likely has familial adenomatous polyposis and should be further evaluated.

Question 22.29 The patient undergoes hysterectomy with ful staging, including pelvic washing for cytology, removal of both tubes and ovaries as wel as pelvic and para-aortic lymph nodes. She is noted to have cancer involving three pelvic lymph nodes, but not the para-aortic lymph nodes. Her stage is designated:

A. IIIB.

B. IIIC1.

C. IIIC2.

D. IVA.

Question 22.30 For this patient with three positive pelvic lymph nodes and a grade 2

endometrioid endometrial cancer, you recognize adjuvant therapy is controversial but ultimately recommend:

A. Hormone therapy with a progestational agent

B. Referral for pelvic radiation therapy

C. Chemotherapy with combined paclitaxel, cisplatin, and doxorubicin D. Combination of radiation and chemotherapy

Question 22.31 The most active (improved disease-free and overal survival) chemotherapy regimen as determined in randomized clinical trials in women with advanced or recurrent endometrial cancer with measurable disease is: A. Doxorubicin plus paclitaxel

B. Cisplatin/doxorubicin

C. Cisplatin/doxorubicin/paclitaxel

D. Ifosfamide plus paclitaxel

Question 22.32 A 17-year-old female patient presents to your o ce with pelvic ultrasound suggesting intrauterine gestational trophoblastic neoplasia (GTN). The most common of the distinct clinicopathologic entities of GTN is: 276

A. Complete hydatidiform mole.

B. Partial hydatidiform mole.

C. Choriocarcinoma.

D. Placental site trophoblastic tumor.

Question 22.33 This patient has a beta-human chorionic gonadotropin (hCG) of 122,300

and undergoes therapy with a suction D&C. Final pathology con rms the diagnosis of complete hydatidiform mole. The patient is fol owed with the fol owing: A. CT scan every 3 months.

B. Ultrasound of the pelvis every 3 months.

C. Pelvic examination with Pap smear every 6 weeks.

D. Beta-hCG weekly.

Question 22.34 After a complete metastatic workup, the patient is determined to have low-risk disease. You recommend the fol owing chemotherapy: A. Etoposide

B. Vincristine

C. Methotrexate

D. Cyclophosphamide

277

Question 22.1 The answer is B.

The Type I endometrioid adenocarcinomas account for 80% of endometrial cancer.

Estrogen acts as a growth factor for the endometrium by promoting glandular proliferation; thus, unopposed estrogen, anovulation, obesity, early age at menarche, and nul iparity are risk factors for endometrioid adenocarcinomas. They demonstrate a large number of genetic changes including microsatel ite instability (approximately 20%) or specific mutations of PTEN, KRAS, and β-catenin genes. The precursor lesion is atypical hyperplasia and these tumors are usual y superficial and low grade.

Question 22.2 The answer is C.

Type II endometrial cancers have serous or clear cel histology. Most tumors are aggressive and progress rapidly. They are not associated with estrogen exposure. The usual precursor lesion is endometrial intraepithelial neoplasia.

Question 22.3 The answer is D.

Genetic changes that are characteristic of type I endometrial cancer include KRAS, PTEN, and β-catenin mutations and MSI.

Question 22.4 The answers are B, C, and D.

MSI is seen in type I endometrial cancers. Genetic changes characteristic of type II endometrial cancers include p53 mutations, HER2/neu and BCL2

amplification/overexpression.

Question 22.5 The answers are A and C.

Risk factors for endometrial cancer include increasing age, white race, obesity, family history of endometrial cancer, prior pelvic radiation, non–insulin-dependent diabetes mel itus, estrogen-only hormone-replacement therapy, estrogen-producing tumors, nuliparity, early menarche, and late menopause. Combined oral contraceptive preparations actual y have a protective effect.

Question 22.6 The answer is D.

Infection with high-risk HPV appears to be the common cause for these cancers.

Question 22.7 The answer is D.

Several genes, including CMYC, ERBB2, CFMS, and BCL2, have been implicated in the pathogenesis of complete moles though p53 mutations have not been identified. Most complete moles are diploid with duplication of the haploid paternal genome and have a predominance of paternal chromosomes.

278

Question 22.8 The answer is D.

The increased incidence of cervical cancer in Blacks and Hispanics in the United States is thought to be secondary to barriers in screening because of the lack of insurance, low income, and cultural differences. Increased risk of cervical cancer exists in women who are of young age at time of first coitus, have multiple sexual partners, have partners with multiple partners, or who bear children at a young age. Cervical cancer is caused by exposure to high-risk strains of HPV. The presence of HPV DNA has been identified in more than 99% of cervical carcinomas.

Question 22.9 The answer is C.

HPV infections are not rare. There is no currently effective antiviral therapy that is active against HPV. Treatments of the precancerous and cancerous changes that develop from HPV are usual y indicated, but the virus can stil be often detected even after therapy. Multiple HPV vaccines have been FDA approved as a preventative vaccine.

It appears that primarily those patients who are naive to the virus benefit from vaccination. Young women between the ages of 9 and 26 years are currently approved for vaccination. Ideal y, vaccination should occur before the onset of sexual activity.

Question 22.10 The answers are A, B, and D.

Al of the factors are correct except that current antiretroviral therapy has not demonstrated benefit against HPV.

Question 22.11 The answer is A.

The incidence of nodal (extracervical) involvement is directly correlated with tumor stage, size, histology, depth of invasion, and lymphovascular space invasion, but not presence/absence of microinvasion or history of pelvic surgery. For patients with stage I disease treated with radical hysterectomy, 15% to 20% and 1% to 5% of pelvic and para-aortic lymph nodes, respectively, wil be involved. Cervical cancer usual y fol ows an orderly pattern of spread from the cervix to the pelvic nodes, then to the common iliacs, and final y to the para-aortic lymph nodes before systemic spread. Lung, extrapelvic lymph nodes, liver, and bone as the most common sites of distant metastases.

Question 22.12 The answer is D.

Patient with stage IA1 cancers have been safely managed with conization only or simple hysterectomy. These patients typical y are not treated with radiation or chemotherapy.

The difficulty and confusion that arise result from practitioners attempting to make the diagnosis from smal biopsies. To make the diagnosis, the patient should have less than 3

mm of invasion and no more than 7 mm of lateral spread, along with negative margins.

The management of patients with LVSI remains controversial, but its presence is typical y treated as frankly invasive disease. Therefore, patients with superficial invasion 279

on a smal biopsy and without visible tumor on the cervix, should be further evaluated with cervical conization to al ow a proper stage prior to deciding the most appropriate therapy.

Question 22.13 The answer is B.

Staging of cervical cancer is clinical, which is based on careful clinical examination and routine radiographic studies (e.g., chest radiograph, intravenous pyelogram, lower gastrointestinal) and procedures (cystoscopy, proctoscopy). Because cervical cancer is primarily a disease of the developing world, staging procedures have been kept simple to al ow consistency staging throughout the world. CT and PET are often used for treatment planning in the United States but should not be the basis for changing the stage.

Question 22.14 The answer is C.

For patients with smal stage IB1 tumors, either radiation or radical hysterectomy with lymphadenectomy are appropriate. Factors such as patient preference, anesthetic, and surgical risks should be considered. Surgical treatment tends to be preferred for young women with smal tumors because it permits preservation of the ovaries and likely better vaginal function. Radiation invariably leads to menopause with loss of ovarian hormone production and possible vaginal stenosis. Simple hysterectomy would be considered inadequate therapy for this size and stage of cancer. Chemoradiotherapy would typical y be indicated for patients with more advanced cancers. Brachytherapy alone would also be inadequate because the patient is at risk for nodal involvement, and external beam therapy would also be indicated to treat the nodal area at risk.

Question 22.15 The answer is D.

Several randomized trials have demonstrated a benefit to the addition of chemotherapy, to standard radiation therapy, for treating women with locoregional y advanced cervical cancer. Based on these trials, regimens that are commonly used in practice include 5FU with cisplatin and concurrent radiation, and weekly cisplatin with radiation. None of the combined chemotherapy and radiation trials included the use of carboplatin. Hysterectomy fol owing radiation and chemotherapy is no longer considered routine.

Question 22.16 The answer is D.

This patient has developed an apparently isolated central pelvic recurrence after combined chemoradiotherapy. Her only real curative option is surgery, which likely involve pelvic exenteration. Patients typical y receive the maximum tolerated dose of radiation during their primary therapy, and further meaningful doses of radiation are usual y not possible. Chemotherapy is typical y pal iative in nature only. Recent randomized trials have suggested improved survival with combination chemotherapy 280

over single-agent cisplatin, but this approach remains pal iative.

Question 22.17 The answers are A and B.

DES is a synthetic estrogen previously given to women during pregnancy primarily in women with a history of miscarriage or premature birth. First reported in 1971, an association between DES exposure in utero and clear cel vaginal cancer was made. Few cases of cancer in DES-exposed women have been reported in those aged more than 40

years, and these women continued to be fol owed closely. If a cancer in the vagina is in contact with the cervix or the vulva, then it is not classified as a vaginal cancer and the primary is consider either the cervix or the vulva, respectively. Vaginal cancers are thought to be related to HPV in at least 60% to 65% of cases. Staging for primary vaginal cancer is clinical, similar to cervical cancer.

Question 22.18 The answer is C.

Stage II vaginal cancer involves the subvaginal tissues and is typical y not amendable to local resection without injury to the bladder or rectum. The most appropriate therapy is radiation, likely with both brachytherapy and external beam radiotherapy to treat the regional nodal areas. Chemotherapy is not indicated for primary therapy. Extrapolating from randomized studies in patients with cervical cancer, the combination chemoradiotherapy could be considered for patients with vaginal cancer.

Question 22.19 The answers are B and D.

There appears to be only two types of invasive squamous vulvar cancers. HPV-related cancers typical y occur in younger women and can be multifocal and associated with vulvar intraepithelial neoplasia (VIN), whereas non-HPV cancers occur in older women and are often associated with chronic vulvar inflammation or lichen sclerosis. Vulvar melanoma is not thought to be related to HPV infection.

Question 22.20 The answer is C.

Although al options are used to treat patients with invasive vulvar cancer, the apparent best option is typical y radical vulvectomy with inguinal lymphadenectomy. Staging is then determined on the basis of the surgical findings, which also dictate adjuvant therapy. Typical y, neoadjuvant and definitive chemoradiation are often necessary with very large cancers involving the urethra or anus and can help achieve organ preservation, but would not be typical y used with a 3-cm tumor.

Question 22.21 The answers are C and D.

Depth of invasion, tumor diameter, and tumor thickness are al directly related to lymph node involvement and the patient’s ultimate survival. Tumor grade has been inconsistent and has not typical y been found to be an independent risk factor. LVSI is a 281

very strong predictor of positive inguinal lymph nodes.

Question 22.22 The answer is C.

Staging for carcinomas of the vulva has been established by the FIGO. In 1983, FIGO

initial y adopted a clinical TNM staging system. The reliability of clinical assessment of regional lymph node status was found to be poor. In 1988, FIGO adopted a surgical staging system, and this was updated in 1994 to include an additional substage for minimal y invasive cancers (IA) and again in 2009 to expand Stage III. IIIA includes one lymph node metastasis ≥5 mm or one or two lymph node metastasis(es) <5 mm, IIIB disease involves two or more lymph node metastases ≥5 mm, or three or more lymph node metastases <5 mm, and IIIC involves positive nodes with extracapsular spread. Typical y, both TNM and FIGO stages are provided.

Question 22.23 The answer is C.

Radiation is indicated for patients with more than one positive lymph node and should be considered with any positive lymph nodes or if resection margins are positive and further resection is not possible. Chemotherapy has not been demonstrated to be of benefit in the adjuvant setting. A randomized trial evaluating the role of pelvic lymphadenectomy for patients with positive groin lymph nodes was completed, suggesting there is no role for routine pelvic lymphadenectomy for these patients.

Question 22.24 The answer is A.

Local recurrence of vulvar cancer is not uncommon. These patients can often be successful y managed with repeat resection. Large surgical defects from further resections in the vulva can be managed with the use of flaps and skin grafting.

Chemotherapy is usual y of limited efficacy and not needed if the lesion is resectable.

Radical surgical resection, including pelvic exenterations, has been used successful y for large recurrent cancers.

Question 22.25 The answer is A.

The majority (90%) of uterine corpus cancers arise from the endometrium with sarcomas representing less than 10% of cases. Exogenous estrogen use appears to cause a minority of endometrial cancers. In the past, when estrogens were given frequently to women without progestins to protect the endometrial lining, this was a more frequent cause of endometrial cancer. Abnormal uterine bleeding typical y leads to early presentation and evaluation of patients with endometrial cancer.

Question 22.26 The answers are A, B, and D.

Risk factors for the development of endometrial cancer are typical y related to chronic estrogenic stimulation. Estrogen therapy, obesity, early age of menarche, late age of 282

menopause, anovulation, and estrogen-producing tumors have al been associated with the development of endometrial cancers. Interestingly, diabetes mel itus imparts an increased relative risk of 3, even when control ing for other known factors.

Question 22.27 The answer is C.

Hysterectomy, whether performed through a large open incision, laparoscopical y, or vaginal y, is indicated. Ovarian preservation has been performed in rare circumstances but is typical y discouraged. Preoperative imaging, beyond a chest radiograph for patients with disease apparently confined to the uterus on clinical examination, is rarely helpful. Thus, CT, MRI, and PET scans are not typical y recommended as a preoperative evaluation for these patients. The office endometrial biopsy is sufficiently accurate in this setting, and a D&C would not offer any further benefit to the preoperative evaluation. Radiation can be used as primary therapy for the treatment of endometrial cancer but is typical y reserved for patients with severe medical comorbidities in whom surgery is thought to be too high a risk. These patients wil stil typical y require general anesthesia to al ow for brachytherapy implantation into the uterine fundus.

Question 22.28 The answer is A.

The family history presented is worrisome for Lynch II syndrome. Approximately 5% of endometrial cancers are hereditary, with the majority being Lynch II (hereditary nonpolyposis colorectal cancer syndrome). Lynch syndrome is caused by a defect in mismatch repair genes. Women who carry one of these abnormal genes have a 22% to 60% chance of developing endometrial cancer, which is similar to their risk of developing colorectal cancer. Patients with the diagnosis of endometrial cancer with a strong family history should be counseled and offered genetic testing. Families with BRCA1 or BRCA2 mutations confer an increased risk in breast and ovarian cancer.

Endometrial cancer is not related to familial adenomatous polyposis syndrome.

Question 22.29 The answer is B.

There are both clinical and surgical staging systems for endometrial cancer. A minority of patients with major medical comorbidities would typical y not undergo surgical management and require staging via the older clinical staging system. This patient is staged as IIIC1 due to the involvement of pelvic nodes but not para-aortic nodes.

Question 22.30 The answer is D.

Adjuvant therapy for patients with stage IIIC disease remains controversial. GOG-122

compared whole abdomen/pelvic radiation therapy with chemotherapy (cisplatin plus doxorubicin for eight cycles) and demonstrated a progression-free and overal survival benefit to chemotherapy. The GOG-184 evaluated “volume-directed” radiation therapy that included pelvic and para-aortic lymph nodes when indicated, fol owed by chemotherapy. Patients were randomized to two differing chemotherapy arms (cisplatin 283

plus doxorubicin or cisplatin plus doxorubicin, and paclitaxel). There was no significant benefit to the addition of paclitaxel for these patients. Methods to reduce toxicity of radiation therapy including intensity-modulated radiotherapy (IMRT) are being investigated. Lower toxicity with potential y sparing the pelvic bone marrow should al ow for combination of radiation and chemotherapy to maximize efficacy.

Question 22.31 The answer is C.

The Gynecologic Oncology Group (GOG) has conducted several randomized trials in patients with advanced or recurrent endometrial cancer. GOG-177 demonstrated the combination of cisplatin, doxorubicin, and paclitaxel to have an improved progression-free and overal survival benefit that was statistical y significant. This regimen had a response rate of 57% compared with 34% in the cohort treated with cisplatin and doxorubicin alone. Ifosfamide plus paclitaxel is a regimen that has been developed and demonstrated superiority in uterine carcinosarcomas.

Question 22.32 The answer is A.

GTN includes rare gynecologic tumors that represent less than 1% of gynecologic malignancies. These tumors are potential y life-threatening but usual y should be highly curable when treated appropriately. The most common pathologic entity in GTN is complete hydatidiform mole.

Question 22.33 The answer is D.

Beta-hCG is an extremely sensitive and specific marker used in the management of these patients. Patients are typical y fol owed post evacuation with weekly beta-hCG

determinations. The diagnosis of persistent GTN is based on the fol owing: a plateau in the level for at least 3 weeks, a 10% or greater increase in the level for three or more values during a 2-week time period, persistence of beta-hCG levels greater than 6

months after evacuation, or histologic evidence of choriocarcinoma.

Question 22.34 The answer is C.

Treatment for GTN is based on risk assessment either by the WHO or the FIGO

guidelines. Low-risk disease is typical y treated with methotrexate or actinomycin-D.

Treatment is continued until the hCG levels are normal for 3 consecutive weeks. The patient is then fol owed monthly for 12 months. Hysterectomy can be offered for patients who have completed childbearing.

Corresponding chapters in Cancer: Principles & Practice of Oncology, Tenth Edition: 71

(Molecular Biology of Gynecologic Cancers), 72 (Cancer of the Cervix, Vagina, and Vulva), 73 (Cancers of the Uterine Body), 74 (Genetic Testing in Uterine Cancer), and 75

(Gestational Trophoblastic Neoplasms).

284





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 23.1 A 35-year-old premenopausal woman of Ashkenazi-Jewish ancestry presents to you because her 60-year-old paternal aunt was recently diagnosed with ovarian cancer, and she is concerned about her own risk for ovarian cancer. She has no siblings, and there is no other family history of cancer. She has two living children and is in good health, and her pelvic examination is unremarkable. You should advise her that: A. Ovarian cancer cannot be inherited through the paternal side and she does not need any particular screening.

B. A single second-degree relative with cancer at age more than 50 years does not confer a significantly increased risk for her.

C. She should visit a genetic counselor.

D. Annual transvaginal ultrasound and CA-125 screening can reduce her risk of mortality.

E. She should have a prophylactic total abdominal hysterectomy/ bilateral salpingo-oophorectomy (TAH/BSO) if/when she does not want to have any more children.

Question 23.2 A 35-year-old woman presents to you for recommendations regarding therapy of her newly diagnosed mucinous ovarian cancer. This was a 5-cm, grade 1, left-sided mass that was incidental y found at the time of surgery for endometriosis as part of an infertility workup. The ovary was removed, and the operative note states that there was no evidence of tumor on the external surface of the ovary or elsewhere in the abdomen, but ful surgical staging was not performed. A postoperative computed tomography (CT) scan of the abdomen and the pelvis is unremarkable, and CA-125 is within normal limits.

Pelvic examination is unremarkable. The patient would like to have children but does not want to compromise her survival. You should advise her that: A. She is unlikely to have any residual cancer or a recurrence, and further surgery or chemotherapy is not needed.

B. She should have a positron emission tomography (PET) scan, and if there is no uptake, she does not need further surgery or chemotherapy.

C. Because her CT scan and CA-125 are normal, she is unlikely to have any residual disease, and further surgery is not needed. However, because the mucinous subtype of ovarian cancer has a very poor prognosis, she wil require three to six cycles of 285

carboplatin/paclitaxel chemotherapy.

D. She should have complete surgical staging, if possible, via laparoscopy, with the option of preserving her uterus and contralateral ovary if there is no further evidence of tumor, which is associated with a >90% chance of 5-year survival and does not require chemotherapy.

E. She should have complete surgical staging, including TAH/BSO. If no further disease is found, she wil need only three cycles of carboplatin/paclitaxel chemotherapy, but if there is disease outside the ovary, she wil need six cycles.

Question 23.3 In what aspect of ovarian cancer management is CA-125 most useful?

A. Screening

B. Diagnosis

C. Monitoring treatment

D. Equal y useful in al of the above

Question 23.4 Which of the fol owing increases the risk of a woman developing ovarian cancer?

A. Use of oral contraceptives for >5 consecutive years B. Nul iparity

C. Breastfeeding

D. Tubal ligation

Question 23.5 A 50-year-old woman presents with a pelvic mass. She is found to have a tumor of low malignant potential. With TAH/BSO and staging, there is no gross disease but the washings were positive on nal pathology and there was one positive lymph node, making her disease stage IIIC. What is the most appropriate therapy postoperatively?

A. Intraperitoneal cisplatin and intravenous (IV) taxane B. IV platinum and a taxane

C. Hormonal therapy with tamoxifen or an aromatase inhibitor D. No further therapy

Question 23.6 A 50-year-old woman was diagnosed with stage III ovarian cancer and underwent primary resection fol owed by chemotherapy. She is asymptomatic but has an elevated CA-125. Imaging studies do not identify recurrent disease. Which of the fol owing is the best treatment option?

A. Hormonal therapy

B. Platinum-based chemotherapy

C. Single-agent doxorubicin

D. Single-agent paclitaxel

Question 23.7 Which of the fol owing is/are a founder BRCA mutation(s) associated with 286

individuals of Ashkenazi descent?

A. 185delAG

B. 5382insC

C. 617delT

D. Al of the above

Question 23.8 What percentage decrease in the incidence of ovarian cancer is associated with oral contraceptive use for more than 5 years?

A. 5%

B. 10%

C. 20%

D. 50%

E. 80%

Question 23.9 A 25-year-old woman has her left ovary removed because of an ovarian mass. The nal pathology shows that this is a moderately di erentiated papil ary serous cancer. There was no other evidence of disease in the abdominal cavity. What is the likelihood that this patient has a positive pelvic or para-aortic lymph node metastasis?

A. 5%

B. 15%

C. 30%

D. 50%

Question 23.10 A 55-year-old woman who has just achieved a complete clinical remission (normal CT scan, pelvic examination, and CA-125) after six cycles of chemotherapy for stage IIIC optimal y debulked serous ovarian cancer presents to you for a second opinion regarding her prognosis and treatment options at this point. She is in excel ent general health and tolerated chemotherapy wel except for some numbness in her ngers and toes, which caused her treating oncologist to switch her treatment from paclitaxel/carboplatin to docetaxel/carboplatin after cycle three. You should advise her that: A. The risk of eventual relapse for an optimal y debulked patient with a complete clinical remission is approximately 30%. No therapy is proven to be of any further survival benefit at this point.

B. She should have second-look surgery. If residual disease is found, she should have four to six cycles of intraperitoneal platinum-based therapy because this can improve survival in patients with platinum-sensitive, minimal residual disease.

C. She should have a PET scan. If residual disease is found, she should have four to six cycles of a non–cross-resistant drug, such as topotecan.

D. Her risk of eventual relapse is approximately 70%. She should be offered consolidation therapy with paclitaxel 175 mg/m2 every 3 weeks for 12 months with the 287

expectation of a 30% improvement in survival.

E. Her risk of relapse is approximately 70%. No therapy is proven to be of any survival benefit at this point.

Question 23.11 Which of the fol owing statement(s) is/are TRUE about granulosa cel tumors of the ovary?

A. They usual y occur in premenopausal women

B. They are usual y stage III/IV

C. Survival of patients with stage I disease is general y good, but they may relapse later D. Survival of patients with stage III/IV disease is poor, and they should consider chemotherapy

E. They may be associated with endometrial cancer

F. C, D, and E

Question 23.12 Which of the fol owing statements is TRUE about germ cel tumors of the ovary?

A. They occur more often in younger women.

B. They are usual y stage III/IV.

C. Appropriate therapy includes TAH/BSO/ful surgical staging and chemotherapy regimens similar to those used in male testicular cancer.

D. Survival of patients with stage III/IV disease is poor.

E. The chemotherapy wil usual y result in infertility.

Question 23.13 A 51-year-old woman presents to you for recommendations regarding the treatment of her recurrent ovarian cancer. She was optimal y debulked for stage IIIC serous ovarian carcinoma and completed six cycles of carboplatin/paclitaxel 36 months ago with a clinical complete remission. She now has recurrent ascites, which is histological y positive for tumor compatible with her original primary. CT scan shows peritoneal carcinomatosis and a pelvic mass. You should advise her that:

A. Prognosis of recurrent ovarian cancer is poor. She may achieve short-term benefit from chemotherapy although hospice is a reasonable option.

B. Tamoxifen has a 40% chance of response.

C. She has a very high likelihood of disease shrinkage and symptom pal iation with further platinum-based chemotherapy.

D. She has a chance of cure with autologous stem cel transplant.

E. Liver metastases and liver failure wil probably be her ultimate cause of death.

Question 23.14 A 45-year-old woman has undergone surgical resection fol owed by adjuvant chemotherapy for her stage IIIC ovarian cancer. She is now in complete remission and is interested in further treatment to reduce the risk of recurrent disease. Which of the fol owing would you recommend?

288

A. Maintenance treatment with single-agent paclitaxel for 12 months B. Clinical surveil ance

C. Maintenance treatment with single-agent topotecan

D. Maintenance treatment with bevacizumab

Question 23.15 Three randomized control ed trials utilizing intraperitoneal chemotherapy in optimal y cytoreduced advanced ovarian cancer have shown: A. Al showed that intraperitoneal therapy has a progression-free survival (PFS) benefit over intravenous therapy.

B. Al showed that intraperitoneal therapy has an overal survival (OS) benefit over intravenous therapy.

C. Intraperitoneal and intravenous therapy are equivalent in this patient population.

D. Dose-dense intravenous therapy is equivalent to intraperitoneal therapy.

Question 23.16 A 53-year-old patient presents with ascites, omental caking, and peritoneal nodularity. Her ovaries are normal. She undergoes surgery and al gross tumors are removed. The nal diagnosis is papil ary serous primary peritoneal cancer. How should this patient be treated?

A. As if she had a standard ovarian cancer

B. As if she had a peritoneal mesothelioma

C. As if she had breast cancer

D. As a germ cel cancer

289

Question 23.1 The answer is C.

This woman should be referred for genetic counseling and possible genetic testing. Some 40% to 60% of patients of Jewish descent who have epithelial ovarian cancer carry one of the three founder BRCA1 or BRCA2 mutations (irrespective of family history), which are inherited in an autosomal dominant manner, through either the paternal or maternal side. If this woman carries a BRCA1 mutation, her lifetime risk of ovarian cancer is 20% to 60%, and her risk of breast cancer is even higher. Although transvaginal ultrasound and CA-125 screening are general y recommended for mutation carriers who have their ovaries in place, there is no good evidence that such screening wil decrease mortality. Oral contraceptives have been suggested to decrease the risk of ovarian cancer by up to 50%. Removal of the ovaries likely confers the best method for reducing the risk of ovarian cancer. It remains controversial whether the uterus should be removed as wel .

Question 23.2 The answer is D.

Understaging is common, particularly when the preoperative diagnosis is that of a benign process. Earlier laparoscopic surgical staging series suggested that up to 30% to 40% of patients thought to have FIGO stage I or II disease actual y had disease in the upper abdomen. The incidence of extraovarian spread is lower with a grade 1 tumor.

Nonetheless, complete surgical staging, if possible, is advised in this case, because the recommendation for a stage IA grade 1 mucinous tumor is not chemotherapy. Although some data have suggested that advanced-stage mucinous tumors may lower response to chemotherapy compared to serous tumors, a low-grade early stage mucinous tumor does not have a poor prognosis. However, chemotherapy would be recommended in the case of any extraovarian spread. In the hands of an experienced surgeon, laparoscopic staging, including omentectomy and para-aortic lymph node examination, is an option.

Preservation of the uterus and contralateral ovary is reasonable if no further disease is found at the time of staging. CA-125 is frequently normal in women with mucinous ovarian tumors, even when of advanced stage. A PET scan wil not detect microscopic disease, may not be positive in low-grade malignancies, and is not likely to be helpful.

Question 23.3 The answer is C.

CA-125 is not useful for screening because early stage ovarian cancer has an elevated CA-125 approximately 50% of the time. Furthermore, the positive predictive value of an elevated CA-125 is very low because many other disorders also cause an elevated CA-125 and the prevalence of the disease is quite low. Although CA-125 is not particularly helpful in the diagnosis of ovarian cancer, it is useful in monitoring treatment.

Question 23.4 The answer is B.

290

Any factor that decreases ovulation is also associated with a decreased the risk of ovarian cancer. Thus, oral contraceptives, multiparity, and breastfeeding decrease the likelihood that an individual wil develop ovarian cancer. Several population-based studies show that tubal ligation decreases the likelihood of developing ovarian cancer.

Question 23.5 The answer is D.

There are no data that suggest any adjuvant therapy wil improve the survival in patients with tumors of low malignant potential.

Question 23.6 The answer is A.

Elevated CA-125 indicates disease recurrence and in patients who are asymptomatic with no other objective evidence of disease recurrence, the appropriate treatment would be hormonal therapy or observation. Chemotherapy is considered when patients have symptomatic disease or there is objective evidence for disease recurrence.

Question 23.7 The answer is D.

The majority of inherited disease in the Jewish population is due to one of the three founder mutations in BRCA1 and BRCA2.

Question 23.8 The answer is D.

Oral contraceptives used for more than 5 years wil decrease the risk of ovarian cancer by more than 50%.

Question 23.9 The answer is B.

Up to 15% of patients with gross stage I diseases have nodal metastases. This is why it is very important for these patients to undergo comprehensive staging.

Question 23.10 The answer is E.

Although the majority (almost 80%) of patients with advanced-stage (III to IV) ovarian cancer wil achieve a clinical y complete remission with taxane/platinum combination therapy, approximately 70% wil ultimately relapse from a clinical complete remission.

Even patients with a surgical y confirmed complete remission (negative second look) have an eventual relapse rate of approximately 50%. Although patients with optimal y debulked stage III disease are a relatively favorable subgroup, those optimal y debulked patients who have a larger presurgical tumor burden (IIIC) fare worse than those with a lesser presurgical tumor burden (IIIA). One randomized trial has demonstrated that maintenance paclitaxel improved progression-free survival (PFS) of women with a clinical complete response from 21 to 28 months in a randomized trial, although no survival benefit was, and there was a significant incidence of neuropathy. Little data exist on PET scans in this situation, and consolidation topotecan has shown no benefit 291

in two randomized trials. Although intraperitoneal therapy is a theoretical y attractive option, cisplatin, the most widely used drug, carries a significant risk of neurotoxicity, and there are no data showing any survival benefit to its use in the setting of minimal residual disease.

Question 23.11 The answer is F.

Sex cord–stromal tumors, of which granulosa cel tumors are the most common subtype, comprise only approximately 5% of al ovarian neoplasms. The peak incidence is in women aged more than 50 years, although a significant proportion occurs in premenopausal women. Granulosa cel tumors may secrete estrogen and be associated with endometrial hyperplasia and endometrial carcinoma. The majority of patients are diagnosed in stage I, with 10-year survivals of 75% to 95%. However, late relapses may be observed. Patients with advanced-stage disease have poor outcomes. Although the rarity of the tumor precludes randomized trial data, most such patients wil be offered chemotherapy, traditional y with bleomycin, etoposide, cisplatin (BEP), or other regimens used in germ cel tumors. Recent data suggest that a platinum /taxane regimen may be as effective.

Question 23.12 The answer is A.

Germ cel tumors almost always occur in young women, with a peak incidence in their early 20s. Some 60% to 70% are stage I at diagnosis. With the use of platinum-based chemotherapy regimens similar to those used for men with testicular cancer, even patients with an advanced stage have a good prognosis. Because most of these tumors occur in young women, often before they have had children, and because the type of chemotherapy used wil not cause infertility in most young female patients, the surgical approach is critical. In many patients, the contralateral ovary and uterus can and should be spared. Pre-treatment infertility consultation should be considered as egg harvesting and storage is effective and of reasonable cost.

Question 23.13 The answer is C.

Recurrent ovarian cancer is not general y curable with transplant or any other modality, but patients whose disease recurs with a disease-free interval of more than 1 year have more than a 50% chance of responding to platinum-based combination therapy and should usual y be offered chemotherapy. Secondary debulking surgery may also be of benefit. Hormonal therapy in ovarian cancer general y produces response rates of only 10% to 15% and is usual y reserved for patients who cannot tolerate other therapy. It has also been recommended as the initial salvage therapy in patients who have an increasing CA-125 as their only manifestation of recurrent disease.

Question 23.14 The answer is B.

Current evidence does not support maintenance chemotherapy with paclitaxel or 292

topotecan after adjuvant chemotherapy for patients with advanced disease. The role of maintenance bevacizumab is being investigated in ongoing clinical trials.

Question 23.15 The answer is A.

Al three studies showed that intraperitoneal therapy offered a PFS benefit over intravenous therapy. Two studies (GOG 104 and 172) showed an overal survival benefit but GOG 114 showed a trend only. Dose-dense therapy has not been compared directly to intraperitoneal therapy. However, it appears to improve survival over standard intravenous therapy.

Question 23.16 The answer is A.

Since primary peritoneal cancers, fal opian tube cancer, and ovarian cancers are considered to be histological y and molecularly identical, the treatment recommendation for al three malignancies is the same.

Corresponding chapters in Cancer: Principles & Practice of Oncology, Tenth Edition: 76

(Ovarian Cancer, Fal opian Tube Carcinoma, and Peritoneal Carcinoma) and 77 (Genetic Testing in Ovarian Cancer).

293





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 24.1 What percentage of breast cancers is caused by germline mutations?

A. 20%

B. 10%

C. 15%

D. 2%

Question 24.2 BRCA1-associated breast cancers are characterized by: (Select two correct responses)

A. Aggressive features.

B. ER positive.

C. Younger age at presentation.

D. Al of the above.

Question 24.3 Li–Fraumeni syndrome is characterized by which clinical features?

A. Lobular breast cancer, gastric cancer

B. Breast cancer, soft tissue sarcoma, central nervous system tumors, adrenocortical cancer, leukemia, prostate cancer

C. Breast cancer, hamartoma, thyroid cancer, oral mucosa cancer, endometrial cancer, brain tumors

D. Male breast cancer, pancreas cancer, gal bladder cancer, pharynx cancer, gastric cancer, melanoma, prostate cancer

Question 24.4 Which of the fol owing statements about Luminal A subtype is TRUE?

A. It is more common in premenopausal black women

B. Luminal A breast cancers frequently carry TP53 mutations C. It is characterized by high-expression levels of ER-related genes and low expression of the HER2 cluster and proliferation-associated genes.

D. It has a worse prognosis than other molecular subtypes of breast cancer.

Question 24.5 NCCN, ASCO, and/or St. Gal en clinical practice guidelines support Oncotype DX testing in which of the fol owing scenarios?

294

A. ER positive HER2-negative patients with T1–3 and N0 or N1mi disease B. As a marker of recurrence risk in untreated HER2 positive, node-negative patients C. Predicts 10-year distant relapse risk in patients with early stage ER positive node-negative breast cancer who wil receive adjuvant hormonal therapy D. A and C

Question 24.6 Which of the fol owing factors is a risk factor for developing breast cancer?

A. Cowden syndrome

B. Early age at first ful term pregnancy

C. Breast density <10%

D. Simple breast cysts

Question 24.7 American Cancer Society guidelines for magnetic resonance imaging (MRI) screening is supported for which of the fol owing patients?

A. A 47-year-old woman with a deleterious mutation in BRCA1

B. A 60-year-old woman with biopsy proven lobular carcinoma in situ (LCIS) C. A 55-year-old woman with a personal history of ER positive breast cancer treated 8

years ago

D. A 65-year-old woman who underwent chest radiation at age 60 years Question 24.8 Which of the fol owing scenarios are considered a contraindication to the use of tamoxifen?

A. Major surgical procedure within the previous 6 months B. A history of deep vein thrombosis, stroke, pulmonary embolism, or transient ischemic attack

C. A 60-year-old woman with bilateral asymptomatic cataracts D. A 65-year-old woman currently on an SSRI for hot flashes Question 24.9 A 44-year-old woman presents to your o ce with a new palpable breast mass. A biopsy has been recommended based on the results of mammogram and ultrasound. In general, the most appropriate way to diagnose suspected invasive carcinoma is:

A. Either a core or fine-needle biopsy.

B. An excisional biopsy.

C. Diagnosis by core needle biopsy.

D. A fine-needle aspiration biopsy.

Question 24.10 You are advising a 42-year-old premenopausal woman with a history of atypical hyperplasia on prevention strategies. Which of the fol owing is CORRECT?

A. Tamoxifen reduces her risk by #x223C;50%.

295

B. Oophorectomy reduces her risk by ∼50% to 65%.

C. Bilateral mastectomy completely eliminates her risk of breast cancer.

D. Raloxifene would provide similar benefit as tamoxifen.

Question 24.11 The Gail model includes which of the fol owing risk factors?

A. Second-degree relatives with breast cancer

B. Previous breast biopsies

C. Age at first pregnancy conception

D. Age at menopause

Question 24.12 Which of the fol owing statement about DCIS is TRUE?

A. DCIS accounts for 15% to 30% of mammographical y detected cancers.

B. DCIS is most common in women aged 40 to 59 years.

C. Younger women have a lower rate of local recurrence after local therapy D. Sentinel lymph node biopsy should be performed routinely during breast-conservation surgery for nonpalpable DCIS.

Question 24.13 The use of radiation therapy (RT) after lumpectomy in patients with DCIS:

A. Improves overal survival (OS).

B. Reduces the risk of recurrent DCIS, but not invasive disease, in the treated breast.

C. Does not decrease local recurrence when tamoxifen therapy is administered.

D. None of the above.

Question 24.14 What stage describes a patient with a 2-cm primary breast tumor metastatic to a movable ipsilateral lymph node?

A. T1N1M0 (IIA)

B. T2N0M0 (IIA)

C. T2N1M0 (IIB)

D. T3N1M0 (IIIA)

Question 24.15 Which of the fol owing statements concerning local recurrences after breast-conserving therapy is TRUE? (Select two correct responses) A. The underlying molecular subtype is the most significant determinant of the likelihood of local recurrence after breast-conserving therapy and mastectomy, particularly when negative margins are achieved.

B. Most local recurrence events appear to be residual disease as opposed to second primary cancers fol owing BCS and RT.

C. Widely clear margins of at least 2 cm decrease the risk of a local recurrence in young patients under 40 years.

296

D. Adjuvant chemotherapy affects the risk of both systemic and local recurrences.

Question 24.16 Which of the fol owing is an absolute contraindication to breast-conserving surgery (BCS) requiring radiation therapy?

A. Radiation therapy during pregnancy

B. Diffuse suspicious or malignant-appearing microcalcifications C. Widespread disease that cannot be incorporated by local excision through a single incision that achieves negative margins with a satisfactory cosmetic result D. Al of the above

Question 24.17 Identify the CORRECT statement.

A. Patients age 70 and above with stage 1, ER+ breast cancer treated by lumpectomy and tamoxifen alone have no difference in locoregional recurrence rates relative to those who receive whole breast radiation in addition.

B. Preoperative chemotherapy has a long-term survival advantage relative to adjuvant chemotherapy.

C. Concurrent use of pertuzumab with trastuzumab and chemotherapy is appropriate in women receiving preoperative chemotherapy for HER2+ breast cancer.

D. Al of the above.

Question 24.18 The gains associated with adjuvant tamoxifen: A. Are independent of patient age.

B. Are less in patients who also receive adjuvant chemotherapy.

C. Are dependent on patient menopausal status.

D. Decline 10 years after diagnosis.

Question 24.19 Identify the CORRECT statement.

A. A maximum duration of 5 years is the only duration for which safety and efficacy data exists for an aromatase inhibitor.

B. Ovarian suppression in combination with tamoxifen has no benefit relative to tamoxifen alone in high-risk premenopausal women with breast cancer.

C. Concurrent use of an aromatase inhibitor and tamoxifen is appropriate therapy for high-risk node-positive breast cancer patients.

D. Al patients treated with aromatase inhibitors should undergo monitoring of bone mineral density and treatment with denosumab when osteoporosis is detected.

Question 24.20 Identify the CORRECT statement regarding the use of taxanes in the adjuvant setting:

A. Concurrent administration of docetaxel/doxorubicin/cyclophosphamide chemotherapy is better tolerated than sequential dose-dense AC fol owed by paclitaxel 297

due to lower rates of neutropenia.

B. Weekly paclitaxel is associated with increased grade 3 and 4 neutropenia relative to dose-dense paclitaxel.

C. Weekly paclitaxel is associated with increased grade 3 and 4 neuropathy relative to dose-dense paclitaxel.

D. Incorporation of gemcitabine into adjuvant anthracyclines- and taxanes-based chemotherapy improves efficacy.

Question 24.21 Risk factors for cardiac dysfunction with trastuzumab include: A. Preexisting cardiac disease, age >65 years.

B. Non–anthracycline-based chemotherapy, age >60 years.

C. Age >65 years, current aspirin use for cardio protection, hyperthyroidism.

D. None of the above.

Question 24.22 A 57-year-old woman has been taking anastrozole as adjuvant therapy for a moderately-di erentiated T1N1 stage II breast cancer for 3 years. During a routine fol ow up visit you recommend:

A. History and physical examination, complete blood count and liver function tests.

B. History and physical examination, complete blood count and liver function tests, cancer antigen 15-3.

C. History and physical examination.

D. History and physical examination, complete blood count and liver function tests, cancer antigen 15-3, and yearly computed tomography scans.

Question 24.23 Regarding inflammatory breast cancer (IBC): A. Patients presenting with clinical features of IBC but no discrete palpable breast mass may forego systemic staging

B. The presence of dermal lymphatic involvement indicates IBC regardless of the clinical features

C. Adjuvant radiation is not necessary in IBC patients who achieve a pathologic complete response to neoadjuvant systemic therapy.

D. None of the above

Question 24.24 With regard to the clinical and pathologic characteristics of male breast cancer, which of the fol owing is TRUE?

A. Male breast cancer is found, more often than female breast cancer, to be estrogen-receptor negative, and the older a man is with breast cancer, the more likely the cancer is estrogen-receptor negative.

B. Liver cirrhosis and mumps orchitis are associated with a decreased risk of male breast cancer

C. The median age of onset is 10 years younger than the median age of onset for 298

females.

D. Sentinel node biopsy is the preferred treatment for clinical y node-negative patients.

Question 24.25 Regarding bone metastases, which of the fol owing is TRUE?

A. The optimal duration of RANK-ligand inhibition is 2 years.

B. Intravenous bisphosphonates and RANK-ligand inhibitors lessen the pain associated with bone metastases.

C. Bone directed therapies in patients with widespread bone metastases improve overal survival.

D. Only patients with asymptomatic sclerotic bone metastases benefit from bone-directed therapies.

299

Question 24.1 The answer is B.

Approximately 10% of al breast cancers are associated with germline mutations, while the rest occur sporadical y.

Question 24.2 The answer are A and C.

BRCA1-associated breast cancers usual y occur in younger women, have aggressive features, and are characterized by a “triple negative” phenotype (ER, PR, and HER2

negative).

Question 24.3 The answer is B.

Li–Fraumeni syndrome is characterized by TP53 mutations leading to breast cancer, soft tissue sarcoma, central nervous system tumors, adrenocortical cancer, leukemia, and prostate cancer

Question 24.4 The answer is C.

Luminal A breast cancer is characterized by high-expression levels of ER-related genes and low expression of the HER2 cluster and proliferation-associated genes. It rarely has mutations in TP53 and has an overal better prognosis than other forms of breast cancer.

Question 24.5 The answer is D.

Clinical practice guidelines support consideration for multigene testing to guide the addition of combination chemotherapy to standard hormone therapy for hormone receptor positive patients with T1–3 tumors who are node negative or have pN1mi (less or equal to 2 mm axil ary node metastasis) involved.

Question 24.6 The answer is A.

Cowden syndrome confers a 25% to 50% lifetime risk of breast cancer. Other risk factors include late age (after age 30) at first ful term pregnancy, >75% breast density, proliferative breast lesions.

Question 24.7 The answer is A.

ACS guidelines for MRI screening include individuals with BRCA mutations, untested first-degree relative of BRCA carrier, those with lifetime risk of breast cancer 20% to 25%, radiation to the chest between ages 10 to 30 years, Li–Fraumeni, Cowden, or Bannayan–Riley–Ruvalcaba syndromes and first-degree relatives.

Question 24.8 The answer is B.

300

Histories of deep vein thrombosis, stroke, pulmonary embolism, or transient ischemic attacks are considered contraindications to the use of tamoxifen and raloxifen.

Question 24.9 The answer is C.

Diagnosis by core needle biopsy is the most appropriate way to diagnose suspected invasive disease. Fine-needle aspiration does not reliably distinguish invasive cancer from DCIS. Excisional biopsy as a diagnostic technique should be reserved for patients with imaging abnormalities that cannot be targeted by core biopsy.

Question 24.10 The answer is B.

In the P1 trial, tamoxifen reduced the risk of breast cancer by 84% in patients with atypical hyperplasia. Although raloxifene provided similar benefits with a more favorable safety profile than tamoxifen in the STAR trial, this trial only included postmenopausal women. Oophorectomy before menopause decreases the risk of breast cancer by 50% to 65% depending on age at the time of surgery. Although bilateral mastectomy decreases the risk by more than 90%, the risk is not completely eliminated.

Question 24.11 The answer is B.

The Gail model includes first-degree relatives with breast cancer, previous breast biopsies, age at menarche, age at first live birth, race/ethnicity.

Question 24.12 The answer is A.

DCIS accounts for 15% to 30% of mammographical y detected cancers and is most common among women ages 49 to 69 years. Several studies have reported an increased risk of local recurrence in younger women. Initial studies suggested that MRI can both over- and underestimate the extent of DCIS and does not improve surgical planning.

Question 24.13 The answer is D.

The use of RT after BCS for DCIS reduces both invasive and noninvasive recurrences but does not alter OS.

Question 24.14 The answer is A.

The patient has T1 (tumor size ≤2 cm), N1 (movable ipsilateral level 1 lymph node), and M0. T1N1M0 represents stage IIA.

Question 24.15 The answers are A and D.

The underlying molecular subtype is the most significant determinant of the likelihood of local recurrence after breast-conserving therapy or mastectomy, particularly when negative margin is achieved. Most local recurrence events appear to be second primary cancers fol owing BCS and RT. Although RT is effective in eliminating subclinical multi-301

centric foci of breast cancer present at the time of diagnosis, it does not prevent subsequent development of new cancers. Widely clear margins do not appear to decrease the risk of a local recurrence in young patients. Adjuvant chemotherapy affects the risk of both systemic and local recurrences.

Question 24.16 The answer is D.

Al of the above are absolute contraindications according to NCCN 2014.

Question 24.17 The answer is C.

In 2013, the FDA approved concurrent use of pertuzumab with trastuzumab and chemotherapy in women receiving preoperative chemotherapy for HER2+ breast cancer. Patients age 70 and above with stage I, ER+ breast cancer treated by lumpectomy and tamoxifen alone have no difference in overal survival relative to those who receive whole breast radiation in addition, but have an improvement in locoregional recurrence of 10% versus 2%. Preoperative chemotherapy has no long-term survival advantage relative to adjuvant chemotherapy.

Question 24.18 The answer is A.

Adjuvant tamoxifen results in an improvement in OS for at least 15 years. The benefits are independent of age, menopausal status, and the use of chemotherapy.

Question 24.19 The answer is A.

A maximum duration of 5 years is the only duration for which safety and efficacy data exists for an aromatase inhibitor. Ovarian suppression in combination with tamoxifen has proven benefit relative to tamoxifen alone in high-risk premenopausal women with breast cancer. Concurrent use of an aromatase inhibitor and tamoxifen is not standard therapy for breast cancer patients. Al patients treated with aromatase inhibitors should undergo monitoring of bone mineral density and be considered for denosumab to prevent bone loss and fracture.

Question 24.20 The answer is B.

Weekly paclitaxel is associated with increased grade 3 and 4 neutropenia relative to dose-dense paclitaxel as pegfilgrastim support is not administered with the weekly paclitaxel, whereas dose-dense paclitaxel is associated with increased grade 3 and 4

neuropathy.

Incorporation of gemcitabine into adjuvant anthracyclines- and taxanes-based chemotherapy does not improve efficacy.

Question 24.21 The answer is A.

Preexisting cardiac disease, age >65 years, anthracycline-based chemotherapy, 302

borderline left ventricular ejection fraction, and hypertension are al risk factors for cardiac dysfunction with adjuvant trastuzumab.

Question 24.22 The answer is C.

Complete blood counts and liver function tests, cancer antigen 15-3, and yearly computed tomography scans are not indicated in routine surveil ance for early stage breast cancer patients.

Question 24.23 The answer is D.

Al patients presenting with clinical features of IBC should undergo ful -staging work up due to the substantial risk of metastatic disease. Involvement of dermal lymphatics in the absence of clinical findings does not indicate IBC as it is a clinical diagnosis. Due to the high risk of local recurrence, al patients with IBC should undergo postmastectomy radiation regardless of the response to neoadjuvant therapy.

Question 24.24 The answer is D.

Male breast cancer is found, more often than female breast cancer, to be estrogen-receptor positive. Chronic liver disorders, Klinefelter syndrome (XXY), BRCA 1 or 2

mutations, mumps orchitis, undescended testis, testicular injury, and feminization are al associated with an increased risk of male breast cancer. The median age of onset is later than in females. The same considerations regarding nodal surgery pertain for men as for women.

Question 24.25 The answer is B.

The optimal duration of intravenous bisphosphonates or RANK-ligand inhibitors is not wel characterized. Intravenous bisphosphonates and RANK-ligand inhibitors lessen the pain associated with bone metastases and prevent skeletal-related complications, such as hypercalcemia and fractures. Bone-directed therapies in patients with widespread bone metastases do not impact overal survival.

Corresponding chapters in Cancer: Principles & Practice of Oncology, Tenth Edition: 78

(Molecular Biology of Breast Cancer), 79 (Malignant Tumors of the Breast), and 80

(Genetic Testing in Breast Cancer).

303





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 25.1 Linkage studies have identi ed genes associated with neuro bromatosis type 2 (NF2), Turcot syndrome, and Li–Fraumeni syndrome in which of the fol owing chromosomes?

A. 10q, 22q, and 17q

B. 22q, 5q, and 17p

C. 5q, 10q, and 17p

D. 5q, 10q, and 17q

Question 25.2 Of the fol owing, the most common primary brain tumor in adults in the United States is:

A. Glioblastoma.

B. Meningioma.

C. Astrocytoma.

D. Oligodendroglioma.

Question 25.3 The gene that is frequently altered and plays a key role in the development of diffuse fibril ary astrocytoma is:

A. p53.

B. KRAS.

C. MDM2.

D. MDM4.

Question 25.4 Primary (de novo) glioblastoma multiforme (GBM) is commonly associated with which of the fol owing?

A. PTEN inactivation

B. Loss of heterozygosity of chromosomes 1p and 19q

C. IDH1 mutation

D. Median age <40 years

Question 25.5 Which gene mutation identi ed in GBM is frequently seen in younger patients, and is associated with better prognosis:

304

A. EGFR.

B. p53.

C. IDH1.

D. Gain in chromosome 4.

Question 25.6 Loss of heterozygosity of chromosomes 1p and 19q is common in: A. GBM.

B. Ependymoma.

C. Oligodendroglioma.

D. Meningioma.

Question 25.7 The central nervous system (CNS) tumor that is commonly associated with NF2 mutations is:

A. GBM.

B. Spinal ependymoma.

C. Cerebral ependymoma.

D. Oligodendroglioma.

Question 25.8 Patients with GBM have a higher likelihood of responding to therapy with epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors if which of the fol owing biomarkers is present?

A. Methyl guanine methyl transferase (MGMT) gene methylation B. Activated EGFRvIII

C. Retained PTEN function

D. B and C

Question 25.9 The primary CNS neoplasm that is associated with Epstein–Barr virus (EBV) is:

A. Primary CNS lymphoma.

B. Ependymoma.

C. Oligodendroglioma.

D. GBM.

Question 25.10 Which of the fol owing tumors exhibit contrast enhancement on magnetic resonance imaging (MRI) scan?

A. Pilocytic astrocytoma

B. Grade 2 oligodendroglioma

C. Grade 2 astrocytoma

D. Craniopharyngioma

Question 25.11 Which of the fol owing is associated with good prognosis in patients with 305

low-grade gliomas?

A. Age ≥40 years

B. Tumor diameter ≥6 cm

C. Tumor crossing midline

D. Oligodendroglioma

Question 25.12 A 45-year-old man presents with generalized seizures, and MRI of the brain reveals a nonenhancing mass measuring 7 cm. Biopsy is done, and the tumor histology is reported as grade II astrocytoma. The patient undergoes surgery, and a partial (85% to 90%) tumor resection is achieved. Further treatment should include: A. Watchful waiting.

B. Chemotherapy.

C. Radiotherapy with 50.4 Gy in 1.8 Gy fractions.

D. Radiotherapy with chemotherapy (procarbazine, CCNU, and vincristine).

Question 25.13 In patients with GBM, who have disease recurrence fol owing initial treatment with temozolomide and radiation, the second-line treatment of choice is: A. Erlotinib.

B. Imatinib.

C. Topotecan.

D. Bevacizumab.

Question 25.14 A 55-year-old man presents with headache and mental status changes.

MRI scan of the brain reveals a 5-cm contrast-enhancing mass with surrounding edema. A stereotactic biopsy reveals GBM. The patient undergoes gross total resection of the tumor.

Further treatment should include:

A. Focal external beam irradiation with 45 Gy in 30 fractions plus concurrent temozolomide.

B. Focal external beam irradiation with 60 Gy plus a 10 Gy boost plus concurrent temozolomide.

C. Focal external beam irradiation with 60 Gy in 30 fractions plus concurrent temozolomide.

D. Hyperfractionated dose of 72 Gy in 1.2 Gy fractions plus concurrent temozolomide.

Question 25.15 A 62-year-old man presents with nausea, vomiting, and severe headache.

MRI scan of the brain reveals a 5-cm mass in the posterior fossa. The patient undergoes surgical resection of the mass, and pathology is reported as ependymoma. Further treatment should include:

A. Radiation therapy.

B. Concurrent chemoradiation with temozolomide.

306

C. Chemotherapy alone with temozolomide if MGMT gene methylated.

D. Chemotherapy alone with cisplatin plus etoposide.

Question 25.16 A 53-year-old woman presents with mental status changes; brain MRI identi es a left frontal tumor with dural marginal thickening. She undergoes a gross total resection of the tumor and the involved dural attachments. The histopathology is WHO

grade I meningioma. Further treatment should include:

A. Watchful waiting.

B. Adjuvant radiation therapy.

C. Chemotherapy.

D. Radiosurgery.

Question 25.17 In immunocompetent patients with primary CNS lymphoma, with good performance status and adequate renal function, appropriate first-line therapy comprises of: A. High-dose methotrexate.

B. R-CHOP.

C. Whole brain radiation.

D. None of the above.

Question 25.18 Long-term fol ow-up data showed improved survival for patients with GBM, receiving concurrent brain radiation with temozolomide compared to radiation alone, with the exception of patients with:

A. Age >50 years.

B. Unmethylated MGMT.

C. EGFR mutation positive.

D. None of the above.

Question 25.19 Which of the fol owing is most commonly associated with craniopharyngioma?

A. Sexual dysfunction

B. Visual dysfunction

C. Hypothyroidism

D. Diabetes insipidus

Question 25.20 In adult patients diagnosed with ependymoma, adjuvant radiation therapy after resection is associated with improved overal survival in patients with: A. Supratentorial location.

B. High-grade tumors.

C. Incomplete resection.

D. Poor performance status.

307

Question 25.21 In patients with anaplastic oligodendrogliomas, which gene mutation is an independent prognostic factor for improved overal survival?

A. IDH1

B. EGFR

C. p53

D. NF2

Question 25.22 Which GBM gene expression pro le is most commonly associated with focal deletions or mutations in NF1?

A. Proneural

B. Neural

C. Classical

D. Mesenchymal

Question 25.23 Which three core pathways are commonly mutated in primary GBMs?

A. SHH, NF2, TRAF7

B. WNT, SHH, MAPK

C. PI3K, p53, Rb

D. NF-kB, p53, STAT

Question 25.24 Which somatic mutation is most often associated with Grade II astrocytomas?

A. CIC

B. ATRX

C. FUBP1

D. TERT promoter

308

Question 25.1 The answer is B.

Linkage studies have revealed the NF1 gene to reside in chromosome 17q and the NF2

gene to reside in chromosome 22q. For Turcot syndrome, the APC gene has been identified in chromosome 5q. For Li–Fraumeni syndrome, the cancer disposition has been shown to be associated with chromosomes 17p and 22q.

Question 25.2 The answer is B.

According to data from the Central Brain Tumor Registry of the United States (1998 to 2002), the proportionate distribution of incidence is 30.1% for meningioma, 20.3% for glioblastoma, 9.8% for astrocytoma, and 2.3% for ependymoma.

Question 25.3 The answer is A.

Alterations of p53 gene are found in 30% of al three grades of astrocytoma. Other reported gene alterations include the amplification of MDM2 or MDM4 gene.

Chromosome 9p deletions resulting in loss of the p14 product of the CDKN2A gene have also been reported.

Question 25.4 The answer is A.

Primary (de novo) GBM is associated with age greater than 62 years, amplified EGFR

(polysomy chromosome 7), dysregulated p53, PTEN inactivation, homozygous loss of CDKN2A, and decreased survival.

Question 25.5 The answer is C.

A comprehensive effort to sequence the tumor genome of GBM involved the sequencing of 20,661 genes for somatic mutations from 22 GBM samples. This study also integrated results from copy number and expression analysis of tumor tissue. In addition, to identify previously known dysregulated gene pathways such as p53, EGFR, and PTEN, this study identified mutations involving the isocitrate dehydrogenase 1

(IDH1) gene in 11% of GBM samples. Patients with mutated IDH1 gene were more likely to be younger and had better prognosis than patients with wild-type IDH1, the median survival was 3.7 years versus 1.1 years, respectively ( p <001).

Question 25.6 The answer is C.

Al elic loss of chromosome 1p and 19q occurs in 40% to 80% of grade 2 and 3

oligodendrogliomas. The loss of tumor suppressor genes from these chromosomes is believed to play an important role in the early stage of oligodendroglial tumorigenesis.

Question 25.7 The answer is B.

309

Chromosome 22q loss is common in ependymomas. In spinal ependymomas, this loss is associated with mutations of the NF2 gene. In cerebral ependymomas, loss of chromosome 22q is not associated with NF2 mutations.

Question 25.8 The answer is D.

Patients with GBM had improved survival when treated with EGFR-TK inhibitors when the tumors expressed the common form of mutated EGFR (activated EGFRvIII) and retained PTEN function compared with patients not expressing both of these biomarkers. Patients with MGMT gene methylation were shown in a randomized phase III trial to have significantly improved survival when treated with concurrent temozolomide and radiation when compared with patients who were either negative for MGMT gene methylation or received radiation only.

Question 25.9 The answer is A.

Primary CNS neoplasms are not usual y associated with viral infections in humans, except for primary CNS lymphoma, which is strongly associated with EBV. The majority of primary CNS lymphomas are large B-cel histology, and EBV DNA is detectable in most of these tumors. In addition, the incidence of primary CNS lymphoma is higher in patients with HIV infection.

Question 25.10 The answer is A.

Contrast-enhanced MRI images help differentiate between different types of CNS

tumors. MRI also helps to differentiate between high- and low-grade tumors. Low-grade CNS tumors general y do not enhance, except for pilocytic astrocytoma and pleomorphic xanthoastrocytoma.

Question 25.11 The answer is D.

Oligodendroglioma, specifical y in patients with 1p/19q codeletion, has a high response rate to chemotherapy and is associated with an improved overal survival. Conversely, multivariate analysis from two large European phase III trials have reported age greater than or equal to 40 years, tumor diameter greater than or equal to 6 cm, tumor crossing the midline, astrocytoma histology, and neurologic deficits to be associated with adverse prognosis.

Question 25.12 The answer is C.

Radiotherapy is not routinely recommended in patients undergoing resection for low-grade gliomas. In the European Organization for Research and Treatment of Cancer (EORTC) 22,845 trial, patients receiving immediate postoperative radiotherapy had a progression-free survival advantage compared with those receiving radiation therapy on tumor progression (5.3 vs. 3.4 years, p <0001). There was no significant difference in 310

overal survival (7.4 years vs. 7.2 years). In another study, age greater than or equal to 40 years, tumor diameter greater than or equal to 6 cm, astrocytoma histology, and incomplete resection were identified as adverse prognostic factors, with the presence of three or more of these factors conferring poor prognosis. In such patients, immediate postoperative radiotherapy is recommended.

Question 25.13 The answer is D.

The prognosis for recurrent GBM is poor with a median survival of 3 to 9 months when using traditional chemotherapeutic agents. However, several recent publications have demonstrated a significant improvement in quality of life among patients with recurrent GBM using the angiogenesis inhibitor, bevacizumab, though no difference in overal survival has been demonstrated.

Question 25.14 The answer is C.

For patients with GBM, standard radiation therapy is 60 Gy in 30 or 33 fractions. The Medical Research Council study reported a survival advantage in patients receiving a 60

Gy dose versus a 45 Gy dose (12 months vs. 9 months, p = .007). In an RTOG/ECOG

study, patients receiving 60 Gy fol owed by a 10 Gy boost did not have a survival advantage over patients receiving the standard 60 Gy dose. Hyperfractionated and accelerated regimens have likewise not shown survival advantage. In the phase I/II RTOG 8302 study, hyperfractionated doses with 64.8 Gy, 72 Gy, 76.8 Gy, and 81.6

Gy in 1.2 Gy twice daily fractions did not show a survival benefit between the different treatment arms. This study included treatment arms with accelerated hyperfractionated regimens of 48 Gy and 54.4 Gy in 1.6 Gy twice daily fractions, which also did not lead to survival benefit. Adjuvant temozolomide with radiation was shown to improve overal survival compared with radiation alone in a randomized, phase III trial for patients with GBM (14.6 months vs. 12.1 months).

Question 25.15 The answer is A.

Surgical resection is the primary treatment of patients with ependymoma. There are no definitive recommendations for the addition of radiotherapy to the treatment.

However, tumors in the posterior fossa cannot always be ful y resected, and patients undergoing resection alone have a very high incidence of local recurrence. Therefore, adjuvant focal radiotherapy to the site of the tumor may be added in the treatment of patients with ependymoma. In one study, patients receiving focal radiotherapy of more than 45 Gy to the tumor bed had 5- and 10-year survival rates of 67% and 57%, respectively. The addition of focal radiotherapy has been shown to improve 10-year survival from 67% in patients treated with gross total resection (GTR) alone to 83% in patients treated with GTR and radiotherapy. While MGMT gene methylation is associated with better survival in patients with GBM, there has been no reported association between MGMT gene methylation and survival in ependymomas. Likewise, 311

there is no evidence to date supporting the use of chemotherapy for treating ependymoma in general.

Question 25.16 The answer is A.

Surgical resection is the mainstay for the treatment of meningioma, and it is classified into Simpson grades based on the extent of surgery. Grade I is gross total resection (GTR) of the tumor, with removal of the dural attachments and hyperostotic bone. The relapse rate after this procedure is 9%. Grade II does not include removal of hyperostotic bone (relapse rate 19%). Grade III is GTR of the tumor alone (relapse rate 29%). Grade IV is partial resection (relapse rate 44%). Grade V refers to biopsy alone without resection. Adjuvant radiotherapy is not recommended for patients with low-grade meningioma who undergo Simpson grade I to II, and sometimes grade III, resection. The patient in this case has undergone grade II resection for a low-grade meningioma and therefore does not require further radiotherapy. For patients with resected anaplastic and malignant meningioma, adjuvant radiotherapy is recommended. Radiosurgery can be used in patients with unresectable disease, but there is no evidence to support the use of chemotherapy (Tamoxifen, mifepristone, and hydroxyurea) in patients with meningioma.

Question 25.17 The answer is A.

High-dose methotrexate is the treatment of choice for immunocompetent patients with primary CNS lymphoma. The 5-year survival with high-dose methotrexate treatment is approximately 20%. Whereas whole brain radiation therapy is effective, it is associated with serious neurotoxicity and 5-year survival is only 5%. Whole brain radiation is used upfront in patients who are not candidates for methotrexate, due to poor renal function and poor PS. A phase III, noninferiority trial comparing high-dose methotrexate with or without whole brain radiation therapy showed no significant overal survival benefit to combining whole brain radiation with high-dose methotrexate. R-CHOP is not an appropriate choice for frontline therapy, though it is used to treat many types of non-Hodgkin lymphoma.

Question 25.18 The answer is D.

Long-term fol ow-up data from the phase III EORTC-NCIC trial showed improved survival in al patients treated with combined temozolomide and radiation, fol owed by temozolomide compared to patients treated with radiation alone.

Question 25.19 The answer is A.

Some degree of sexual dysfunction occurs in approximately 90% of al adult patients presenting with craniopharyngioma. Visual dysfunction occurs in 40% to 70% of these patients. Hypothyroidism occurs in 40% of patients and diabetes insipidus occurs in 10% to 20% of patients. However, the incidence of diabetes insipidus after surgical 312

resection increases substantial y. In one study, it increased from 16.1% in the preoperative setting to 59.4% after surgery.

Question 25.20 The answer is C.

Several retrospective case series have shown that incomplete tumor resection, high tumor grade, supratentorial location, and poor performance status to be associated with poor outcomes in patients with intracranial ependymoma. However, improvement in overal survival with adjuvant radiation is limited to patients with incomplete tumor resection.

Question 25.21 The answer is A.

In a retrospective analysis of tumor tissue samples from patients with oligodendrogliomas who received treatment on the EORTC study 26951, both IDH1 and IDH2 mutations were found to be a prognostic marker for overal survival.

Question 25.22 The answer is D.

Gene expression profiling has classified GBM into four clusters—proneural, neural, classical, and mesenchymal. While there is some overlap among the groups, the mesenchymal group is most often associated with loss of NF1 expression. In contrast, the proneural group is often associated with IDH1 mutation, PDGFRA amplification, and G-CIMP. While the neural group has a high frequency of EGFR amplification without polysomy of chromosome 7, classical GBMs are general y found to have amplification of the entire chromosome 7 as wel as loss of chromosome 10, and homozygous deletion of CDKN2A.

Question 25.23 The answer is C.

A large gene sequencing study by The Cancer Genome Atlas (TCGA) found that the three most commonly dysregulated core pathways in primary GBMs were p53 (85.3%), Rb (78.9%), and PI3K (67.3%). Increased expression of the WNT (10%) and SHH

(30%) pathways have been observed in pediatric medul oblastoma, while activation of the MAPK pathway frequently drives tumorigenesis of pilocytic astrocytomas. In pediatric meningiomas, loss of NF2/22q occurs in 50% of sporadic meningiomas (up to 75% of WHO grade II), along with mutations in the TRAF7 (25%) and SHH (3%) pathways.

Question 25.24 The answer is B.

ATRX is often comutated with p53 and IDH1 in grade II astrocytomas whereas grade II oligodendrogliomas frequently possess somatic mutations in CIC (chr 19) and FUBP1

(chr 1) that often co-occur with codeletion of chromosomes 1p/19q. Mutations in the TERT promoter is often found in oligodendrogliomas as wel and are mutual y exclusive 313

with ATRX mutations.

Corresponding chapters in Cancer: Principles & Practice of Oncology, Tenth Edition: 96

(Molecular Biology of Central Nervous System Tumors) and 97 (Neoplasms of the Central Nervous System).

314





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 26.1 Which of the fol owing inherited syndromes represent a predisposing factor for the development of soft tissue sarcoma?

A. Retinoblastoma

B. Li–Fraumeni syndrome

C. Neurofibromatosis type I

D. Al of the above

Question 26.2 Which of the fol owing are TRUE about radiation-induced sarcomas?

A. Cancer history usual y includes breast cancer, lymphoma, and cervical cancer.

B. They usual y occur 10 to 30 years after radiation exposure.

C. Osteogenic sarcoma, undifferentiated pleomorphic sarcoma (UPS), angiosarcoma, and lymphangiosarcoma are the usual histologic subtypes.

D. Al of the Above.

Question 26.3 Which clonal cytogenetic abnormality is associated with the CORRECT

sarcoma subtype?

A. Ewing sarcoma and t(11;22) (q24;q12)

B. Synovial sarcoma and t(12;16) (q13;p11)

C. Myxoid liposarcoma and t(X;18) (p11;q11)

D. Alveolar rhabdomyosarcoma and t(17;22) (q22;q13) Question 26.4. A 20-year-old man presents with right knee pain. X-ray reveals a “sun-burst” appearance in the distal femur. Biopsy reveals high-grade osteosarcoma. No distant metastases are identified. Which of the fol owing is the most appropriate treatment?

A. Limb-sparing resection

B. Limb-sparing resection and adjuvant chemotherapy

C. Definitive radiation

D. Neoadjuvant chemotherapy, limb-sparing resection, and adjuvant chemotherapy Question 26.5 In addition to site, which of the fol owing variables is used to estimate the risk of sarcoma-specific death for a given patient?

315

A. Tumor grade and histology

B. Tumor size and depth

C. Age

D. Al of the above

Question 26.6 Which of the fol owing is TRUE regarding the staging of soft tissue sarcomas?

A. Staging involves a four grade system.

B. Stage IV includes N1 disease.

C. High-grade tumors can be classified as stage I depending on the size of the tumor.

D. Histologic grade, size, depth, and presence or absence of nodal and distant metastases are variables used to determine tumor stage.

Question 26.7 A 52-year-old man underwent resection of a 3-cm mass from the lateral left thigh. Pathology revealed a high-grade leiomyosarcoma, and the lateral surgical margin was positive. The most appropriate next step in the treatment of this patient’s cancer would be:

A. Radiation.

B. Adjuvant chemotherapy.

C. Reresection.

D. Observation.

Question 26.8 A 68-year-old woman presented with a purplish nodular lesion in the occipital scalp. Resection revealed an angiosarcoma measuring 3 cm. Surgical margins were negative. What is the most appropriate next step in the treatment of this patient’s cancer?

A. Radiologic imaging to look for nodal metastases and referral for adjuvant radiation B. Monitoring

C. Adjuvant chemotherapy with an anthracycline

D. Adjuvant chemotherapy with paclitaxel

Question 26.9 A 65-year-old woman presented with abdominal pain and iron-de ciency anemia. Workup revealed a gastric mass and multiple large intra-abdominal masses and liver hypodensities. Biopsy of the gastric mass revealed a spindle cel neoplasm thought to be a leiomyosarcoma. After three cycles of doxorubicin and ifosfamide, imaging showed disease progression. The appropriate next step in the management of this patient’s cancer would be: A. Docetaxel and gemcitabine.

B. Dacarbazine.

C. Request the pathologist to perform a CD117 (c-Kit) stain.

D. Pal iative radiation.

Question 26.10 A 55-year-old man presented with a 10-cm mass in the medial left thigh.

316

Biopsy revealed a high-grade liposarcoma. Imaging revealed no evidence of distant metastases. The most appropriate treatment of this patient’s cancer would be: A. Definitive radiation.

B. Definitive radiation and concurrent doxorubicin.

C. Limb-sparing resection fol owed by adjuvant radiation.

D. Preoperative chemotherapy fol owed by resection.

Question 26.11 A 52-year-old man with metastatic unresectable gastrointestinal stromal tumor (GIST) was treated with imatinib (400 mg/d). Imaging showed initial disease response; however, the disease progressed after 28 months on therapy. The most appropriate treatment would be:

A. Erlotinib.

B. Sunitinib.

C. Doxorubicin.

D. Imatinib 800 mg/d.

Question 26.12 Which of the fol owing factors are independent predictors of poorer disease-specific survival in patients with nonmetastatic soft tissue sarcoma?

A. Large tumor size (>10 cm)

B. High-grade histology

C. Older age (>60 years)

D. Al of the above

Question 26.13 A 48-year-old woman underwent complete resection of a 9-cm high-grade leiomyosarcoma arising in the lower extremity. Postoperative adjuvant radiation was administered. Two years later, a chest computed tomography (CT) scan revealed a new single 3-cm, round, noncalci ed pulmonary nodule. What is the most appropriate next treatment?

A. Complete resection of the lung nodule

B. Radiation

C. Ifosfamide and doxorubicin

D. Docetaxel and gemcitabine

Question 26.14 Which of the fol owing is TRUE about patients with metastatic or local y recurrent soft tissue sarcoma?

A. Median survival is 12 months, although 20% to 25% of patients are alive 2 years after diagnosis.

B. Complete resection of oligometastases to the lung never results in long-term survival.

C. Radiation is the preferred treatment of a local y recurrent sarcoma.

D. Combination chemotherapy improves overal survival compared with single-agent 317

chemotherapy.

Question 26.15 Which of the fol owing is TRUE about chemotherapy treatment of metastatic soft tissue sarcoma?

A. Escalating doses of doxorubicin or ifosfamide do not improve tumor response rates over standard doses of these agents.

B. Leiomyosarcoma is uniquely sensitive to ifosfamide, whereas synovial sarcoma is not.

C. Paclitaxel shows broad-spectrum activity.

D. Dacarbazine has modest activity.

Question 26.16 A 30-year-old man presents with a permeative bone tumor in the distal femur. Open biopsy reveals a MFH. Radiologic imaging does not nd distant metastases.

What is the most appropriate treatment?

A. Limb-sparing resection with wide margins

B. Definitive radiation

C. Chemotherapy

D. Preoperative chemotherapy, limb-sparing resection, and adjuvant chemotherapy Question 26.17 Which of the fol owing is TRUE regarding osteosarcoma?

A. Approximately 20% of patients with localized high-grade disease treated with resection and chemotherapy remain disease free 5 years later.

B. Approximately 60% to 80% of patients with localized high-grade disease treated with resection and chemotherapy remain disease free 5 years later.

C. Parosteal (low-grade cortical) osteosarcoma is best treated with resection and chemotherapy.

D. Periosteal osteosarcoma is best treated with resection.

Question 26.18 A 45-year-old man presents with a left-sided pelvic pain. CT reveals a 5

cm mass with appearance of chondroid matrix, arising from the left side of the pelvic girdle.

Bone biopsy reveals chondrosarcoma. Which of the fol owing is TRUE regarding chondrosarcomas?

A. Most are low-grade tumors.

B. Most are treated with resection and radiation therapy.

C. Children have a better prognosis than adults.

D. Adjuvant chemotherapy has no role in the management of nonmetastatic disease.

Question 26.19 A 22-year-old woman presents with a giant cel tumor (GCT) of the distal femur. Appropriate treatment would be:

A. Curettage and debridement.

B. Amputation.

318

C. Radiation.

D. Preoperative chemotherapy, resection, and adjuvant chemotherapy.

Question 26.20 A 16-year-old female patient presents with a painful rapidly growing scapular mass. Core needle biopsy reveals a Ewing sarcoma. Staging evaluation shows no evidence of metastatic disease. The most appropriate therapy is: A. Resection.

B. Preoperative chemotherapy (with vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide, IE), resection, and adjuvant chemotherapy.

C. Resection and radiation.

D. Preoperative chemotherapy (with vincristine, doxorubicin, and cyclophosphamide), resection, and adjuvant chemotherapy.

Question 26.21 A 25-year-old woman presents with a painless right thigh mass, which has been slowly growing over a span of 8 years. Core needle biopsy reveals alveolar soft part sarcoma. What cytogenetic abnormality would you expect to see in this tumor?

A. t(11;22) (q24;q12)

B. t(12;16) (q13;p11)

C. der (17) t(X;17) (p11;q25)

D. t(X;18) (p11;q11)

Question 26.22 Which of the fol owing targeted agents is used to treat alveolar soft part tissue sarcoma?

A. Imatinib

B. Sunitinib

C. Dasatinib

D. Nilotinib

Question 26.23 Which of the fol owing sites of soft tissue sarcomas carries the best prognosis?

A. Head and neck

B. Extremity

C. Visceral

D. Retroperitoneal

Question 26.24 A 60-year-old woman with advanced soft tissue sarcoma is on third-line therapy with pazopanib and develops jaundice. Which of the fol owing should be done next?

A. Abdominal imaging

319

B. Laboratory testing

C. Dose reduction

D. Immediately discontinue pazopanib

Question 26.25 Which of the fol owing criteria are predictive of the behavior of GIST

tumors and are useful for strati cation of risk of recurrence and metastasis? (Select two correct responses)

A. Mitotic rate

B. Nuclear atypia

C. Tumor site

D. Mucosal invasion

Question 26.26 What is the mechanism of action of mesna?

A. Binds and detoxifies ifosfamide metabolites in the kidney and bladder B. Coats the bladder

C. Inhibition of monoamine oxidase (reducing further chloroacetaldehyde formation) D. Rescuing impaired hepatic metabolic pathways by acting as an electron acceptor 320

Question 26.1 The answer is D.

Patients with Li–Fraumeni syndrome have an increased risk for developing soft tissue sarcomas. Neurofibromatosis type I increases the risk for the development of malignant peripheral nerve sheath tumors. Patients with retinoblastoma also have an increased risk for developing soft tissue and bone sarcomas.

Question 26.2 The answer is D.

Radiation-induced sarcomas usual y occur 10 to 30 years after exposure to radiation.

The most common cancers for which radiation was administered include breast and cervical cancer, and lymphomas. Most radiation-induced sarcomas are osteogenic sarcoma or UPS, and the prognosis is poor.

Question 26.3 The answer is A.

Ewing sarcoma is associated with five known cytogenetic abnormalities, including t(11;22) (q24;q12). Synovial sarcoma is associated with t(X;18) (p11;q11), whereas myxoid liposarcoma is associated with t(12;16) (q13;p11). Alveolar rhabdomyosarcoma is associated with t(2;13) (q35;q14).

Question 26.4 The answer is D.

The current standard of care for the treatment of osteosarcomas is neoadjuvant chemotherapy, fol owed by limb-sparing resection and adjuvant chemotherapy. The percentage of tumor cel necrosis on pathology from the resection gives an idea of prognosis and helps determine the adjuvant chemotherapy regimen. Surgery alone, or definitive radiation, offers lower chances of success.

Question 26.5 The answer is D.

The Memorial Sloan Kettering Cancer Center (MSKCC) nomogram for sarcoma-specific mortality incorporates the fol owing variables: age, tumor size, depth, histology, grade of tumor, and site. Zero points are assigned for the low-risk features (age 16, size ≤5 cm, superficial depth, fibrosarcoma histology, and low-grade and upper-extremity site). A sum of the points assigned for each variable helps predict the risk of sarcoma-specific death.

Question 26.6 The answer is B.

N1 disease is considered Stage III disease. Stage I disease includes only low-grade tumors. High-grade tumors are never stage I. Staging of soft tissue sarcoma requires knowledge of histologic grade, size, depth, and presence of metastatic disease and is based on a three-grade system.

321

Question 26.7 The answer is C.

Positive surgical margin predicts a higher risk of local recurrence. Reresection in an attempt to achieve negative surgical margins would be the next most appropriate step in the management of this patient. If negative surgical margins are achieved after reresection, adjuvant radiation would not be required. Adjuvant chemotherapy would have no clear benefit in this case.

Question 26.8 The answer is A.

Soft tissue sarcoma of the head and neck is associated with a poor prognosis.

Angiosarcoma has a higher risk of nodal metastases and local recurrence after resection alone. Adjuvant radiation reduces the risk of local and regional disease recurrence.

Although angiosarcomas tend to be sensitive to anthracyclines and taxanes, there would be no known benefit of adjuvant chemotherapy in this case.

Question 26.9 The answer is C.

Intra-abdominal leiomyosarcomas and GISTs have similar characteristics by light microscopy; however, GISTs stain positive for the CD117 (c-Kit) protein, whereas leiomyosarcomas usual y do not. Leiomyosarcomas frequently respond to chemotherapy, whereas GISTs do not. However, GISTs are uniquely responsive to c-Kit inhibitors. In this case, a c-Kit immunostain should be requested to determine whether the sarcoma is a GIST and not a leiomyosarcoma. Because this patient has metastatic disease, systemic therapy would be favored over pal iative radiation.

Question 26.10 The answer is C.

Resection of the primary tumor with intent to achieve negative surgical margins fol owed by adjuvant radiation would be the most appropriate treatment of a large high-grade extremity liposarcoma. Definitive radiation with or without concurrent chemotherapy would be less effective treatment. Preoperative chemotherapy may be used when the tumor is marginal y resectable, but its role in this situation is controversial.

Question 26.11 The answer is D.

Studies have demonstrated that approximately one-third of patients with GIST resistant to imatinib 400 mg/d wil benefit with increasing the dose of imatinib of 800 mg/d.

Should that step fail, sunitinib would be the next most appropriate therapy. GIST is general y resistant to chemotherapy drugs, such as doxorubicin. Epidermal growth factor receptor inhibitors, such as erlotinib, would not be expected to benefit patients with GIST.

Question 26.12 The answer is D.

322

Independent predictors of prognosis of patients with nonmetastatic soft tissue sarcoma include age, histologic subtype, histologic grade, tumor site, and tumor size. Factors predictive of better disease-specific survival include younger age, selected histologic subtypes (fibrosarcoma), low histologic grade, smal er (<5 cm) tumor size, and extremity location. Nomograms are available that accurately predict the prognosis of patients with nonmetastatic soft tissue sarcoma treated with surgery with or without adjuvant radiation.

Question 26.13 The answer is A.

In this patient, the most likely cause of the new lung nodule is metastases of the leiomyosarcoma. Retrospective series have observed that 20% to 30% of such patients who undergo complete resection of the lung metastases were alive 5 years later. Factors that predict for a lower success rate with resection in such patients include more than four lung nodules, bilateral lung nodules, and a disease-free interval of less than 12

months. Chemotherapy and radiation provide only pal iative intent in this case.

Question 26.14 The answer is A.

For local y recurrent sarcoma without distant metastases, reresection is the preferred treatment. For patients with metastatic sarcoma, median survival is 1 year; however, a subset of these patients live for more than 2 years. It is important to consider complete resection of oligometastases to the lung because approximately 25% of those patients wil be alive 5 years later. Nearly al randomized trials have shown no overal survival benefit with combination (vs. single agent) chemotherapy, although tumor response rates were consistently higher. A single, recent randomized trial demonstrated a modest survival benefit with the addition of docetaxel to gemcitabine in patients with metastatic sarcoma.

Question 26.15 The answer is D.

Several studies have shown higher tumor response rates (but not improved survival) with larger doses of doxorubicin and ifosfamide; however, this does result in greater toxicity. Ifosfamide is an active agent in synovial sarcoma but has little activity in leiomyosarcoma. Paclitaxel appears to only be effective in the treatment of angiosarcoma and Kaposi sarcoma. Perhaps the first drug identified to be active in adult soft tissue sarcoma, dacarbazine resulted in tumor response rates of 10% to 30%.

Question 26.16 The answer is D.

In contrast with UPS of soft tissue, which is primarily treated with resection, MFH of bone is treated like high-grade osteosarcoma with preoperative chemotherapy, limb-sparing resection, and adjuvant chemotherapy. Outcomes of patients with MFH of bone and with osteosarcoma are similar when treated this way. Limb-sparing resection alone or definitive radiation would offer lower chances of success. Chemotherapy alone would 323

provide pal iation, but the chance of cure is unclear.

Question 26.17 The answer is B.

Parosteal osteosarcoma is usual y a low-grade tumor that involves the bone cortex and is associated with a better prognosis than classic osteosarcoma. Resection is the preferred treatment, and there is no clear role for chemotherapy. In contrast, periosteal osteosarcoma is an aggressive, high-grade cortical sarcoma that is best treated like classic osteosarcoma with resection and chemotherapy. For classic high-grade osteosarcoma, resection alone is curative in 20%, but the addition of chemotherapy to resection improves cure rates to 60% to 80%.

Question 26.18 The answer is A.

The preferred therapy for chondrosarcoma is resection. Although chondrosarcomas as a group are known to be resistant to chemotherapy, mesenchymal and dedifferentiated chondrosarcomas have a high metastatic potential and appears to benefit from adjuvant chemotherapy. Most chondrosarcomas are low grade and usual y occur in patients aged more than 40 years. Children have a worse prognosis than adults.

Question 26.19 The answer is A.

GCT of bone is a tumor with a high risk for local recurrence but a low risk for distal metastases. Appropriate treatment is resection, preferably by curettage and debridement. Amputation is reserved for massive local recurrences. Radiation is reserved for lesions of the spine that can lead to cord compression. There is no benefit of preoperative or adjuvant chemotherapy for GCT of bone. There is a role for denosumab for patients with unresectable GCT.

Question 26.20 The answer is B.

A randomized trial of patients with Ewing sarcoma treated with either vincristine, doxorubicin, and cyclophosphamide (VAC) alone or alternating with IE given as preoperative and adjuvant chemotherapy clearly showed an overal survival and progression-free survival advantage with the alternating regimen of VAC and IE versus VAC alone in patients with nonmetastatic (but not in patients with metastatic) disease.

Resection alone or with radiation would be significantly less effective than when used in combination with chemotherapy.

Question 26.21 The answer is C.

Alveolar soft part sarcoma is associated with der (17) t(X;17) (p11;q25). Ewing sarcoma is associated with five known cytogenetic abnormalities, including t(11;22) (q24;q12).

Synovial sarcoma is associated with t(X;18) (p11;q11), whereas myxoid liposarcoma is associated with t(12;16) (q13;p11).

324

Question 26.22 The answer is B.

Sunitinib is an oral smal molecule, multitargeted receptor tyrosine kinase inhibitor that is an active agent in the treatment of alveolar soft part sarcoma. Imatinib, dasatinib, and nilotinib are tyrosine kinase inhibitors that have activity against GIST. Sunitinib also is used to treat GIST.

Question 26.23 The answer is B.

Extremity soft tissue sarcomas have the best prognosis, fol owed by visceral and retroperitoneal. Head and neck soft tissue sarcomas carry the worst prognosis.

Question 26.24 The answer is D.

Pazobanib has a black box warning for severe and fatal hepatotoxicity. This can occur at any time during treatment. CMPs should be fol owed on regular bases (LFTS should be checked on weeks 3, 5, 7, and 9, then at months 3 and 4 and as clinical y indicated.

Patients should be counseled to immediately contact their physician and stop the medication should they notice jaundice.

Question 26.25 The answers are A and D.

Tumor size, mitotic rate, and tumor site (jejunal and ileal sites having more malignant behavior) are criteria that can be used to predict the behavior of GIST. Other histopathologic criteria including cel ularity, nuclear atypia, mucosal invasion, and ulceration have not been shown to correlate wel with prognosis.

Question 26.26 The answer is A.

Mesna functions to reduce the risk of hemorrhagic cystitis by binds and detoxifies ifosfamide metabolites in the kidney and bladder. Two proposed mechanisms of action for methylene blue treatment of ifosfamide induced neurotoxicity include inhibition of monoamine oxidase (reducing further chloroacetaldehyde formation) and rescuing impaired hepatic metabolic pathways by acting as an electron acceptor.

Corresponding chapters in Cancer: Principles & Practice of Oncology, Tenth Edition: 89

(Molecular Biology of Sarcomas), 90 (Soft Tissue Sarcoma), and 91 (Sarcomas of Bone).

325





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 27.1 What is the most prevalent signi cantly mutated gene in cutaneous melanoma?

A. BRAF V600K

B. BRAF V600R

C. BRAF V600E

D. NRAS Q61R

E. NRAS Q61K

Question 27.2 Which of the fol owing is included in referral criteria for hereditary melanoma genetic counseling?

A. Parent with multiple skin cancers.

B. Pancreatic cancer and melanoma on the same side of the family.

C. Three or more siblings with actinic keratosis.

D. Two relatives on the same side of the family with melanoma and prostate cancer.

Question 27.3 Which of the fol owing genes act as founding mutations implicated in the early transformation of cutaneous melanoma (Select two correct responses)?

A. NRAS

B. BRAF

C. TP53

D. MEK1

Question 27.4 Which of the fol owing statements best explains the increased incidence of melanoma over the past 25 years?

A. Decreasing use of sunscreen among middle age persons.

B. High penetrance rate of CDKN2A mutations.

C. Increasing exposure to ultraviolet light.

D. Increasing use of birth control pil s.

Question 27.5 What is the most common site for primary skin melanoma in females?

326

A. Back

B. Face

C. Lower extremities

D. Scalp

Question 27.6 Which one of the fol owing features of primary melanoma is the most important prognostic factor?

A. Clark level

B. Breslow thickness

C. Mitotic rate

D. Anatomical location

Question 27.7 Basal cel nevus syndrome has been associated with mutations in which one of the fol owing genes?

A. Patched gene 1

B. Sonic hedgehog

C. MEK1

D. NF1

Question 27.8 A 48-year-old woman was recently diagnosed with a nonulcerated 1.6-mm depth primary super cial-spreading melanoma excised from her back. The melanoma is nonmitogenic and the margins are negative. She is referred to you for further evaluation and no adenopathy is noted on examination. Which of the fol owing is the most appropriate next step in clinical management?

A. PET-CT to complete the staging evaluation.

B. Referral back to the Dermatologist for annual skin checks.

C. Wide excision and sentinel lymph node mapping.

D. Wide excision fol owed by interferon for 1 year.

Question 27.9 A 55-year-old woman in excel ent health presents to the Emergency Department with a 7-day history of headache and ataxia. She denies any recent il ness and states that acetaminophen is no longer relieving her symptoms. You evaluate the patient and order a head CT examination, which reveals a 3-cm solitary lesion with surrounding vasogenic edema, present in the posterior fossa. The patient denies any past history of malignancy; however, your physical examination detects a cutaneous nonpigmented lesion on her ankle. You order dexamethasone 10 mg intravenously and the patient’s symptoms improve after 90 minutes. She wants to go home. You suspect a solitary brain metastasis.

What is the next step in management?

A. Discharge the patient to home and make a referral to the patient’s primary care physician.

B. Discharge the patient to home and make a referral to the radiation and dermatology 327

clinics.

C. Admit the patient and request a brain MRI fol owed by a neurosurgical consultation.

D. Admit the patient and request a pal iative care consultation.

Question 27.10 A 29-year-old man is recently diagnosed with primary cutaneous melanoma. The pathology report con rms a T3b N2b M0 primary nodular melanoma excised from the left shoulder. The primary lesion was ulcerated and mitogenic (4/mm2).

The patient is in excel ent health and has no signi cant past medical history. The patient is referred to you for adjuvant treatment. What is the final stage of this patient’s melanoma?

A. Stage IIIA

B. Stage IIIB

C. Stage IIIC

D. Stage IV, M1A

Question 27.11 A 40-year-old woman with a history of ulcerative colitis, mitral valve prolapse, eczema, and stage 1 cutaneous melanoma presents with right inguinal adenopathy. Physical examination con rms a 4-cm node and core biopsy con rms malignant melanoma. BRAF mutational analysis is requested and BRAF V600E mutation is detected. Brain MRI is unremarkable; however, CT examination reveals numerous (>10) bilateral pulmonary metastases with the largest lesion measuring 1.2 cm in the left upper lobe. No other sites of distant metastases are evident and you conclude that this patient has stage IV, M1b disease. The patient does not want to participate in a clinical trial and wants to begin treatment as soon as possible. What is the best initial treatment for this individual?

A. Ipilimumab

B. BRAF inhibitor

C. MEK inhibitor

D. BRAF and MEK inhibitor combination

Question 27.12 A 73-year-old man with a past history of stage IIC nodular melanoma excised from his back 3 years ago presents to your o ce with lower back pain and fatigue for the past 2 weeks. Your physical examination is unrevealing. However, several laboratories are elevated, including serum alkaline phosphatase, and serum LDH (two times upper limit of normal). PET-CT examination the fol owing day documents metastatic disease involving lungs, liver, peritoneum, and multiple osseous areas, including the lumbar spine. What is the most appropriate next step in management?

A. Request a brain MRI and a biopsy of a lung lesion.

B. Request a pal iative care consultation.

C. Request a second opinion review of the primary cutaneous lesion excised 3 years ago.

D. Begin systemic therapy as soon as possible.

Question 27.13 A 36-year-old woman with a past history of cutaneous melanoma (stage 328

IIB) has been fol owed by her dermatologist. She has active rheumatoid arthritis and is receiving methotrexate under the care of a local rheumatologist. She recently presented to the emergency department with complaints of headaches and was found to have a 3.5-cm solitary right parietal metastasis. The metastasis was surgical y resected and con rmed as metastatic melanoma, BRAF V600E mutated. A postoperative body PET-CT examination was negative for additional disease and the hospital physicians told her that she has no additional evidence of disease. She is referred to you for treatment recommendations.

What is the next best step in the management of her care?

A. Request radiation oncology consultation for stereotactic radiosurgery.

B. Request radiation oncology consultation for whole brain radiation.

C. Administer adjuvant chemotherapy.

D. Administer adjuvant interferon.

Question 27.14 A 27-year-old woman has metastatic melanoma, BRAF wild type (no mutation), stage IV, M1B. You recommended initial systemic treatment with ipilimumab and she completed four doses with no side e ect or toxicity. Two weeks after the four dose a restaging CT examination is performed which reveals the appearance of a new 6-mm left upper lobe lesion as wel as an increase of a baseline right lower lung lesion from 17 mm to 23 mm. The other lung metastases remain unchanged. You see the patient in your o ce the fol owing day. She feels ne and has no complaints. Her laboratories are al within normal limits. However, the patient is anxious after you discuss the CT imaging results with her. She and her husband have many questions regarding other treatment options. What is your recommendation to this patient?

A. Despite the fact that her tumor is BRAF wild type, there is some evidence that treatment with a MEK inhibitor would be beneficial.

B. You recommend a repeat CT scan in 4 weeks based upon reports that 10% to 15% of patients treated with ipilimumab can have evidence of progression prior to documented response.

C. You recommend retreatment with four additional doses of ipilimumab.

D. You recommend immediate surgical consultation.

Question 27.15 A 66-year-old man with metastatic melanoma is receiving treatment with combination ipilimumab and nivolumab on a clinical trial. Fourteen days after the second dose, he cal s your o ce to tel you that he has been having watery loose stools up to ten times a day for the past week. However, you are out of town and your nurse practitioner cal ed in sick for the day. What is your recommendation to this patient?

A. Cal your primary physician immediately.

B. Keep your scheduled appointment next week for the third dose but cal sooner if the diarrhea gets worse.

C. Take loperamide as directed and keep hydrated.

D. Go to the local emergency department immediately for evaluation.

329

Question 27.16 A 70-year-old man from out of town presents to the emergency department with complaints of profound fatigue and headaches for the past 3 days. His vital signs are normal except for a blood pressure of 90/50. He denies fevers and diarrhea.

His medical history is signi cant for gout, type 2 diabetes, and metastatic melanoma. He is receiving treatment with ipilimumab along with an experimental immunotherapy drug but he can’t remember the name of the investigational drug. He has received four cycles of treatment and is due for a restaging evaluation when he returns home in a week.

Unfortunately, it’s a holiday weekend and no medical records are available. You request a CBC, CMP, and EKG along with a head CT and CT examination of the chest, abdomen, and pelvis. The chest CT con rms the presence of innumerable (>20) pulmonary metastases but none greater than 2 cm. The head CT is unremarkable. You are perplexed and unsure of the cause of his symptoms. You decide to order additional blood work. What is the most appropriate test to order?

A. Blood cultures

B. Serum LDH

C. Thyroid function tests

D. C-reactive protein

E. Discharge to home with instructions to cal his oncologist Question 27.17 A 75-year-old woman with a past history of recurrent basal cel carcinoma of the skin was recently found to have bilateral lung lesions. CT examination con rms 10

pulmonary lesions as wel as several liver lesions. The 2.5-cm right upper lobe lesion is biopsied and confirmed as basal cel carcinoma. Her primary care physician tel s her that she wil need chemotherapy. She arrives in your o ce along with several additional family members, including her daughter who is a physician. They are distraught over the recent diagnosis and have solicited the opinions of various physicians. They understand her condition is incurable but desire the best treatment. What is your treatment recommendation?

A. Platinum-based chemotherapy for six cycles

B. Vismodegib

C. Trametinib

D. Immediate radiation oncology consultation

E. Immediate surgical consultation

330

Question 27.1 Answer is C.

BRAF is the most common mutation in patients with melanoma, occurring in 40% to 50% of cases. Among patients with BRAF mutations, the vast majority has the V600E

subtype. NRAS mutations are present in 15% to 20% of cases.

Question 27.2 Answer is B.

Approximately 5% of melanomas occur in high-risk families. The melanoma suppressor gene that has the highest frequency and penetrance is a germline mutation in CDKN2A, which is present in approximately 25% of melanoma-prone families and also associated with pancreatic cancer.

Question 27.3 Answers are A and B.

Both NRAS and BRAF are founding mutations frequently present in dysplastic nevi and early thin-cutaneous melanoma.

Question 27.4 Answer is C.

Ultraviolet light is considered the primary risk factor for cutaneous melanoma. Many social factors influence UV light exposure including increased time spent outside for recreational activities, less clothing, and environmental changes.

Question 27.5 Answer is C.

The most common anatomical sites for melanoma are lower extremities in women and trunk and head/neck for men.

Question 27.6 Answer is B.

The Breslow thickness remains the most important pathologic variable. The presence or absence of ulceration is also an important variable. Clark level is no longer recommended as a staging criterion.

Question 27.7 Answer is A.

Approximately 75% of BCC harbor somatic mutations in the PTCH1 gene.

Question 27.8 Answer is C.

The current guidelines are clear and recommend wide excision with 1 to 2 cm margins with sentinel lymphatic mapping for cutaneous primary melanoma >1 mm depth.

Question 27.9 Answer is C.

331

Patients with a suspected solitary intracranial metastasis (from an unknown primary, including suspected melanoma) should have a contrast-enhanced brain MRI along with a formal neurosurgical consultation to determine if the lesion is resectable. This wil aid in a tissue diagnosis, and provide symptomatic relief.

Question 27.10 Answer is C.

This patient has stage IIIC according to the current seventh edition AJCC staging criteria.

Question 27.11 Answer is D.

Ulcerative colitis is a relative contraindication to the use of ipilimumab and the risks of clinical y significant/severe autoimmune colitis must be careful y weighed against the potential benefits in this situation. Most experts would select BRAF and MEK inhibitor combination based on the superiority of the combination (improved PFS and OS) over either single agent inhibitor.

Question 27.12 Answer is A.

The patient needs a tissue biopsy for a suspected malignancy, including melanoma. The tumor biopsy wil also al ow for BRAF mutational analysis. A brain MRI examination wil complete the staging evaluation regardless of the final pathologic diagnosis.

Question 27.13 Answer is A.

There is no role for adjuvant cytotoxic chemotherapy or interferon alpha-2b in this setting. The role of adjuvant ipilimumab (and BRAF inhibitors) is currently under evaluation in clinical trials. The best answer is adjuvant stereotactic radiosurgery to reduce the risk of a recurrence in/near the resection cavity.

Question 27.14 Answer is B.

Lessons from the initial ipilimumab clinical trials in metastatic melanoma suggest that about 10% of treated patients develop an unconventional response (such as a response after an increase in total tumor burden), which led to the development of the immune-related response criteria that have been incorporated into immunotherapy protocols in the past several years. Repeat imaging in such situations in 4 to 6 weeks is recommended.

Question 27.15 Answer is D.

The patient has grade III autoimmune colitis due to the checkpoint blockade until proven otherwise. Clinical y this is considered an urgent situation that must be recognized and treated in a timely manner. Delaying treatment poses the threat of worsening colitis and a risk of bowel perforation and death.

332

Question 27.16 Answer is C.

This patient has ipilimumab-related endocrinopathy. Thyroid function tests, initial y with TSH, should be monitored at regular intervals and prior to each dose of ipilimumab.

If endocrinopathy is suspected, additional laboratories such as serum cortisol, ACTH, free T4, total T4, LH, FSH, prolactin should be drawn and brain MRI with pituitary cuts is suggested.

Question 27.17 Answer is B.

Vismodegib is an approved treatment option for patients with local y advanced or metastatic BCC.

Corresponding chapters in Cancer: Principles & Practice of Oncology, Tenth Edition: 92

(Cancer of the Skin), 93 (Molecular Biology of Cutaneous Melanomas), 94 (Cutaneous Melanomas), and 95 (Genetic Testing in Skin Cancer).

333





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 28.1 An 8-year-old child is brought to clinic by his mother due to a jaw lump that has been increasing in size over the past month. The mother states that the lump is preventing her child from eating. Physical examination reveals a child in moderate distress with a left jaw mass that displaces teeth and is impinging on the trachea. Biopsy reveals sheets of atypical lymphocytes with areas of necrosis and hemorrhage. Ki-67 is 99%. Flow cytometry shows B-cel markers as wel as CD10 and BCL-6. CD5, BCL-2, and TdT are absent. Which of the fol owing is the most common translocation in this malignancy?

A. t(1;14)

B. t(2;8)

C. t(8;14)

D. t(8;22)

Question 28.2 Which of the fol owing characterize/s a di erence between endemic and sporadic Burkitt lymphoma in children?

A. Endemic disease occurs more commonly in Africa and is associated with EBV

infection.

B. Common sites of endemic disease are the mediastinal and hilar lymph nodes, which often leads to rapid respiratory compromise.

C. Dysregulation of both c-myc and BCL-2 are required for tumor cel growth.

D. Sporadic Burkitt lymphoma occurs in nonmalaria endemic areas, with common areas of development including the abdomen.

Question 28.3 Which one of the fol owing syndromes is associated with a higher risk of adult lymphoma as opposed to childhood lymphoma?

A. Ataxia-telangiectasia

B. HIV/AIDS

C. Wiskott–Aldrich syndrome

D. X-linked lymphoproliferative syndrome

Question 28.4 A 35-year-old Caucasian male presents to his primary doctor due to 2

months of gradual y worsening fevers, chil s, and night sweats that soak through multiple 334

pil ows. He recal s having lost some weight over the past months, involuntarily, but is most bothered by an itchy rash on his abdomen that has recently started to ulcerate. Physical examination reveals painless lymphadenopathy. Biopsy shows pleomorphic large cel s with prominent nucleoli. Immunophenotyping shows cel s positive for CD30 and ALK, and negative for B-cel markers. Which of the fol owing is TRUE regarding this condition?

A. ALK-positive cases are more common in adults.

B. ALK protein is detected in a minority of cases.

C. Cel s are often derived from mature, activated T cel s.

D. Prognosis in ALK-positive cases is worse than ALK-negative cases.

Question 28.5 A 55-year-old African-American man presents to his PCP with abdominal pain that has been gradual y increasing over 3 months. He notes that he has been urinating less than normal. Furthermore, he complains of persistent fevers and drenching night sweats. His wife notes that he looks thinner than before. The patient is less active than his baseline but is able to perform light housework without di culty. Physical examination reveals nontender adenopathy in the bilateral cervical and left axil ary regions. PET/CT

shows FDG-avid bilateral cervical, left axil ary, and mediastinal lymphadenopathy as wel as a 7-cm retroperitoneal mass resulting in bilateral hydronephrosis. CBC is within normal limits. LDH is 210 IU/L (upper limit of normal 250 IU/L). Bone marrow biopsy demonstrates no evidence of disease. Which of the fol owing best describes the patient’s International Prognostic Index (IPI) score?

A. 0

B. 1

C. 2

D. 3

Question 28.6 Human herpesvirus-8 is implicated in which of the fol owing diseases?

A. Burkitt lymphoma

B. GCB DLBCL

C. Monocytoid B-cel lymphoma

D. Primary effusion lymphoma

Question 28.7 Which of the fol owing is/are mature T-cel neoplasms?

A. Anaplastic large-cel lymphoma

B. Hairy cel leukemia

C. Mycosis fungoides

D. Primary effusion lymphoma

Question 28.8 Which of the fol owing B-cel lymphomas may have CD10 positivity and the t(14;18) translocation? (Select two correct responses)

335

A. Diffuse large B-cel lymphoma

B. Fol icular lymphoma

C. Lymphoplasmacytic lymphoma

D. Mantle cel lymphoma

Question 28.9 A 66-year-old Caucasian male with HIV and CD4 count of 53 is being worked up by his oncologist for a new diagnosis of di use large B-cel lymphoma, which involves di use lymphadenopathy, the paranasal sinuses, testes, and bone marrow based on initial studies. What is the next best step in management?

A. Initiation of testicular radiation

B. Lumbar puncture

C. Orchiectomy

D. Upper and lower endoscopy

Question 28.10 A 71-year-old man presents to clinic with abdominal pain. Review of systems is also positive for fatigue and easy bleeding from the nose and gums. Physical examination reveals splenomegaly. Pertinent labs include hemoglobin of 12 g/dL, platelets of 16,000, LDH of 400 IU/L (upper limit of normal 250 IU/L), and albumin of 3.6 g/dL.

Peripheral smear reveals “vil ous lymphocytes.” Flow cytometry is positive for CD19, CD20, and CD22 and negative for CD5, CD25, and CD103. Which of the fol owing are possible steps in initial management? (Select three correct responses) A. Autologous stem cel transplantation

B. Chemotherapy with alkylating agents

C. Splenectomy

D. Single agent rituximab

Question 28.11 Which of the fol owing findings portend a shorter survival/worse prognosis for patients with splenic marginal zone lymphoma? (Select three correct responses) A. Albumin <3.5 g/dL

B. Hemoglobin <12 g/dL

C. LDH >normal

D. Presence of vil ous lymphocytes

Question 28.12 A 69-year-old Caucasian man presents to his primary care doctor for persistent nausea associated with nonbloody, nonbilious emesis, loss of appetite, and 30-lb weight loss over approximately 1 year. He also recal s having occasional dark stools. Physical examination reveals splenomegaly. PET/CT reveals FDG avidity of intra-abdominal lymph nodes as wel as uptake in the stomach and smal and large bowel. Upper and lower endoscopy reveals a nonbleeding gastric ulcer and di use polyps in the colon. Biopsies are performed. Cel s express surface IgM and IgD along with CD5, CD19, and CD20.

Cytogenetics reveals t(11;14). Which of the fol owing statement(s) is/are accurate 336

regarding the next step in management?

A. Consolidation with autologous stem cel transplantation in first remission is an approach often considered for fit patients.

B. Treatment with ibrutinib in the upfront setting is limited because of its association with peripheral neuropathy.

C. Front-line therapy for elderly patients with good performance status includes bendamustine and rituximab.

D. Hyper-CVAD with rituximab may be administered to patients with more aggressive disease.

Question 28.13 A 46-year-old Caucasian man presents to clinic due to drenching night sweats associated with persistent, high-grade fevers and 40-lb weight loss over the past 6

months. Physical examination reveals lymphadenopathy of the cervical and axil ary nodes as wel as hepatospenomegaly. PET/CT reveals avid uptake throughout the mediastinum, stomach, and smal bowel, with multiple nodes measuring up to 2 cm. FISH reveals BCL-1/IgH fusion gene product. Additional studies show decreased expression of p21, p27, and p53. Which of the fol owing statement(s) regarding the il ness is/are CORRECT?

A. Cel s arise from antigen-naive B-cel s of the inner mantle zone.

B. Most patients present in early-stage disease.

C. The condition is more common in females.

D. Tumor cel s strongly express surface IgG and IgD as wel as CD19 and CD20.

Question 28.14 A 26-year-old Caucasian man with no past medical history presents to the emergency department with right knee pain that occurred suddenly while playing vol eybal . He is found to have a pathologic fracture of the right distal femur. Further imaging with PET/CT reveals localized uptake of the right femur and tibia. Flow cytometry shows that cel s are CD19, CD20, and CD22 positive. Immunohistochemistry also reveals that cel s are CD10 positive and negative for BCL-6 and MUM-1. Which of the fol owing statement(s) regarding disease subtype is/are accurate?

A. Ig gene shows intraclonal homogeneity.

B. Nuclear factor kappa beta signaling is the primary driver of proliferation and metastases.

C. Survival is worse compared to other subtypes.

D. The subtype is often associated with t(14;18).

Question 28.15 A 63-year-old African-American woman with a past medical history of HIV presents to the emergency room with shortness of breath. She notes that it has been worsening over the past 3 to 4 months, but became unbearable over the past week. Review of systems is positive for involuntary weight loss of 30 lb over 4 months and pedal edema.

Physical examination reveals pitting edema to the knees bilateral y. PET/CT scan shows di use adenopathy of the mediastinum and the pelvis, with the largest nodes measuring 337

2.5 cm. No extranodal disease is appreciated. Excisional biopsy reveals proliferating large and smal lymphocytes. Ki-67 is 85%. Flow cytometry reveals cel s that are CD19, CD20, and CD22 positive and negative for CD10 and BCL-6. Which of the fol owing statements regarding management is accurate?

A. R-CHOP chemotherapy is appropriate.

B. ABVD chemotherapy is preferred as first-line management.

C. Al ogeneic stem cel transplant is the treatment of choice if the patient were to relapse with chemosensitive disease.

D. Rituximab with CHOP confers greater benefits in patients who lack BCL-6 expression, based on the GELA R-CHOP trial.

Question 28.16 A 55-year-old Chinese man presents to his primary care physician due to chronic sinus pain that has been present for 5 months. He also complains of epistaxis, fevers, drenching night sweats, and 30-lb weight loss. Physical examination is pertinent for temporal wasting and tenderness to palpation around the paranasal sinuses as wel as cervical adenopathy. Labs reveal LDH of 425 IU/L (upper limit of normal 250 IU/L). CT of the sinuses reveals an in ltrating mass in the midline nasal sinus. Immunophenotype reveals atypical cel s that are positive for CD2, CD56, and cytoplasmic CD3, and negative for CD4, CD8, and surface CD3. EBV is detected. The cytoplasmic granule proteins, granzyme B and TIA-1, are present. Cytogenetics reveals del(6)(q21;q25). Which of the fol owing statement(s) regarding treatment is/are CORRECT?

A. Al ogeneic stem cel transplantation is a standard first-line therapy in fit patients.

B. EBV-related hemophagocytic syndrome is often fatal and treated with front-line radiation.

C. Localized disease is initial y managed with concurrent chemotherapy and radiation D. Patients with disseminated disease that is chemotherapy sensitive are effectively treated with a combination of R-CHOP and radiotherapy

Question 28.17 A 43-year-old woman presents to a dermatologist with a di use skin rash, described as red and itchy with associated thickening of the palms and soles that has been slowly progressing for the past 4 years. Physical examination reveals erythematous plaques on 20% of the body surface area. FDG PET reveals absence of extracutaneous disease. Skin biopsy reveals Pautrier microabscesses. Immunophenotyping reveals expression of CD2, CD3, CD5, and CD7. What is the next best step in management?

A. EPOCH chemotherapy combined with pentostatin and fludarabine with interferon alpha

B. Extracorporeal photochemotherapy

C. Local y applied denileukin diftitox with or without vorinostat D. Topical carmustine or mechlorethamine, bexarotene, or ultraviolet B with or without interferon alpha

338

Question 28.18 Which of the fol owing accurately describes an aspect of primary CNS

lymphoma (PCNSL)?

A. AIDS patients tend to have large, invasive unifocal masses that rapidly progress without HAART therapy.

B. Incidence has decreased fivefold from 1985 to 1997 due to advances in treatment of immunosuppressed patients.

C. Many masses are periventricular, al owing tumor cel s access to cerebrospinal fluid.

D. Presents most commonly in the occipital lobe, manifesting as vision changes and gait abnormalities.

Question 28.19 Which of the fol owing statement(s) regarding the presentation of primary CNS lymphoma is/are CORRECT?

A. Approximately 20% of patients have ocular involvement at the time of presentation, particularly of the optic nerve, vitreous, retina, and choroid.

B. Most patients present in stage I, explaining the good prognosis of the condition.

C. Primary leptomeningeal lymphoma in the absence of a brain mass accounts for 40% of cases, with symptoms including leg weakness and incontinence/retention.

D. Studies have shown that 10% of patients can have spread of disease outside of the CNS, mostly to the bone marrow and lymph nodes.

Question 28.20 A 71-year-old Caucasian man is brought to his primary care physician by his wife, who says that he has been exhibiting increasingly aggressive behavior over the past 5 months, manifesting as irritability and outbursts of anger, both of which are outside of his norm. She also says that he has had two motor vehicle accidents in the same time period, due to not noticing tra c lights. Neurologic examination reveals decreased ability to fol ow commands, 20/200 vision in both eyes, and left-sided weakness. Brain MRI shows a 4 × 5

cm solitary, nonhemorrhagic mass in the right frontal lobe. Lumbar puncture reveals predominance of clonal lymphocytes. Biopsy indicates cel s positive for BCL-2, BCL-6, and MUM1 as wel as CD19, CD20, and CD22. What is the next best step in management?

A. High-dose methotrexate and rituximab, with or without Ara-C and temozolomide.

B. R-CHOP chemotherapy with intrathecal methotrexate.

C. Six weeks of concurrent chemotherapy with methotrexate and dexamethasone combined with focal radiation therapy.

D. Systemic adriamycin and etoposide with high-dose dexamethasone.

Question 28.21 Which of the fol owing statements best characterizes nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in contrast to classic Hodgkin lymphoma (cHL)?

A. Approximately 80% of patients with NLPHL have stage I to II disease at the time of diagnosis.

B. Bone marrow involvement is frequent with stage III to IV disease.

339

C. Disease presentation manifests predominantly in thoracic nodes before spreading to the mediastinum.

D. NLPHL cel s express CD30 and CD45 as wel as B-cel antigens.

Question 28.22 A 24-year-old G1P0 woman presents to her physician with fever, neck pain, fatigue, and 10-lb weight loss during the rst trimester of pregnancy. She is concerned about the health of her fetus. Physical examination reveals nontender cervical adenopathy, leading to a biopsy, which reveals cel s that are positive for CD15 and CD30

and negative for CD3, CD7, CD20, and CD45. Morphology is pertinent for Reed–Sternberg cel s in a background of in ammatory cel s. Which of the fol owing accurately describe(s) an aspect of care for such patients?

A. BEACOPP chemotherapy is preferred to ABVD for treatment during the first trimester due to the lack of antimetabolites in the regimen.

B. MRI scanning is preferred for staging because it is nonteratogenic.

C. Long-term survival of treated pregnant women is inferior to that of nonpregnant women with the disease.

D. Radiation therapy with abdominal shielding can be safely used for bulky disease above the diaphragm.

340

Question 28.1 The answer is C.

This patient has Burkitt lymphoma. The classic translocations are t(2;8), t(8;14), and t(8; 22) causing dysregulation of the c-myc oncogene. The most common translocation is t(8;14). The t(1;14) occurs in MALT lymphoma.

Question 28.2 The answers are A and D.

Endemic disease, commonly seen in areas of chronic malaria, occurs in children and in the jaw region. In contrast, sporadic disease occurs more commonly in the abdomen. C-myc, rather than BCL-2, is required for pathogenesis.

Question 28.3 The answer is B.

HIV/AIDS increases the risk of adult lymphomas, compared to the other choices, which are associated with an increased risk of childhood lymphomas.

Question 28.4 The answer is C.

This patient has anaplastic large-cel lymphoma. ALK is detected in more than half of patients, being more common in children and associated with better prognoses.

Question 28.5 The answer is B.

The International Prognostic Index (IPI) score for lymphomas is based on five factors including age greater than 60, performance status (PS) greater than or equal to 2, LDH

> normal, stage III/IV, and greater than or equal to two extranodal sites. Scores of 0 to 1, 2, 3 and 4 to 5 are classified as low-risk, low-intermediate-risk, high-intermediate-risk, and high-risk respectively. The patient has stage III/IV disease, but is younger than 60 with an ECOG PS of 0, normal LDH, and no extranodal sites. Therefore, his IPI score is 1 (low-risk).

Question 28.6 The answer is D.

Endemic Burkitt lymphoma is associated with EBV, while hepatitis C viruses are associated with monocytoid B-cel lymphoma. There is no established viral etiology for diffuse large B-cel lymphoma. Primary effusion lymphoma is associated with HHV-8.

Question 28.7 The answers are A and C.

Both mycosis fungoides and anaplastic large-cel lymphoma are T-cel neoplasms, while hairy cel leukemia and primary effusion lymphomas are B-cel malignancies.

Question 28.8 The answers are A and B.

341

The two malignancies associated with CD10 positivity and t(14;18) that result in increased expression of the antiapoptotic protein, BCL-2, are fol icular lymphoma and diffuse large B-cel lymphoma (DLBCL).

Question 28.9 The answer is B.

Patients with large-cel lymphoma and involvement of the paranasal sinuses, testes, and bone marrow are more prone to meningeal spread, thus necessitating a lumbar puncture. The presence of CNS involvement wil impact the treatment plan. While testicular radiation may be administered fol owing chemotherapy, it is not the next best step. An orchiectomy is not indicated. Similarly upper and lower endoscopies are rarely indicated in DLBCL unless needed to obtain the initial diagnosis.

Question 28.10 The answers are B, C and D.

The patient has splenic marginal zone lymphoma (SMZL), which is characterized by circulating vil ous lymphocytes that express CD19, CD20, CD22, and BCL-2. The lack of CD103 and CD25 differentiates it from hairy cel leukemia. Hemoglobin less than 12

g/dL, high LDH, and albumin less than 3.5 g/dL predict a shorter survival of 50%.

Possible treatment options include chemotherapy with alkylating agents, rituximab, and splenectomy. Upfront autologous stem cel transplantation would not be a routine approach for this indolent lymphoma that often responds wel to single-agent rituximab.

Question 28.11 The answers are A, B and C.

Vil ous lymphocytes do not portend a worse prognosis, while the aforementioned three answer choices are associated with poorer outcomes.

Question 28.12 The answers are A, C and D.

The patient has mantle cel lymphoma. Bortezomib, not ibrutinib, is characterized by its tendency to cause peripheral neuropathy. Ibrutinib is only approved in the relapsed setting. The optimal front-line regimen for mantle cel lymphoma is highly debated.

Treatment options include intensive regimens such as hyper-CVAD and upfront autologous stem cel transplant. The less intensive regimen of bendamustine and rituximab is another option with demonstrated high overal response rates.

Question 28.13 The answer is A.

Mantle cel lymphoma is more common in males and typical y presents as stage IV

disease. The tumor cel s express IgM and IgD, as wel as B-cel associated antigens. The cel s arise from antigen-naive B cel s of the inner mantle zone. Nuclear cyclin D1 is present in al cases and is the gold standard for diagnosis.

Question 28.14 The answer is D.

342

The patient has germinal center B-cel (GCB) DLBCL, based on the Hans criteria. GCB is associated with a better prognosis than the activated B-cel (ABC) subtype DLBCL, which is associated with NF kappa beta signaling. The GCB subtype is associated with t(14;18), which indicates a fol icle center cel origin.

Question 28.15 The answer is A.

For patients with advanced-stage DLBCL, the standard-of-care treatment is with R-CHOP chemotherapy. Abbreviated R-CHOP chemotherapy combined with involved field radiotherapy is an appropriate treatment option for low-risk, nonbulky, early stage DLBCL. ABVD is the standard regimen for patients with Hodgkin lymphoma. Autologous stem cel transplant is reserved for patient with relapsed chemosensitive disease.

Rituximab has a greater benefit for patients that express BCL-2 on IHC.

Question 28.16 The answer is C.

The patient has extranodal NK/T-cel lymphoma. Localized disease can be treated with a combination of chemotherapy and radiotherapy. Treatment failure is common with RT alone. Rituximab is not indicated in this T-cel lymphoma. Patients with disseminated disease have very poor prognoses and should be enrol ed in clinical trials.

Early use of high-dose chemotherapy combined with autologous transplantation may be beneficial in some patients.

Question 28.17 The answer is D.

The patient has mycosis fungoides. For localized disease, treatment options include carmustine, mechlorethamine, bexarotene, ultraviolet B, near ultraviolet light, interferon alpha, and electron beam radiation. Options for systemic disease, which the patient does not have, include EPOCH, extracorporeal photochemotherapy, denileukin diftitox, and monoclonal antibodies.

Question 28.18 The answer is C.

The incidence of PCNSL has increased in immunocompetent individuals. Frontal lobe presentation is the most common, leading to changes in personality, level of alertness, headaches, and signs/symptoms of increased intracranial pressure. AIDS patients also universal y have multifocal lesions, compared to patients without HIV, which have a 40% incidence of multiple foci.

Question 28.19 The answer is A.

Primary leptomeningeal lymphoma occurs in 7% of patients. Primary CNS lymphoma (PCNSL) very rarely spreads outside of the CNS. Despite the confinement of the disease to only one location, the prognosis is typical y worse compared with other stage I diffuse large B-cel lymphomas. This is an area where Ann Arbor staging is not particularly 343

helpful and many authors classify PCNSL as stage IV, rather than stage IE (extranodal).

Question 28.20 The answer is A.

The patient has primary CNS lymphoma for which the backbone of therapy is high-dose methotrexate combined with rituximab. In patients older than 60 years of age, HD-MTX

combined with whole-brain radiotherapy causes significant encephalomalacia with cognitive decline and should be avoided.

Question 28.21 The answer is A.

The atypical cel s in NLPHL are CD45 positive and express B-cel antigens such as CD19, CD20, CD22, CD79a, and PAX5. The cel s do not express CD30. The condition can transform into DLBCL in 2% to 6% of cases. Most patients present with early-stage disease. Bone marrow involvement is rare even with more advanced disease. Unlike the contiguous spread seen in classical Hodgkin lymphoma, NLPHL often involves peripheral nodes in a noncontiguous fashion. Inguinal node involvement is common. Overal , the response to therapy is more favorable, since more than 90% of patients have a clinical remission and are alive at 10 years.

Question 28.22 The answer is B.

Hodgkin lymphoma is the fourth most common cancer diagnosed during pregnancy.

ABVD chemotherapy is the preferred regimen during pregnancy since it does not include antimetabolites. MRI is preferred to CT scanning, in order to avoid exposing the fetus to ionizing radiation. Radiation therapy can be used above the diaphragm in the second or third trimester if the patient has rapid progression of lymphadenopathy.

Corresponding chapters in Cancer: Principles & Practice of Oncology, Tenth Edition: 101

(Molecular Biology of Lymphomas), 102 (Hodgkin Lymphoma), 103 (Non-Hodgkin Lymphoma), 104 (Cutaneous Lymphomas), and 105 (Primary Central Nervous System Lymphomas)

344





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 29.1 The (8;21) cytogenetic rearrange, which is associated with favorable risk in acute myeloid leukemia (AML), juxtaposes which genes?

A. AML1-ETO

B. RUNX1-RUNX1T1

C. A core-binding factor and a zinc finger protein

D. Al of the above

Question 29.2 You are caring for a 25-year-old woman with AML-M2 and normal cytogenetics. She receives 7 + 3 induction therapy, and her day-14 bone marrow biopsy is ablated. She returns to clinic and her day-45 bone marrow shows normal hematopoiesis.

However, she relapses after 18 months. Which of the fol owing likely contributed to her relapse?

A. DNMT3A mutation

B. CEBPA mutation

C. NPM mutation without FLT3-ITD

D. Her age

Question 29.3 Your wel -read 30-year-old patient with AML asks you how you wil fol ow her disease once she is in remission. She asks which is the most sensitive test for minimal residual disease. In which order are these assays most sensitive (least to most sensitive)?

A. Cytopathology < fluorescence in situ hybridization (FISH) < polymerase chain reaction (PCR)

B. FISH < cytogenetics < PCR

C. PCR < cytopathology < FISH

D. Cytogenetics < PCR < flow cytometry

Question 29.4 Mutation of which of the fol owing genes is associated with a worse prognosis in core-binding factor AML?

A. ABL

B. CKIT

C. NPM1

345

D. GATA-1

Question 29.5 A 52-year-old man presents with AML. On day 2 of induction therapy, he develops di use alveolar hemorrhage. An expected physical nding on examination would be:

A. Diffuse ecchymosis.

B. Diffuse intravascular coagulopathy.

C. Swol en gums.

D. Cardiac rub.

Questions 29.6–7 You have been fol owing a 75-year-old woman in clinic with mild renal insu ciency and progressive anemia. She has good performance status and presents to clinic with a 3-day history of progressive fatigue and new headaches. Her white blood cel (WBC) count is 53,000 with 50% blasts.

Question 29.6 Given her history, what is the expected finding in the cytogenetics?

A. t(15;17)

B. –7

C. inv(16)

D. t(8;21)

Question 29.7 Which of the fol owing is associated with improved prognosis in this patient?

A. Probable leukostasis

B. Her age

C. Prior myelodysplastic syndrome (MDS)

D. Good performance status

Question 29.8 Which of the fol owing cytogenetic pro les from an AML patient is an example of monosomal karyotype?

A. −7

B. +8, inv(3), del(5q)

C. inv(16)

D. −7, −5, t(3;21)

Question 29.9 Which of the fol owing is a poor prognostic factor in adult ALL?

A. Age <55 years

B. WBC <10,000

C. Diploid chromosomes on karyotyping

D. t(4;11)

346

Question 29.10 A 70-year-old man presents with newly diagnosed AML-M4 with eosinophilia. Which of the fol owing factors wil have the greatest impact on the choice of therapy?

A. His age

B. His performance status

C. His cytogenetics

D. Excel ent response to 7 + 3 induction therapy in the elderly Question 29.11 You have been fol owing a 54-year-old woman with acute promyelocytic leukemia (APL) in clinic. After 2 years she returns to clinic with fatigue, an elevated WBC, and increased promyelocytes. Peripheral blood PCR con rms recurrence of her t(15;17) translocation. Before starting arsenic salvage therapy, which test you obtain?

A. Liver function test

B. Erythrocyte sedimentation rate

C. D-dimer

D. Electrocardiogram

Question 29.12 You have been caring for a 65-year-old woman with a distant history of breast cancer treated with adjuvant cyclophosphamide and adriamycin. During the last year, she developed progressive anemia and thrombocytopenia. She also recently developed leukopenia. Her bone marrow biopsy shows decreased cel ularity with dysplastic features and 25% blasts. Which of the fol owing cytogenetic changes might you expect to find?

A. t(15;17)

B. t(9;21)

C. Complex cytogenetics

D. Trisomy 21

Question 29.13 Which of the fol owing statements is TRUE regarding elderly patients (age

>65 years) with AML? (Select two correct responses)

A. In general, older patients with AML have poor outcomes when compared to younger patients.

B. Treatment with hypomethylating agents leads to the same response rate as more intensive chemotherapy.

C. Older patients are more likely to have favorable risk cytogenetics than younger patients.

D. Treatment with decitabine leads to better response rates but similar survival compared to low-dose cytarabine.

Questions 29.14–18 You are consulted to see a 20-year-old Hispanic woman who presented with progressive fatigue during the last week and then signi cant epistaxis. Her WBC is 12,000/ L with 40% promyelocytes and a platelet count of 15,000/ L. Her 347

international normalized ratio (INR) is 2.7 with a prothrombin time of 45 and partial thromboplastin time of 65. Her brinogen is 82. On review of her peripheral smear, you observe many promyelocytes with large granules and multiple Auer rods.

Question 29.14 After review of her peripheral smear, you suspect that she has APL. While awaiting con rmation of the diagnosis, your initial therapy should include which of the fol owing?

A. Steroids

B. Cytarabine

C. Fresh-frozen plasma

D. Arsenic trioxide

Question 29.15 Three days after starting idarubicin and ATRA, her coagulopathy has improved. She has shortness of breath in the morning and rapidly becomes hypoxic over the course of the day. Which of the fol owing would prove most helpful in treating her hypoxia?

A. High-flow facemask oxygen

B. Lasix

C. Methylprednisolone

D. Albuterol

Question 29.16 Fifteen days into treatment she develops a severe headache. Her neurologic and fundoscopic evaluations are normal. Review of her morning laboratory tests reveal a WBC of 0.6/ L, hematocrit of 9.8, platelet count of 25,000/ L, INR of 1.4, and brinogen of 190. You obtain a noncontrast head computed tomography scan but are more worried that this is a result of:

A. Relapse.

B. ATRA.

C. Idarubicin.

D. Transfusion reaction.

Question 29.17 Six months later you are reviewing her chart. Her CBC has normalized, and she has tolerated consolidation therapy. Her most recent PCR showed no sign of residual disease. You are most concerned about relapse because of: A. Her microgranular variant presentation.

B. Her presenting coagulopathy.

C. Her presenting WBC.

D. Her ethnicity.

Question 29.18 Three years later she presents to clinic with an elevated leukocyte count.

PCR of peripheral blood con rms the presence of her initial t(15;17) translocation.

Treatment options at this point include which of the fol owing?

348

A. Arsenic trioxide

B. Gemtuzumab ozogamicin

C. Autologous transplant after achieving CR

D. Al of the above

Question 29.19 A 30-year-old, otherwise healthy woman is diagnosed with AML.

Cytogenetics reveal inv(16). She undergoes induction therapy. Day-14 bone marrow biopsy shows an ablated marrow. Her day-45 marrow shows restored cel ularity without evidence of disease. Repeat cytogenetics do not reveal the inv(16) rearrangement. Appropriate consolidation therapy would be:

A. Al ogeneic transplant if a matched sibling donor is available.

B. High-dose cytarabine (HIDAC) 3 g/m2 every 12 hours on days 1, 3, and 5 for four 28-day cycles.

C. Intermediate-dose cytarabine (IDAC) 300 mg/m2 every 12 hours on days 1, 3, and 5

for four 28-day cycles.

D. Arsenic 0.15 mg/kg on days 1 to 5 for four 28-day cycles.

Question 29.20 Which of the fol owing regimens require graft-versus-tumor e ects to treat residual AML blasts?

A. Busulfan-cyclophosphamide

B. Cyclophosphamide-TBI

C. Busulfan-fludarabine

D. Busulfan-VP16

Question 29.21 Central nervous system (CNS) prophylaxis should be considered in which of the fol owing patients?

A. A 25-year-old Hispanic woman with APL who presents with a WBC of 2500/μL, an INR of 2.5, and fibrinogen of 100

B. A 78-year-old man with AML evolved from MDS

C. A 30-year-old woman with AML who develops headaches while receiving ondansetron for nausea on day 9 of induction therapy

D. A 20-year-old man with Down syndrome and ALL who presents with leukocytosis (WBC 120,000/μL)

Question 29.22 Dexamethasone has replaced prednisone in ALL induction therapy because of improved penetration in which tissue?

A. Testes

B. Spleen

C. Bone marrow

D. Brain

349

Question 29.23 How long should maintenance therapy for ALL with daily 6-mercaptopurine, weekly methotrexate, and monthly vincristine and prednisone be continued?

A. 6 months

B. 12 months

C. 24 to 36 months

D. Until relapse

Question 29.24 Which of the fol owing targeted agents have been shown to be bene cial in adult ALL?

A. Imatinib

B. Alemtuzumab

C. Gemtuzumab ozogamicin

D. Sunitinib

Question 29.25 For which of the fol owing patients would you consider myeloablative stem cel transplantation in CR1?

A. A 30-year-old woman with inv(16) AML-M4 with eosinophilia B. A 50-year-old man with complex cytogenetics AML-M1

C. A 65-year-old man with complex cytogenetics AML-M1

D. A 50-year-old woman with t(15;17) AML-M3

Question 29.26 Which of the fol owing statements is TRUE regarding the nucleophosmin 1 (NPM1) mutation in AML? (Select two correct responses) A. In normal karyotype AML, NPM1 mutation without FLT3-ITD confers a prognosis similar to good-risk cytogenetics.

B. NPM1 mutations are found mostly in patients with AML with normal karyotype.

C. NPM1 mutation combined with FLT3-ITD is associated with good prognosis.

D. Al the above

350

Question 29.1 The answer is D.

The favorable t(8;21) translocation results in the juxtaposition of the initial y named AML1 gene with the ETO gene (the AML gene and the eight-twenty-one gene). These two have been renamed RUNX1 and RUNX1T1, respectively. RUNX1 is a member of the core-binding factor family of transcription factors, which regulate differentiation of normal blasts. This fusion protein creates a dominant negative protein, which results in a differentiation block. Inv(16) and the t(16;16) rearrangements likewise result in dominant negative effects on core-binding factors and are associated with a favorable prognosis.

Question 29.2 The answer is A.

The DNMT3A gene encodes the DNA (cytosine-5)-methyltransferase 3A enzyme that catalyzes the addition of a methyl group to the cytosine residue of CpG dinucleotides.

In patients with AML with normal cytogenetics, the presence of DNMT3A mutations is independently associated with poor outcomes. CEBP/α is a transcription factor involved in myeloid differentiation thought to be activated by ATRA treatment in APL. Mutations in the CEBPA gene have been noted in other FAB-AML classifications and have been associated with a superior outcome compared with the wild-type transcript. NPM

mutations, in the absence of the FLT3-ITD, have also been associated with improved prognosis. Age is a strong prognostic factor, with patients older than 65 having decreased survival. Her young age would be a marker of a good prognosis.

Question 29.3 The answer is A.

Cytopathology requires greater than 5% blasts on a bone marrow biopsy to diagnose AML

relapse. This results in a sensitivity of 1 in 20. A cytogenetic review of 30 metaphases results in a 1 in 30 sensitivity. FISH has a sensitivity of approximately 1 in 500. PCR

techniques al ow sensitivity of approximately 1 in 104. However, both FISH and PCR

require screening for defined cytogenetic changes. Because initial cytogenetic changes typical y recur during AML relapse, this is general y not a significant barrier, unless patients present with uncommon cytogenetic changes for which FISH and PCR probes are not commercial y available.

Question 29.4 The answer is B.

Core-binding factor (CBF) AML includes AML with t(8;21) and inv(16). These leukemias are general y associated with good prognosis. However, patients whose CBF

AML has a mutation in CKIT have a worse prognosis than other CBF AML patients. They may benefit from treatment with a kinase inhibitor or al ogeneic stem cel transplant.

351

Question 29.5 The answer is C.

Diffuse alveolar hemorrhage is a rare complication of induction therapy in AML, which carries significant mortality risk. It is most commonly reported in patients with AML and myelomonocytic or monocytic features (M4 or M5). These myelomonoblasts and monoblasts display a predilection for tissue invasion, such as in the gums, as wel as into the lungs. This is thought to result from their high expression of adhesion molecules: intercel ular adhesion molecule and vascular cel adhesion molecule. During initial treatment, activation and death of circulating blasts may lead to pulmonary inflammation and alveolar hemorrhage. Because of the rarity of such events, treatment options remain poorly studied. In smal series, high-dose steroids have shown benefit.

Question 29.6 The answer is B.

AML which has evolved from MDS is especial y recalcitrant to therapy. It may be associated with –5 or –7 cytogenetic abnormalities but is most commonly associated with complex cytogenetics. This patient is presenting with many poor-risk features (age

>65 years, symptoms suggestive of leukostasis, and underlying organ insufficiency), which wil decrease the probability of response and survival.

Question 29.7 The answer is D.

There are many prognostic factors for AML. Of particular importance are age, cytogenetics, and performance status. Age greater than 65 years has been associated with worse outcomes independently of cytogenetics. AML evolving from prior MDS also confers a worse prognosis. Leukostasis at presentation presents significant early morbidity and mortality, especial y in an older patient. An elevated peripheral blast count, which may be associated with leukostasis, is also associated with a poor long-term prognosis.

Question 29.8 The answer is D.

Monosomal karyotype is defined by the presence of two or more autosomal monosomies or by the presence of one autosomal monosomy and a structural change (translocation).

Monosomal karyotype is associated with a particularly poor prognosis.

Question 29.9 The answer is D.

Age greater than 50 years, poor performance status, African-American ethnicity, and leukocytosis (>30,000/μL B-lineage or >100,000/μL T-lineage) are associated with high-risk ALL. Immunophenotypes including early and mature-T ALL and pro-B ALL are also considered high risk. Cytogenetics including the Philadelphia chromosome t(9;22) and t(4;11) are both high-risk prognostic factors. Normal diploid chromosomes on karyotyping are not associated with poor prognosis.

Question 29.10 The answer is B.

352

Treatment of AML in the elderly (>65 years) is difficult because of the heterogeneous nature of response and the general y high rate of treatment-related mortality. Older patients at MD Anderson with a performance status >2, bilirubin greater than 1.9

mg/dL, or serum creatinine greater than 1.9 mg/dL had a treatment-related mortality of 62% and only a 27% complete remission rate. Thus, decision to undergo standard induction therapy must be based on a careful assessment of the patient’s ability to tolerate the therapy and his/her prognosis.

Question 29.11 The answer is D.

Arsenic trioxide has demonstrated considerable activity in both initial and salvage treatment of APL. Arsenic trioxide has been associated with prolonged QTc syndrome.

Therefore, electrocardiograms should be performed before and during therapy.

Electrolytes should also be monitored and corrected. Additional medications that may prolong the QTc should be eliminated if possible.

Question 29.12 The answer is C.

Prior alkylator therapy increases the risk of MDS and treatment-related AML. Her recent history of progressive anemia and thrombocytopenia, with dysplastic features seen in her marrow, are al suggestive of an underlying MDS. Her blast count greater than 20%

meets criterion for AML under the current World Health Organization standards. AML

evolved from MDS could carry a loss of chromosome 5 or 7 associated with the prior MDS, but most often is associated with complex cytogenetics. It also carries an unfavorable prognosis in multiple studies. t(15;17) is associated with APL but is not associated with prior breast cancer or alkylator therapy. t(9;21) is associated with the Philadelphia chromosome and seen in chronic myelocytic leukemia or acute lymphocytic leukemia, but is rarely associated with AML or MDS. Trisomy 21 is associated with AML-M7 with increased megakaryocytes.

Question 29.13 The answers are A and D.

Older patients with AML have worse outcomes when compared to younger patients irrespective of their performance status or comorbidities. Treatment with the hypomethylating agents, azacitidine and decitabine, is associated with lower response rates but similar overal survival compared to more intensive chemotherapy regimens.

Favorable cytogenetics is less common in older AML patients. Treatment with decitabine is associated with better response rate, but not improved survival, compared to low-dose cytarabine.

Question 29.14 The answer is C.

Patients with APL are at risk of early morbidity and mortality because of disseminated intravascular coagulation and bleeding complications. Aggressive management of coagulopathy is mandatory, with the goal of maintaining the fibrinogen greater than 353

150, INR less than 1.5, and platelet count greater than 30,000.

Question 29.15 The answer is C.

Differentiation syndrome can be a life-threatening complication of APL and ATRA treatment. As the granule-laden promyelocytes differentiate, the granular products stimulate pulmonary edema and fluid retention. Fevers and weight gain are common symptoms of differentiation syndrome. Treatment includes steroids and management of coagulopathy. Differentiation syndrome may affect as many as 10% to 25% of patients with APL.

Question 29.16 The answer is B.

Headache is a common side effect from ATRA. Treatment options include dose reduction and symptom management with analgesics. Unfortunately, patients occasional y require drug discontinuation because of this side effect.

Question 29.17 The answer is C.

The greatest risk of relapse in APL is associated with an elevated WBC greater than 10,000/μL on presentation. Patients with presenting WBC less than 10,000/μL

achieve CR approximately 90% of the time.

Question 29.18 The answer is D.

Arsenic trioxide has demonstrated significant efficacy in relapsed APL and in consolidation protocols. APL promyelocytes commonly express high levels of CD33, and gemtuzumab ozogamicin (anti-CD33) has demonstrated efficacy in relapsed APL. APL

is one of the few cases in AML in which autologous transplantation has demonstrated significant benefit, and it is often used in a salvage consolidation protocol.

Question 29.19 The answer is B.

Although most patients with AML wil relapse without consolidation therapy, the appropriate consolidation therapy remains unclear for the majority of these patients.

Young patients with good-risk cytogenetics represent one of the few cohorts with AML

in whom specific consolidation recommendations are supported by clinical data. A study sponsored by the Cancer and Leukemia Group B (CALGB) found that young patients with inv(16) had a 78% CR rate at 5 years after four cycles of HIDAC therapy, whereas 57% remained in CR in the IDAC arm and only 16% remained in CR with conventional 100 mg/m2 dosing. Patients with normal cytogenetics fared less wel as a group with equivalent outcomes (47% vs. 37% CR at 5 years) in the HIDAC and IDAC arms and worse outcomes with conventional dosing (20%). Patients with unfavorable cytogenetics should be considered for al ogeneic transplant in first CR. Arsenic has shown benefit in a consolidation protocol for APL, but it has not been evaluated in 354

general AML consolidation protocols.

Question 29.20 The answer is C.

Nonmyeloablative conditioning regimens require a graft-versus-leukemia effect to improve the clearance of residual AML blasts not eliminated by the conditioning regimen.

Question 29.21 The answer is D.

CNS prophylaxis may consist of intrathecal chemotherapy (methotrexate, cytarabine, corticosteroids), high-dose chemotherapy (methotrexate, cytarabine, L-asparaginase), or CNS irradiation. Patients with ALL with increased risk for CNS disease include those with an elevated WBC count, an elevated lactate dehydrogenase, a traumatic lumbar puncture, and T-lineage ALL. Although APL may relapse in the CNS, relapse is uncommon in patients with a presenting WBC less than 10,000/μL. CNS evaluation and prophylaxis are not routinely recommended in patients with APL. There is no role for CNS prophylaxis in elderly patients with AML without neurologic deficits. Although CNS disease must be considered in a patient with AML and headaches, a new headache caused by CNS leukemia on day 9 of induction therapy would be unusual and treatment could be delayed until proper evaluation is completed.

Question 29.22 The answer is D.

Dexamethasone has improved penetration in the CNS. Given the high risk of CNS

disease in patients with ALL, dexamethasone is preferred over prednisone.

Question 29.23 The answer is C.

Maintenance therapy for ALL should be administered for 2 to 3 years since attempts to shorten to 12 to 18 months have been associated with decreased survival.

Question 29.24 The answer is A.

Philadelphia chromosome-positive ALL carries a high-risk prognosis, but this has improved with the ABL tyrosine kinase inhibitor imatinib. Second-generation inhibitors such as dasatinib and nilotinib may also prove of value in the future. Alemtuzumab is an anti-CD52 monoclonal antibody that has demonstrated significant efficacy in the treatment of CLL. It has not been evaluated in ALL, which typical y does not express CD52. Gemtuzumab ozogamicin is an anti-CD33 monoclonal antibody cross-linked to a cytotoxin, calicheamicin. It has been shown to improve outcomes in relapsed AML.

Sunitinib is a nonspecific tyrosine kinase inhibitor. It has significant activity against FLT3

and may prove of value in the treatment of AML with FLT3-ITD.

Question 29.25 The answer is B.

355

Stem cel transplantation for AML remains a developing field. Current studies and meta-analysis have not found benefit in CR1 for patients with favorable cytogenetics (e.g., inv[16] and t[15;17]). Benefit is uncertain in patients with normal cytogenetics. Future trials may be able to assess the benefit of transplant in CR1 in higher-risk subpopulations of normal cytogenetics (e.g., FLT3-ITD or DNMT3A mutations). Patients aged less than 55 years who have unfavorable cytogenetics (e.g., –5, –7, complex cytogenetics) appear to benefit from myeloablative transplantation in CR1. However, older patients tolerate this approach less wel , with increased treatment-related morbidity and mortality.

Decision making in older patients must be individualized, and nonmyeloablative transplant approaches are usual y preferred.

Question 29.26 The answers are A and B.

NPM1 gene encodes a protein that functions as a molecular chaperone between the nucleus and cytoplasm. Mutations involving this gene are found in 50% to 60% of al AML patients with normal karyotype, and less frequently are seen in patients with abnormal cytogenetics. Aberrant cytoplasmic localization of NPM1 is associated with point mutations in the gene. In the absence of FLT3-ITD, the NPM1 mutation is associated with favorable prognosis.

Corresponding chapters in Cancer: Principles & Practice of Oncology, Tenth Edition: 106

(Molecular Biology of Acute Leukemias) and 107 (Management of Acute Leukemias).

356





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 30.1 The Sokal score was developed to predict the probability of disease progression in CML. Which of the fol owing variables are used to calculate this score?

A. Percentage of blasts in peripheral blood

B. Platelet count

C. Spleen size (centimeters below the costal margin)

D. Age of the patient

E. Al of the above

Question 30.2 Which of the fol owing cytogenetic response is CORRECT?

1. Partial cytogenetic response is ≥35% of Ph-positive metaphases on bone marrow biopsy

2. Minor cytogenetic response is ≥35% of Ph-positive metaphases on bone marrow biopsy

3. Major cytogenetic response is 0% to 35% of Ph-positive metaphases on bone marrow biopsy

4. Partial cytogenetic response is 1% to 35% of Ph-positive metaphases on bone marrow biopsy

5. Complete cytogenetic response is 0% of Ph-positive metaphases on bone marrow biopsy 6. Major cytogenetic response is 35% to 99% of Ph-positive metaphases on bone marrow biopsy

A. 1, 3, 5 only

B. 1,2,3,5 only

C. 2,3,4,5 only

D. 2,4,5,6 only

Question 30.3 Real-time quantitative polymerase chain reaction (RQ-PCR) has emerged as the most e ective and sensitive way to assess response to therapy in CML and has the added exibility of utilizing peripheral blood instead of bone marrow for the measurement of cytogenetic response. How does molecular response correspond to complete cytogenetic response (CCyR)?

357

A. 2-log reduction in transcript levels or 1% International scale (IS) or MR2

B. 3-log reduction in transcript levels or 0.1% IS or MR3

C. 4-log reduction in transcript levels or 0.01% IS or MR4

D. 3-log reduction in transcript levels or 1% IS or MR2

Question 30.4 A 59-year-old male with a history of coronary artery disease and diabetes mel itus was diagnosed with chronic-phase chronic myeloid leukemia (CML). What is the most appropriate therapeutic intervention?

A. Imatinib 400 mg QD

B. Dasatinib 100 mg QD

C. Nilotinib 300 mg BID

D. Ponatinib 30 mg QD

Question 30.5 A 60-year-old female has been under your care for chronic-phase CML for the past 2 years. She achieved complete response on nilotinib. She subsequently developed thrombocytopenia with elevated RQ-PCR and a bone marrow biopsy showed 42% Ph-positive metaphases. Mutational analysis showed T315I mutation in the ABL domain. What is the appropriate treatment for this patient?

A. Imatinib

B. Ponatinib

C. Dasatinib

D. Nilotinib

Question 30.6 A 56-year-old female was diagnosed with chronic-phase CML 6 months ago and was started on imatinib at 400 mg QD. Treatment however, was discontinued due to skin rash and diarrhea and replaced by dasatinib at 100 mg QD. She came to the ER 2

weeks later with new onset of dyspnea and found to have moderate bilateral pleural effusions. What is the appropriate management?

A. Diagnostic thoracentesis

B. Temporary dasatinib discontinuation

C. Prednisone 0.5 mg/kg for 1 or 2 weeks

D. Start diuresis with furosemide

E. B, C, and D

Question 30.7 What is the appropriate frequency of testing for responses in CML patients who are currently on imatinib therapy?

A. Bone marrow biopsy every 6 months, RQ-PCR every 3 months for first 2 years, then q4–6 months

B. Bone marrow biopsy every 3 months, RQ-PCR every 6 months for first 2 years, then q4–6 months

C. Bone marrow biopsy every 12 months, RQ-PCR every 3 months for first 2 years, then 358

q4–6 months

D. None of the above

Question 30.8 What constitutes a relapse in a patient with CML who achieved complete hematologic response while on tyrosine kinase inhibitor therapy? (Select two correct responses)

A. Rise of RQ-PCR from 0.01% to 0.05%

B. Drop in platelets from 180,000 to 80,000 ten months into therapy C. Rise in the Ph-positive metaphase levels from 0% to 20% on bone marrow biopsy ten months into therapy

D. None of the above

Question 30.9 What are the expected landmarks that are known to be associated with better outcomes while on imatinib therapy?

A. Complete hematologic response (CHR) at 3 months

B. Major cytogenetic response (MCyR) at 6 months

C. Complete cytogenetic response (CCyR) at 12 months

D. 3-log reduction in BCR-ABL transcripts (MR3) measured by RQ-PCR at 12 months E. Al of the above

Question 30.10 With the advent of tyrosine kinase inhibitors (TKIs), al ogeneic stem cel transplantation (al o-HCT), once a primary therapy for CML, is now reserved for speci c CML patients. What are the indications for al o-HCT in CML? (Select two correct responses) A. Progression to CML accelerated/blast phase

B. Resistance to multiple lines of TKIs but continues to be in chronic phase C. Availability of a matched sibling donor

D. Young patients (<50 years of age)

Question 30.11 What are the current accepted criteria to de ne accelerated phase in CML?

A. Progressive splenomegaly and/or myelofibrosis

B. Bone marrow or peripheral blood blasts ≥15% but <30%

C. Platelet count <100 × 109/L unrelated to therapy

D. Clonal evolution in a Ph-chromosome–positive clone

E. Al of the above

Question 30.12 BCR-ABL translocation leads to the synthesis of the fusion oncoprotein that has constitutive tyrosine kinase activity seen in CML and Ph-chromosome–positive ALL.

What are the resultant BCR-ABL fusion proteins that are commonly found in these patients?

359

1. p210BCR-ABL

2. p230BCR-ABL

3. p190BCR-ABL

4. p250BCR-ABL

A. 1, 3 only

B. 1, 2, 3 only

C. 1, 2, 4 only

D. 2, 3 only

Question 30.13 What are the mutations that are commonly observed in CML blast-phase transformation? (Select three correct responses)

A. Homozygous deletion of p16 tumor suppressor gene

B. Lengthened telomeres

C. Shortened telomeres

D. Loss of BCR-ABL

E. Acquired additional cytogenetic abnormalities.

Question 30.14 Important factors associated with poor prognosis in CLL include the fol owing:

A. CD38 positivity

B. IGHV-unmutated status

C. ZAP-70 expression

D. Short lymphocyte doubling time (<6 months)

E. Al of the above

Question 30.15 A 49-year-old business man was diagnosed with CML 6 months ago and was started on imatinib therapy. He initial y achieved CHR and MCyR at 3 and 6 months, respectively. He does travel frequently and missed a fol ow-up appointment and saw you at 12 months. A repeat bone marrow biopsy showed 45% Ph-positive metaphases. What is the best next approach?

A. Change imatinib to dasatinib/nilotinib

B. Send blood for ABL kinase domain sequencing for possible mutations C. Address the importance of therapy adherence

D. Refer to a transplant physician for al o-HCT

Question 30.16 What is TRUE about autoimmune complications in CLL?

A. The autoantibodies are often polyclonal and are produced by nonleukemic clone B. The severity of the autoimmune phenomenon does not necessarily correlate with the severity of CLL

C. Can lead to hemolytic anemia, thrombocytopenia, granulocytopenia, or pure red cel 360

aplasia

D. Al of the above

Question 30.17 A 67-year-old male presented with a 3-month history of progressive weight loss, weakness, and night sweats. Initial examination showed massive splenomegaly.

Initial CBC revealed WBC of 2.1 cel s/uL (di erential 67% lymphocytes, 15% Neutrophils, 12% monocytes), platelets are 45,000/uL. Peripheral smear showed few large lymphocytes with open chromatin and cytoplasmic projections. Bone marrow biopsy showed that these cel s are positive for CD19, CD20, CD22, CD25, CD103, FMC7, and surface immunoglobulins but negative for CD5 and CD23. What is the recommended treatment?

(Select two correct responses)

A. Cladribine at 0.1 mg/kg/d—continuous infusion for 7 days B. Cladribine at 0.14 mg/kg/d—2-hour infusion for 5 days C. Interferon-α

D. Alemtuzumab

Question 30.18 A 56-year-old man was recently diagnosed with Rai stage 0 CLL. He read about newer therapies and wanted to know when he can start treatment. Which of the fol owing findings would be an indication for initiation of systemic therapy?

A. Availability of newer treatment modalities such as ibrutinib, idelalisib, and CAR-T cel s B. An increase in his absolute lymphocyte count from 25 × 109/L to 40 × 109/L over the last 2 years

C. Recent diagnosis of hypogammaglobulinemia

D. Fever of 38°C for the last 2 weeks without evidence of infection Question 30.19 Which of the fol owing statements are TRUE about rituximab in the treatment of CLL?

A. By targeting CD 20 on normal B-cel s, it can lead to hypogammaglobulinemia requiring immunoglobulin replacements.

B. Maintenance rituximab has shown to improve overal survival in CLL.

C. Rituximab monotherapy with 375mg/m2 IV weekly in frontline setting can achieve 60% CR rates.

D. Along with fludarabine and cyclophosphamide, chemoimmunotherapy with rituximab can achieve excel ent remission rates.

Question 30.20 A 61-year-old female with a history of CLL and 17p deletion was treated with six cycles of FCR and subsequently achieved complete remission. One year later, she started noticing increased di use lymph node swel ing and progressive unintentional weight loss. Initial workup demonstrated WBC count of 1.2 × 105 cu mL and a platelet count of 65,000 cu mL. A repeat lymph node biopsy showed CLL. What is the next best 361

treatment?

A. Ibrutinib 420 mg PO Q daily

B. Ibrutinib 840 mg PO Q daily

C. Ofatumumab

D. Fludarabine + cyclophosphamide + rituximab

E. Al o-HCT

F. None of the above

Question 30.21 Which actionable mutation is present in almost al patients with hairy cel leukemia?

A. EGFR

B. FLT-3

C. BRAF

D. No actionable mutation

Question 30.22 Which of the fol owing statements regarding monoclonal B lymphocytosis (MBL) are TRUE?

A. Rate of progression of MBL to CLL is 1% to 2% per year B. Can be an incidental finding in 3.5% of otherwise normal individuals aged >40

C. Early initiation of therapy is associated with improved survival D. It is a benign finding and is of no significance

362



Question 30.1 The correct answer is E.

The Sokal risk score was developed during the pre-tyrosine kinase inhibitor (TKI) era of CML. It utilizes a complex equation that takes four patient characteristics into account.

These are patient age, percentage of blasts in peripheral blood, platelet count, and spleen size (centimeters below the costal margin). Based on the score, patients were divided into three risk groups and as a predictor of response to non-TKI therapy. It was found to be stil valid in predicting the probability of achieving an optimal response to imatinib.

Question 30.2 The correct answer is C.

Cytogenetic response in CML is based on the conventional bone marrow cytogenetic analysis and is defined as fol ows:

One of the most prognostical y significant landmarks is achieving CCyR at 12 months and many other parameters are based on the likelihood of obtaining this response. For example, for patients who do not achieve a MCyR by 6 months, the probability of obtaining a CCyR at 12 months is 50% or lower.

Question 30.3 The correct answer is A.

Peripheral blood RQ-PCR is a sensitive test that can be used in monitoring for minimal residual disease (MRD) in CML. It is usual y expressed as an absolute ratio of BCR-ABL1

transcripts to a control gene such as ABL1 or as log reductions from the 100% value.

This value is adjusted to a standardized reference IS. It is general y accepted that CCyR

corresponds to an approximately 2-log reduction in transcript levels (MR2) or 1% IS.

Major molecular response (MR3) is defined as a 3-log reduction in transcript levels or 0.1% IS. A complete molecular response (CMR) is general y defined as the absence of detectable BCR-ABL transcripts, a status that depends on the technology and criteria for negativity employed, with the limits of technology being somewhere between MR4 and MR5.

Question 30.4 The correct answer is A.

Currently, imatinib, dasatinib, and nilotinib are the FDA-approved TKIs for frontline use.

363

The choice of therapy depends on patient comorbidities and the individual TKI side-effect profile. Nilotinib associated with hyperglycemia is peripheral vascular disease and is probably not the best choice for this patient. The newer, more potent TKIs induce faster cytogenetic and molecular responses, but in only the imatinib versus nilotinib study this has translated into a significant difference in progression-free survival (PFS) at 3 years. Dasatinib is associated with pleural effusions, pulmonary hypertension and can be associated with significant morbidity in patients with pre-existing pulmonary disease. Imatinib does not have specific contraindications. Until a solid body of evidence that newer TKIs carry a superior survival benefit, imatinib remains a solid first-line choice. The approved doses in the frontline setting are imatinib 400 mg QD, nilotinib 300 mg BID, and dasatinib 100 mg QD. Second-line approved doses are nilotinib 400

mg BID, dasatinib 100 mg QD, bosutinib 500 mg QD, and ponatinib at 30 mg Po QD.

Question 30.5 The correct answer is B.

A loss of disease control in the first 5 years of therapy occurs in approximately 15% of chronic-phase patients treated with imatinib. The majority (40%) of the patients who relapse have point mutations in the ABL kinase domain that render the kinase less sensitive to imatinib. Substitution of threonine by isoleucine in position 315 of the kinase domain (T315I) is the most common mutation that emerges in patients with resistance to newer TKIs. Ponatinib is the only TKI that has activity against T315I mutation. The optimal dose is not defined in this setting although 45 mg daily was used in the PACE clinical trial. When this dose was used in the frontline setting, it led to several cardiac, cerebral, and peripheral vascular thrombotic events in up to 27% of patients and have included fatal myocardial infarction and stroke that led to the early termination of phase III study and further led to a recommended initial dose of 30 mg daily.

Question 30.6 The correct answer is E.

Pleural effusions are one of the common side effects of dasatinib and reported at an incidence of 14% to 54%. They can occur at any time during the therapy and can recur even after a dose reduction. Routine surveil ance chest radiographs and diagnostic thoracentesis are not required and temporary discontinuation of the drug is often enough for spontaneous resolution. In a symptomatic patient such as the current woman, this process can be hastened through diuresis, corticosteroids (often as 0.5

mg/kg of prednisone for 1 or 2 weeks). Pulmonary hypertension is also a rare side effect of dasatinib.

Question 30.7 The correct answer is A.

The optimal monitoring for the achievement of landmarks for someone being treated with imatinib is as fol ows: Bone marrow biopsy every 6 months until CCyR is achieved, RQ-PCR every 3 months for first 2 years, then every 4 to 6 months. With the advent of 364

RQ-PCR standardized to international scale (IS), peripheral blood can be used for molecular surveil ance and the bone marrow biopsies may be avoided in the future.

Question 30.8 The correct answers are B and C.

Relapse on therapy in CML is defined as a loss of a previously obtained response, such as a loss of CHR, loss of CCyR, or increase in RQ-PCR transcript level. Minor changes in RQ-PCR are common and a 2–3 factor increase on international scale is considered normal as accuracy of the test varies substantial y depending on the depth of response. It is important to confirm the rise through a repeat testing before changing the therapy.

Decrease in the previously normal platelet count, constitute a loss of CHR and the rise of Ph-positive metaphase levels from 0% to 20% represents loss of CCyR. Both are considered relapse and warrant for change in therapy.

Question 30.9 The correct answer is E.

Important landmarks that are considered to be associated with good prognosis are CHR

at 3 months, MCyR at 6 months, CCyR at 12 months, and 3-log reduction in BCR-ABL

transcripts (MR3) measured by RQ-PCR at 12 months. Of al these parameters, CCyR at 12 months is considered the most important prognostic landmark and the other parameters predict the likelihood of achieving this response. Of note, patients who achieve a CCyR at 12 months but did not achieve MR3 tend to achieve this eventual y without any further intervention. Patients who do not achieve these landmarks on first-line therapy constitute primary cytogenetic resistance, an event that occurs rarely, is associated with persistent cytopenias and considered to be a poor risk category.

Question 30.10 The correct answers are A and B.

With the advent of imatinib and newer TKIs, hematopoietic cel transplantation (HCT) for chronic-phase CML has decreased significantly. But HCT stil remains an effective therapy for patients who are resistant to TKIs and remain in chronic phase and for patients with advanced phase disease whose leukemia can be restored to the chronic phase. Reduced-intensity conditioning regimens (AKA nonmyeloablative regimens) have shown to be superior to myeloablative HCT in patients >60 years of age with disease-free survival ranging from 40% to 85% at 3 to 5 years. However, infections and acute and chronic graft versus host disease remain significant problems.

Question 30.11 The correct answer is E.

The current accepted criteria for the diagnosis of accelerated phase include (1) progressive splenomegaly and myelofibrosis; (2) bone marrow or peripheral blood blasts

≥15% but <30%; (3) bone marrow or peripheral blood blasts plus promyelocytes

≥30%; (4) bone marrow or peripheral blood basophils ≥20%; (5) platelet count <100

× 109/L unrelated to therapy; and (6) clonal evolution in a Ph-chromosome–positive 365

clone. The blastic phase is defined as bone marrow or peripheral blood blast ≥30% or the presence of extramedul ary blast infiltrates.

Question 30.12 The correct answer is B.

Breakpoints within BCR localize to one of three breakpoint cluster regions that lead to three different sized BCR-ABL1 transcripts in CML. More than 90% of CML patients and one-third of Ph-positive ALL patients express the 210 kDa due to a breakpoint in major breakpoint cluster region (M-bcr), which spans exons e12–e16 (formerly exons b1–b5).

The remainder of Ph-positive ALL patients and rare CML cases harbor breakpoints in minor breakpoint cluster region ( m-bcr), generating an e1a2 transcript that is translated into p190BCR-ABL1. A third breakpoint down-stream of exon 19 (e19a2) in the micro breakpoint cluster region (μ-bcr) gives rise to p230BCR-ABL1 and is associated with neutrophilia.

Question 30.13 The correct answers are A, C, and E.

Disease progression is believed to be due to the accumulation of molecular abnormalities that lead to a loss of terminal differentiation capacity of the leukemic clone, which continues to depend on BCR-ABL1 activity. The molecular basis is poorly defined, but point mutations or deletions in the p53 tumor suppressor gene have been observed in up to 25% of patients with myeloid blast crisis, and as many as 50% of patients with lymphoid transformation show a homozygous deletion in the p16 tumor suppressor gene. Studies have demonstrated that telomere length decreases with disease progression from chronic to blast phase. Clonal evolution in a Ph-chromosome–positive clone is one of the causative and accepted criteria for progression of CML into advanced phase.

Question 30.14 The correct answer is E.

CD38 positivity, IGHV-unmutated status, ZAP-70 expression, and Short lymphocyte doubling time (<6 months) are associated with shorter survival. ZAP-70 is normal y expressed on T-cel s. Its expression on CLL cel s (B cel s) is associated with activation of these malignant cel s. Zap-70 expression is associated with IGHV-unmutated state, increased disease progression, and worse overal survival. Other factors associated with shortened survival in CLL are diffuse pattern of bone marrow infiltration, advanced age and male gender, abnormal karyotype, high serum levels of β2-microglobulin and soluble CD23, and a CLL-PLL category (11% to 54% prolymphocytes in the blood).

Question 30.15 The correct answer is C.

This patient developed relapsed disease based on the loss of MCyR and that he did not attain CCyR at 12 months probably secondary to noncompliance. Before considering the change of therapy, patient compliance and development of resistance to TKIs need to be addressed. Noncompliance is one of the important reasons for loss of therapy and 366

adherence to therapy needs to be addressed in every visit. In a compliant patient, resistance to therapy should be considered and investigated by testing for ABL kinase domain mutations (particularly for T315I mutation).

Question 30.16 The correct answer is D.

Autoantibodies in CLL are often polyclonal and are Ig G, indicating that they are not produced by the leukemic clone. They are usual y targeted against hematopoietic cel s and can lead to cytopenias of any of the three lineages (RBC, WBC, and platelets) or can lead to hemolytic anemia. The severity of the autoimmune phenomenon does not necessarily correlate with the severity of CLL, and such events may develop in patients whose disease is responding to therapy.

Question 30.17 The correct answers are A and B.

This patient has hairy cel leukemia (HCL), a rare B-cel lymphoproliferative disorder that comprises 2% of al leukemias. Classic “hairy cel s” are seen on the peripheral smear albeit less frequently. These cel s are positive for B-cel markers CD19, CD20, CD22, and CD25. CD103 positivity obviated the need for tartrate-resistant acid phosphatase (TRAP) testing. Pentostatin and cladribine are the major treatment options for HCL.

Cladribine at 0.1 mg/kg/d given either as continuous infusion for 7 days or at 0.14

mg/kg/d as 2-hour infusion for 5 days is the preferred frontline therapy. Interferon-α is reserved for relapsed HCL. Prolymphocytic leukemia (PLL), an important differential diagnosis for HCL, is often associated with lymphocytosis, the prolymphocytes have prominent nucleoli and are negative for CD25 and CD103. Nucleoside analogues and alemtuzumab are treatment options for PLL.

Question 30.18 The correct answer is D.

The IWCLL revised criteria for active disease, an indication to initiate treatment include constitutional symptoms attributable to CLL: weight loss (>10% of baseline weight within the preceding 6 months), extreme fatigue (ECOG performance status ≥2), fever (temperature higher than 38°C or 100.5°F for at least 2 weeks) or night sweats without evidence of infection; evidence of progressive bone marrow failure characterized by the development of or worsening of anemia and/or thrombocytopenia; autoimmune hemolytic anemia and/or autoimmune thrombocytopenia, poorly responsive to corticosteroid therapy; massive (>6 cm below the left costal margin) or progressive splenomegaly; bulky (>10 cm in longest diameter) or progressive lymphadenopathy; and progressive lymphocytosis defined as an increase in the absolute lymphocyte count by >50% over a 2-month period, or a doubling time predicted to be <6 months.

Hypogammaglobulinemia or monoclonal gammopathy alone is not a sufficient criterion to initiate therapy. Disease course in low- or intermediate-risk groups is not uniform and can be indolent or rapidly progressive. Of note, approximately one-third of patients with early-stage never require therapy. It is known that early treatment of low-grade patients 367

does not translate into better survival. Newer better therapies such as ibrutinib, idelalisib, chimeric antigen receptor–bearing T-cel (CAR-T cel s), BCL-2 inhibitors, and lenalidomide have been shown to be effective in relapsed and refractory CLL. However, it is unknown whether treating the low-risk patients with these novel agents improves survival.

Question 30.19 The correct answer is D.

Rituximab is a chimeric immunoglobulin IgG1 CD20 monoclonal antibody (mAb) that became an important adjunct in the treatment of CLL. It does not have significant activities in CLL when used as monotherapy but when used in combination with fludarabine and cyclophosphamide it demonstrated superior remission rates (95% in FCR arm vs. 88% with FC), improved PFS (52 months vs. 33 months with FC) and OS

(84% vs. 79% at 38 months with FC). Maintenance rituximab has not been routinely used in patients with CLL. Although rituximab targets normal B cel s, studies have shown that there is no significant effect on immunoglobulin levels.

Question 30.20 The correct answer is A.

Del(17p) is associated with poor prognosis and shortened survival in patients with CLL.

Ibrutinib is a Bruton tyrosine kinase (BTK) inhibitor that has shown promising overal response rate in the relapsed and fludarabine-refractory setting. Similar responses were noted across risk categories, including for high-risk del(17p), heavily pretreated, and advanced stage disease. The 2-year PFS rate was 75% and OS rate was 83% with durable responses. Ibrutinib is approved at a dose of 420 mg PO once daily in the relapsed/refractory setting and as such is the preferred choice of treatment for this patient population. While al o-SCT was associated with long-term remissions and possible cure, with the availability of newer therapies, it may be reserved for patients with high-risk and relapsed CLL.

Question 30.21 The correct answer is C.

BRAF V600E mutation is present in almost al cases of hairy cel leukemia (HCL). It is currently being explored as a potential therapeutic target using vemurafenib in relapsed HCL patients.

Question 30.22 The correct answer is A and B.

Monoclonal B lymphocytosis (MBL) is an often incidental diagnosis of defined as a population of clonal CD5+/19+/23+ B cel s in up to 3.5% of otherwise normal individuals over the age of 40. These individuals are often asymptomatic with no adenopathy or splenomegaly. Furthermore, as many as 13% of family members of patients with familial CLL harbor a population of cel s with an immunophenotype consistent with CLL, but do not fulfil CLL diagnostic criteria. It is estimated that the rate of progression from MBL to CLL is 1% to 2% per year. Currently, there is no 368

indication to perform screening for MBL.

Corresponding chapters in Cancer: Principles & Practice of Oncology, Tenth Edition: 108

(Molecular Biology of Chronic Leukemias), 109 (Chronic Myelogenous Leukemia), and 110

(Chronic Lymphocytic Leukemias).

369





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 31.1 A healthy and active 62-year-old man presents to his primary care physician for a routine annual physical. A complete metabolic panel is signi cant for an elevated total protein of 10 mg/dL, an albumin of 4 mg/dL, a creatinine of 0.6 mg/dL, and a calcium of 8.8 mg/dL. A complete blood count shows a white blood cel count of 5.2, a hemoglobin of 12 g/dL, and a platelet count of 242. Subsequent serum protein electrophoresis and immuno xation shows an IgG kappa monoclonal peak of 0.9 g/dL.

Serum-free light chains show a total kappa-free light chain concentration of 242 mg/dL

and a lambda-free light chain concentration of 1.2 mg/dL. A skeletal survey shows no evidence of lytic lesions and a bone marrow biopsy reveals a monoclonal plasma cel population comprising 70% of the core biopsy sample. Which of the fol owing management options should be pursued next?

A. Initiation of antimyeloma therapy

B. Repeat SPEP in 12 months

C. Obtain a HeavyLite Assay

D. Fusion PET/MRI scanning to assess need for therapy

Question 31.2 A 65-year-old man presents to a local emergency room with fatigue, myalgias, and lightheadedness. Laboratory evaluation reveals a white blood cel count of 7.5, a hemoglobin of 6.3 g/dL and a platelet count of 135. Chemistry panel shows a creatinine of 1.56 mg/dL and a calcium of 14.0 mg/dL. Workup of his anemia includes a serum protein electrophoresis that shows a monoclonal protein at a concentration of 4.0

g/dL. Serum immuno xation reveals an IgA kappa monoclonal protein. Bone marrow biopsy shows a kappa-restricted plasma cel population comprising 30% of the core biopsy.

Cytogenetics reveal hypodiploidy and FISH studies show t(4;14). Which of the fol owing best characterizes the risk category of this patient’s multiple myeloma?

A. High Risk due to FISH findings of t(4;14)

B. High Risk due to cytogenetic findings of hypodiploidy C. Intermediate Risk by FISH and cytogenetics

D. Standard Risk by FISH and cytogenetics

Question 31.3 A 52-year-old woman presents to her Oncologist 1 year fol owing an 370

autologous stem cel transplantation for multiple myeloma. She has been continued on maintenance therapy fol owing her transplant and has tolerated this wel . She reports that she watched a television documentary about genomics a week prior to her appointment and asks her physician what genomic sequencing has revealed in multiple myeloma. Which of the fol owing is the best response?

A. Genomic sequencing has revealed a conserved set of consistent mutations in TP53

and CCND1 for patients with multiple myeloma.

B. Mutations in VHL are common.

C. Deep sequencing has revealed that there is a consistent pattern of clonal evolution in multiple myeloma.

D. There have been few consistently mutated genes, but the most common include KRAS and NRAS.

Question 31.4 A 69-year-old woman is diagnosed with an IgG lambda multiple myeloma.

Her initial labs reveal a monoclonal peak of 4.5 g/dL, with lambda-free light chains of 120

mg/dL and kappa-free light chains of 1.1 mg/dL. A bone marrow biopsy showed 50%

involvement by a lambda-restricted plasma cel population. She began induction with lenalidomide and dexamethasone and attained a very good partial response after four cycles of therapy. She undergoes autologous stem cel transplant and on workup 100 days post-transplant, a bone marrow biopsy shows no evidence of persistent plasma cel s. Serum protein electrophoresis and immuno xation are negative for any evidence of monoclonal protein. Serum-free light chains are repeated and are normal. She has minimal residual disease testing performed as part of a clinical trial, which shows her to have persistent disease by multiparameter ow cytometry (MFC). What would be the appropriate information to pass onto the patient regarding this finding?

A. She needs to have the testing repeated using next-generation–based sequencing technology.

B. The patient should undergo repeat ASCT with a goal to obtain minimal residual disease (MRD) negativity.

C. MRD positive patients have inferior PFS when compared to patients achieving stringent CR who are MRD negative.

D. There are no differences in outcomes among patients achieving a CR regardless of MRD status.

Question 31.5 A 59-year-old man has a new diagnosis of multiple myeloma made after he presented with a monoclonal peak of 6.0 g/dL, IgG-Lambda by serum immuno xation. CBC

showed a hemoglobin of 9.5 g/dL and a metabolic panel revealed no abnormalities. Bone marrow biopsy reveals evidence of 65% involvement by a lambda-restricted monoclonal plasma cel population. He is deemed to be an appropriate candidate for autologous transplantation. He starts therapy with bortezomib, lenalidomide, and dexamethasone which he tolerates wel . After 3 cycles of therapy, his M-spike has improved to 4.8 g/dL, and 371

after 6 cycles of therapy his M-spike is 4.0 g/dL. Which of the fol owing is the next best step in management?

A. Continue bortezomib, lenalidomide, and dexamethasone until nadir value achieved and then proceed to autologous transplantation

B. Proceed to autologous stem cel transplantation

C. Carfilzomib-based salvage therapy for 4 to 6 cycles and then proceed to autologous transplantation

D. Switch to carfilzomib-based regimen and abandon plans for autologous transplantation

Question 31.6 A patient with a history of multiple myeloma presents to your clinic with a newspaper clipping describing some recent successes with monoclonal antibodies in this disease. The patient is curious about the role of these potential new drugs in therapy and inquires about their mechanism of action. Which of the fol owing is accurate regarding the new medications in this class?

A. In a phase III trial, the PFS difference noted at 1 year was maintained at 2 years on therapy with elotuzumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone.

B. Daratumumab had a high rate of discontinuation due to adverse events.

C. Daratumumab has no activity in patients with extra-medul ary disease.

D. In a phase III trial, elotuzumab in combination with lenalidomide and dexamethasone produced responses even in lenalidomide refractory patients.

Question 31.7 A 63-year-old man with a history of multiple myeloma presents to clinic for ongoing evaluation. He was diagnosed 3 years ago, and received induction treatment with bortezomib, lenalidomide, and dexamethasone fol owed by autologous stem cel transplantation. On workup today, he has evidence of progressive disease with a rising monoclonal protein from 1.0 g/dL to 3.2 g/dL. His performance status is ECOG 0, and the treating physician makes the decision to initiate panibinostat, bortezomib, and dexamethasone. Which of the fol owing regarding panibinostat should the physician inform the patient prior to initiation?

A. Potential for serious and possibly fatal arrhythmia

B. Risk of Stevens–Johnson syndrome

C. Diarrhea is self-limiting and transient

D. Risk for hemolytic uremic syndrome

Question 31.8 A 65-year-old man with a history of multiple myeloma presents for initial evaluation. He was diagnosed 1 year ago and underwent initial induction therapy with bortezomib, cytoxan, and dexamethasone, fol owed by autologous stem cel transplantation approximately 6 months ago. He was not treated with maintenance therapy fol owing transplant due to his personal preference. He presents now with worsening anemia 372

(hemoglobin 9 g/dL) and a rising M-protein level (0.8 g/dL to 4.5 g/dL). What is the most appropriate statement regarding the role of carfilzomib therapy in this setting?

A. In a phase III trial, patients treated with lenalidomide and dexamethasone had improved progression-free survival compared to those treated with carfilzomib, lenalidomide, and dexamethasone.

B. In a phase III trial, patients treated with the combination of carfilzomib, lenalidomide, and dexamethasone had inferior health-related quality of life compared to those treated with lenalidomide and dexamethasone alone.

C. In a phase III trial, the benefit of carfilzomib (20/56 mg/m2) and dexamethasone was limited to patients who had no prior exposure to bortezomib.

D. In a phase III trial, carfilzomib (20/56 mg/m2) and dexamethasone was associated with a doubling of PFS when compared to bortezomib (1.3 mg/m2) and dexamethasone.

Question 31.9 A 57-year-old previously healthy woman presents to her primary care physician with fatigue and weight loss over the preceding 3 months. Physical examination reveals palpable lymphadenopathy in the axil a bilateral y. Workup is signi cant for a WBC

count of 7.3, a hematocrit of 21%, and a platelet count of 42. A metabolic panel is within normal limits. SPEP and immuno xation reveal an IgM monoclonal protein and a bone marrow biopsy shows a lymphoplasmacytic in ltrate comprising 20% of the marrow. Serum viscosity is within normal limits. She is initial y treated with bortezomib, rituximab, and dexamethasone with a partial response. One year later she now has a recurrence of symptoms. A tumor sample is sent for exome sequencing studies. Which of the fol owing is most likely to predict for best response to BTK inhibitor therapy?

A. MYD88 L365P mutation positive and CXCR4 mutation negative B. MYD88 L365P mutation negative and CXCR4 mutation negative C. MYD88 L365P mutation positive and CXCR4 mutation positive D. Presence of CXCR4 WHIM mutation irregardless of MYD88 status Question 31.10 A 52-year-old man presents to your clinic for an initial consultation. He was referred after he was noted to have lower extremity edema and further workup revealed the presence of a nephrotic syndrome. He underwent a renal biopsy which showed evidence of amyloid deposition, positive by Congo red staining. His labs revealed a kappa-free serum light chain concentration of 140 mg/L and a lambda-free light chain concentration of 2 mg/L. His NT-proBNP is 10,000 ng/L and his troponin is 0.09 ng/mL.

His performance status is rated as an ECOG 1. What should be the next step in management?

A. Start cyclophosphamide, bortezomib, and dexamethasone B. Autologous stem cel transplantation with melphalan 140 g/m2

373

C. Autologous stem cel transplantation with melphalan 200 g/m2

D. Start therapy with ixazomib-based therapy

374

Question 31.1 The correct answer is A.

The International Myeloma Working Group released an update to the criteria for diagnosis of multiple myeloma in 2014 [Rajkumar et al. Lancet Oncol. 2014;15:e538–

e548]. Historical y defined by the presence of the CRAB (hypercalcemia, renal failure, anemia, or bony disease) criteria, denoting the presence of end-organ damage, the newly updated criteria include a number of radiographic or biochemical criteria. These take into account the potential benefits available to patients from expanding and improved treatment options and data that show early intervention in high-risk asymptomatic patients improves survival [Mateos et al. N Engl J Med. 2013;369:438–

447]. The defining criteria for multiple myeloma now include a clonal bone marrow plasma cel population ≥10% or biopsy-proven bony or extramedul ary plasmacytoma and one or more of the fol owing defining elements:

• Evidence of end-organ damage attributed to the plasma cel disorder

• Hypercalcemia (>1 mg/dL above ULN or >11 mg/dL)

• Renal insufficiency (CrCl <40 or sCr >2 mg/dL)

• Anemia (Hbg >2 g/L below LLN or an Hbg <10 g/L

• Bone lesions (one or more osteolytic lesions on radiograph, CT or PET-CT)

• Any of the fol owing biomarkers of malignancy:

• Clonal bone marrow population ≥60%

• Involved:uninvolved serum-free light chain ratio ≥100 (The involved free light chain must be ≥100 mg/L)

• >1 focal lesions on MRI

Since this patient’s bone marrow biopsy reveals a monoclonal plasma cel population encompassing 70% of the bone marrow, he meets the diagnosis of multiple myeloma based on the newly established criteria. Additional y, this patient’s ratio of involved:uninvolved serum-free light chains is >100, with an involved chain concentration >100 mg/L. By current definition the patient has overt multiple myeloma and wil benefit from treatment with an active antimyeloma regimen. Under prior definitions of multiple myeloma the patient would have been classified as smoldering multiple myeloma, and repeating the SPEP and labs would be a reasonable approach. The HevyLite assay is a novel technique of quantifying intact light and heavy chain monoclonal proteins. It measures intact immunoglobulin proteins by measuring unique junctional epitopes between heavy and light chain constant regions. This is particularly useful for IgA monoclonal proteins which often have limited detection by serum protein electrophoresis, but other roles in multiple myeloma are currently under investigation. Fusion PET-MRI is an evolving imaging strategy in multiple myeloma and its role is currently being evaluated.

Question 31.2 The correct answer is C.

375

Prognosis in multiple myeloma is dependent on several factors, including age, comorbidities, stage, and disease biology. FISH and cytogenetic studies are ideal to assess for the presence of genetic alterations and are crucial to pursue for newly diagnosed patients. Integrating these factors, a risk classification system for newly diagnosed multiple myeloma has been developed by the Mayo clinic, the Mayo Stratification for Myeloma and Risk-adapted Therapy (mSMART) criteria [Mikhael et al. Mayo Clin Proc 2013;88:360–376]. This divides newly diagnosed patients into risk categories based on cytogenetics, FISH, gene expression profiling (GEP) and plasma cel labeling index studies. High-Risk patients are defined by a high-risk GEP signature, or FISH studies showing deletion of 17p, t(14;16), or t(14;20). Intermediate-risk disease is denoted by a high plasma cel S-phase labeling study, FISH showing t(4;14), 1q gain, cytogenetics with a complex karyotype, deletion 13 or hypodiploidy. Standard risk disease encompasses al other abnormalities. Mikhael et al. report overal survival and incidence rates for mSMART risk classes as fol ows:

• High-risk: incidence of 20% with a median OS of 3 years

• Intermediate-risk: incidence of 20% with a median OS of 4 to 5 years

• Standard-risk: incidence of 60% with a median OS of 8 to 10 years Risk-adapted strategies to improve these outcomes have been investigated in multiple myeloma, particularly for patients with high-risk multiple myeloma. In the HOVON-65/GMMG-HD4 trial [Sonneveld et al. J Clin Oncol. 2012;30(24):2946] newly diagnosed multiple myeloma patients were randomized to bortezomib-based induction fol owed by bortezomib post-transplant maintenance therapy versus thalidomide posttransplant maintenance. Significant improvement in PFS and median OS was seen in 17p-deleted patients who were randomized to bortezomib-based therapy. A further phase II study [Nooka et al. Leukemia. 2014;28(3):690–693] evaluated the efficacy of lenalidomide, bortezomib, and dexamethasone maintenance therapy fol owing autologous transplantation. Given for up to 3 years, fol owed by lenalidomide maintenance, the study had a median PFS of 32 months and a 3-year OS of 93%.

Further research is necessary to determine the most appropriate strategy to mitigate adverse outcomes in patients with high-risk disease.

Question 31.3 The correct answer is D.

The initial study evaluating the genomic architecture of multiple myeloma was published in 2011 [Chapman et al. Nature. 2011;471:467–472]. These findings, which evaluated sequencing of 38 tumor genomes revealed a lack of consistently conserved mutations among individual multiple myeloma genomes. The most frequent mutations included those in NRAS (9/38) and KRAS (10/38). Frequent mutations were also seen in genes involved in RNA processing and protein homeostasis, including DIS3, XBP1, LRRK2, and FAM46C. The NF-kB pathway was the most frequently affected pathway, with mutations and rearrangements noted in 11 NF-kB pathway genes. Additional mutations were seen in histone-modifying enzymes, including HOXA9. One genome 376

contained a possibly clinical y actionable mutation in BRAF. An additional analysis genotyping 161 multiple myeloma patients found 7 BRAF mutations, which raised the possibility of benefit from BRAF inhibitors. Overal , there are few consistently mutated genes in the multiple myeloma genome, with the most commonly mutated being NRAS

and KRAS.

Two additional studies have investigated an additional 203 patients [Lohr et al.

Cancer cel . 2014. 25:91–101] and 67 patients [Bol i et al. Nat Commun. 2014;5] using whole-genome and whole-exome sequencing to identify frequent mutations in multiple myeloma. These studies supported the frequent mutations in KRAS, NRAS, FAM46C, and BRAF. Subclonal structure was investigated in these studies, revealing complex structures with clusters of subclonal variants and driver mutations, including frequent mutations in the same pathway within single patients. Serial sampling revealed diverse patterns of clonal evolution, with significant heterogeneity across samples.

Question 31.4 The correct answer is C.

There is a clear link between depth of response and prolonged survival in multiple myeloma. Autologous stem cel transplantation has been successful in producing deep responses among eligible patients, and deeper responses have been found to be associated with improved clinical outcomes [Lahuerta et al. J Clin Oncol.

2008;26(35):5775–5782]. Likewise, novel agents have al owed an increasing number of transplant ineligible patients to achieve a deep response and overal depth of response has been associated with improved outcomes in this population as wel [Gay et al. Blood.

2011;117(11):3025–3031]. With modern regimens capable of producing high rates of CR, it is felt that one needs to define even greater depths of response to distinguish therapies and better prognosticate among individual therapies. The definition of a stringent CR (including normalization of serum-free light chains and absence of clonal PCs in Bone Marrow Biopsy) was meant to address this issue, and achievement of a stringent CR has been shown to be predictive of improved overal survival [Kapoor et al. J

Clin Oncol. 2013;31(36):4529–4535].

Modern technology permits us to define yet deeper levels of disease response. Several technologies have been utilized to detect MRD, MFC, next-generation sequencing (NGS), and al ele-specific oligonucleotide-based quantitative polymerase chain reaction (ASO-PCR). Levels of detection of these technologies enable the identification of as low as 1 cel in 100,000 for MFC and 1 in 1,000,000 for NGS and ASO-PCR. ASO-PCR

analysis is largely a research tool requiring patient-specific probes to be generated for MRD assessment. The clonoSEQ MRD assessment is a commercial y available tool, which utilizes NGS of the IgH V(D)J regions to monitor MRD in multiple myeloma patients.

The utility of MRD assessment has been investigated in several clinical trials. In the PETHEMA/GEM 2000 study, patients who were negative by multiparameter flow cytometry for MRD after ASCT had significantly improved PFS and OS rates. Likewise in the MRC Myeloma IX study, MRD negativity after ASCT correlated with improved PFS

377

and OS. This has also been observed in the transplant ineligible population with patients showing molecular CR after induction therapy having a statistical y significant improvement in PFS over those with MRD-positivity [Puig et al. Leukemia.

2014;28(2):391–397].

Martinez-Lopez et al. evaluated the clonoSEQ method of monitoring MRD assessment in a study assessing 133 multiple myeloma patients who had achieved at least a very good partial response (VGPR) fol owing frontline therapy [Martinez-Lopez et al. Blood.

2014;123(20):3073–3079]. MRD was assessed by the IgH-V(D)J sequencing technique utilized by the clonoSEQ commercial assay and compared and contrasted with those of the MFC and ASO-PCR techniques. A total of 91% of patients were effectively sequenced using the novel NGS technique, and concordance with the MFC

and ASO-PCR techniques was 83% and 85%, supporting the widespread applicability and accuracy of the method. Patients who were MRD negative by sequencing had a significantly longer time to progression (median 80 vs. 31 months, P < 0.001) and overal survival (median not reached vs. 81 months, P = 0.02). A total of 92% of VGPR

patients were MRD positive. Time to progression improved continuously with decreasing levels of residual disease detected. Among patients achieving a complete response (CR) the time to progression was longer for MRD negative patients versus those who were MRD positive (131 months vs. 35 months, P = 0.0009).

At this time, MRD assessment remains a research tool. Though several publications now seem to suggest that patients who are MRD negative after a finite period of therapy do better than those who are MRD positive, there is no data to support giving additional therapy to patients who are not MRD negative to improve outcomes. Additional y, there is no current consensus on the definition of MRD negativity with both flow cytometry and deep sequencing–based technology having their advantages and disadvantages.

Question 31.5 The correct answer is B.

The optimal depth of disease response necessary to proceed with autologous stem cel transplantation has been a matter of controversy. Previously, data have suggested that patients with a better pretransplant paraprotein nadir have had improved outcomes

[Wang et al. Bone Marrow Transplant. 2010;45:498–504.]. However, some centers had experienced benefit for patients even with disease progression after initial induction therapy [Kumar et al. Bone Marrow Transplant. 2004;34:161–167]. A recently published study evaluated the outcomes of patients who had achieved less than a partial response to initial treatment for their multiple myeloma [Vij et al. Biol Blood Marrow Transplant.

2015;21(2):335–341]. A total of 539 patients were identified who had an ASCT after less than a PR to initial chemotherapy. While additional pretransplant chemotherapy resulted in deepening responses in 68% of patients, there was no impact of pretransplant salvage chemotherapy on treatment-related mortality, progression-free survival, or overal survival. Additional pretransplant therapy for those who achieved less than a PR to initial chemotherapy was not found to be beneficial in this large study.

Based on their analysis, switching to carfilzomib-based therapy would likely have little 378

impact. Transplant stil offers the best option for prolonged PFS.

Question 31.6 The correct answer is A.

Currently, there are several monoclonal antibodies under investigation in multiple myeloma. Daratumumab targets CD38, and elotuzumab is a CS-1/SLAMF7 targeting antibody. Elotuzumab is postulated to function solely via immune-mediated processes, while daratumumab has dual effects including direct action on multiple myeloma cel s as wel as immune stimulation targeting tumor cel s. The ELOQUENT-2 trial was a phase III trial comparison of elotuzumab in combination with lenalidomide and dexamethasone to lenalidomide and dexamethasone alone [Lonial et al. N Engl J Med.

2015;373:621–631]. The median PFS was 19.4 months for elotuzumab compared with 14.9 months with lenalidomide and dexamethasone. The absolute PFS differences at 1 and 2 years were 11% (68% vs. 57%) and 14% (41% vs. 27%). The hazard ratio for progression of disease at 2 years was 0.70 [0.57–0.85] which implies a 30% overal reduction in risk for disease progression. This long-term response to therapy raises the possibility that a subset of patients may have prolonged benefit with the drug and increases the likelihood that an overal survival benefit may be appreciated with longer-term fol ow-up. Notably, this trial excluded patients who were refractory to lenalidomide and it is not known if the addition of elotuzumab wil prove effective in patients whose disease has progressed on lenalidomide alone.

The SIRIUS trial was a phase II study of single-agent daratumumab in patients who had received >3 lines of prior therapy or were double refractory to a proteasome inhibitor and an immunomodulatory drug [Lonial et al. J Clin Oncol. 2015;33(suppl; abstr LBA8512)]. Among 106 patients with relapsed and refractory multiple myeloma who had been treated with a median of 5 prior lines of therapy (range 2 to 14), single-agent daratumumab produced an overal response rate (ORR) of 29% in this population.

Among these responses, 3% were stringent CRs and 12% were a VGPR, despite the late-stage disease population that was enrol ed. Responses were seen regardless of age, number, and type of prior therapy, or the presence or absence of extramedul ary disease.

The median duration of response was 7.4 months with a progression-free survival of 3.7

months (95% CI [2.8, 4.6]) and a 1-year overal survival (OS) rate of 65% (95% CI

[51.2, 75.5]). Median OS data are not yet available (not reached). Among enrol ed patients, 95% were refractory to a proteasome inhibitor and an immunomodulatory drug. A total of 42% were refractory to bortezomib, lenalidomide, carfilzomib, pomalidomide, and/or thalidomide. The SIRIUS study also showed that daratumumab had a response rate of 20% in patients with extramedul ary disease. Overal , daratumumab was wel tolerated with no discontinuations due to adverse events attributable to the drug.

Question 31.7 The correct answer is A.

Panibinostat is a histone deacetylase (HDAC) inhibitor that was approved by the FDA in 379

combination with bortezomib and dexamethasone for use in patients with multiple myeloma who had received at least two lines of prior therapy, including bortezomib and an immunomodulatory drug. The efficacy of panibinostat has been investigated in a large phase III study, the PANORAMA-1 trial [San-Miguel et al. Lancet. 2014;15:1195–

1206]. In this study, 768 patients with relapsed/refractory multiple myeloma who had received between 1 and 3 prior lines of therapy were randomized to receive either panibinostat, bortezomib, and dexamethasone or bortezomib and dexamethasone. With a median fol ow-up of 6.5 months, median progression-free survival was longer in the panibinostat group (12 months) versus patients treated with a doublet (8.1 months).

The overal response rate was not different between groups (61% for the panibinostat arm versus 54.6%). Survival data continue to mature, but were not different between groups. Serious adverse events were reported in 60% of the panibinostat patients and 42% of the placebo group. Diarrhea was common (68%) in panibinostat patients and was severe (requiring IV fluids or hospitalization) in 25% of patients. Cardiac deaths were increased on the panibinostat arm, prompting a Boxed Warning over the risk of ischemic events or arrhythmia. Excessive diarrhea is also included in this warning due to its high incidence in the panibinostat-treated patients. Recommendations for management of diarrhea for patients on panibinostat include initiation of antidiarrheal medications at the first sign of symptoms and interruption of dose until symptom resolution for those with at least 4 stools per day. Panibinostat may be resumed at its prior dose for those with 6 or less stools per day, and dose adjustments are necessary for those with ≥7 stools daily. There was no increase in the rates of hemolytic uremic syndrome or Stevens–Johnson syndrome among patients taking panibinostat.

Thrombocytopenia was a common toxicity, occurring in 67% of panibinostat patients and 37% of the bortezomib and dexamethasone arm. Platelet counts <50 should be monitored weekly, while a drop below 25 or any evidence of bleeding should result in holding panibinostat until improvement in counts (>50) and a resumption of panibinostat at a lower dose.

Question 31.8 The correct answer is D.

The ASPIRE trial was a randomized, open-label, multicenter phase III study of carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma [Stewart et al. N Engl J

Med. 2015;372:142–152]. The patients al had relapsed multiple myeloma with 1 to 3

prior lines of treatment, and patients with lenalidomide were eligible so long as they had not progressed on lenalidomide and dexamethasone. With a median fol ow-up of 32

months, the primary endpoint, progression-free survival, was superior for the three-drug combination (26.3 months vs. 17.6 months; P = 0.0001), and median OS was not reached for either cohort. The Kaplan–Meier 24-month OS rates were 73.3% in the three-drug regimen and 65.0% in the two-drug regimen. Grade 3 or higher adverse events were reported in 83.7% of the three-drug group and 80.7% of the two-drug regimen. There were similar rates of trial discontinuation due to adverse events in the 380

three- and two-drug regimens (15.3% vs. 17.7%). Other side effects occurred at similar rates in the two arms: dyspnea (2.8% in KRd vs. 1.8% in Rd), cardiac toxicity (3.8% in KRd and 1.8% in Rd), and peripheral neuropathy (17.1% in KRd and 17.0% in Rd).

There appeared to be a higher rate of high blood pressure in the KRd arm (14.3 percent vs. 6.9 percent). Patient-reported health-related quality of life was higher in the KRd arm as compared to the Rd arm.

Evaluating the role of doublet therapy in relapsed and refractory multiple myeloma, the ENDEAVOR trial was a large phase III comparison of the second-generation proteasome inhibitor carfilzomib in combination with dexamethasone to bortezomib and dexamethasone [Dimopoulos et al. J Clin Oncol. 2015:33(suppl; abstr LBA8509)]. It demonstrated that carfilzomib at a dose of 56 mg/m2 resulted in a PFS of 18.7 months compared with 9.4 months for bortezomib (1.3 mg/m2) and dexamethasone. The benefit was seen in both patients who had prior exposure to bortezomib (15.6 months vs.

8.1 months) and no prior bortezomib exposure (not reached vs. 11.2 months). This benefit was also maintained across age subgroups. The median duration of treatment was 40 weeks for carfilzomib/dexamethasone versus 27 weeks for bortezomib and dexamethasone. A total of 23% of patients receiving carfilzomb and dexamethasone required a dose reduction due to toxicity compared with 47% of patients receiving bortezomib and dexamethasone. Treatment with carfilzomib was associated with higher rates of hypertension (25% vs. 9%) and somewhat higher rates of cardiac failure (8%

vs. 3%).

Question 31.9 The correct answer is A.

MYD88 is a protein that interacts in tol -like receptor and IL-1 signaling and has been implicated in prolonged B-cel survival. Activating point mutations in MYD88 such as the L265P mutation have been implicated in the pathogenesis of Waldenstrom’s macroglobulinemia (WM) [Hunter et al. Blood. 2014;123(11):1637–1646]. This study, likewise, found frequent activating CXCR4 mutations in patients with WM. These mutations in CXCR4 are similar to germline mutations detected in patients with the WHIM syndrome (warts, hypogammaglobulinemia, infection, and myelokathexis). At least 30 different WHIM mutations have been described in WM, and in vitro tumor cel s engineered to express CXCR4 WHIM receptors have been shown to have decreased ibrutinib-related apoptosis [Cao et al. Leukemia. 2015;29:169–176]. Ibrutinib has been recently investigated in WM and approved by the FDA for treatment of these patients.

This approval was based on findings from a phase II study of ibrutinib in 63 patients with symptomatic WM who had received at least one prior treatment. This study found an overal response rate (ORR) of 90.5% and a median time to response of 4 weeks among the study population [Treon et al. NEJM. 2015:372:1430–1440]. Estimated progression-free survival and overal survival at 2 years were 69% and 95%, respectively.

Responses to ibrutinib were found to differ by MYD88 and CXCR4 mutational status. The highest response rates were among patients with MYD88L265P mutations who were 381

CXCR4 wild-type, with a 100% ORR in this population. This was fol owed by patients who had MYD88L265P mutations who were CXCR4WHIM mutated, with an 85.7%

ORR. MYD88L265P and CXCR4 wild-type patients had a 71.4% ORR. As such, best responses are seen in MYD88L265P mutated patients who are CXCR4 wild-type.

Question 31.10 The correct answer is A.

The optimal treatment of amyloidosis is not clear at this time and treatment on clinical trials is often prioritized when possible. Up to eight cycles of cyclophosphamide, bortezomib, and dexamethasone (CyBorD) have been found in a series of 43 patients to have an overal hematologic response rate of 81.4%, including a complete response (CR) rate of 41.9% and VGPR of 51.4% [Venner et al. Blood. 2011;119(19):4387–4390].

This has established CyBorD as a key therapy for patients with AL amyloidosis.

Autologous stem cel transplantation has been investigated in phase II studies and has been found to produce long-term durable remissions in AL amyloidosis patients [Gertz et al. Bone Marrow Transplant. 2004;32(4):149–154]. It remains a mainstay of treatment for patients who are eligible. Determination of this eligibility is largely a case-by-case decision, but general guidelines include the fol owing: appropriate physiologic age, Troponon T <0.06 ng/mL, no more than two organs significantly involved, ECOG ≤2, New York Heart Association functional class I or II, creatinine clearance ≥30 mL/min, and NT-proBNP <5,000 ng/L. Given this patient’s elevated troponin and NT-proBNP, he is ineligible for transplantation at this time.

Ixazomib, a novel oral proteasome inhibitor, has been investigated in relapsed/refractory multiple myeloma as a single agent and as combination therapy (with lenalidomide and dexamethasone). It has shown impressive outcomes in early trials. In a phase I study of 60 patients who were heavily pretreated with a median of 4

prior lines of therapy (88% with prior bortezomib), ixazomib had a response rate of 15%

(PR or better) with stable disease in 76% of patients [Richardson et al. Blood.

2014;124(7):1038–1046]. Investigation of ixazomib in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients revealed excel ent tolerability with 37% achieving a very good partial response or better.

Corresponding chapter in Cancer: Principles & Practice of Oncology, Tenth Edition: 112

(Plasma Cel Neoplasms).

382





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 32.1 In human immunode ciency virus (HIV)-infected patients, which of the fol owing malignancies is considered to be an acquired immunode ciency syndrome (AIDS)-defining cancer?

A. Colon cancer

B. Cervical cancer

C. Anal cancer

D. Penile cancer

Question 32.2 Cytotoxic chemotherapy is NOT wel tolerated with which of the fol owing antiretroviral medications?

A. Zidovudine, nucleoside reverse transcriptase inhibitor therapy B. Protease inhibitors

C. Raltegravir, integrase inhibitor

D. Fuzeon, HIV entry inhibitor

Question 32.3 What is the response rate to HAART therapy, in a treatment-naive patient with favorable-risk Kaposi sarcoma (KS)?

A. 20%

B. 40%

C. 60%

D. 80%

Question 32.4 Which of the fol owing is TRUE about the combination of rituximab with chemotherapy for AIDS-associated lymphomas?

A. Adding rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy in patients with CD4 <50/mm3 may result in higher rate of neutropenic infections.

B. Rituximab is of no added benefit to CHOP or infusional etoposide, vincristine, and doxorubicin, bolus cyclophosphamide, and daily prednisone (EPOCH) chemotherapy for AIDS-associated diffuse large B-cel lymphoma (DLBCL).

383

C. Rituximab with chemotherapy is usual y beneficial in plasmablastic lymphoma.

D. Rituximab with chemotherapy is usual y beneficial in primary effusion lymphoma.

Question 32.5 Which is TRUE concerning primary central nervous system (CNS) lymphoma in AIDS?

A. Positive cerebrospinal fluid (CSF) Epstein–Barr virus (EBV) polymerase chain reaction (PCR) test and a consistent radiologic picture are sufficient to diagnose primary CNS

AIDS lymphoma.

B. In patients with CD4 count <50/mm3 and poor performance status, high dose methotrexate should be instituted.

C. In patients with CD4 count >50/mm3 and good performance status, cranial radiotherapy provides potential y curative therapy.

D. HAART has no role in the treatment of primary CNS lymphoma.

Question 32.6 A 38-year-old man with HIV infection presents with 3-month history of weight loss and night sweats. He is not on antiretroviral therapy and his last CD4 count 3

months ago was 300/mm3. On examination, he has multiple enlarged cervical lymph nodes. His hemoglobin is 10 g/dL, white blood cel count is 3.6 × 103 /mm3, and platelet count is 190 × 103/mm3. Serum LDH is 300. Infectious workup is negative. CT of the neck and chest demonstrates di use cervical and mediastinal lymphadenopathy. You suspect lymphoma and arrange for an excisional biopsy of a neck lymph node. Which of the fol owing lymphomas is a non-AIDS defining cancer?

A. Hodgkin lymphoma

B. Diffuse large B-cel lymphoma

C. Burkitt lymphoma

D. Primary CNS lymphoma

Question 32.7 Which of the fol owing statements is CORRECT regarding KS?

A. Tumor, node, metastasis (TNM) system is useful for staging KS.

B. Extent of tumor and AIDS-related systemic il nesses is useful in stratifying patients with KS into prognostic risk groups.

C. Response Evaluation Criteria in Solid Tumors (RECIST) is useful in assessing KS

response to therapy.

D. Al of the above are correct.

Question 32.8 How does the presentation of HIV-associated Hodgkin lymphoma (HL) differ from that of HL in immunocompetent patients?

A. Patients with HIV-associated HL present at an older age.

B. B symptoms are rare in patients with HIV-associated HL.

384

C. Extranodal sites are less frequently involved in patients with HIV-associated HL.

D. Mediastinal involvement is less frequent in patients with HIV-associated HL.

Question 32.9 Which of the fol owing is CORRECT regarding anogenital cancers in patients infected with HIV?

A. In HIV-infected women with preinvasive cervical neoplasia, standard therapy results in a comparable rate of recurrence, compared to their immunocompetent counterparts.

B. In patients with a CD4 count of less than 200/mm3, who are treated with chemotherapy and radiation for invasive anal cancer, the side effect profile is similar to that of HIV-negative patients

C. In patients with HIV, anal cancer and cervical cancer are associated with high-risk subtypes of human papil oma virus (HPV) infection in the large majority of individuals.

Question 32.10 Which of the fol owing viruses are implicated in the development of cancers in patients with HIV infection?

A. EBV

B. Hepatitis C virus

C. Human herpes virus-8 (HHV-8)

D. Al of the above

Question 32.11 A 43-year-old HIV-positive man presents with multiple pigmented skin nodules, hemoptysis and dyspnea without fever or chil s, a bloody pleural e usion, and diffuse adenopathy. Biopsy of a 4-cm supraclavicular lymph node is most likely to show: A. Kaposi Sarcoma.

B. Non-Hodgkin Lymphoma.

C. Tuberculosis.

D. Hodgkin Lymphoma.

Question 32.12 A 45-year-old HIV-positive man on HAART with CD4 240, presents with an anal mass and 3-cm R inguinal node, and biopsy of the anal mass and inguinal node reveal moderately di erentiated squamous cel carcinoma. PET examination showed no other evidence of disease. The most appropriate initial treatment is: A. Cisplatin–Fluorouracil therapy

B. Mitomycin–Fluorouracil therapy concurrent with radiation C. Abdominoperineal resection

D. Radiation therapy alone

Question 32.13 Sorafenib therapy for hepatocel ular carcinoma is wel tolerated with 385

which of the fol owing antiretroviral combinations?

A. Truvada and ritonavir boosted prezista

B. Truvada and Raltegravir

C. Atripla

D. Stribild

386

Question 32.1 The answer is B.

Cervical cancer in a patient with HIV is considered to be an AIDS-defining cancer, whereas penile cancer, colon cancer, and anal cancer fal in the non–AIDS-defining cancer category.

Question 32.2 The answer is A.

Zidovudine is poorly tolerated with cytotoxic chemotherapy because of myelosuppression. Protease inhibitors are general y wel tolerated with chemotherapy, although they may affect metabolism of many drugs through effects on cytochrome P450-associated enzymes. The integrase inhibitor raltegravir, coreceptor inhibitor, maraviroc, and fusion inhibitor, fuzeon are also wel tolerated with chemotherapy.

Question 32.3 The answer is D.

In patients with favorable-risk KS (confined to skin or lymph nodes, CD4 count >200, no B symptoms or opportunistic infections, and good performance status) who are treatment-naive, response rates of up to 80% have been reported with HAART therapy.

However, it is rare for patients with extensive poor-risk KS (tumor associated edema or ulceration, extensive oral or gastrointestinal involvement, CD4 <200, opportunistic infections, B symptoms, HIV-related il ness, poor PS) to respond to HAART alone. In addition, worsening of KS may occur with initiation of HAART, due to an immune reconstitution inflammatory response.

Question 32.4 The answer is A.

Although the role of rituximab with chemotherapy in non–HIV-infected patients has been documented, its role in AIDS lymphoma is more controversial. Although several studies have suggested that there is a benefit to the addition of rituximab to CHOP or EPOCH chemotherapy, in patients with CD4 less than 50 to 100/mm3 there are reports of excess neutropenic fevers and infections. It has been suggested that this adverse result can be ameliorated with prophylactic quinolone antibiotics. Rituximab is usual y not beneficial for treatment of plasmablastic lymphomas and primary effusion lymphomas, because CD20 is usual y not expressed on the malignant cel s.

Question 32.5 The answer is A.

CSF EBV PCR is a rather sensitive (>80%) and highly specific test (>95%) for diagnosis of primary CNS lymphoma, and together with a consistent radiologic picture, brain biopsy may not be required to establish the diagnosis. In patients with low CD4 counts or poor performance status, cranial radiotherapy is the treatment of choice for primary CNS

lymphoma, because opportunistic infections cause much greater morbidity and 387

mortality than recurrent lymphoma. In contrast, for patients with higher CD4 counts and good performance status, high-dose systemic methotrexate therapy with leucovorin rescue may be associated with improved responses, as reported in non–HIV-associated primary CNS lymphoma.

Question 32.6 The answer is A.

Hodgkin disease is a non–AIDS-defining cancer, whereas Burkitt lymphoma, DLBCL, and primary CNS lymphoma are considered to be AIDS-defining cancers.

Question 32.7 The answer is B.

TNM staging is not useful in KS. The most widely used staging system is the TIS system, which attempts to stratify risk of poor prognosis in patients with KS. It is based on the extent of tumor involvement (T), immune status of the patient (I), and the presence of AIDS-related system il ness. In the era of HAART, assessing the immune system (CD4

count) does not provide prognostic information in patients with HIV sensitive to HAART, although it is useful in patients with multidrug resistant HIV. RECIST criteria are not useful in assessing KS response to therapy. The AIDS Clinical Trials Group Oncology Committee criteria for assessing response include a 50% decrease in the total number of lesions, a 50% decrease in the area of measured cutaneous lesions, or a flattening of 50% of nodular lesions.

Question 32.8 The answer is D.

Patients with HIV-associated HL present at a younger age, B symptoms are more frequent, and they usual y have higher-stage disease at presentation. Mediastinal involvement is less frequent in patients with HIV-associated HL, whereas extranodal involvement is more frequent.

Question 32.9 The answer is C.

Cervical cancer and anal cancer in patients infected with HIV appear to be related to HPV infection. In women who are newly diagnosed with HIV, cervical cancer screening is recommended. If preinvasive cervical neoplasia is found, standard therapy (cryotherapy, laser therapy, cone biopsy, and loop excision) should be used. However, the recurrence rate in patients with HIV infection is twice that of HIV-seronegative women.

In HIV-infected patients with anal cancer (CD4 <200/mm3), who are treated with chemotherapy and radiation, treatment-related toxicities (diarrhea, cytopenias) are also significantly higher than those in HIV-negative patients with anal cancer. High risk HPV

subtypes associated with anogenital cancers includes types 16 and 18.

Question 32.10 The answer is D.

EBV is involved in the pathogenesis of HL and the EBV genome has been detected in 388

tumor nuclei. Hepatitis C and HIV coinfection is common and leads to increased risk of cirrhosis and hepatocel ular carcinoma. HHV-8 is implicated in the development of KS

and primary effusion lymphomas.

Question 32.11 The answer is A

Pigmented skin lesions in an HIV-positive individual may be due to purpura, angioma, dermatofibroma, nevi, melanoma, bacil ary angiomatosis, or Kaposi sarcoma (KS). KS is also associated with lymphadenopathy and pulmonary disease, including interstitial or bronchial nodules or pleural lesions. Although a lymph node larger than 2 cm is suspicious for lymphoma, given the entire clinical picture, KS is more likely. The lack of fevers would make tuberculosis less likely. Although Hodgkin lymphoma is approximately 10-fold more frequent in HIV-positive than HIV-negative individuals, pleural effusions are uncommon without bulky mediastinal adenopathy, and are rarely hemorrhagic.

Question 32.12 The answer is B

The patient has stage IIIB anal carcinoma. Anal carcinoma is approximately 100-fold more frequent in HIV-positive than HIV-negative individuals. Approximately half of such individuals wil achieve 5-year tumor-free survival after treatment with fluoropyrimidine-based chemoradiotherapy using either cisplatin or mitomycin as part of the chemotherapy typical y provided on weeks 1 and 5 of therapy. Chemoradiotherapy results in superior results as compared to radiation or chemotherapy alone. Patients who fail to achieve complete remission with this approach, may be candidates for abdominoperineal resection.

Question 32.13 The answer is B.

Sorafenib therapy is superior to best supportive care for patients with good performance status and Child-Pugh A cirrhosis and hepatocel ular carcinoma. Sorafenib is metabolized predominantly by the CYP3A4 pathway. Other substrates include erlotinib, temsirolimus, and sunitinib. Protease inhibitors, like darunavir and ritonavir, are strong CYP3A4 inhibitors. Cobicistat, a component of Stribild, which also includes elvitegravir, tenofovir, and emtricitabine, is also a potent CYP3A4 inhibitor. Efavirenz, a nonnucleoside reverse transcriptase inhibitor component of atripla is a moderate inducer of CYP3A4 activity. In contrast, integrase inhibitor, raltegravir, and nucleoside and nucleotide analogs like those in truvada, have little effect on CYP3A4 activity.

Corresponding chapters in Cancer: Principles & Practice of Oncology, Tenth Edition: 117 (HIV-Associated Malignancies) and 118 (Transplantation-Related Malignancies).

389





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Question 33.1 The curative potential of al ogeneic stem cel transplantation (al ogeneic SCT) may be derived from which of the fol owing?

A. High-dose chemotherapy

B. Graft-versus-leukemia (GVL) effect

C. Graft-versus-host effect

D. A and B

Question 33.2 The al ogeneic SCT conditioning regimen serves to achieve which of the fol owing?

A. Provide immunosuppression to prevent rejection

B. Provide immunosuppression to prevent graft-versus-host disease (GVHD) C. Eradicate malignant cel s

D. A and C

Question 33.3 A 54-year-old male is diagnosed with AML with complex cytogenetics. After achieving complete remission with standard 7+3 chemotherapy he is evaluated for al ogeneic SCT from his HLA-matched brother. Which of the fol owing regimens is considered myeloablative for his upcoming transplant?

A. Cyclophosphamide 60 mg/kg/d intravenously (IV) × 2 days plus 1,200 cGy total body irradiation (TBI)

B. Cyclophosphamide 60 mg/kg/d IV × 2 days plus busulfan 3.2 mg/kg/d IV × 4 days C. Fludarabine 30 mg/m2 × 3 days plus 200 cGy TBI

D. A and B

Question 33.4 Which conditioning regimen leads to improved disease-free survival in chronic myeloid leukemia (CML)?

A. Cyclophosphamide 60 mg/kg/d IV × 2 days plus busulfan 3.2 mg/kg/d IV × 4 days B. 1,200 cGy TBI and cyclophosphamide 60 mg/kg/d IV × 2 days C. Chemotherapy and radiation-based conditioning are equivalent D. Fludarabine 30 mg/kg/d IV × 5 plus busulfan 3.2 mg/kg/d IV × 2 plus ATG 2.5

390

mg/kg/d IV × 4

Question 33.5 Which of the fol owing drugs used in the conditioning regimens for stem cel transplant (SCT) is the most common cause of acute cardiac toxicity?

A. Cytarabine

B. Fludarabine

C. Cyclophosphamide

D. Busulfan

Question 33.6 A 64-year-old female is diagnosed with multiple myeloma. She has experienced a very good partial response after four cycles of induction therapy but her creatinine remains elevated at 3.9 g/dL and her creatinine clearance remains less than 15

mL/min. What is the most appropriate management in regards to her conditioning regimen for upcoming autologous stem cel transplant?

A. Melphalan 200 mg/m2

B. Dose reduce melphalan to 140 mg/m2

C. Dose reduce melphalan to 100 mg/m2

D. Her elevated creatinine is a contraindication to autologous transplant Question 33.7 The GVL e ect after transplant is most pronounced in which of the fol owing malignancies?

A. Acute myelogenous leukemia (AML)

B. Acute lymphoblastic leukemia (ALL)

C. Chronic-phase CML

D. Accelerated-phase CML

Question 33.8 Which of the fol owing increases the risk of relapse after al ogenic stem cel transplantation?

A. Human leukocyte antigen (HLA)-mismatched transplant

B. CD34 cel dose >2 × 106 but <5 × 106/kg recipient body weight C. Acute and chronic GVHD

D. Use of T-cel –depleted graft

Question 33.9 Which of the fol owing therapies in a patient with multiple myeloma would potential y hinder stem cel mobilization and col ection for future autologous stem cel transplant?

A. Melphalan

B. Long-term use of lenalidomide

C. Velcade

391

D. A and B

Question 33.10 Sinusoidal obstruction syndrome (SOS) of the liver is associated with which of the fol owing factors?

A. TBI 12 Gy conditioning

B. Oral busulfan conditioning

C. Advanced age

D. Al of the above

Question 33.11 Which of the fol owing factors is associated with increased risk of engraftment failure in al ogeneic stem cel transplantation?

A. T-cel depletion of the product

B. Less than 1 × 106 CD34+ cel s/kg recipient body weight C. HLA-mismatched stem cel donor

D. Al of the above

Question 33.12 In which setting is the risk of CMV reactivation the highest after al ogeneic SCT?

A. CMV-positive donor to a CMV-negative recipient

B. CMV-negative donor to a CMV-positive recipient

C. CMV-negative donor to a CMV-negative recipient

D. CMV-positive donor to a CMV-positive recipient

Question 33.13 Peripheral blood mobilized stem cel al ografts, compared with bone marrow, are associated with which of the fol owing?

A. Shorter period of neutropenia

B. Shorter period to platelet recovery

C. Equivalent T-cel numbers

D. Equivalent incidence of acute GVHD

E. A, B, and D

Question 33.14 For which of the fol owing patients with an HLA-matched donor is al ogeneic SCT most appropriate?

A. A 35-year-old man with AML with inversion 16 in CR1 after 7+3

B. A 40-year-old woman with AML and complex cytogenetics in first clinical remission (CR)

C. A 48-year-old woman with diffuse large B-cel lymphoma with chemosensitive relapse after initial remission of 18 months

D. A 55-year-old man with RAI stage III chronic lymphocytic leukemia (CLL) in first remission

392

Question 33.15 Which of the fol owing are potential complications of donor lymphocyte infusion (DLI)?

A. Bone marrow aplasia

B. GVHD flare

C. SOS

D. A and B

Question 33.16 Factors that in uence the choice of conditioning regimen in al ogeneic stem cel transplantation include:

A. Underlying malignancy and prior treatment.

B. Patient age and comorbidity.

C. Donor:recipient HLA compatibility.

D. Al of the above.

Question 33.17 Late complications after al ogeneic SCT include: A. Skeletal complications, including osteoporosis and avascular necrosis.

B. Secondary malignancies.

C. Endocrine failure.

D. Al of the above.

Question 33.18 What is the most common cause of late hemorrhagic cystitis in patients undergoing al ogeneic SCT?

A. Cyclophosphamide

B. BK virus

C. EBV

D. CMV

Question 33.19 Autologous stem cel transplantation is indicated in certain situations for which of the fol owing solid tumors?

A. Testicular cancer

B. Neuroblastoma

C. Breast cancer

D. A and B

Question 33.20 Graft manipulation ex vivo to purge contaminating tumor cel s is a strategy that has been successful in reducing the rate of relapse after autologous stem cel transplantation.

A. True

B. False

393

Question 33.21 Which of the fol owing should be considered for autologous stem cel transplant?

A. DLBCL that has relapsed after first-line R-CHOP chemotherapy B. Fol icular lymphoma that has relapsed after first-line Bendamustine and Rituxan C. ALK-positive T-cel lymphoma in first remission

D. Nodal Marginal zone lymphoma that has progressed after a 6-month period of observation

Question 33.22 A mismatch of which of the fol owing HLA genes would NOT adversely influence the outcome in an HLA mismatched unrelated donor al ogeneic SCT?

A. HLA-A

B. HLA-B

C. HLA-C

D. HLA-DQB1

E. HLA-DRB1

Question 33.23 Which of the fol owing cel s present in the stem cel graft are thought to play a major role in mediating GVL effect seen in al ogeneic stem cel transplants?

A. Donor T lymphocytes

B. Donor B cel s

C. Donor NK cel s

D. A and C

Question 33.24 A 42- year-old male is undergoing transplant for relapsed AML. He has no matched related or unrelated donors available and thus he is undergoing referral for a haploidentical transplant from his brother. Which of the fol owing would be appropriate in order to decrease the likelihood of acute GVHD in this setting?

A. Post transplant Cytoxan 50 mg/m2 on day +3 and day +4

B. Reduce dose of calcineurin inhibitor started on day 0

C. Reduced intensity conditioning

D. Posttransplant Rituximab 375 mg/m2 on day +4

394

Question 33.1 The answer is D.

High-dose chemotherapy (and/or radiation) conditioning regimens have significant antitumor activity and are typical y used in younger patients with aggressive hematologic malignancies. Historical y, it was believed that the curative potential of al ogeneic SCT was derived entirely from the conditioning regimen, and that the donor graft served only as hematopoietic “rescue.” It is now known that the graft can mediate a powerful immunologic “graft-versus-leukemia (GVL) effect” that can contribute significantly to the curative potential of the transplant. GVHD represents the deleterious reverse of GVL, an immunologic attack on normal tissue.

Question 33.2 The answer is D.

The primary objectives of al ogeneic transplant conditioning are to provide sufficient immunosuppression of the host immune system to permit donor engraftment, and particularly with ful y myeloablative regimens, to achieve significant cytoreduction of the tumor cel s by incorporating agents with known activity against the underlying malignancy.

Question 33.3 The answer is D.

High-dose cyclophosphamide in combination with 1,200 to 1,350 cGy TBI or busulfan 13.8 mg/m2 IV constitute the two most commonly used myeloablative conditioning regimens for al ogeneic SCT. Fludarabine 30 mg/m2 × 3 days and low dose TBI is a common nonmyeloablative regimen.

Question 33.4 The answer is C.

Two randomized clinical trials have failed to demonstrate differences in disease-free survival among patients with CML conditioned with either cyclophosphamide and busulfan or cyclophosphamide and TBI. Although the use of reduced-intensity conditioning regimens (option D) has shown promise in older patients with CML, there are insufficient data comparing such approaches with traditional myeloablative regimens to recommend their routine use in younger patients who are candidates for myeloablative conditioning.

Question 33.5 The answer is C.

Although acute cardiac toxicity, characterized by cardiomyopathy, arrhythmia, or pericarditis, may be seen with cytarabine, this toxicity is most commonly caused by cyclophosphamide. Busulfan is not commonly associated with cardiac toxicity but may cause VOD and pneumonitis. Fludarabine is not associated with cardiac cytotoxicity.

395

Question 33.6 The answer is B.

Patients with advanced renal impairment (CR >3 g/dL) or undergoing hemodialysis should be considered for dose reduction in melphalan conditioning. This is however not an absolute contraindication to transplant and it is recommended that the melphalan be dose reduced to 140 mg/m2.

Question 33.7 The answer is C.

It was primarily on the basis of retrospective studies of outcomes among patients with chronic-phase CML that the GVL effect was first recognized, and a majority of CML

patients treated with DLI for posttransplant relapse achieve a durable molecular remission. In contrast to CML, only a minority of patients with relapsed acute leukemia (AML or ALL) or more advanced CML have durable long-term responses with DLI.

Question 33.8 The answer is D.

Posttransplant disease relapse risk is inversely related to the incidence of acute and chronic GVHD. T-cel depletion, although an effective strategy for lowering the risk of GVHD, confers increased risk of disease relapse.

Question 33.9 The answer is D.

Therapies such as melphalan, long-term use of lenalidomide, or radiation to significant volume of the bone marrow can al hinder future stem cel mobilization for autologous stem cel transplant. Lenalidomide that is used as induction therapy in multiple myeloma for a limited number of cycles preceding transplant does not significantly alter stem cel col ection.

Question 33.10 The answer is D.

The incidence of SOS, thought to result from chemotherapy or radiation-induced injury to the smal venules in the liver, is associated with advanced age, cyclophosphamide or oral busulfan conditioning, and pre-existing liver disease.

Question 33.11 The answer is D.

T cel s in the graft are important for mediating stem cel engraftment and therefore the use of T-cel depleted (or CD34+ cel selected) grafts are associated with an increased risk of engraftment failure. Reduced CD34+ cel dose, use of HLA mismatched donor (haploidentical donor transplants or mismatched cord blood transplants) and prior al o-immunization (multiparous females and patients who have received multiple blood products prior to transplantation) are also associated with increased risk of engraftment failure in HSCT recipients.

Question 33.12 The answer is B.

396

The risk of developing CMV infection with a CMV-negative donor and recipient is negligible. Among CMV-positive recipients, a CMV-positive donor confers a lower risk of reactivation because of the transfer of pre-existing CMV immunity to the recipient, compared with a CMV-naive donor.

Question 33.13 The answer is E.

Mobilization and harvest of hematopoietic stem cel s from peripheral blood with G-CSF

leads to significantly higher numbers of CD34+ cel s and results in a shorter time to engraftment of both neutrophils and platelets, compared with bone marrow. Despite significantly higher numbers of T cel s, there was no evidence of a significant increase in the incidence of acute GVHD in a randomized trial of peripheral blood mononuclear cel (PBMC) versus bone marrow, although a trend toward increased chronic GVHD in PBMC recipients was observed.

Question 33.14 The answer is B.

Because of its substantial treatment-related morbidity and mortality, al ogeneic stem cel transplantation is general y reserved for patients with hematologic malignancies with a low likelihood of cure with conventional chemotherapy and/or autologous SCT.

Patients with AML with inversion 16 and translocation (8;21) in remission have a favorable prognosis for cure with high-dose cytarabine consolidation and are general y only considered for al ogeneic SCT in the event of relapse. In contrast, patients with AML with high-risk cytogenetics, including deletions of chromosomes 5 and 7, and complex karyotypes, are rarely cured with conventional chemotherapy, and should be referred for consideration of al ogeneic SCT when in first complete remission (CR1).

Relapsed patients with intermediate-grade non-Hodgkin lymphoma who respond to salvage chemotherapy may be cured with autologous stem cel transplantation with a relatively low risk of treatment-related morbidity and mortality. Because of the general y indolent nature of CLL, initial remissions may persist for years. Although potential y curative for CLL, the early mortality risk associated with al ogeneic SCT is general y not justified in this scenario, although it may be appropriate in selected patients with more advanced, multiply relapsed disease.

Question 33.15 The answer is D.

DLIs by design result in the infusion of large numbers of effector T cel s with the goal of augmenting an al oimmune response directed against residual host-derived tumor cel s.

An unintended negative consequence, however, is the simultaneous infusion of al oreactive T-cel clones directed at normal tissue that may result in a significant flare in GVHD. In the case of relapsed CML, a substantial percentage of host hematopoiesis may be derived from the residual leukemic clone at relapse, in which case the development of the desired GVL effect may be associated with transient marrow aplasia.

SOS is typical y observed during the first 2 to 3 weeks posttransplant and is thought to 397

result from endothelial damage caused by the conditioning regimen.

Question 33.16 The answer is D.

The choice of conditioning regimen is driven by multiple factors including, for both autologous and al ogeneic SCT recipients, the underlying malignancy and its predicted responsiveness to various therapeutic agents. Similarly, the age and comorbidities of the recipient may dictate the use of a regimen with a lower predicted toxicity profile. For recipients of al ogeneic SCT, donor:recipient HLA mismatching may influence the use of a more immunosuppressive conditioning regimen to lower the risk of graft rejection.

Question 33.17 The answer is D.

Al ogeneic SCT recipients remain at risk for various long-term complications, including skeletal complications (especial y with chronic steroids), infertility, secondary malignancies, and endocrine failure, for which ongoing fol ow-up and monitoring are indicated.

Question 33.18 The answer is B.

Unlike the early hemorrhagic cystitis that is usual y caused by high-dose cyclophosphamide, the late counterpart is usual y secondary from BK viral infection.

Question 33.19 The answer is D.

Autologous stem cel transplantation has a role in the treatment of patients with various solid tumors including neuroblastoma, Ewing sarcoma, and testicular cancer. Since randomized clinical trials did not show survival benefit with autologous stem cel transplantation in breast cancer patients, this approach should be used only in the context of clinical trials.

Question 33.20 The answer is B.

Attempts to purge tumor cel s from autologous hematopoietic stem cel grafts, using either negative or positive selection strategies, have not been proven to reduce the risk of relapse or prolong overal survival.

Question 33.21 The answer is A

The standard of care for patients with DLBCL in first relapse is autologous STC. Fol icular lymphomas are often not referred for autologous stem cel transplant as there are many other, less toxic options available (i.e., chemoimmunotherapy; Ibrutinib–Rituxan; Lenalidomide–Rituxan). T cel lymphomas are often referred to transplant in first remission. This however does not apply to the subset of T-cel lymphomas that are ALK+, as they tend to have a better prognosis. Patients with nodal marginal zone lymphoma often have a very indolent course and rarely are considered for autologous 398

stem cel transplant.

Question 33.22 The answer is D

Answer D: The preferred donor for any recipient wil have a match of HLA-A, -B, -C, and

-DRB1. Recent data also supports favorable outcomes when matched at HLA-DPB1

locus however there is no data to support matching at HLA-DQB1 is associated with a survival benefit in al ogeneic SCT recipients.

Question 33.23 Answer D

Donor T lymphocytes and NK cel s are thought to mediate the GVL effect through a number of mechanisms, including the T-cel recognition of the minor histocompatibility antigens on leukemic cel s. Donor KIR and recipient HLA genotypes seem to play a major role in mediating GVL effect of the donor derived NK cel s in al ogeneic SCT. Donor B

cel s are thought to be involved in the pathogenesis of chronic graft-versus-host disease but there is no evidence that they have a role in the GVL effect.

Question 33.24 Answer A

Answer A: Numerous studies have shown that use cyclophosphamide early after al ogeneic SCT (on days +3 and +4) is effective in reducing the incidence of acute and chronic graft-versus-host disease in haploidentical transplants. Decreasing the dose of the patient’s calcineurin inhibitor such as tacrolimus would likely increase the risk for acute GVHD. Posttransplant rituximab does not decrease acute GVHD after al ogeneic SCT.

Corresponding chapters in Cancer: Principles & Practice of Oncology, Tenth Edition: 130

(Autologous Stem Cel Transplantation) and 131 (Al ogeneic Stem Cel Transplantation).

399





Each of the numbered items below is fol owed by let ered answers. Select the ONE let ered answer that is BEST in each case unless instructed otherwise.

Questions 34.1–3 A 48-year-old White man presents with a history of progressive facial swel ing, ful ness in the head and shortness of breath for 1 month. He has a 40 pack-year smoking history. On examination, the patient has venous distention of the neck and chest wal . Laboratory test results revealed normal blood counts, basic metabolic pro le, and liver functions. Computed tomography (CT) scan revealed an 8 × 6-cm lung mass with multiple liver lesions.

Question 34.1 What is the most likely cause of his condition?

A. Smal cel lung cancer

B. Hodgkin lymphoma

C. Diffuse large B-cel lymphoma

D. Superior vena cava (SVC) thrombosis

Question 34.2 Biopsy was performed and showed smal cel lung cancer. Which is the best initial modality of treatment for this patient?

A. Surgery

B. Radiation therapy

C. Chemotherapy

D. SVC stent

Question 34.3 What is the most likely location for the primary tumor?

A. Peripheral left lung

B. Peripheral right lung

C. Central left lung

D. Central right lung

Question 34.4 Which among the fol owing is the earliest fundoscopic sign for increased intracranial pressure?

A. Papil edema with blurring of the disc margins

B. Foster–Kennedy syndrome

C. Disc hemorrhage

400

D. Absence of venous pulsations within the center of the optic disc Questions 34.5–6 A 57-year-old man presents with severe back pain and bilateral leg weakness for 3 days. Magnetic resonance imaging (MRI) of the spine reveals metastatic lesion at T10 vertebral body with significant cord compression.

Question 34.5 Which of the fol owing are most likely primary cancers in this patient?

A. Lung cancer and breast cancer

B. Lung cancer and lymphoma

C. Colon cancer and lymphoma

D. Colon cancer and prostate cancer

Question 34.6 What is the most appropriate initial therapy for this patient with malignant spinal cord compression?

A. Chemotherapy

B. Radiation therapy

C. Strontium-89

D. Dexamethasone

Question 34.7 In patients with increased intracranial pressure, which of the fol owing signs indicates midbrain dysfunction?

A. Midsize pupils unresponsive to light

B. Coma

C. Absence of oculocephalic reflex

D. Ataxic breathing

Question 34.8 Which of the fol owing laboratory abnormalities are associated with tumor lysis syndrome? (Select two correct responses)

A. Hypokalemia

B. Hypophosphatemia

C. Hypocalcemia

D. Hyperuricemia

Question 34.9 A 28-year-old man presents with newly diagnosed acute myeloid leukemia.

He has a white cel count of 140,000/mm3, glucose of 96 mg/dL, sodium of 138 mEq/L, potassium of 4 mEq/L, creatinine of 1.1 mg/dL, blood urea nitrogen (BUN) of 15 mg/dL, uric acid of 4.8 mg/dL, albumin of 5.2 g/dL, and calcium of 10.2 mg/dL. He is started on induction chemotherapy, aggressive intravenous uids and al opurinol. Twelve hours later, the patient developed cardiac arrest not responsive to cardiopulmonary resuscitation and died. What is the most likely cause of his death?

401

A. Leukostasis

B. Severe hyperkalemia

C. Pulmonary embolism

D. Chemotherapy-induced cardiac arrhythmia

Questions 34.10–11 A 40-year-old woman presents with fever and headache 3 days after receiving chemotherapy. Her blood pressure is 130/85 and heart rate 101. Laboratory tests revealed hemoglobin of 8.5 g/dL, WBC of 11,500/mm3, platelets of 69,000/mm3, sodium of 142 mEq/L, potassium of 4.3 mEq/L, bicarbonate of 24 mEq/L, BUN of 44 mg/dL, creatinine of 1.8 mg/dL, albumin of 3.8 g/dL, total bilirubin 2.4 mg/dL, and direct bilirubin 0.3 mg/dL. Her prothrombin time and partial thromboplastin time were normal. Peripheral blood smear showed several fragmented red blood cel s and helmet cel s. Direct Coombs test is negative.

Question 34.10 What is the most likely diagnosis?

A. Disseminated intravascular coagulopathy

B. Malignant hypertension

C. Brain metastases

D. Hemolytic uremic syndrome

Question 34.11 Which of the fol owing chemotherapy drugs are implicated in the etiology of this syndrome? (Select two correct responses)

A. Paclitaxel

B. Mitomycin

C. Gemcitabine

D. Pemetrexed

Question 34.12 A 63-year-old man with metastatic squamous cel carcinoma of the lung presents with constipation and nausea for 3 days. Laboratory tests revealed hemoglobin of 13.5 g/dL, WBC of 12,500/mm3, platelets of 155,000/mm3, sodium of 146 mEq/L, potassium of 4.8 mEq/L, bicarbonate of 28 mEq/L, BUN of 44 mg/dL, creatinine of 1.7

mg/dL, albumin of 2.8 g/dL, and calcium of 13.1 mg/dL. What is the most appropriate therapy, in addition to intravenous fluids?

A. Gal ium nitrate

B. Furosemide

C. Bisphosphonates

D. Calcitonin

Question 34.13 Denosumab is approved for prevention of skeletal-related events in patients with bone metastases from solid tumors. Which of the fol owing describes the 402

mechanism of action of denosumab?

A. Inhibits osteoclasts by binding RANKL (receptor activator of nuclear factor-κΒ

ligand) to prevent RANKL activation by RANK.

B. Inhibits active form of vitamin D, 1,25-dihydroxyvitamin D and prevents intestinal calcium absorption

C. Activates osteoblasts by binding RANKL (receptor activator of nuclear factor-κΒ

ligand)

D. Impede protein prenylation and bone resorption by osteoclasts by inhibiting the mevalonate pathway.

Question 34.14 Which of the fol owing ndings are required for diagnosis of syndrome of inappropriate antidiuretic hormone secretion (SIADH)? (Select two correct responses) A. Decreased effective serum osmolality (<275 mOsm/kg of water) B. Inappropriate urinary concentration: Urine osmolality >100 mOsm/kg of water with normal renal function

C. Clinical evidence of hypovolemia (orthostasis, tachycardia, decreased skin turgor, dry mucous membranes)

D. Urine sodium <10 mmol/L in the face of normal salt and water intake Question 34.15 Rasburicase, indicated for treatment of hyperuricemia, is a recombinant version of which of the fol owing enzymes involved in purine metabolism?

A. Xanthine oxidase

B. Urate oxidase

C. Guanase

D. Hypoxanthine phosphoribosyltransferase

403

Question 34.1 The answer is A.

Malignant disease is the most common cause of SVC syndrome. Among the malignancies, the most common is smal cel lung cancer, fol owed by squamous cel lung cancer and lymphoma in most series. Diffuse large B-cel lymphoma and lymphoblastic lymphoma are the most common among lymphomas that cause SVC

syndrome. Although Hodgkin disease frequently involves mediastinum, it rarely causes SVC syndrome. Breast cancer is the most common metastatic cancer that causes SVC

syndrome. Nonmalignant conditions causing SVC syndrome are being more frequently observed due to increased use of intravascular devices such as catheters and pacemakers that can lead to SVC thrombosis.

Question 34.2 The answer is C.

Combination chemotherapy with an appropriate regimen is the treatment of choice for Smal cel lung cancer and non-Hodgkin lymphoma. Radiation therapy of the lesion and adjacent nodal areas may enhance control after initial response to chemotherapy.

Surgery is not a good option for this patient with extensive-stage smal cel lung cancer, and an SVC stent may be used in case of lack of response or relapsed obstruction after initial therapy. Although radiation therapy could be used for immediate symptomatic relief, combination chemotherapy is highly effective and preferable as initial therapy, avoiding the large radiation field and also addressing the metastatic lesions. Non–smal cel lung cancer causing superior vena cava syndrome is best treated with radiation therapy.

Question 34.3 The answer is D.

Smal cel lung cancer is frequently central in location. The SVC extends from the junction of the right and left innominate veins to the right atrium and is completely encircled by lymph node chains draining from the right thoracic cavity and lower part of the left thorax. Approximately 80% of the tumors causing SVC syndrome are located in the right lung. In the absence of mediastinal lymph node enlargement, the most likely cause of the SVC is direct extension from the central y located right-sided tumor.

Question 34.4 The answer is D.

Absence of venous pulsations within the center of the optic disc is usual y one of the earliest signs of increased intracranial pressure, with papil edema with blurring of the optic disc and hemorrhage occurring at later stages. The Foster–Kennedy syndrome—

optic nerve atrophy as a result of a sphenoid wing meningioma and contralateral papil edema from increased ICP—is rarely seen in the days of improved neuroimaging methods and earlier diagnosis.

404

Question 34.5 The answer is B.

Although most patients with malignant spinal cord compression (MSCC) have a history of malignancy, approximately 20% develop this complication at the initial presentation.

Breast cancer is a common cause of MSCC during the course of the disease, but this manifestation rarely occurs at presentation. MSCC occurring late in the course of the disease is common in breast cancer. In this male patient, breast cancer would be unlikely. Colon cancer is an uncommon cause of MSCC and prostate cancer usual y affects the lumbosacral spine. The most common types of cancer that account for MSCC

are breast, prostate, lung cancer, and lymphoma.

Question 34.6 The answer is D.

Treatment with corticosteroids should be initiated immediately when MSCC is suspected. Corticosteroids not only facilitate pain management but also reduce vasogenic cord edema and may prevent additional damage to the spinal cord from decreased perfusion. After an initial intravenous bolus, doses of up to 10 mg every 6

hours are most commonly used. Systemic chemotherapy is an appropriate treatment only for patients with MSCC caused by highly chemosensitive tumors such as non-Hodgkin lymphoma or germ cel tumors. Radiation therapy is commonly employed as subsequent therapy for control of MSCC, but should not preclude early corticosteroid therapy. Strontium-89 is used as pal iative treatment for widely metastatic bone metastases from prostate cancer.

Question 34.7 The answer is A.

Midsize and nonresponding pupils indicate midbrain dysfunction, whereas coma is seen with damage to the mesencephalic reticular activating system. Ataxic breathing may be observed with cerebel ar tonsil herniation and indicates damage to the medul ary respiratory center. Absence of the oculocephalic reflex (dol ’s head maneuver) and horizontal eye movements in response to caloric stimulation of the vestibular system are signs of pontine damage.

Question 34.8 The answers are C and D.

Cel death in tumor lysis syndrome leads to the release of intracel ular potassium, phosphate, uric acid, and other purine metabolites overwhelming the kidney’s capacity for clearance with resultant hyperkalemia, hyperphosphatemia and secondary hypocalcemia, and hyperuricemia.

Question 34.9 The answer is B.

Despite vigorous hydration, the most likely cause of death soon after initiating chemotherapy is tumor lysis syndrome (TLS). Among the metabolic complications of tumor lysis syndrome, hyperkalemia caused by the release of intracel ular potassium 405

from tumoral cel s represents the most important cause of early mortality. Leukostasis, pulmonary embolism, and cardiac arrhythmia are possible causes that are far less likely in this patient.

Question 34.10 The answer is D

This patient has hemolytic uremic syndrome (HUS), which is a microvascular disorder characterized histopathological y by disseminated microthrombi occluding the microvasculature. The clinical manifestations of HUS include the classic pentad of microangiopathic hemolytic anemia, thrombocytopenia, fever, renal failure, and neurologic deficits. Severe disseminated intravascular coagulopathy (DIC) can cause similar presentation, but normal coagulation studies are unlikely in DIC. Her blood pressure is normal which makes malignant hypertension unlikely. Brain metastases can lead to headache but are not associated with the rest of the abnormalities.

Question 34.11 The answers are B and C.

Chemotherapy drugs that have been implicated to cause HUS are mitomycin-C, 5-fluoruracil, cisplatin, and gemcitabine. Gemcitabine-associated HUS reflects the widespread use of this agent. Other agents that have been implicated in the etiology of this syndrome include bleomycin, cytosine arabinoside, daunomycin, deoxycoformycin, estramustine, and methyl-CCNU.

Question 34.12 The answer is C

This patient has hypercalcemia related to malignancy. Intravenous hydration is the most important initial step. Together with hydration, bisphosphonates are the cornerstone of therapy for malignancy-associated hypercalcemia. Bisphosphonates are also very effective and wel tolerated. Furosemide can be considered as it may enhance the renal calcium excretion, but is not as important as bisphosphonates. Gal ium nitrate is usual y given by continuous infusion for 5 days, with a gradual reduction in the calcium during the infusion time. Calcitonin is safe and relatively nontoxic, and may result in a rapid decrease in calcium levels within 2 to 6 hours. It can be utilized in hypercalcemia refractory to bisphosphonates, but requires frequent administration.

Tachyphylaxis can also develop with calcitonin.

Question 34.13 The answer is A

Denosumab is a ful y human monoclonal antibody with a high affinity and specificity for RANKL (receptor activator of nuclear factorκΒ ligand). RANKL is part of a cytokine system that belongs to the tumor necrosis factor superfamily. The components include the ligand RANKL, its specific receptor RANK (receptor activator of nuclear factor-κΒ) and OPG, a soluble “decoy” receptor. By binding to RANK, RANKL enhances bone resorption by increasing osteoclast formation, inhibiting osteoclast apoptosis and increasing osteoclast activity. The activity of RANKL is counterbalanced physiological y 406

by circulating OPG. Denosumab binds RANKL (similar to OPG) and inhibits RANK

induced activation of RANKL, thus suppressing osteoclasts. Nitrogen-containing bisphosphonates (aminobisphosphonates), including pamidronate, ibandronate, and zoledronate, impede protein prenylation and bone resorption by osteoclasts by inhibiting the mevalonate pathway (farnesyl diphosphate synthase) disrupting the signaling functions of key regulatory proteins.

Question 34.14 The answers are A and B

SIADH is defined as a hypo-osmolar or dilutional hyponatremia with excessive natriuresis. Hyponatremia occurs because ADH secretion continues even after plasma osmolality fal s below the threshold for ADH release. Patients are clinical y euvolemic, and presence of hypovolemia or hypervolemia should prompt alternate diagnosis.

Decreased effective serum osmolality (<275 mOsm/kg of water) with excessive natriuresis (Urine sodium >20 to 30 mmol/L) and inappropriate urinary concentration (Urine osmolality >100 mOsm/kg of water) are hal marks of SIADH. SIADH is commonly reported with smal cel lung cancer, head and neck carcinomas, hematologic malignancies, and non–smal cel lung cancer.

Question 34.15 The answer is B

Rasburicase is a recombinant version of urate oxidase, an enzyme that metabolizes uric acid to al antoin. Because urate oxidase degrades uric acid rather than prevent its synthesis, as does al opurinol, rapid reduction in uric acid occurs fol owing its administration without the accumulation of precursors. It has a quick onset of action and studies in adults and children have shown uric acid levels fal to 0.5 to 1 mg/dL

within 4 hours of rasburicase injection with low levels maintained throughout treatment. Al opurinol lowers uric acid by inhibiting xanthine oxidase, the enzyme responsible for converting hypoxanthine to xanthine and xanthine to uric acid. Guanse and Hypoxanthine phosphoribosyltransferase are other enzymes involved in purine metabolism.

Corresponding chapter in Cancer: Principles & Practice of Oncology, Tenth Edition: 119

(Superior Vena Cava Syndrome), 120 (Increased Intracranial Pressure), 121 (Spinal Cord Compression), and 122 (Metabolic Emergencies).

407





AAW. See Antiandrogen withdrawal (AAW) Abiraterone, 82, 86, 128

Abscopal effect of radiation, 70, 75

Absolute risk reduction, 44, 48

ABT-737, 17, 24

Accelerated fractionation, 75–76

ACOG. See American Col ege of Obstetricians and Gynecologists (ACOG) ACP. See American Col ege of Physicians (ACP)

Acquired immunodeficiency syndrome (AIDS)

AIDS-defining cancer, 327, 330

CNS lymphoma in, 328, 330

non–AIDS-defining cancer, 328, 330

Acute lymphoblastic leukemia (ALL)

CNS prophylaxis in, 297, 302

imatinib in, 297, 302

maintenance therapy for, 297, 302

Acute megakaryocytic leukemia, mediastinal NSGSTs and, 142, 148

Acute myeloid leukemia (AML), 293, 299

BEP and, 217, 221

consolidation therapy in, 296, 302

core-binding factor, 293, 299

cytopathology, 293, 299

DNMT3A mutations in, 293, 299

in elderly, treatment of, 294, 295, 300, 301

induction therapy in, 294, 299

monosomal karyotype, 294, 300

nucleophosmin 1 (NPM1) mutation in, 298, 303

poor prognostic factor in, 294, 300

prognostic factors for, 294, 300

residual AML blasts, treatment of, 297, 302

Acute promyelocytic leukemia (APL)

arsenic salvage therapy in, 295, 300

ATRA and headache, 296, 301

and differentiation syndrome, 296, 301

fresh-frozen plasma in, 295, 301

relapsed, treatment in, 296, 301–302

risk of relapse in, 296, 301

ADCC. See Antibody-dependent cel -mediated toxicity (ADCC) 408

Adenocarcinomas

endometrioid, 225, 232

esophageal, 151, 156

of gastroesophageal (GE) junction, 152, 157

of pancreas, 165, 174

smal bowel, 183, 186

Adjuvant chemotherapy

purpose of, 98, 102

relapses in early-stage colon cancer treated with, 98, 103

Adoptive cel therapy, 92, 95

purpose of, 91, 95

Afatinib, 131, 136

AIDS. See Acquired immunodeficiency syndrome (AIDS) AIDS-associated lymphomas, combination of rituximab with chemotherapy for, 327, 330

Akt, 12

Alcohol consumption, and risk of cancer, 35, 40

Alemtuzumab, 302–303

ALK. See Anaplastic lymphoma kinase (ALK)

ALL. See Acute lymphoblastic leukemia (ALL)

Al ele-speci c oligonucleotide-based quantitative polymerase chain reaction (ASO-PCR), 321

Al ogeneic stem cel transplantation, 333, 338

candidate for, 335, 339–340

choice of conditioning regimen, 335, 340

cyclophosphamide and cardiac toxicity, 334, 338

graft-versus-host disease, 337, 341

HLA mismatched unrelated donor al ogeneic SCT, 336, 341

late complications after, 336, 340

late hemorrhagic cystitis in, causes of, 336, 340

myeloablative conditioning regimens in, 333, 338

objectives of, 333, 338

risk of CMV reactivation after, 335, 339

Al -trans retinoic acid (ATRA), topical, 55

5-alpha-steroid reductase inhibitors, in prostate cancer, 53, 56

Alpha-Tocopherol, Beta-Carotene Trial (ATBC), 55

Alveolar rhabdomyosarcoma, 270

Alveolar soft part sarcoma

cytogenetic abnormality with, 268, 273

sunitinib for, 268, 273

American Col ege of Obstetricians and Gynecologists (ACOG), 45, 48

American Col ege of Physicians (ACP), 45, 48

AML. See Acute myeloid leukemia (AML)

409

Amyloidosis, 318, 324–325

Anal cancer, early localized, therapy for, 192, 196

Anaplastic large-cel ymphoma, 284, 289

Anaplastic lymphoma kinase (ALK), 84

Anaplastic oligodendroglioma, IDH1 mutations in, 258, 263

Androgen receptor, 206, 213

Angiogenesis, 2, 7, 38

Angiogenesis inhibitors, and apoptosis induction, 17, 24

Angiosarcoma, and risk of nodal metastases, 266, 271

Anthracycline cardiotoxicity, 80, 85

Antiandrogen withdrawal (AAW), 205, 212

Antiangiogenesis agents, 82, 87

Antiangiogenic therapy, side effects of, 19, 26

Antibody-dependent cel -mediated toxicity (ADCC), 87

Anti-CD19 CAR T cel s, immunotherapy with, 92, 95

Antimitogenic signaling, activation of, 16, 22–23

APC gene mutation, 195

APL. See Acute promyelocytic leukemia (APL)

Apoptosis, 7, 16, 23

and lysosome activation, 18, 24

Aromatase inhibitors, use of, in breast cancers, 250, 254

Arsenic trioxide, 301

Asparaginase and methotrexate, 82, 86

ASPIRE trial, 323

Aspirin, in colorectal cancer, 52, 56

Astrocytomas, 260

alterations of p53 gene in, 255, 260

grade II, 257, 261

grade II, somatic mutation in, 259, 264

Ataxia-telangiectasia mutated (ATM) kinase, 39

Atelomeric chromosomes, 12

ATR/CHK1 signaling, 4, 10

Aurora kinase B, role of, 4, 10

Autoantibodies in CLL, 308, 313

Autoimmune adverse events, 89, 93

Autologous stem cel transplantation, 320–322, 324–325

DLBCL in first relapse and, 336, 341

in multiple myeloma, 316, 320–322

neuroblastoma and, 336, 340

testicular cancer and, 336, 340

Autophagy, 7, 17, 24

5-Azacytidine, 3, 9

410

5-Aza-2′-deoxycytidine, 9

Bacil us Calmette–Guérin (BCG) vaccine, intravesical, 201, 208

Bad, 24

BAP1 tumor suppressor gene, mutations in, 133, 137

Barrett esophagus, 151, 156

high-grade dysplasia in, 152, 157

Basal cel nevus syndrome, mutations in PTCH1 gene and, 276, 280

Base excision repair (BER), 4, 10

Bayesian methods, in planning phase I and II trials, 110, 116

B-cel lymphomas, 284, 289

Bcl-2 inhibitors, 17, 24

BCS. See Breast-conserving surgery (BCS)

Benign teratoma, 141, 147

BEP. See Bleomycin, etoposide, and cisplatin (BEP) BER. See Base excision repair (BER)

Berry formulations, 53, 57

Beta-human chorionic gonadotropin (hCG), 231, 237

Bevacizumab, 18, 25, 87, 102

for recurrent GBM, 257, 261

Bicalutamide, 128

discontinuation of, 205, 212

Bilateral salpingo-oophorectomy (BSO), in BRCA carriers, 61, 66

Biliary cancers, adjuvant therapy for, 168, 176–177

Bim, 17, 24

Birt–Hogg–Dubé syndrome, 208

Bisphosphonates

for malignancy-associated hypercalcemia, 345, 349

nitrogen-containing, 349

for pain associated with bone metastases, 251, 254

and risk of recurrent breast cancer, 53, 57

Bladder cancer

cisplatin-based multiagent chemotherapy for, 201, 208–209

combined radiation and chemotherapy in, 202, 209

intravesical therapy, 201, 208

muscle-invasive, 208–209

neoadjuvant chemotherapy for, 202, 209

Schistosoma haematobium and, 204, 211

tumor suppressor genes in pathogenesis of, 201, 208

urinary diversion after cystectomy, options for, 202, 209

Bleomycin, etoposide, and cisplatin (BEP)

411

for granulosa cel tumors, 244

for nonseminomatous germcel tumor, 216, 217, 220, 221

Bone marrow and GI precursor cel s, 99, 104

Bortezomib, 24, 87, 290

anticancer activity of, 98, 103

for multiple myeloma, 82, 86

Brachytherapy, 72, 77

BRAF inhibitors, 81, 86

BRAF V600E mutations

and resistance to cetuximab in colorectal cancer, 99, 103

treatment in, 81, 86

BRCA1 and BRCA2 gene mutations, 62, 66–67

BRCA2 gene variant, and genetic testing, 61, 66

BRCA1 mutation, and risk of ovarian cancer, 243

Breakage–fusion–bridge cycles, 5, 12

Breast cancer

ACS guidelines for MRI screening, 248, 252

adjuvant tamoxifen and, 250, 253

annual mammography and MRI at age 30, 44, 48

aromatase inhibitors and, 250, 254

BRCA1-associated, 247, 252

core needle biopsy for diagnosis of, 248, 252

Cowden syndrome and, 248, 252

DCIS, 249, 253

Gail model, 249, 253

by germline mutations, 247, 252

Her2/neu amplification in, 3, 10

incidence of, 32

inflammatory, 251, 254

Li–Fraumeni syndrome and, 247, 252

local recurrence after breast-conserving therapy, 249, 253

Luminal A subtype, 247, 252

male, 251, 254

obesity and physical activity as risk factors for, 36, 41

oncotype DX testing in, 248, 252

oophorectomy before menopause and risk of, 248, 253

preoperative chemotherapy for HER2+ breast cancer, 250, 253

P1 trial, 253

routine surveil ance for early stage cancer patients, 251, 254

screening for, 44, 45, 48

stage IIA, 249, 253

STAR trial, 253

412

tamoxifen and raloxifen, contraindications to use of, 248, 252

taxanes, use of, 250, 254

Breast-conserving surgery (BCS)

contraindication to, 249, 253

local recurrences after, 249, 253

Breast self-examination (BSE), 44, 48

Bruton tyrosine kinase (BTK) inhibitor, 314

BSE. See Breast self-examination (BSE)

Burkitt lymphoma, 184, 187

endemic and sporadic, 283, 289

translocation t(8;14) in, 283, 289

CA 19-9, 171

CA-125, and ovarian cancer, 240, 243

Cabazitaxel, 81, 85

Cadherins, 20, 27

Calcitonin, 349

Calcium, and recurrent colorectal adenoma, 52, 56

Calretinin, 133, 137

Cancer. See also specific type

cel culture experiments in preclinical studies of, 1, 7

cytogenetic abnormalities in, 4, 10–11

gene amplification in, 3, 9–10

genetic mutations in, 1, 7

as hereditary disease, 60, 65

progression of, 2, 7

risk ofalcohol consumption and, 35, 40

dietary influence on, 35, 40

fruit and vegetable consumption and, 36, 40

specific nutrients and, 36, 40–41

strategy to promote apoptosis in, 5, 12

Cancer immunotherapy, approaches to, 90, 93

Cancer vaccines, treatment with, 90, 91, 94–95

Carbamazepine, 84

Carboplatin and paclitaxel, for NSCLC with squamous histology, 130, 134–135

Carcinogenic effects of chemicals, 34, 38–39

Carcinoids of smal bowel, 183, 186

Carfilzomib, 86

in multiple myeloma, 317, 323–324

Carney triad, and GIST, 183, 186

413

Carotene and Retinol Efficacy Trial (CARET), 55

CARs, 95

Case-control studies, 29, 31

Caspases, role in apoptosis, 98, 102

Castrate-resistant prostate cancer (CRPC), 211, 212

Catenins, 27

CD 10, 222

CD 20, 222

CD 30, 222

CDH1 carriers, optimal surgical therapy for, 54, 57–58

CDH1 gene, mutations in, 154, 159

CDK2, 213

CDKs. See Cyclin-dependent kinases (CDKs)

CD117 (c-Kit) stain, 266, 271

CEBPA gene, 299

Celecoxib, 56, 87

Cel culture experiments, in studies of cancer cel s, 1, 7

Cel cycle, 1, 7

DNA damage checkpoints, 2, 8

regulation of, 7

Cel -cycle exit, 15, 22

Cel lysis, 24

Cel ular assays, 7

Central nervous system (CNS) prophylaxis, 297, 302

Central nervous system (CNS) tumor

contrast-enhanced MRI images, 256, 261

primary CNS lymphoma, 256, 261

spinal ependymoma, 256, 260

Cerebrospinal uid (CSF) Epstein–Barr virus (EBV) polymerase chain reaction (PCR) test, 328, 330

Cervical cancer

cervical conization, 227, 233

epidemiology of, 226, 232–233

extracervical involvement, 227, 233

in HIV-infected patients, 327, 330

locoregional y advanced, treatment of, 228, 234

recurrence after combined chemoradiotherapy, 228, 234

screening for, 45, 48–49

smal stage IB1 tumors, therapy for, 227, 233

spread of, 227, 233

staging of, 227, 233

Cetuximab, 136

414

in colorectal cancer, 100, 104

in HNSCC, 121, 125, 126

Charged particle beams, 73, 77

Chemical carcinogens, 34, 35, 38–39

Chemotherapy. See also specific type of cancer

in incurable, advanced, metastatic disease, goals of, 97, 102

indicator of effectiveness of, 98, 102–103

and radiation therapy, combining of, 71, 76

Child–Pugh C cirrhosis and unresectable HCC, 170, 179

Cholangiocarcinoma, risk factor for, 167, 176

Chondrosarcomas, 268, 272

Chromosomal rearrangements, 12

Chronic lymphocytic leukemia (CLL)

autoimmune complications in, 308, 313

ibrutinib in, 309, 314

IWCLL revised criteria, 308, 313–314

rituximab in, 309, 314

Chronic myeloid leukemia (CML)

adherence to therapy in, 308, 313

BCR-ABL fusion proteins in, 307, 312

blast-phase transformation, mutations in, 307, 312

conditioning regimens in, 333, 338

criteria for diagnosis of accelerated phase, 307, 312

cytogenetic response in, 305, 310

GVL effect in, 334, 338

hematopoietic cel transplantation (HCT) in, 307, 312

imatinib in, 306, 310–312

minimal residual disease in, 310

ponatinib in, 306, 311

poor prognosis in, factors associated with, 308, 313

relapse on therapy in, 306, 311

Sokal risk score, 305, 310

T315I mutation in, 306, 311

Cigarette smoking, and lung cancer, 33, 37

Circulating tumor cel s (CTCs), 20, 27

extravasation of, 20, 27

Cisplatin radiosensitization, 76

Clinical trials, 107, 113

Bayesian methods in planning of, 110, 116

planning with interim analyses, 111, 116

power and hypothesis testing in, 110, 115

survival data. analysis of, 111, 116

415

CLL. See Chronic lymphocytic leukemia (CLL) Clonidine, for tobacco dependence, 51, 55

Clonorchis sinensis, 211

ClonoSEQ MRD assessment, 321

CML. See Chronic myeloid leukemia (CML)

C-myc amplification, in smal cel lung cancer, 3, 9–10

60Cobalt teletherapy unit, 75

Cobicistat, 332

Cohort studies, 29, 31

Colitis from T-cel activation, 89, 93

Colon cancer, obesity and physical activity as risk factors for, 36, 41

Colorectal cancer (CRC), 9. See also Hereditary nonpolyposis colon cancer (HNPCC) BRAF V600E in, 193, 197

colonoscopy for screening for, 46, 49

endoscopy with polypectomy for, 46, 49

HNPCC and, 194

incidence of, 32

maintenance therapy with capecitabine and bevacizumab, 193, 196–197

microsatel ite instability (MSI) and, 189, 194

resistance to cetuximab in, 99, 103

resistant to treatment with cetuximab, 192, 196

stage II, high-risk features for, 193, 197

stage III, adjuvant therapy for, 190, 195

Compton scattering, 76

Computed tomography contrast perfusion, 100, 104–105

Conditioning regimen, choice of, 335, 340

Confidence intervals, 29, 31

Confounding factors and interaction, 29, 31

Conventional 3 + 3 phase I designs, 107, 113

Core-binding factor (CBF) AML, 293, 299

Cowden syndrome, 186

and risk of breast cancer, 248, 252

Craniopharyngioma, sexual dysfunction in, 258, 263

CRC. See Colorectal cancer (CRC)

Crizotinib, 136

Crizotinib resistant tumors, treatment for, 131, 136

CROSS trial, 157–158

CRPC. See Castrate-resistant prostate cancer (CRPC) CT colonography, 46, 49

CTCs. See Circulating tumor cel s (CTCs)

CTLA-4, 91, 94

and inhibition of T cel s, 90, 94

416

CXCL12, 20, 27

CXCR4, 20, 27

Cyclin-dependent kinase 4, 7

Cyclin-dependent kinases (CDKs), 7, 15, 22

Cyclins, 22

B-type, 15, 22

Cyclophosphamide, cardiac toxicity by, 334, 338

Cytokeratin, 222

Cytostatic agents, 114

early-phase trials of, 109, 114

Cytotoxic chemotherapy, zidovudine and, 327, 330

Daratumumab, 322

Dasatinib, 310

side effects of, 306, 311

Death receptor pathway, 17, 24

Denosumab, mechanism of action of, 345, 349

Depsipeptide, 9

DES. See Diethylstilbestrol (DES)

Desmoid tumors, 189, 194

Dexamethasone

in ALL induction therapy, 297, 302

in malignant spinal cord compression, 344, 348

DIC. See Disseminated intravascular coagulopathy (DIC) Dicentric chromosome, 12

Diet-derived natural products, 53, 57

Diethylstilbestrol (DES), 234

exposure in utero and clear cel vaginal cancer, 228, 234

Differentiation syndrome, 296, 301

Diffuse alveolar hemorrhage, induction therapy in AML and, 294, 299

Diffuse large B-cel lymphoma (DLBCL), 284, 289, 347

advanced-stage, 286, 290

extranodal NK/T-cel , 287, 291

germinal center B-cel (GCB), 286, 290

R-CHOP chemotherapy for, 286, 290

Dihydropyrimidine dehydrogenase (DPD), 195

deficiency and risk for 5FU toxicities, 190, 195

deficiency of, 80, 84

Disseminated intravascular coagulopathy (DIC), 348

DLBCL. See Diffuse large B-cel lymphoma (DLBCL) DLI. See Donor lymphocyte infusion (DLI)

417

DLL4, 26

DNA double-strand breaks

dose-related cel ular response to, 70, 74

mechanisms of repair for, 69, 74

radiation-induced, 69, 74

DNA hypomethylating agents, 3, 9

DNA mismatch repair (MMR) gene, germline mutations in, 189, 194

genetic counseling and testing of at-risk family members, 190, 194–195

DNMT3A gene, 299

Donor lymphocyte infusion (DLI), 335, 340

Dose-dense chemotherapy, 99, 103

Double-strand breaks (DSBs), 10. See also DNA double-strand breaks DPD. See Dihydropyrimidine dehydrogenase (DPD)

Drop-ins and drop-outs, effect of, 43, 47

DSBs. See Double-strand breaks (DSBs)

Dutasteride, and prostate cancer, 53, 56

Dynamic-contrast magnetic resonance imaging, 100, 104–105

EBV. See Epstein-Barr virus (EBV)

E-cadherin, 20, 27

E-cadherin mutation testing, 154, 159

Ecologic studies, 30, 32

Efavirenz, 332

Effect modification. See Confounding factors and interaction EGFR mutations, 129, 134

EGFR–tyrosine kinase inhibitors (TKIs), 131, 134, 135

ELOQUENT-2 trial, 322

Elotuzumab, 322

EML4-ALK translocation, 134

ENDEAVOR trial, 324

Endometrial cancer

hysterectomy for grade 2 endometrioid cancer, 230, 236

IIIC1 stage, 231, 236

radiation and chemotherapy for, 231, 237

risk factors for, 226, 232

risk factors for development of, 230, 236

type I, 225, 232

type II, 225, 232

Endometrioid adenocarcinomas

genetic changes in, 225, 232

risk factors for, 225, 232

418

Enzalutamide, 128

EORTC 40983 study, 196

Ependymoma, 260

adjuvant radiation therapy after resection in, 258, 263

radiation therapy for, 257, 262

surgical resection for, 262

Epidermal growth factor receptor (EGFR), role of, in head and neck SCC (HNSCC), 119, 124

Epigenetic therapy, 81, 86

Epithelial mesotheliomas, 133, 137

Epstein–Barr virus (EBV), 34, 38, 256, 261

Epstein–Barr virus latent gene EBNA, 89, 93

Erlotinib, 85, 97, 102, 136, 145

resistance to, 129, 134

Esophageal adenocarcinoma, risk factors for, 151, 156

Esophageal cancer, 151, 152, 156–157

molecular biology of, 152, 157

perioperative chemotherapy in, 153, 158

European Organization for Research and Treatment of Cancer (EORTC) trial, 261

Ewing sarcoma, 268, 273

and cytogenetic abnormalities, 265, 270

Excisional biopsy, 252

Excision repair mechanisms, 4, 10

Exclusive inhibitors, 87

EXTREME trial, 125, 128

Ezrin, 27

Familial adenomatous polyposis (FAP), 54, 58

Familial cancer syndromes, germ line mutations in, 1, 7

Familial malignant melanoma syndrome, 23

Fanconi anemia

defects in, 10

Fanc genes, abnormalities in, 4, 10

FAP. See Familial adenomatous polyposis (FAP)

Fibrolamel ar HCC, 168, 177

Finasteride, and prostate cancer, 53, 56

Fluorescence in situ hybridization (FISH), 299

5-Fluorouracil (5-FU), 21, 28, 80, 84

and leucovorin, 155, 160

and mitomycin for anal cancer, 192, 196

FOLFIRINOX, in adenocarcinoma of pancreas, 165, 174

419

FOLFOX, in pancreatic cancer, 174

Folic acid, in children with lymphoblastic leukemia, 97, 102

Fol icular lymphoma, 284, 289, 341

Fol icular thyroid cancer, 67

Foster–Kennedy syndrome, 347

FOXA1, 213

5-FU. See 5-Fluorouracil (5-FU)

Fumarate hydratase gene, 208

Furosemide, 349

Fusion PET-MRI, in multiple myeloma, 319

Gail model, breast cancer, 249, 253

Gal bladder cancer

and cholecystectomy, 168, 176

T2 NX (stage II), 167, 176

Gal ium nitrate, 349

Gardasil vaccine for HPV, 33, 37–38

Gastric cancer, 151, 154, 156, 158–159

diagnostic modalities in, 154, 159

early-onset diffuse, 154, 159

metastatic, combination chemotherapy for, 155, 160

Gastroesophageal reflux disease (GERD), 151, 156

Gastrointestinal stromal tumors (GISTs), 181, 185, 271

criteria predictive of behavior of, 269, 273

familial and genetic syndromes with, 183, 186

imatinib for, 267, 271

imatinib-resistant, 182, 185

KIT mutations in, 185

regorafenib for, 182, 186

from smal intestine, 183, 187

sunitinib therapy for, 182, 185

GBM. See Glioblastoma multiforme (GBM)

Gefitinib (Iressa), 12

Gemcitabine, 76, 97, 102

and cisplatin, 169, 178

and hemolytic uremic syndrome, 345, 348

Gemtuzumab ozogamicin, 301–302, 303

Gene amplification, 3, 9–10

Gene array technology, 3, 8–9

Genetic testing, noninformative, 62, 66, 67

Genome-wide association studies (GWAS), 30, 32

420

GERD. See Gastroesophageal reflux disease (GERD) German Rectal Cancer Study, 195–196

Germ-cel cancers, 97, 102

Germ cel tumors of ovary, 242, 245

Germinal center B-cel (GCB) diffuse large B-cel lymphoma, 286, 290

Gestational trophoblastic disease (GTD) with complete mole, 226, 232

Gestational trophoblastic neoplasia (GTN), 231, 237

methotrexate for low-risk disease, 231, 237

Giant cel tumor (GCT), of bone, 268, 272

GISTs. See Gastrointestinal stromal tumors (GISTs) Glasgow prognostic score (GPS), 34, 38

Glioblastoma, 260

Glioblastoma multiforme (GBM), 255, 256, 260

concurrent brain radiation with temozolomide in, 258, 263

dysregulated core pathways in, 259, 263

gene expression profiling, 263

mesenchymal group and loss of NF1 expression, 258, 263

radiation therapy for, 257, 261–262

recurrent, 257, 261

Gompertzian kinetics, 99, 103

Graft manipulation ex vivo to purge tumor cel s, 336, 341

Graft-versus-leukemia (GVL) effect, 338

in chronic-phase CML, 334, 338–339

donor T lymphocyte and, 336, 341

NK cel s and, 336, 341

Granulosa cel tumors, 223

of ovary, 241, 244

G1/S phase, cel cycle, 2, 8

G1/S-phase transition, cyclins E and A accumulation for, 15, 22

GTN. See Gestational trophoblastic neoplasia (GTN) Guanase, 349

GVL effect. See Graft-versus-leukemia (GVL) effect Gynecologic Oncology Group (GOG), 231, 237

Hairy cel leukemia (HCL), 308, 313

BRAF V600E mutation in, 309, 314

Hayflick phenomenon, 4, 11

HCC. See Hepatocel ular carcinoma (HCC)

hCG. See Beta-human chorionic gonadotropin (hCG) HCL. See Hairy cel leukemia (HCL)

HDGC. See Hereditary diffuse gastric cancer syndrome (HDGC) 421

Head and neck squamous cel carcinoma (HNSCC) adjuvant chemotherapy in, 121, 126

cetuximab in, 121, 126

combinations of chemotherapy agents, 120, 125

concurrent chemotherapy and radiation therapy in, 121, 125

epidermal growth factor receptor in, role of, 119, 124

HPV-related, 120, 124

induction chemotherapy in, 122, 127–128

local y advanced, 122, 127

neck dissections, complications from, 120, 125

risk factors for, 119, 124

second primary cancers with, 122, 127

stage IVA, 120, 124

Helicobacter pylori infection, 151, 156

and risk of intestinal-type gastric adenocarcinoma, 53, 57

Hemolytic uremic syndrome (HUS), 345, 348

gemcitabine and, 345, 348

mitomycin and, 345, 348

Hemorrhagic cystitis, 80, 84

Hepatitis B virus, 177

Hepatitis C infection, 169, 177

Hepatitis C virus, 34, 38

Hepatitis D virus (HDV), 38

Hepatoblastoma, 168, 177

Hepatocel ular carcinoma (HCC), 34, 38, 166, 175

clinical suspicion for, 168, 177

fibrolamel ar, 168, 177

hypoglycemia and, 166, 175

liver transplantation in, criteria for, 166, 175

paraneoplastic syndromes with, 166, 175

risk factors for, 167, 175

screening and prevention for, 167, 175–176

staging systems for, 166, 175

surveil ance for, 170, 178

Hereditary cancer syndromes, expression in, 60, 64

Hereditary diffuse gastric cancer syndrome (HDGC), 61, 65–66, 159

informative genetic test, 61, 66

noninformative genetic test, 66

Hereditary leiomyomatosis and renal cancer syndrome, 208

Hereditary nonpolyposis colon cancer (HNPCC), 9, 10, 159

and colorectal cancer, 194

diagnosis of, 190, 194

422

microsatel ite instability (MSI) by mutations in DNA MMR genes, 194

MSH2 gene and, 190, 195

Hereditary nonpolyposis colorectal cancer syndrome, 230, 236

Hereditary papil ary renal cancer, 207, 208

MET mutations in, 199, 207

Her2/neu amplification, in breast cancer, 3, 10

HER2 testing, 153, 158

HevyLite assay, 319

Hierarchy model of tumor heterogeneity, 21, 27

HIF. See Hypoxia-inducible factor (HIF)

High-grade dysplasia, in Barrett esophagus, 152, 157

Hilar cholangiocarcinoma, 167, 176

HIV. See Human immunodeficiency virus (HIV)

HIV-associated Hodgkin lymphoma (HL), 328, 331

HIV-infected patients

anogenital cancers in, 328, 331

cervical cancer in, 327, 330

stage IIIB anal carcinoma, treatment for, 329, 331–332

viruses in development of cancers in, 329, 331

HNPCC. See Hereditary nonpolyposis colon cancer (HNPCC) HNSCC. See Head and neck squamous cel carcinoma (HNSCC) Hodgkin lymphoma, 327, 330, 347

in pregnancy, 288, 292

Homologous recombination (HR), 69, 74

Hoosier Oncology Group (HOG), 136

Hormonal therapy in ovarian cancer, 240, 244, 245

Hormone replacement therapy (HRT), decline in use of, 30, 32

HOVON-65/GMMG-HD4 trial, 320

HPV. See Human papil oma virus (HPV)

HPV-associated vulvar cancer, 228, 235

HPV vaccines, 233

Human cancers, cytogenetic abnormalities in, 4, 10–11

Human cel s, expressed genes in, 1, 7

Human Genome Project, 1, 7

Human herpesvirus-8, and primary effusion lymphoma, 284, 289

Human immunodeficiency virus (HIV), 227, 233

Human papil omavirus (HPV), 226, 232

prevention and treatment of infection, 226, 233

Human papil oma virus (HPV)

related HNSCC, 120, 124

vaccine, 90, 93

HUS. See Hemolytic uremic syndrome (HUS)

423

Hyperfractionation, 71, 75

Hyperkalemia, tumor lysis syndrome and, 344, 348

Hypoxanthine phosphoribosyltransferase, 349

Hypoxia-inducible factor (HIF), 208

pathway, 85

and tumor angiogenesis, 200, 208

IBC. See Inflammatory breast cancer (IBC)

Ibrutinib, 290

in chronic lymphocytic leukemia, 309, 314

IGRT. See Image-guided radiation therapy (IGRT)

IL-2 for melona, 90, 93–94

Image-guided radiation therapy (IGRT), 78

Imatinib, 12, 24, 81, 85, 100, 104, 145, 181, 185

in chronic myeloid leukemia, 306, 310–312

Immune lymphocytes, 89, 93

Immunotherapy to destroy cancer cel s, mechanism for, 89, 93

IMRT. See Intensity-modulated radiation therapy (IMRT) Inflammation, role of, in carcinogenesis, 34, 38

Inflammatory breast cancer (IBC), 251, 254

INK family proteins, 23

Intensity-modulated radiation therapy (IMRT), 71, 76, 78

and risk of xerostomia, 122, 127

Intention-to-treat analysis, 111, 116

Intention to treat (ITT) analysis, 99, 103

Interferon (IFN)-α, 16, 22

Intergroup Trial, 155, 160

International Gastric Cancer Linkage Consortium (IGCLC), 159

International Germ Cel Consensus Classification, 219, 222

International Myeloma Working Group, 319

Intracranial pressure, increased

and midbrain dysfunction, 344, 348

signs of, 343, 347

Intraepithelial neoplasias, 52, 55

Intravesical therapy, for bladder cancer, 201, 208

Ionizing radiation (IR)

and DNA damage/repair process, 69, 74

repair of damage from, 35, 39

risk of cancer from, 35, 39

Ipilimumab, and nivolumab, 91, 94

Ipilimumab-related endocrinopathy, 278, 281

424

IR. See Ionizing radiation (IR) Irinotecan, and neutropenia, 191, 195

Isochromosome 12p (i[12p]), 147

Isocitrate dehydrogenase 1 (IDH1) gene, 260

Ixazomib, 325

Kaposi sarcoma (KS), 329, 331

and HAART therapy, 327, 330

staging system for, 328, 331

Ketoconazole, 84

Kidney cancer, anti-VEGF drugs in, 81, 85

Klinefelter syndrome

and germcel tumor, 216, 220–221

mediastinal NSGSTs and, 142, 148

KRAS mutation, 84

KS. See Kaposi sarcoma (KS)

Lapatinib, 81, 85

Large B-cel lymphoma, 219, 223

Laryngeal squamous cel carcinoma (SCC)

adjuvant chemotherapy in, 121, 126

concurrent chemotherapy and radiation therapy in, 119, 121, 124, 126

Lead-time bias, 43, 47, 49

Leiomyosarcoma

intra-abdominal, 266, 271

lung metastases, 267, 271

recurrence of, 266, 270

Lenalidomide, 334, 339

Length bias, 47

Leukoplakia, 52, 55

Leuprolide, 128

Leydig cel tumor, 223

Li–Fraumeni syndrome, 23, 186, 247, 252, 255, 260

and soft tissue sarcomas, 265, 270

Linear accelerator (LINAC), modern, 70, 75

Liposarcoma, high-grade extremity, 266, 271

Liver, sinusoidal obstruction syndrome of, 334, 339

Liver transplantation, 169, 178

Lovastatin, 56

LS. See Lynch syndrome (LS)

425

Lumbar puncture, 285, 289–290

Luminal A breast cancer, 247, 252

Lung Adjuvant Cisplatin Evaluation (LACE) meta-analysis, 137

Lung cancers

CT-guided biopsy, 129, 134

genomic profile of, 134

tumors from never smokers, 134

tumors from smokers, 129, 134

incidence of, in women, 32

and malignant spinal cord compression, 344, 347

platinum-based doublet chemotherapy, 130, 134

Lymphoma

adult, 283, 289

anaplastic large-cel , 284, 289

B-cel , 284, 289

Burkitt, 283, 289

childhood, 283, 289

International Prognostic Index (IPI) score for, 284, 289

and malignant spinal cord compression, 344, 347

mantle cel , 285, 290

primary effusion, 284, 289

T-cel neoplasms, 284, 289

Lynch II syndrome, 230, 236

Lynch syndrome (LS), 54, 57, 59, 64

autosomal-dominant inheritance in, 64

cancer risk from, 64

and cancer screening, 60, 64

and cervical cancer, 63, 67

and endometrial cancer risk, 54, 57

gastric cancers and, 154, 159

and genetic testing, 60, 65

MSH2 gene mutation, inheritance of, 64

Malabsorption after Whipple surgery, 164, 172–173

Male breast cancer, 251, 254

Male urethral cancers, risk factors for, 201, 209

Malignant mesotheliomas

epithelial, 133, 137

immunohistochemistry markers in, 133, 137

poor prognostic factors in, 133, 137

Malignant spinal cord compression (MSCC), 347

426

causes of, 344, 347

corticosteroids in, 344, 348

Malignant teratoma, 147

Mammography, 48

Mantle cel lymphoma, 285, 286, 290

Maximum tolerated dose, 113

Mayo Stratification for Myeloma and Risk-adapted Therapy (mSMART) criteria, 319–320

MBL. See Monoclonal B lymphocytosis (MBL)

MDS. See Myelodysplastic syndrome (MDS)

Mediastinal germ cel tumors, 141, 146–147

Mediastinal seminoma, 142, 148

cisplatin plus etoposide for, 143, 148

Medul ary thyroid carcinoma (MTC), and preoperative basal calcitonin levels, 54, 57

MEK mutations, 79, 84

Melanoma

adjuvant stereotactic radiosurgery for, 277, 281

anatomical sites for, 276, 280

BRAF V600E mutation in, 275, 280

brain MRI for suspected solitary intracranial metastasis, 276, 280

Breslow thickness, 276, 280

cutaneous, 275, 280

genetic counseling, 275, 280

grade III autoimmune colitis, 278, 281

incidence of, 30, 32

ipilimumab in metastatic melanoma, 278, 281

risk factor for, 275, 280

stage IIIC, 277, 281

tumor biopsy and brain MRI examination, 277, 281

wide excision and sentinel lymph node mapping, 276, 280

Melphalan, 334, 339

Memorial Sloan Kettering Cancer Center (MSKCC) nomogram, for sarcoma-speci c mortality, 266, 270

Meningioma, 255, 260

grade II resection for, 257, 262

6-Mercaptopurine (6MP), 80, 84

Mesnahemorrhagic cystitis and, 80, 84

mechanism of action of, 269, 273

Meta-analysis, 112, 117

Metastasis progression genes, 20, 26

Metastasis, risk of, 19, 26

Metformin, 57

427

Methotrexate

for gestational trophoblastic neoplasia, 231, 237

high-dose, for immunocompetent patients with primary CNS lymphoma, 258, 262–

263

Methylation, 12

Methyl guanine methyl transferase (MGMT) gene methylation, 261

Metronomic low-dose chemotherapy, 19, 26

Microarray technology, 2, 8

MicroRNA (miRNA), 2, 8, 16, 23

Microsatel ite instability (MSI), 10, 189, 194

in colon cancer, 3, 10

and 5-fluorouracil chemotherapy, 3, 9

in type I endometrial cancers, 232

Minimum Information About A Microarray Experiment (MIAME), 2, 8

miRNA array signatures, 8

Mismatch repair machinery of cel , 4, 10

Missense variants, 66

Mitomycin, and hemolytic uremic syndrome, 345, 348

Mitosis, 15, 22

Mitoxantrone, 102

MMR mutation testing, 190, 194

Modified radical neck dissection (MRND), 125

Monoclonal B lymphocytosis (MBL), 309, 314

Monosomal karyotype, 294, 300

MOSAIC study, 195

MSCC. See Malignant spinal cord compression (MSCC) MSI. See Microsatel ite instability (MSI)

Mucosal-associated lymphoid tissue (MALT) lymphoma, 183, 186

Muir–Torre syndrome, 194

Multiple myeloma

antimyeloma therapy for, 315, 319

autologous stem cel transplantation in, 316, 320–322

carfilzomib therapy in, 317, 323–324

conditioning regimen for autologous stem cel transplant, 334, 338

depth of response and prolonged survival in, link between, 316, 320–321

diagnosis of, 319

FISH and cytogenetic studies, 315, 319–320

genomic sequencing in, 316, 320

monoclonal antibodies under investigation in, 322

MRD assessment, 321

panibinostat in, 317, 323

prognosis in, 319

428

risk classification system, 315, 319–320

Myasthenia gravis, 139, 144

Mycosis fungoides, 287, 291

MYD88, 324

Myeloablative transplantation in CR1, 297, 303

Myelodysplastic syndrome (MDS), 295, 301

MYH-associated polyposis, 192, 195, 196

Myxoid liposarcoma, 270

Nasopharyngeal carcinomas, 126–127 121

subtypes of, 126

treatment for, 127

National Comprehensive Cancer Network, 194

National Lung Screening Trial (NLST) eligibility criteria, 46, 49

Nbk/Bik, 24

NBS1 gene, 16, 23

Necitumumab, 136

Necrosis, 24–25

Negative predictive value (NPV), 47

Neoadjuvant chemotherapy, 98, 102

Neuroblastoma, N-myc amplification in, 3, 9

Neurofibromatosis, and GIST, 183, 186

Neurofibromatosis type 2 (NF2), 255, 260

Neurofibromatosis type I, 270

Next-generation sequencing (NGS), 321

NGS. See Next-generation sequencing (NGS)

Nicotine replacement therapy (NRT), 51, 55

Nijmegen breakage syndrome 1, 23

Nijmegen disease, 16, 23

Nilotinib, 310

Nitrogen-containing bisphosphonates, 349

Nivolumab, 91, 94

ipilimumab and, 91, 94

in lung cancer, 91, 94

N-myc amplification, in neuroblastoma, 3, 9

Nodal Marginal zone lymphoma, 341

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), 288, 291

Non-Hodgkins lymphoma, 23

Nonhomologous end-joining (NHEJ) pathway, 69, 74

Non–HPV-associated invasive squamous vulvar cancer, 228, 235

Noninformative censoring, 111, 117

429

Nonseminomatous germ cel tumor (NSGCT), 141, 146, 220

bleomycin, etoposide, and cisplatin (BEP) for, 216, 217, 220, 221

chemotherapy in, 215, 218, 220, 222

and CNS metastases, 215, 220

in first relapse, 219, 223

and hyperthyroidism, 219, 222–223

late relapse, 217, 221

mediastinal, 146–149, 216, 220–221

risk factor for recurrence of, 218, 222

and surgical resection, 216, 220

Non–smal cel lung cancer (NSCLC)

adjuvant chemotherapy after resection for, 130, 135

concurrent chemoradiation for local y advanced NSCLC, 131, 135

concurrent definitive cisplatin and etoposide therapy for, 132, 136

with nonsquamous histology, 134

pemetrexed maintenance therapy in, 130, 135

ROS1 translocations in, 132, 136

with squamous histology, 130, 134–135

Nonsteroidal anti-inflammatory drugs (NSAIDs), in colorectal cancer, 52, 56

Nortriptyline, for tobacco dependence, 51, 55

NRIP1, 213

NRT. See Nicotine replacement therapy (NRT)

NS5A protein product of HCV genome, 169, 177

NSCLC. See Non-smal cel lung cancer (NSCLC)

NSGCT. See Nonseminomatous germ cel tumor (NSGCT) Nucleotide excision repair (NER) pathway, 4, 10

Nurse’s Health Study, 56

OCT3/4, 222

Octreotide, 140, 145

Ofatumumab, and rituximab, 83, 87

Oligodendroglioma

al elic loss of chromosome 1p and 19q in, 256, 260

IDH1 mutations in, 258, 263

prognosis of, 256, 261

Oncogenes, 1, 7

Opisthorchis viverrini, 211

Oral cavity SCC

stage II (T2N0M0), close monitoring in, 123, 128

stage IVA (T4aN1M0), surgery for, 120, 125

Osteosarcomas, 268, 272

430

treatment of, 265, 270

Ovarian cancer, 239, 243

advanced-stage, and risk of relapse, 241, 244

Ashkenazi-Jewish ancestry and, 239, 240, 243, 244

BRCA1 or BRCA2 mutations and, 240, 243, 244

CA-125 and, 240, 243

clinical surveil ance in, 242, 245

elevated CA-12, and hormonal therapy, 240, 244

germ cel tumors, 242, 245

granulosa cel tumors, 241, 244

intraperitoneal chemotherapy, use of, 242, 245

nodal metastases, 241, 244

nul iparity and risk of, 240, 243

oral contraceptives and, 241, 243, 244

recurrent, and platinum-based chemotherapy, 242, 245

screening for, 45, 48

stage IA grade 1 mucinous tumor, 239–240, 243

tumor of low malignant potential, therapy for, 240, 243

Overdiagnosis, 45, 49

Oxygen enhancement ratio (OER), 71, 75

p53, 99, 104

alterations of, in astrocytoma, 255, 260

mutations of, 3, 9

and senescence, 5, 12

urothelial carcinoma of bladder, alterations in, 202, 210

Paclitaxel radiosensitizing, 76

Pair production, 76

Palbociclib, 100, 104

Pancoast tumor of lung, therapy for, 132, 136

Pancreatic cancer, 163, 171

adjuvant therapy for, 164, 173

familial, BRCA2 gene mutation in, 165, 174

KRAS mutation and development of, 163, 171–172

local y advanced, 164, 173

multiphase CT scan for, 164, 172

nab-paclitaxel and gemcitabine in, combination of, 165, 173

OFF chemotherapy regimen in, 165, 174

p16-mediated CDK inhibition and, 166, 174

risk factors for, 165, 174

stage III, T4N1M0, 163, 172

431

telomere shortening and, 166, 174

TGF-β receptors in, underexpression of, 166, 174

tobacco smoke and, 171

Pancreatic enzyme supplementation, 164, 172–173

Pancreatic intraepithelial neoplasms (PanINs), 171

Panibinostat, adverse events from, 317, 323

Parosteal osteosarcoma, 268, 272

Parotid gland cancers, treatment for, 122, 127

Partial response, definition of, 98, 103

Patched gene 1, 276, 280

Pazobanib, hepatotoxicity from, 269, 273

Pazopanib, 79, 84

PCNSL. See Primary CNS lymphoma (PCNSL)

PD-1, 91, 94

Pemetrexed, 21, 28

Penetrance, 64

reduced, 59, 64

Penile carcinoma, 206, 213

Peptidome, 3, 9

Pericytes, 18, 25

Peripheral blood mobilized stem cel al ografts, 335, 339

Peritoneal mesothelioma, 133, 137–138

Peutz–Jeghers syndrome, 63, 68

Phase III trials, 109, 114–115

Phase II trials, 108, 113

early elimination of ineffective drugs, 108, 113–114

two-stage design, 108, 114

and welfare of patients, 108, 114

Phase I trials, 107, 113

limitations of, 107, 113

Phase 0 trials, 112, 117

Phenytoin, 79, 84

Photoelectric effect, 72, 76

PI3-kinase pathway, 28

Pilocytic astrocytoma, 256, 261

p16INK4a, 1, 7

and senescence, 5, 12

Placental alkaline phosphatase (PLAP), 222

Platinum-based doublet chemotherapy, for metastatic disease, 130, 134

Platinum-resistant tumor cel s, 80, 85

Pleural mesothelioma

cisplatin and pemetrexed for, 133, 138

432

unresectable, 133, 137

Polymerase chain reaction (PCR), 299

Poly (ADP-ribose) polymerase (PARP) inhibition, 82, 86

Positive predictive value (PPV), 47

decrease in, 43, 47

Posttransplant disease relapse risk, 334, 339

Prednisone, 82, 86

Primary CNS lymphoma (PCNSL), 287, 291

methotrexate and rituximab for, 288, 291

Primary (de novo) glioblastoma multiforme (GBM), 255, 260

Primary intestinal lymphomas and secondary intestinal lymphomas, distinction between, 183, 186–187

Primary leptomeningeal lymphoma, 291

Prognostic biomarker, 79, 84

Programmed-cel death pathway, 100, 104

Prolymphocytic leukemia (PLL), 313

Prophylactic total gastrectomy, 57–58

Prostate cancer

adjuvant radiotherapy in, 204, 211

androgen ablation and risk of osteoporosis, 204, 211–212

androgen ablation in high-risk patients, 203, 211

androgen receptor and, 206, 213

antiandrogen withdrawal response, 204, 211

chromosomal translocations involving TMPRSS2 in, 201, 209

high-risk features and therapy, 203, 210

metastasis to liver, 20, 27

nonmetastatic CRPC, 205, 212

and osteoblastic bone metastases, 20, 27

predictors of cancer on biopsy, 203, 210

PTEN and, 206, 212–213

radical retropubic prostatectomy and complications, 204, 211

risk factors, 205, 212

risk factors for, 203, 210

surveil ance in, 205, 212

Proteome, 2, 8

Proteomic signatures, 9

Proteomic technologies, 3, 8–9

Protonation, 8

Protooncogene, 23

definition of, 2, 7

Pulmonary carcinoid tumors, 131, 135

Puma, 24

433

Quiescence, 5, 11

Radiation

adverse effects of, 77

depth dose characteristics of, 72, 77

subacute toxicity from, 72, 77

tissue effects from, 71, 76

Radiation effects, role of oxygen in, 71, 75

Radiation-induced cel death, 70, 75

Radiation-induced pneumonitis, 77

Radiation-induced sarcomas, 265, 270

Radiation Therapy Oncology Group (RTOG 9704), 173

Radical neck dissection (RND), 125

Radiotherapy, for localized mediastinal seminoma, 142, 148

Raloxifene, 52, 56

and risk of stroke, 53, 56

Raltitrexed, 174

Ramucirumab (IMC-1121B), 155, 161

Randomized assignment to treatment, 109, 115

Randomized discontinuation design, 100, 104

RANK-ligand inhibitors, for pain associated with bone metastases, 251, 254

Rasburicase, 346, 349

R-CHOP, 263

Real-time quantitative polymerase chain reaction (RQ-PCR), 305, 310

REAL-2 trial, 155, 160

Receptor phosphotyrosine phosphatases (RPTPs), 6, 13

Receptor tyrosine kinases, 6, 12, 13

RECIST criteria, 100, 104

Rectal cancer

T3+/N0-2, 191, 195–196

transanal excision, 191, 196

Reduced penetrance, 59, 64

REGARD study, 160–161

Regorafenib, for GIST, 182, 186

Relative risk reduction, 48

Renal cel cancer, 199, 207

Memorial Sloan Kettering Cancer Center (MSKCC) risk factors, 200, 207

prognostic factors, 200, 207

recurrent metastatic disease, 200, 207

subtypes, 207

434

temsirolimus in, 200, 208

Renal pelvis urothelial cancers

radical nephroureterectomy and bladder cuff resection for, 202, 210

Replicative senescence, 16, 23

Repopulation, during fractionated radiotherapy, 70, 74–75

Retinoblastoma, 270

Retinoids and beta-carotene, and skin cancer incidence in xeroderma pigmentosum, 52, 55

RET protooncogene, germ line mutations in, 54, 58

Rituximab, in chronic lymphocytic leukemia, 309, 314

Rofecoxib, 56

RTOG 91-11, 124, 126

RUNX1, 299

Salivary gland cancers, 128

expression of androgen receptor in, 123, 128

histologic types, 128

Salpingo-oophorectomy, 54, 57

Sarcomas

Ewing sarcoma, and cytogenetic abnormalities, 265, 270

MSKCC nomogram for sarcoma-specific mortality, 266, 270

radiation-induced, 265, 270

soft tissue, 265, 270

Schistosoma haematobium, bladder cancer by, 204, 211

SCLC. See Smal cel lung cancer (SCLC)

Selection bias, 30, 31, 47, 49

Selective neck dissection (SND), 125

SELECT trial, 55

Selenium supplementation, and nonmelanoma skin cancer, 52, 55

Seminoma, chemotherapy for, 217, 221

Senescence, 2, 7

and quiescence, 11

as tumor suppressor mechanism, 5, 12

Sensitivity of test, 47

Sequenced human genome, analysis of, 1, 7

Sex cord–stromal tumors, 244

Sexual dimorphism, pharmacokinetic, 79, 84

Sexual dysfunction, in craniopharyngioma, 258, 263

SIADH. See Syndrome of inappropriate antidiuretic hormone secretion (SIADH) Simon phase 2.5 designs, 109, 114

Sinusoidal obstruction syndrome (SOS), 334, 339

435

Sipuleucel-T, 91, 95

SIRIUS trial, 322

Smal bowel adenocarcinomas, 183, 186

Smal cel lung cancer (SCLC)

C-myc amplification in, 3, 9–10

combination chemotherapy for, 343, 347

genomic characterization of, 132, 137

limited-stage, management of, 130, 135

location for primary tumor, 343, 347

and SVC syndrome, 343, 347

Smoking

and lung cancer, 33, 37

and radiotherapy-associated toxicities, 51, 55

SN-38, 195

and glucuronidation, 195

and neutropenia, 191, 195

Soft tissue sarcomas, 265, 270

extremity, 269, 273

of head and neck, 271

local y recurrent, 267, 272

metastatic, 267, 272

chemotherapy treatment of, 267, 272

nonmetastatic, independent predictors of prognosis of, 267, 271

staging of, 266, 270

Sokal risk score, 305, 310

Sorafenib, 17, 24

for hepatocel ular carcinoma, 329, 332

Southwest Oncology Group (SWOG), 136

Specificity of test, 47

Spermatic cord liposarcomas, 223

Spinal ependymoma, 256, 260

Splenic marginal zone lymphoma (SMZL), 285, 290

Src, 8

Stage shift, 48, 49

Standard fractionation for radiation therapy, 76

Statins, and cancer risk, 53, 56

Stem cel engraftment, 335, 339

Stem cel transplantation, 333–341. See also Al ogeneic stem cel transplantation; Autologous stem cel transplantation

Stochastic model of tumor heterogeneity, 21, 27

Strontium-89, 348

Suberoylanilide hydroxamic acid (SAHA), 9

436

Sulindac, 56

Sunitinib-associated hypothyroidism, 182, 185–186

Sunitinib, for alveolar soft part sarcoma, 268, 273

Superior vena cava syndrome, in thymic carcinoma, 140, 145–146

Superior vena cava (SVC) thrombosis, 347

Surveil ance, Epidemiology, and End Results (SEER) Program, 30, 32

Survival data. analysis of, 111, 116, 117

Survival time after diagnosis, 48

Syndrome of inappropriate antidiuretic hormone secretion (SIADH), 346, 349

Synovial sarcoma, 270

Tamoxifen, 52, 56

for breast cancer, 252–253

TAMs. See Tumor-associated macrophages (TAMs)

Tartrate-resistant acid phosphatase (TRAP) testing, 313

Taxanes, 17, 24

T-cel depletion, and risk of engraftment failure, 335, 339

T-cel –mediated immunity, 89, 93

Telomerase, 5, 11, 23

Telomerase-nul mice, 5, 12

Telomeres, 11

Temozolomide, 102

Temsirolimus, 21, 28, 207

Testicular cancer. See also Nonseminomatous germcel tumor (NSGCT) hCG in, 219, 222–223

immunohistochemical proteins and, 218, 222

large B-cel lymphoma, 219, 223

long-term sequelae of cisplatin-based chemotherapy for, 219, 223

risk factors for, 218, 222

The Cancer Genome Atlas (TCGA), 263

Therapeutic equivalence trials, 110, 115

confidence interval, 110, 116

Thiopurine methyltransferase (TPMT) deficiency, 80, 84

Thymic carcinoid, and multiple endocrine neoplasia type 1, 141, 146

Thymoma, 139, 144

classification schemes and staging systems for, 144–145

incidence of, 144

molecularly targeted agents in, 140, 145

paraneoplastic syndromes with, 140, 145

predictor of long-term prognosis for people with, 139, 144

stage IV thymoma, systemic treatment for, 140, 145

437

Thyroid function tests, 278, 281

Time to tumor progression, as end point in clinical trials, 101, 105

T315I mutation, 84

TLS. See Tumor lysis syndrome (TLS)

T790M mutation, 84, 99, 103

Tobacco dependence, second-line pharmacotherapy for, 51, 55

Tobacco-induced cancers, 33, 37

Transarterial chemoembolization (TACE), 178

Transformation, 38

Transforming growth factor (TGF)-β, 16, 22

Trastuzumab, 153, 158

risk factors for cardiac dysfunction with, 250, 254

Treatment planning process, 72, 77

TSP-1, 26

Tumor angiogenesis, 18, 25

IL-6/8 and, 19, 26

Tumor-associated macrophages (TAMs), 20, 26–27

Tumor cel s, and metastases, 19, 26

Tumor colonies, growth of, 18, 25

Tumor heterogeneity

hierarchy model of, 21, 27

stochastic model of, 21, 27

Tumor lysis syndrome (TLS), 344, 348

and hyperkalemia, 344, 348

Tumor suppressor genes, 1, 7, 16, 23

Tumor vasculature, 18, 25

Turcot syndrome, 222, 255, 260

Type II programmed cel death, 17, 24

Tyrosine kinases, 6, 12

UK-ABC-02 trial, 178

Ulcerative colitis, 277, 281

Ultraviolet (UV) light, 35, 40

Undifferentiated pleomorphic sarcoma (UPS) of soft tissue, 272

United States Preventive Services Task Force (USPSTF), 45, 48

Urate oxidase, 349

Uridine diphosphate glucuronosyltransferase (UGT) 1A1, 84

U.S. Preventive Services Task Force (USPSTF), 44, 47

Uterine corpus cancers, 230, 236

438

Vaginal cancers, 228, 234

stage II, 228, 234

Vandetanib, 85

Varenicline (Chantix), side effects of, 51, 55

Vascular endothelial growth factor (VEGF), 19, 25–26

in CTC extravasation, 20, 27

H1F1α and, 19, 26

Vasohibin, 26

VEGF. See Vascular endothelial growth factor (VEGF) Vemurafenib (PLX4032), 21, 28

Veterans Administration Laryngeal Study Group Trial, 126

VHL gene, 200, 208

Vil ous lymphocytes, 285, 290

Vincristine, doxorubicin, and cyclophosphamide (VAC), 268, 273

Viral oncogenes (v-oncogenes), 8

Vismodegib, 279, 281

Vitamin B12 and folic acid supplementation, for hematologic toxicities with pemetrexed, 80, 85

Von Hippel–Lindau disease, 200, 208

Von Hippel–Lindau (VHL) tumor suppressor gene, loss of function in, 85

Vorinostat, 87

Vulvar cancer

HPV-associated, 228, 235

invasive, 228, 229, 235

local recurrence of, 229, 235

lymph node involvement and patient’s ultimate survival, 229, 235

non-HPV-associated, 228, 235

repeat resection for recurrent cancers, 229, 235

staging for, 229, 235

Waldenstrom’s macroglobulinemia (WM), 324

Warburg effect, 18, 25

Wel -differentiated squamous cel carcinoma, thymic carcinoma, 141, 146

WHIM syndrome (warts, hypogammaglobulinemia, infection, and myelokathexis), 324

WHI trial, 56

WM. See Waldenstrom’s macroglobulinemia (WM)

Women’s Health Initiative, 56, 57

Xerostomia, 122, 127

X-rays, effects of, 69, 74

439

Zidovudine, and cytotoxic chemotherapy, 327, 330

440





Document Outline


Title Page

Copyright

Dedicaiton

Contributors

Preface

Preface to Previous Edition

Acknowledgments

Contents

1. Molecular Biology of Cancer • Part 1

2. Molecular Biology of Cancer • Part 2

3. Epidemiology of Cancer

4. Etiology of Cancer

5. Cancer Screening

6. Cancer Prevention

7. Genetic Counseling

8. Principles of Radiation Oncology

9. Systemic Therapy for Cancer

10. Principles of Immunotherapy

11. Assessment of Clinical Responses

12. Design and Analysis of Clinical Trials

13. Cancer of the Head and Neck

14. Lung Cancer and Mesothelioma

15. Neoplasms of the Mediastinum

16. Esophagus and Stomach Cancer

17. Pancreatic and Hepatobiliary Cancer

18. Small Bowel Cancers and Gastrointestinal Stromal Tumors (GIST)

19. Colorectal and Anal Cancers

20. Prostate, Bladder, and Kidney Cancer

21. Testicular Cancer

22. Vulvar, Vaginal, Uterine, and Cervical Cancer

23. Ovarian Cancers

24. Breast Cancer

25. Cancers of the Central Nervous System

26. Sarcomas

27. Cancer of the Skin and Melanoma

28. Lymphomas

29. Acute Leukemias

30. Chronic Leukemias

31. Plasma Cell Neoplasms

32. Immunosuppression-Related Malignancies

33. Stem Cell Transplantation

34. Oncologic Emergencies

Index





